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Abstract in English 
The incidence of cancer in the western world has increased steeply during the last 50 years. For three of the 
most prevalent cancer types in Denmark, prostate, breast and colorectal cancer (PC, BC and CRC, 
respectively), only a small fraction (1-15%) of the incidences are caused by highly penetrant single-gene 
mutations due to their low frequency in the general population. Overall, the contribution from hereditary 
factors to the causation of BC is only 27%, whereas genetics contributes to 35% and 42% for CRC and PC, 
respectively. Additionally, immigrations studies point to environmental factors as having strong influence on 
carcinogenesis. Therefore, very frequent, low effect polymorphisms may have a greater contribution on a 
population level in combination with environmental factors. Indeed, several dietary and life style factors are 
now well-established risk factors for different cancer types, such as alcohol consumption, smoking, obesity, 
inflammation and high meat intake; whereas other factors protect against cancer, such as high intake of 
dietary fibre, fruits and vegetables, and physical activity. Investigating the interactions between genetic 
variations and environmental factors, such as dietary and lifestyle factors may provide information about the 
underlying mechanisms and reveal new biological pathways.  
The aim of this PhD thesis was to investigate relevant risk factors in relation to the three major cancer types 
in Denmark: PC, BC and CRC, respectively. The two major risk factors examined in this thesis are 
inflammation and alcohol consumption. With regard to inflammation, biological pathways involved in 
inflammation and the interaction with different dietary and lifestyle factors modulating the risk of CRC (Paper 
II-IV) and PC (Paper I), respectively, was examined. Moreover, a possible mechanism in alcohol-related BC 
in postmenopausal women involving a specific polymorphism in PPARG (coding the peroxisome proliferator-
activated receptor (PPARγ)) and its interaction with the aromatase (encoded by CYP19A1) was investigated 
(Paper V-VI). 
The Danish prospective “Diet, Cancer and Health” cohort study was used to examine gene-gene and gene-
environment interactions in relation to risk of cancer (Paper I-V). A human intervention trial (Paper V) was 
conducted in order to directly examine the effect on concurrent use of nonsteroidal anti-inflammatory drugs 
(NSAIDs) and alcohol consumption on circulating female sex-hormones. Finally, in vitro assays were 
performed to study the effect on PPARγ transactivation and sex-hormone concentrations following exposure 
to other commonly used organic solvents than alcohol (Paper VI). 
Based on the results from Paper I, inflammation did not seem to be a major risk factor for aggressive PC, 
whereas the results on non-aggressive PC were equivocal. In contrast, Paper II and III indicated that the 
immune system is indeed involved in the carcinogenesis of CRC. Carriage of a pro-inflammatory allele of the 
NFKB1 gene, was not associated with aggressive PC risk, but was associated to lowered risk of non-
aggressive PC, and to increased risk of CRC. Even though none of the results were strong statistically, they 
demonstrated that cancer is a very heterogeneous disease; and indicated that inflammation may not be a 
risk factor for (aggressive) PC, but in relation to CRC, inflammation seems important. In Paper III, a new 
possible mechanism involving the ATP-binding cassette (ABC) transporters, the cytokine interleukin (IL) 10 
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and dietary fibre in relation to protection against inflammation-induced CRC was found. Furthermore, use of 
NSAIDs seemed to interact with the ABC transporters and IL-10 in relation to CRC.  
Paper V illustrated that genetic variations in CYP19A1 predicts circulating sex-hormone levels in post-
menopausal women, and that alcohol intake affects female sex-hormone concentrations in the blood. 
However, it was not possible to put PPARγ and the aromatase in the same pathway as hypothesized a priori 
in alcohol-related BC; and the possible effect modification of concurrent use of NSAIDs and alcohol 
consumption was not confirmed. Nevertheless, results from Paper VI, indicated that exposure to commonly 
used organic solvents may act via PPARγ modulating sex-hormone levels. However, whether there is a 
common mechanism linking the aromatase and PPARγ, and also whether the differences in hormone levels 
increases risk of BC, still needs to be elucidated. Furthermore, these studies illustrated that acute and 
chronic alcohol consumption may have different effects on sex-hormone biosynthesis and metabolism, and 
that it is not straightforward to compare observational studies with experimental studies. 
Overall, this PhD thesis has shown that genetic epidemiology can be used to study biological mechanisms in 
combination with other mechanistic studies, although there are several limitations involved such as missing 
knowledge of confounders and limited statistical power to study gene-environment interactions.  
Future research could establish whether and how dietary fibre, IL-10 and ABC transporters are connected in 
reducing the risk of CRC; and whether red meat per se, specific preparation methods or the life style 
associated with high red meat intake is carcinogenic. The acquired knowledge would improve the current 
dietary recommendations. 
There also seem to be several yet unknown effects of NSAID usage that need to be clarified. Information of 
these potential (side) effects would lead to better and safer medication regimens and, hence, improved 
public health. Also, further knowledge of the harmful health effects related to alcohol consumption, including 
the potential effect modification with concurrent use of NSAIDs, would lead to improved public preventive 
strategies. 
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Dansk resumé 
Cancer incidensen i Vesten er steget stødt de sidste 50 år. For tre af de mest prævalente cancer typer i 
Danmark, prostata-, bryst- og kolorektal cancer, er kun en lille del (1-15%) af incidensen forårsaget af høj-
penetrans enkelt-genmutationer pga. deres lave frekvens i populationen. Generelt set bidrager nedarvede 
faktorer til årsagsforhold for bryst cancer kun med 27%, hvorimod genetik bidrager med 35% og 42% for 
henholdsvis kolorektal- og prostata cancer. Derudover indikerer immigrationsstudier at miljø-faktorer har en 
stærk indflydelse på karcinogenesen. Derfor kan hyppige, lav-effekt polymorfier have et større bidrag på 
populationsniveau i kombination med miljøfaktorer. Flere kost- og livstilsfaktorer er nu veletablerede 
risikofaktorer for forskellige cancer typer, såsom indtag af alkohol, rygning, fedme, inflammation og højt 
indtag af kød; hvorimod andre faktorer beskytter mod cancer, såsom et højt indtag af kostfibre, frugt og 
grønt, og fysisk aktivitet. Ved at undersøge samspillet mellem genetiske variationer og miljøfaktorer, som 
kost- og livsstilsfaktorer, kan der opnås viden om de bagvedliggende mekanismer og afdækkes nye 
biologiske veje. 
Formålet med denne ph.d. afhandling var at undersøge relevante risikofaktorer i forhold til de tre store 
cancer typer i Danmark: prostata-, bryst- og kolorektal cancer. De to primære risikofaktorer som blev 
undersøgt i denne afhandling var inflammation og alkohol indtag. I forhold til inflammation, blev biologiske 
veje der er involveret i inflammation og disses samspil med forskellige kost- og livsstilsfaktorer som ændrer 
på risikoen for henholdsvis kolorektal- (Paper II-IV) og prostata (Paper I) cancer undersøgt. Ydermere blev 
en mulig mekanisme i alkoholrelateret bryst cancer hos postmenopausale kvinder undersøgt (Paper V-VI). 
Denne mekanisme involverer en specifik polymorfi i PPARG (som koder for peroxisome proliferator-activated 
receptor (PPARγ)) og interaktion med aromatasen (som er kodet af CYP19A1). 
Det danske prospektive “Kost, Kræft og Helbred” kohorte studie blev brugt til at undersøge gen-gen og gen-
miljø interaktioner i forhold til risikoen for cancer (Paper I-V). Et humant interventions studie (Paper V) blev 
udført for direkte at undersøge effekten af samtidig indtag af non-steroide anti-inflammatoriske lægemidler 
(NSAID) og alkohol på cirkulerende kvindelige kønshormoner. Slutteligt blev der udført nogle in vitro forsøg 
for at undersøge effekten på PPARγ trans-aktivering og kønshormon niveau efter eksponering af andre 
almindeligt brugte organiske opløsningsmidler end alkohol (Paper VI). 
På baggrund af resultaterne fra Paper I, syntes inflammation ikke at være en betydelig risikofaktor for 
aggressiv prostata cancer, hvorimod resultaterne fra non-aggressiv prostata cancer var mere tvetydige. 
Derimod indikerede Paper II og III at immunforsvaret er involveret i kolorektal karcinogenesen. At være 
bærer af det pro-inflammatoriske allel fra NFKB1 genet var ikke associeret med aggressiv prostata cancer 
risiko, men var derimod associeret med nedsat risiko for non-aggressiv prostata cancer, og med øget risiko 
for kolorektal cancer. Selvom ingen af resultaterne var statistisk stærke, viste de at cancer er en meget 
heterogen sygdom; og indikerede at inflammation højst sandsynlig ikke er en risikofaktor for (aggressiv) 
prostata cancer, men tyder på at være vigtig i forhold til kolorektal cancer. I Paper III blev en ny mekanisme 
der involverer de ATP-bindende cassette (ABC) transportere, cytokinet interleukin (IL) 10 og kostfibre i 
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forhold til beskyttelse mod inflammations-induceret kolorektal cancer fundet. Ydermere tydede resultaterne 
på at brug af NSAID interagerer med ABC transporterne og IL-10 i forhold til kolorektal cancer. 
Paper V illustrerede at genetiske variationer i CYP19A1 prædikterer cirkulerende kønshormon niveauer hos 
postmenopausale kvinder, og at indtag af alkohol påvirker koncentrationen af kvindelige kønshormoner i 
blodet. Dog var det ikke muligt at anbringe PPARγ og aromatasen i den samme biologiske vej som antaget a 
priori i forhold til alkoholrelateret bryst cancer; og den formodede effekt modifikation af samtidigt brug af 
NSAID og alkohol blev ikke bekræftet. Ikke desto mindre indikerede resultaterne fra Paper VI at eksponering 
til almindeligt brugte organiske opløsningsmidler muligvis ændrer på kønshormonniveauer via PPARγ. Men 
om der er en fælles mekanisme som linker aromatasen og PPARγ; og ligeledes om ændringerne i 
hormonniveau øger risikoen for bryst cancer, er stadig uopklaret. Disse studier viste desuden at akut og 
kronisk alkoholindtag muligvis har forskellig effekt på kønshormon syntese og metabolisme, og at det ikke er 
ligetil at sammenligne observationelle studier med eksperimentelle studier. 
Overordnet har denne ph.d. afhandling vist at genetisk epidemiologi kan bruges til at studere biologiske 
mekanismer i kombination med andre mekanistiske studier på trods af flere begrænsninger såsom 
manglende viden om confounding og begrænset statistisk power til at undersøge gen-miljø interaktioner.  
Fremtidige studier vil kunne påvise om og hvordan kostfibre, IL-10 og ABC transportere er forbundet i forhold 
til at nedsætte risikoen for kolorektal cancer; og afklare hvorvidt rødt kød per se, tilberedelses metoden eller 
livsstilen, som er associeret med højt kød indtag, er karcinogent. Denne viden vil kunne forbedre de 
nuværende kostanbefalinger. 
Der synes også at være adskillige hidtil ukendte effekter af NSAID forbrug som er nødvendige at klarlægge. 
Viden om disse mulige (bi-)virkninger ville kunne medføre bedre og mere sikker medicinering og derfor også 
forbedret folkesundhed. Yderligere viden om de sundhedsskadelige effekter som er relateret til indtag af 
alkohol, inklusiv den mulige effekt modificering af samtidig brug af NSAID, ville også føre til forbedrede 
forebyggende folkesundhedsstrategier. 
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1.1. General introduction 
The incidence of cancer in the western world has increased steeply during the last 50 years. In Denmark, 
one out of three will get cancer during a lifetime 1. For three of the most prevalent cancer types in Denmark, 
prostate, breast and colorectal cancer (PC, BC and CRC, respectively) (Figure 1), only a small fraction (1-
15%) of the incidences are caused by highly penetrant single-gene mutations due to their low frequency in 
the general population 2,3. In twin studies, it has been estimated that the overall contribution from hereditary 
factors to the causation of BC is only 27% 3. Correspondingly, the genetic contribution to the causation of 
CRC and PC has been estimated to 35% and 42%, respectively 3. Additionally, immigrations studies point to 
environmental factors as having strong influence on carcinogenesis 4-7. Therefore, very frequent, low effect 
polymorphisms may have a greater contribution on a population level in combination with environmental 
factors 8. Indeed, several dietary and life style factors are now well-established risk factors for different 
cancer types, such as alcohol consumption 9-14, smoking 12,13, obesity 12-14, inflammation 15 and high meat 
intake 12-14,16,17; whereas other factors protect against cancer, such as high intake of dietary fibre 13,14,18, fruits 
and vegetables 14, and physical activity 13,14. Investigating the interactions between genetic variations and 
environmental factors, such as dietary and lifestyle factors may provide information about the underlying 
mechanisms and reveal new biological pathways.   
In order to examine molecular mechanisms that cause a specific disease, different approaches have been 
used – from molecular in vitro studies to large epidemiological studies or genome wide association studies 
(GWAS). In vitro studies have the possibilities of investigating biological pathways directly without having to 
take ethic aspects into consideration, but it is challenging to extrapolate results from in vitro work to the 
biology of the intact organism. Human intervention studies are very valuable within limitations due to ethical 
reasons. These limitations can to a certain point be overcome in animal studies, but animals are not humans. 
GWAS can bring information on new possible biological pathways which can be further investigated in 
candidate gene studies where the information of confounders is more detailed than in the very large GWAS. 
Results from observational studies, however, are only associations, which are not necessarily causal, and it 
is therefore important to include all available information on conducted studies regarding the mechanism of 
interest when inferring causality. However, observational studies are excellent in generating or possibly even 
confirming hypotheses. New hypotheses can establish the fundament to new research in so far unknown 
biological pathways. 
The knowledge acquired from research on gene-environment interactions can be used to understand the 
underlying mechanism of cancer and thereby reduce cancer incidence in the population by implementing 
national preventive and treatment strategies.  
 
 
4 
 
A B
C D
 
Figure 1. Age-standardized cancer rate per 100,000 in selected countries for breast, prostate and colorectal cancer, 
respectively. A. Breast cancer; B. Prostate cancer; C. Colorectal cancer among men; D. Colorectal cancer among 
women. Source: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. 
 
1.2. General aims and objectives of this PhD thesis  
The aim of this PhD thesis was to investigate relevant risk factors in relation to the three major cancer types 
in Denmark: PC, BC and CRC, respectively, primarily by use of genetic epidemiology, but also by in vitro 
studies and a human intervention trial to complement the observational findings. The two major risk factors 
examined in this thesis are inflammation and alcohol consumption. With regard to inflammation, biological 
pathways involved in inflammation and the interaction with different dietary and lifestyle factors modulating 
the risk of CRC and PC, respectively, will be described. Moreover, a description of a possible mechanism in 
alcohol-related BC in postmenopausal women involving a specific polymorphism in PPARG will be 
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presented. Hereafter, the Danish cohort and all polymorphisms investigated in Paper I-V are described. 
Finally, Paper I-VI are presented followed by a summarizing and supplementary discussion. Supplementary 
data (Tables and Figures termed “S” in front of the number) are provided in the Appendix section. 
1.3. Inflammation-induced carcinogenesis  
As early as 1863, Virchow speculated that there was an association between chronic inflammation and 
cancer. Virchow noticed “lymphoreticular infiltrate” at sites of cancer and hypothesized that these chronic 
inflammatory infiltrates reflected the origin of cancer 19. Today, it is widely accepted that some cancers are 
caused by chronic inflammation, such as cancers of liver, colon, bladder, oesophagus and stomach. The 
molecular and cellular mechanisms mediating this association are very complex and can be caused by both 
infectious agents like Helicobacter pyleri and Mycobacterium tuberculosis and environmental factors like 
asbestos, UV irradiation, alcohol consumption, smoking and diet 15,20-22.  
The term inflammation describes a local response to tissue injury. The cardinal signs of inflammation are 
rubor (redness), tumor (swelling), calor (heat), dolor (pain) and functio laesa (loss of function). It involves a 
vascular phase and a cellular phase. In the vascular phase, blood flow and capillary permeability increases 
leading to accumulation of blood proteins including components of the complement cascade. In the cellular 
phase, leukocytes (neutrophils, monocytes and eosinophils) and tissue mast cells migrate from the venous 
system to the site of inflammation. The neutrophils coordinate recruitment of the inflammatory cells to the site 
of tissue injury and the extracellular matrix where fibroblasts and endothelial cells proliferate and migrate in 
order to reconstruct the tissue: First, members of the selectin family of adhesion molecules are activated 
which facilitate rolling along the vascular epithelium. Secondly, leukocyte integrins are activated and up-
regulated by cytokines and leukocyte-activating molecules. Third, the neutrophils are immobilized on the 
endothelium cells by integrins that binds to endothelial vascular cell-adhesion molecules. Fourth, the 
leukocytes migrate through the endothelium to the site of injury facilitated by extracellular proteases. At the 
site of inflammation, the chemokines – a family of chemotactic cytokines – recruits downstream effector cells 
and orchestrates the process of inflammation. At this point, it is extremely important that the 
cytokines/chemokines is tightly regulated resulting in fast resolution and wound healing. However, 
dysregulation of any of the inflammatory factors can lead to prolonged, chronic inflammation and ultimately 
neoplastic progression. After migration of the neutrophils to the site of injury, the monocytes, which 
differentiate into macrophages, are guided by chemotactic factors to the inflammation site. The activated 
macrophages are the main source of growth factors and cytokines which stimulate local endothelial, 
epithelial and mesenchymal cells to proliferate. Mast cells release histamine, cytokines, reactive oxygen 
species (ROS), nitric oxide (NO), different matrix metalloproteases (MMPs), and lipid mediators (see section 
1.3.2.). Thus, chronic inflammatory states are characterized by an increased cell turnover, a large amount of 
growth factors, and activated phagocytic macrophages producing ROS and NO that are capable of 
damaging cells and DNA. Proliferation of epithelial cells in this environment may cause substantial potential 
for mutational and promoting effects. Therefore, chronic inflammatory states possess the potential of being 
both an initiator and a promoter of carcinogenesis 15,23-26.  
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One of the most convincing pieces of evidence linking inflammation and cancer, arises from several human 
observational and clinical studies illustrating that long-term regular use of Aspirin and other nonsteroidal anti-
inflammatory drugs (NSAIDs) reduces the incidence of cancer; particularly in CRC and other gastro-intestinal 
cancers 27-36. Moreover, animal and in vitro studies have demonstrated that NSAIDs also are capable of 
inhibiting PC 37-40. However, the observational data are less consistent although the majority of the studies 
point to a reduced risk of PC among long-time users of NSAIDs 29,41-56.  Additionally, numerous genetic 
epidemiological studies have found associations between polymorphisms in inflammatory genes and risk of 
cancer 57-62, and inflammatory bowel diseases (IBD) e.g., ulcerative colitis (UC) and Crohns’ disease (CD), 
known to predispose to CRC 63-66.  
1.3.1. Nonsteroidal anti-inflammatory drugs 
NSAIDs function by inhibition of prostanoid synthesis when the drugs bind to cyclooxygenase (COX), an 
inducible pro-inflammatory enzyme that converts arachidonic acid to a range of prostaglandins (PGs) (see 
section 1.3.2.) 67. Aspirin and ibuprofen are two of the classical NSAIDs. They are further divided in aspirin 
and non-aspirin (NA) NSAIDs due to differences in mechanisms of action. Only higher doses of aspirin inhibit 
the COX-2 isoform. The classical NSAIDs encompass anti-inflammatory, anti-pyretic and analgesic effects, 
and inhibit both COX-1 and COX-2 enzymes. Selective COX-2 inhibitors, so-called coxibs (e.g. celecoxib), 
are a newer class of NSAIDs that have little effect on COX-1, but potently inhibit COX-2 and therefore 
reduce the incidence of gastrointestinal ulcers and erosions associated with use of classical NSAIDs 68-70. 
However, selective inhibition of COX-2 with coxibs blocks the formation of vasodilators (prostacyclins and 
PGs – see section 1.3.2.) and shifts the arachidonic acid metabolism to lipoxygenase pathway which may 
result in serious cardiovascular effects. Therefore, some of the selective COX-2 inhibitors have been 
withdrawn from the market and coxibs are now never used as routine therapy, but are reserved to patients in 
high risk of gastrointestinal bleeding 71. In the present thesis, “NSAIDs” covers aspirin and NA-NSAID – not 
selective COX-2 inhibitors. 
Due to the evidence of a protective effect of NSAIDs, it is reasonable to investigate functional polymorphisms 
in COX-2 in relation to inflammation-induced cancer. 
1.3.2. Cyclooxygenase-2 and its products, the prostanoids 
COX or prostaglandin H2 synthase is the key enzyme in the synthesis of PGs from AAs and, as mentioned 
above, two isoforms of COX exist: COX-1 and COX-2 72,73. The two isoforms share significant sequence 
homology and catalytic activity, but their expression pattern is markedly different. COX-1 is often referred to 
as a “housekeeping” gene and is constitutively expressed in almost all tissues. The PGs produced by COX-
1, are important for homeostatic functions. COX-2, in contrast, is an inducible enzyme with varying enzyme 
level due to different regulation in different tissues. COX-2 is significantly upregulated as a response to 
inflammation, and histological studies have found an upregulated COX-2 expression in several human 
cancers, including CRC 74-77 and PC 75,77-79.  
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Regulation of the COX-2 gene expression is very complex since COX-2 is involved in numerous signalling 
pathways, depending on the specific stimulus and cell type (illustrated in Figure 2). The promoter region of 
the COX-2 gene contains several potential transcriptional regulatory elements where transcription factors 
bind in many different ways 80-85. Post-transcriptional regulation involves changes in mRNA stability 82,86. The 
3’ untranslated region of COX-2 contains multiple copies of adelylate- and uridylate-rich elements (AREs) 
composed of the sequence 5’-AUUUA-3’. The AUUUA motif, found in the 3’ untranslated region, is 
characteristic of many unstable cytokine- and proto-oncogene-encoding mRNAs 87. Specific ARE-binding 
factors bind to the AREs in response to interleukin (IL)-1β induced mitogen-activated protein kinase (MAPK) 
cascade signalling, and influence COX-2 mRNA stability and also translational efficiency 88.  
 
Figure 2: Simplified illustration of the main signalling pathways of COX-2 gene induction and suppression including 
environmental triggers: COX-2 gene expression is stimulated in response to several inducers such as pro-inflammatory 
factors, hormones, growth factors and oncogenes through receptor-mediated signalling and various signalling pathways 
including the mitogen-activated protein kinase cascade and the nuclear factor kappa B (NF-κB) signalling pathway 89. 
The regulatory elements in the promoter region and in the 3’ untranslated region regulate the COX-2 gene expression in 
response to different signals. Peroxisome proliferator-activated receptor γ 90 and glucocorticoids 91 suppress COX-2 gene 
expression by interfering with the NF-κB pathway and by inhibition of activator protein 1 92. Green arrows indicate 
induction and red arrows indicate suppression. Orange figures are the studied factors. AP: Activator protein; ARE: 
Adelylate- and uridylate-rich elements; CD14: Cluster of differentiation 14; COX: Cyclooxygenase; IL: Interleukin; LPS: 
Lipopolysaccharide; MAPK: Mitogen-activated protein kinase; PG: Prostaglandin; PGJ2: PGD2 metabolite 15-deoxy-
12,14; ; PPARγ: Peroxisome proliferator-activated receptor γ; RXR: Retinoic X-receptor; TLR: Toll-like receptor; TNF: 
Tumor necrosis factor. (Based on 80,89-93). 
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Prostanoids, which consist of prostacyclins (PGI2), thromboxane A2 (TXA2) and PGs (PGD2, PGE2 and 
PGF2), are paracrine and autocrine lipid mediators that coordinate intercellular events. They regulate the 
changes in blood flow required for leukocytes to exit the blood vessels in the initiation phase in inflammation, 
mediate a class switching of lipid mediators required for termination of the acute response, exert 
immunosuppressive effects by reducing the ability of leukocytes to phagocytosis and kill microorganisms, 
and are able to inhibit the production of downstream pro-inflammatory mediators. However, these PGs also 
contribute to fortification of the inflammatory response by enhancing and prolonging the signals of several 
pro-inflammatory mediators. Indeed, excess PGs has been shown to contribute to chronic inflammation 
26,68,94. Besides its role in inflammation, increasing evidence indicates that PGE2 plays a dominant role in 
cancer progression 95-108, and increased PGE2 production has been found in several types of neoplastic 
tissues compared to normal tissue 109. The prostanoid TXA2 has also been implicated in carcinogenesis by 
acting as a promoter of angiogenesis 110. PGE2 promotes tumour growth by binding to one of its four cognate 
receptors (EP1-4) which then activates downstream signalling pathways 27,111-113 as illustrated in Figure 3.  In 
addition to COX-2, the epidermal growth factor receptor (EGFR) is activated in most human cancers 114. 
PGE2 can trans-activate EGFR, which results in stimulation of cell migration and invasion through increased 
phosphatidylinositol 3’-kinase/Akt signalling 95,100,115. This enhances the cells ability to metastasise and is 
therefore often associated with a poor clinical outcome. The anti-apoptotic action of PGE2 is mediated, 
among others, through activation of the apoptosis inhibitor, Bcl-2 99 and peroxisome proliferator-activated 
receptor (PPAR) δ 98. The ability to escape from apoptosis gives the cells a survival advantage, and may 
therefore increase resistance to chemotherapy. Activation of vascular endothelial growth factor (VEGF) and 
basic fibroblast growth factor through EP1-4 leads to the formation of new blood vessels 102. This property is 
important for the growth and survival of the tumour. 
1.3.3. Nuclear factor kappa B  
NF-κB is a transcription factor that, among others, regulates COX-2 expression 116. NF-κBs are regulators of 
innate immune and inflammatory responses. In mammals, the NF-kB family consists of five members: 
p105/p50 (encoded by NFKB1), p52/p100 (encoded by NFKB2), p65/RelA (encoded by RELA), Rel/cRel 
(encoded by REL), and RelB (encoded by RELB) forming a variety of homodimers and heterodimers. As a 
p65/p50 heterodimer, the complex is pro-inflammatory, whereas the p50 homodimer has anti-inflammatory 
properties. In the inactive state, NF-κB is sequestered in the cytoplasm by inhibitory proteins called IκBs. In 
infectious or inflammatory states, signals such as pathogenic microorganisms, tumor necrosis factor α (TNF-
α), Toll-like receptors (TLR) (see section 1.3.5.) or IL-1β (see section 1.3.4.) activate the dimers that lead to 
the phosphorylation, ubiquitylation, and consequent degradation of IκB. This allows for the NF-κB dimers to 
translocate into the nucleus and stimulate the transcription of specific genes via the NF-κB binding site in 
target genes 15,117-119. 
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Figure 3. Cyclooxygenase 2-derived prostaglandin E2 (PGE2) in carcinogenesis. PGE2 promotes tumour growth by 
stimulating PGE2 receptor 1-4 downstream signalling and subsequent enhancement of cellular proliferation, suppression 
of immune responses, promotion of angiogenesis, and inhibition of apoptosis. Additionally, PGE2 can activate epidermal 
growth factor receptor and thereby stimulate cell migration and invasion. AA: Arachidonic acid; Bcl-2: B-cell lymphoma 2; 
bFGF: basic fibroblast growth factor; COX-2: Cyclooxygenase 2; EGFR: Epidermal growth factor receptor; EP1-4: 
Prostaglandin cognate receptor 1-4; IL: Interleukin; MAPK: Mitogen-activated protein kinase; PI3K: Phosphatidylinositol 
3’-kinase; PPAR: Peroxisome proliferator-activated receptor; VEGF: Vascular endothelial growth factor. (Based on 27). 
 
Dysregulation of NF-κB can lead to the constitutive overproduction of pro-inflammatory cytokines, which is 
associated with a number of chronic inflammatory disorders, including rheumatoid arthritis and CD and 
eventually leads to cancer 120-122. Indeed, dysregulation of NF-κB has been found in several human cancers 
119,123,124, and NF-κB encompasses the capacity of promoting cancer by several mechanisms. The molecules 
intercellular adhesion molecule 1, endothelial leukocyte-adhesion molecule 1 and vascular cell adhesion 
molecule 1 (VCAM-1) are all regulated by NF-κB 125-127 and mediate the ability to cross vessels which can 
lead to metastatic potential in tumor cells. Several angiogenic growth factors, e.g., VEGF and monocyte 
chemo-attractant protein 1 are also regulated by NF-κB 128-130. These growth factors stimulate vascularization 
of tumor cells.  NF-κB also regulates several tumor promoting and potential mutational genes apart from PGs 
via COX-2 131, e.g., TNF-α 132, IL-1 133, inducible nitric oxide synthase (iNOS) 134, MMPs 135, urokinase-type 
plasminogen activator 136 and many chemokines 137-139. Finally, NF-κB possesses both pro-apoptotic (by 
regulating of e.g., Fas, c-myc, p53 and IκBα) and anti-apoptotic properties (by regulating of e.g., TNF 
receptor-associated factor 2, inhibitor of apoptosis proteins and Bcl-2 like proteins) 140-142; and controls 
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regulation of cell cycle proteins (e.g., cyclin D1 and cyclin-dependent kinase 2) 143-145 which may increase 
cellular survival and proliferation. 
Additionally, NSAIDs have been shown to inhibit NF-κB independent of COX inhibition 146. Thus, inherent 
differences in NF-κB activity may modify the risk of inflammation-induced cancer and interact with NSAID 
intake. 
1.3.4. Interleukin 1 beta 
IL-1 is a pro-inflammatory cytokine that affects nearly all cell types and has an important regulatory role in 
inflammation and host defence; nearly all microbes and microbial products induce production of IL-1 
proteins. The IL-1 gene family consists of agonistic and antagonistic molecules, as well as receptors. IL-lα 
and IL-1β are the two major agonists, whereas IL-1 receptor antagonist (IL-1Ra) is a competitive antagonist 
of IL-1 that encompasses a signal peptide and requires transport to escape from the cell. IL-lα, IL-lβ and IL-
1Ra are encoded by the three genes IL1A, IL1B and IL1 RN, respectively 147,148. IL-lα and IL-lβ are 
processed into mature cytokines by specific proteases, and are agonists of cell membrane IL-1 type 1 and 2 
receptors (IL-1R1 and 2). IL-1R1 is a signalling receptor, whereas IL-1R2 functions as a decoy target to 
reduce excessive amounts of IL-1 149. Upon binding to the IL-R1, the IL-1R acceptor protein is recruited. This 
heterodimeric complex triggers IL-1 signalling by activating an IL-1 receptor-associated kinase and MyD88 is 
recruited leading to the activation of NF-κB. IL-1β is induced by inflammatory mediators and is found in 
pathological fluids, whereas IL-1α is involved in homeostatic functions as an intracellular cytokine 147-149. E.g., 
elevated levels of mucosal IL-1β have been detected in animal models of intestinal inflammation and in 
humans with IBD 150. 
As mentioned in section 1.3.3., NF-κB regulates COX-2 expression upon activation by IL-1. However, IL-1 is 
also able to stabilise the mRNA of COX-2 93. As a result, COX-2 production is elevated for several hours and 
PGE2 concentration increases steeply upon IL-1β stimulation 147. Actually, many of the IL-1 induced changes 
are mediated by PGE2 and NSAIDs are therefore potent inhibitors of IL-1-induced activity 147. Moreover, IL-
1β stimulates a cascade of other pro-inflammatory factors, e.g., iNOS, chemokines/cytokines and MMPs in 
an amplification loop where the molecules stimulate each other. This results in broad inflammation 
accompanied by tissue damage and immunosuppression 151. Many of these properties alongside others 
make IL-1β capable of promoting carcinogenesis. Indeed, IL-1β knock out mice develop fewer tumors 
compared to IL-1α-deficient or wild type mice 152. IL-1β also up-regulates expression of VEGF on endothelial 
cells providing a microenvironment for angiogenesis and tumor progression 153. 
Thus, inherent variations in IL-1β activity may affect the risk of inflammation-induced cancer and interact with 
NSAID intake. 
1.3.5. Toll-like receptor 4 
The intestinal epithelium serves to protect the body from invading pathogens. However, a mutually beneficial 
relationship between the bacteria colonising the colon – the ‘microbiota’ - and the mucosal epithelium also 
exists, where the epithelial cells use short-chain fatty acids (SCFAs) produced by bacterial fermentation of 
11 
 
ingested dietary fibre, as a crucial energy source 154. This complex interplay between the mucosal epithelium 
and the microbiota is orchestrated by the TLRs. At least 10 different TLRs exist in humans differing in their 
cellular locations and ligands 154. The TLRs are type I transmembrane proteins with an extracellular domain 
consisting of a leucine-rich repeat region and an intracellular domain homologous to that of human IL1R 155. 
The intracellular region mediates downstream signalling upon recognition of pathogen-associated molecular 
patterns which results in activation of one of two major signalling pathways: the MyD88-dependent pathway 
results in the activation of NF-κB and AP-1 and the TRIF-dependent pathway results in the activation of type 
I interferons (IFNs) 156. Activation of TLR results in epithelial cell proliferation, IgA production, maintenance of 
tight junctions and antimicrobial peptide expression, which all contributes to maintaining a balance between 
microbiota and the mucosal immune system. However, they can also trigger pro-inflammatory responses by 
the underlying lamina propria immune cells 154. Here, the TLR4 is central. TLR4 is the receptor for gram-
negative bacterial lipopolysaccharide (LPS) together with its cofactors CD14 and MD2 which regulates cell 
proliferation in response to cell injury through induction of COX-2 expression in a cascade that involves 
activation of NF-κB resulting in the production of PGE2 by the intestinal epithelial cells and epidermal growth 
factor 154,156-158.  This combination increases the potential for enhanced carcinogenesis in the setting of 
inflammation suggesting that TLR4 is an important element in the transition from inflammation to neoplasia. 
Certainly, increased expression of TLR4 has been linked to development of inflammation-associated 
neoplasia 159-162. Thus, TLR4 is an important factor in inflammation-induced CRC and genetically determined 
alteration in TLR4 activity may modulate risk of CRC and also interact with intake of NSAIDs and dietary 
factors (see section 1.5.). 
1.3.6. Peroxisome proliferator-activated receptor gamma 
PPARγ is one of the three PPARs: PPARα, PPARδ and PPARγ 163,164. The PPARs are members of the 
nuclear hormone receptor super family. They are ligand-dependent and form heterodimers with retinoic X-
receptors (RXRs) and regulate transcription of various target genes after binding to their peroxisome 
proliferator response elements (PPREs). Four different isoforms of PPARγ exist generated from differential 
promoter usage and alternative splicing: PPARγ1, PPARγ2, PPARγ3 and PPARγ4.  PPARs can be activated 
by fatty acids and PPARγ is involved in several mechanisms such as lipid metabolism, cell proliferation, 
adipocyte differentiation and insulin signalling 163,164.  
However, PPARγ is also an essential anti-inflammatory modulator (see Figure 2). PPARγ inhibits COX-2 
expression via NF-κB and AP-1, and inhibits mucosal production of inflammatory cytokines e.g., IL-1β and 
TNF-α, and chemokines, inhibits proliferation of inflammatory cells, represses generation of iNOS and MMPs 
and inhibits expression of adhesion molecules, mainly VCAM-1 92,164-166. The PGD2 metabolite 15-deoxy-
12,14 (PGJ2) is a natural ligand for PPARγ; and COX-2 and PPARγ mRNA levels are inversely regulated 
through PGJ2  in a negative feedback mechanism 90,165. All of these properties provide PPARγ with important 
anti-cancer functions, which have been confirmed in several studies showing decreased expression of 
PPARγ in tumor tissue 167-171 and PPARγ ligand activation is a chemo-preventive target against cancer 172-174. 
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NSAIDs are known to activate PPARγ 175,176 and may therefore interact with genetically determined 
variations in PPARγ expression as well as different dietary and life style factors. Especially the interaction 
with alcohol has been investigated in this thesis. Therefore, in section 1.6., a further description of PPARγ in 
relation to alcohol-related BC in postmenopausal women will be discussed.  
1.4. The ATP-binding cassette transporter family 
The ATP-binding cassette (ABC) transporter superfamily is involved in both mucosal immune defence and 
interacts with dietary factors and drugs and will therefore be described separately in this section.  
The ABC transporter superfamily consists of carrier proteins of major clinical significance due to their ability 
to transport drugs and to cause multidrug-resistance (MDR). They are also involved in homeostatic functions 
such as the excretion of lipids, bile salts, peptides for antigen presentation, toxic compounds from the liver, 
kidney and gastrointestinal tract and in limiting permeability of toxins to the brain, testes and placenta by 
forming a barrier. Genetic variations in these genes have various effects on their expression, mRNA stability, 
protein folding, intracellular localization, degradation, substrate binding, and/or transport kinetics 177-180, 
resulting in differences in the intestinal exposure of the transported compounds. 
The transporter proteins bind ATP and use the energy to transport mostly hydrophobic components across 
the lipid bilayer of cell membranes. The functional transporter protein consists of four domains; two 
hydrophobic domains with 6-11 membrane-spanning α-helixes that determine the substrate specificity, and 
two ATP-binding catalytic domains in the inner side of the cell membrane. The ABC transporters are usually 
unidirectional and are formed either as full transporters containing two membrane-spanning domains and 
two ATP-binding domains. In other cases they are formed as homodimers or heterodimers that assemble 
into a full structure. The ABC genes are divided into seven ABC gene subfamilies based on gene-structure 
(half vs. full transporters), order of the different domains, and on sequence homology 181-183. In this thesis, 
only three of the ABC transporter proteins will be described which are all involved in MDR: P-glycoprotein 
(Pgp)/MDR1 (encoded by ABCB1), multidrug-resistance-associated protein 2 (MRP2) (encoded by ABCC2) 
and breast cancer resistance protein (BCRP) (encoded by ABCG2). These transporter proteins are all efflux 
transporters and are expressed in various tissues including the apical surface of enterocytes where they 
mainly serve to restrict the body from exposure to potentially harmful substances (see Figure 4) 178,179,184,185. 
Moreover, only their intestinal function will be described here. Apart from the ABC transporter superfamily, 
other efflux transporter proteins exists e.g., toxin extrusion proteins and transporter proteins that move 
substrates in to the cell – influx transporters – e.g., the organic anion transporters, organic cation 
transporters, oligopeptide transporters, etc., some of which are bidirectional 178. 
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Figure 4. Illustration of the intestinal localization and transport direction of the three ATP-binding cassette transporters 
Pgp/MDR1, MRP2 and BCRP encoded by ABCB1, ABCC2 and ABCG2, respectively. Other transporter proteins are 
shown in orange colour.  
 
1.4.1. Pgp/MDR1 encoded by ABCB1 
Pgp/MDR1 is the most thoroughly studied efflux transporter and was initially discovered via its ability to 
induce MDR in cancer cells after exposure to chemotherapy 186,187. Pgp/MDR1 has a broad substrate 
specificity  and today it is well-known that overexpression of the transporter protein during chemotherapy 
leads to MDR due to positive selection in those tumor cells that are capable of escaping death induced by 
the chemotherapeutic drugs 185,188. However, Pgp/MDR1 is also involved in homeostatic functions, e.g., 
transport of steroids, regulation of chloride channels, transport of cytokines (particularly IL-1β, IL-2, IL-4 and 
IFN-γ), migration of antigen-presenting dendritic cells and T-lymphocytes, and inhibition of apoptosis 183,185. 
The cytokines can either be transported actively by Pgp/MDR1 183,188-190 or modulate expression or activity of 
Pgp/MDR1 191. However, it was shown that Pgp/MDR1 is pivotal for maintenance of healthy mucosal 
immune function in mdr1a-/- mice 192. The mdr1a-/- mice spontaneously developed intestinal inflammation, 
which was reversed with the treatment of antibiotics suggesting that the colitis was developed as a result of a 
defect in the intestinal epithelial barrier. Moreover, Pgp/MDR1 expression is down-regulated in patients with 
UC 193-195 and in endotoxin-induced inflammation in rats 196. Genetic variation in ABCB1 is associated with 
disease distribution 197 and susceptibility to UC 197-199. In line with this, low ABCB1 gene and mRNA 
expression has been found in CRC tissue 124,200 indicating that low protein level of Pgp/MDR1 is an early 
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event in inflammation-related carcinogenesis of CRC which could be due to an impaired ability to protect the 
mucosal epithelial cells from toxic substances or imbalance in the interaction with inflammatory mediators. 
Several NSAIDs have been shown to either inhibit Pgp/MDR1 expression or activity 201 or function as 
substrates (Pagliarulo et al. 2013). Interestingly, it has been proposed that NSAIDs also may regulate 
Pgp/MDR1 by a different mechanism 201. As mentioned in section 1.3.3., NSAID can also inhibit NF-κB with 
subsequent down-regulation of COX-2.  The ABCB1 promoter contains putative binding sites for NF-κB, 
which is involved in ABCB1 induction 202. Consequently, inhibition of these factors by NSAIDs would result in 
down-regulation of ABCB1 which could lead to increased exposure to toxic substances and/or impairment of 
the mucosal immune defence ultimately leading to cancer. 
Dietary factors may also interact with Pgp/MDR1 modulating the intestinal immune response. In a review 203, 
the author described that numerous food components interact with Pgp/MDR1. Phytochemicals, aminopentol 
– a hydrolysis product of the mycotoxin Fumonisin B1 - flavonoids and Chinese herbs modulate the activity of 
Pgp/MDR1 either by inhibiting the transporter activity or function as a substrate. Moreover, Pgp/MDR1 
expression and activity is modulated by pesticides 204. This is indeed especially relevant in terms of food-
drug interactions, but may also affect the immunological functions and/or carcinogenic potential of Pgp/MDR.  
1.4.2. MRP2 encoded by ABCC2 
MRP2 is an organic anion transporter that participates in drug detoxification by transporting conjugated 
drugs and endogenous metabolites. The most critical function is the transport of bilirubin-glucuronides in the 
canalicular membrane in liver cells. Mutations in ABCC2 lead to Dubin-Johnson syndrome, an autosomal 
recessive disorder characterized by conjugated hyperbilirubinemia 178,179,183. Furthermore, it is involved in 
MDR, hence its name. In the intestine, MRP2 has both excretory and barrier functions since it actively pumps 
back conjugates formed in enterocytes, such as glutathione, glucuronide and sulphate derivatives of dietary 
factors into the intestinal lumen and form a barrier by transporting potentially toxic compounds out of the 
body 179. 
MRP2 is also involved in mucosal immune defence. During an inflammatory attack, e.g., due to invading 
microorganisms, the eicosanoid hepoxilin A3 (HXA3) is formed in epithelial cells. In the apical membrane, 
HXA3 is secreted in to the intestinal lumen to create a chemo-attractant gradient that recruits neutrophils from 
the submucosa to the luminal site of the inflammatory stimulus 205. HXA3 is transported by MRP2 and 
induction of intestinal inflammation up-regulates apical expression of MRP2 206. Additionally, inhibition of 
MRP2 has been shown to reduce inflammation 206 and high mRNA expression of ABCC2 is associated with 
CRC (Andersen et al., in prep.).   
Apart from actively transporting several drugs, MRP2 is also inhibited or modulated by a range of drugs, 
including several NSAIDs 178,179,207,208. Therefore, intake of NSAIDs could influence on the risk of 
inflammation-induced CRC. 
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As earlier mentioned, MRP2 transports conjugated derivates of dietary factors such as flavonoids and 
extracts of grape- and orange juices, but also mycotoxins found in cereal grains, e.g., deoxynivalenol and 
ochratoxin A. Variation in activity or expression of MRP2 could thus have influence on the intestinal exposure 
to these substances.  
1.4.3. BCRP encoded by ABCG2 
BCRP was initially discovered in relation to a multidrug resistance phenotype of a specific human BC cell 
line, MCF-7 209. It has broad substrate specificity, consistent with being a multidrug efflux pump. BCRP is 
also involved in physiological processes, such as uric acid excretion, protection of the fetus, export of 
nutrients into milk, regulation of uptake of substrates from the gastrointestinal tract, and transport of 
substrates across the endothelium of veins and capillaries 178,210,211.  
Decreased mRNA expression of BCRP levels have been found in tissue from patients with UC compared to 
healthy controls 193. Furthermore, the BCRP mRNA levels were inversely associated with the pro-
inflammatory cytokine IL-6, indicating that the cytokine modulates BCRP expression. Indeed, several 
cytokines have been found to modulate BCRP expression and activity in different cell lines other than colon 
cells 210,212-214. However, a down-regulation of BCRP has also been illustrated in CRC tissue 215,(Andersen et al., in 
prep.) indicating a role for BCRP in inflammation-induced CRC. 
Several dietary components and carcinogens are either transported by BCRP or modulate the activity or 
expression of the transporter protein. Numerous flavonoids are known to modulate BCRP or function as 
substrate 178,184,203. BCRP also protects the body by actively transport dietary carcinogens such as 
mycotoxins 184 including the potent Aflatoxin B1 216, polycyclic aromatic hydrocarbons (PAHs) 217 and 
heterocyclic amines (HCAs) 216 including 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIPs) 218,219 
which is one of the most abundant HCAs formed during cooking of meat at high temperatures (which will be 
further described in section 1.5.1.).  
Thus, genetically determined differences in the expression and activity of the ABC transporters may have 
impact on the ability to restrict the body from exposure to dietary carcinogens and on the risk of developing 
inflammation-induced CRC. Dietary factors and NSAID use may interact with these transporters revealing 
important pathways in colorectal carcinogenesis. 
1.5. Dietary and life style factors 
In this section, the dietary and life style factors examined in this PhD thesis will be described, except for 
NSAID use and alcohol consumption, which are described separately in other sections. In Table 1, the 
modifiable dietary and life style factors that the World Cancer Research Fund (WCRF) in collaboration with 
the American Institute for Cancer Research (AICR), has found as having either convincing, probable or 
limited evidence as risk factors for CRC, BC or PC, respectively, are presented 220.  
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Table 1. Modifiable dietary and lifestyle factors according to the WCRF/AICR. 
Dietary and life style factors and CRC 
 DECREASES RISK INCREASES RISK 
Convincing Physical activity 
Dietary fibre 
NSAID use 
HRT (women) 
Red meata 
Processed meatb 
Alcohol consumption (men) 
Body/abdominal fatness 
Smoking 
Probable Garlic 
Milk 
Calcium 
Alcohol consumption (women) 
Limited/suggestive Non-starchy vegetables 
Fruits 
Vitamin D 
Iron 
Cheese  
Animal fat 
Sugar 
Limited/no conclusion Fish; glycaemic index; folate; vitamin C; vitamin E; selenium; low fat; dietary pattern 
Dietary and life style factors and BC (premenopausal) 
 DECREASES RISK INCREASES RISK 
Convincing Lactation Alcohol consumption 
Probable Body fatness  
Limited/suggestive Physical activity  
Limited/no conclusion Dietary fibre; vegetables and fruits; soya and soya products; meat; fish; milk and dairy products; total fat; 
folate; vitamin D; calcium; glycaemic index; dietary patterns; abdominal fatness 
Dietary and life style factors and BC (postmenopausal) 
 DECREASES RISK INCREASES RISK 
Convincing Lactation Alcohol consumption 
Body fatness 
Probable Physical activity Abdominal fatness 
Adult weight gain 
Limited/suggestive  Total fat 
Limited/no conclusion Dietary fibre; vegetables and fruits; soya and soya products; meat; fish; milk and dairy products; folate; 
vitamin D; calcium; selenium; glycaemic index; dietary patterns; energy intake 
Dietary and life style factors and PC 
 DECREASES RISK INCREASES RISK 
Convincing No factor identified No factor identified 
Probable Lycopene 
Selenium 
Calcium 
 
Limited/suggestive Leguminous fruits 
Vitamin E 
α-tocopherol 
Processed meat 
Milk and dairy products 
Limited/no conclusion Cereals (grains) and their products; dietary fibre; potatoes; non-starchy vegetables; fruits; meat; poultry; 
fish; eggs; total fat; plant oils; sugar (sucrose); sugary foods and drinks; coffee; tea; alcohol; carbohydrate; 
protein; vitamin A; retinol; thiamine; riboflavin; niacin; vitamin C; vitamin D; γ-tocopherol; vitamin 
supplements; iron; phosphorous; zinc; other carotenoids; physical activity; energy expendure; vegetarian 
diets; body fatness; abdominal fatness; energy intake 
Since breast cancer mostly is hormone related, and the factors that modify risk of this cancer when diagnosed pre-menopausally and 
when diagnosed post-menopausally (much more common) are not the same, these risk factors are illustrated separately. Based on the 
continuous update of the WCRF/AICR reports on diet and cancer 220. 
a The term ‘red meat’ refers to beef, pork, lamb, and goat . 
b The term ‘processed meat’ refers to meats preserved by smoking, curing, or salting, or addition of chemical preservatives. 
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For CRC, dietary factors are considered as having particularly important roles in the carcinogenesis 12,13, 
whereas factors that are related to increased exposure to female sex-hormones  and alcohol consumption 
are of more importance for BC 221,222. However, for PC, no convincing risk factors have been established, 
except for age, ethnicity and family history of PC 4,5.  
Not all dietary and life style factors that are associated with risk of the three studied cancer types will be 
examined in this PhD thesis. They will, though, be included as variables in the analyses whenever relevant 
e.g., body mass index (BMI), physical activity, hormone replacement therapy (HRT), educational level, 
number of births and age at first birth. Therefore, most of the risk factors described in this section are related 
to CRC and will also mostly be described in relation to colorectal carcinogenesis. 
1.5.1. Red and processed meat 
Even though the WCRF/AICR panel have determined that red and processed meat is convincingly a cause 
of CRC, the underlying mechanism is still not clear and several mechanism have been proposed which are 
either associated with specific components in the red meat or with toxic compounds generated during 
processing or cooking of the meat. ‘Processing’ is the methods used to preserve the meat e.g., smoking, 
curing (adding salt and other additives) and drying; whereas ‘cooking’ is the household preparation of meat, 
but cooking can also be part of the preservation process.   
Heme is the iron-porphyrin pigment of red meat and the concentration of heme pigments is proportional to 
the red color 223. Heme has been shown to induce hyperproliferation and hyperplasia of mucosal epithelium, 
induce lipid peroxidation of fecal water and to catalyze endogenous N-nitrosation, which increases nitrite and 
N-Nitroso compound (NOC) formation (see below) and the activation of HCAs 224,225. Heme-oxygenase 1 
(HO-1, encoded by HMOX1) is the inducible, rate-limiting enzyme converting heme to ferrous iron, carbon 
monoxide (CO) and biliverdin which is subsequently converted to bilirubin. HO-1 activity is induced during 
cellular oxidative stress, where the heme products, CO and bilirubin, exerts cytoprotective effects. 
Furthermore, CO inhibits pro-inflammatory cytokines including TNF-α, IL-1β, IL-2, IL-6, IFN-γ and COX-2, 
and stimulates the anti-inflammatory cytokine IL-10. However, HO-1 activity also produces free ferrous iron 
which produces ROS, including H2O2, which again induces genetic mutations and expression of many 
cytokines e.g., IL-6, IL-8, TNFα, NF-κB, leading to increased cytotoxicity and stimulation of an inflammatory 
response 12,226. Thus, genetic variations in HMOX1 may alter the risk of CRC among people with high intake 
of red meat. 
When red meat is cooked at high temperatures e.g., frying, broiling or barbequing, HCAs are generated 
when amino acids react with creatinine. PAHs, on the other hand, are produced from incomplete combustion 
of organic compounds from cooked, smoked and barbequed meat. Many of the HCAs and PAHs are 
carcinogenic and/or mutagenic and may cause CRC 224. As described in section 1.4.3., BCRP transports 
several HCAs and PAHs, and a high intake of red and processed meat in combination with inherent 
variations in ABCG2 may have impact on the risk of CRC.   
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NOCs are alkylating agents that are capable of reacting with DNA leading to mutagenic and genotoxic 
effects 227. Humans are exposed to NOCs from exogenous as well as endogenous sources. NOCs can be 
formed via nitrosation of organic compounds in meat via nitrite, which is added to meat during curing 
223,228,229. NOCs are also generated from fermentation processes of meat proteins by the microbiotic bacteria 
230. Endogenous NOC production has been shown to be increased in red, but not white meat (poultry), which 
could also explain why only intake of red, not white, meat is associated with CRC. Additionally, a diet high in 
red meat may alter the gut microbiota towards a more harmful composition with species generating 
carcinogenic metabolites 223. Indeed, microbiota composition is different in people from the Western world 
compared to people from low-income countries, which have very low CRC rates 223. A Western diet is 
typically composed of a high protein and fat content, and could thus explain the association between meat 
intake and CRC risk 231,232. The modification in gut microbiota composition caused by red meat consumption 
may also modulate the mucosal immune response 233. In fact, the mucosal microbiota has been shown to be 
necessary for development of colitis 223. Therefore, intake of red meat may indirectly interact with modulators 
of the mucosal immune system via impact on gut bacteria, i.e., TLR4 and NF-κB in relation to inflammation-
induced CRC. 
The toxic compounds associated with red and processed meat intake mentioned above, have also been 
implicated in other cancer types, such as BC and PC 234-237. However, in this PhD thesis, these mechanisms 
will not be examined. 
1.5.2. Dietary fibre, cereals, fruits and vegetables 
Dietary fibre is the indigestible part of food derived from plants and consists of polysaccharides, 
oligosaccharides, lignin, and associated plant substances. Insoluble fibre has bulky actions, which reduce 
fecal transit time and hence the exposure to food carcinogens and some of them are fermented by bacteria 
in the distal colon. Soluble fibre is fermented by bacteria in the proximal colon including the caecum 238. 
Dietary fibre has rather consistently been associated with a reduced risk of CRC 18,239,240. Fermentation of 
dietary fibre and starch provides the colonic epithelium with SCFAs e.g., acetate, propionate, and butyrate. 
SCFAs are used for energy metabolism by colonic epithelial cells and for maintenance of normal colonic 
function 238,241. Butyrate is the major energy source for colonic mucosa and is important for colonic integrity 
242, it inhibits growth of cancer cells in vitro 243,244 and has anti-inflammatory properties mainly by the 
inhibition of NF-κB 245. In addition, a polymorphism in the anti-inflammatory gene IL10 interacts with fibre 
intake so that only wild type carriers have decreased risk of CRC 246.  
Whole grains, which are the natural form of cereals, are a major source of dietary fibre and contain germ, 
endosperm, and bran, in contrast with refined grains that only contain the endosperm, which mostly consists 
of starch. The germ and bran contain several nutrients e.g., vitamins, minerals, and phytochemicals, which 
are removed during the refining process. These nutrients have antioxidant properties and have been linked 
to CRC prevention 18,247. However, as mentioned in section 1.4., many cereals also contain high amounts of 
toxic and carcinogenic mycotoxins 248, which could interact with the ABC transporters. 
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Fruits and vegetables are also sources of dietary fibre with potentially anticancer effects. However, when the 
dietary fibre intake is stratified by source, only those ingested from cereals are protective against CRC 18. 
This may explain the lack of consistent evidence for a protective effect against CRC for fruits and 
vegetables. On the other hand, both fruits and vegetables contain several bioactive components with 
anticancer effects, such as flavonoids, β-carotene and lycopene 249,250, and it has been shown that genetic 
variations in IL10 and COX-2 interact with fruits and vegetables further decreasing the risk of CRC 246. 
Flavonoids are phytochemicals that have been shown to possess antioxidant, antimutagenic, antibacterial, 
antiangiogenic and anti-inflammatory effects in both in vitro and in vivo studies, including the ability to inhibit 
COX-2 activity 249. As described in section 1.4., they are substrates for and modulate ABC transporters and 
may therefore interact with genetic variations in these genes. 
1.5.3. Fish 
A diet high in fish intake is a source of Omega 3 (n-3) polyunsaturated fatty acids (PUFAs) which in 
experimental studies have been shown to reduce IBD activity through inhibition of COX-2 expression and 
activity, inhibition of cytokine production, improvement of epithelial barrier function and mucosal wound 
healing 251,252. However, observational studies do not support the evidence of a chemo-protective effect of n-
3 PUFAs on CRC risk 253. Correspondingly, a protective effect of n-3 PUFA against PC has been suggested, 
but the evidence is also inconsistent 254. Instead, there is evidence that the ratio between n-3 PUFA and the 
pro-inflammatory n-6 PUFA, which is abundant in meat, is of more importance, rather than the individual 
amount of each type of PUFA in the inflammation-induced cancer process. A Western diet, which is 
associated with high risk of CRC, typically consists of an n-6/n-3 PUFA ratio of 15:1, whereas the diet of our 
ancestors contains nearly equimolar ratios 251,252,255. Alternative suggestions include the relatively high 
selenium or vitamin D content of fish as being the chemo-protective factors associated with fish intake 256,257. 
Fish intake has been shown to interact with an IL10 polymorphism so that only wild type carriers have 
decreased risk of CRC 246, and may also interact with other inflammatory mediators in relation to CRC.  
1.5.4. Smoking 
Tobacco contains several carcinogens e.g., HCAs, PAHs and NOCs 12 which are highly carcinogenic as 
described above. In addition, tobacco-specific nitrosamines bind to nicotinic acetylcholine receptors, which 
results in the production of ROS leading to oxidative stress. The oxidative stress activates the NF-κB and 
COX-2 inflammatory pathways 258. Moreover, nicotine activates β-adrenoreceptors, which triggers 
inflammatory and metastatic signalling through the COX-2, PGE2, and VEGF pathways 259. Cigarette 
smoking is associated with increased risk of BC 8,260, PC 261,262 and CRC 12,263 and may interact with genetic 
variations in inflammatory mediators and/or ABC transporter genes. 
1.6. Alcohol consumption 
The term alcohol refers to ethanol in the present thesis, which is the type of alcohol used in alcoholic 
beverages. Chronic alcohol consumption is associated with systemic inflammation characterized by high 
circulating levels of pro-inflammatory cytokines 264 possibly mediated by gut microbiota-derived LPS 265 or 
through the production of ROS and NO during ethanol metabolism 266. Intake of alcohol is associated with 
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increased risk of CRC 11,12,267 and BC 11,268, but not PC 269. Overall, alcohol consumption is estimated to 
contribute to 3.6% of all cancer incidences; however, among women, 60% of cancers that are attributable to 
alcohol occur in the breast 270, indicating that the breast tissue is particularly sensitive to alcohol exposure. 
The underlying mechanism explaining the association between cancer and alcohol consumption is not fully 
understood and may differ by target organ. Apart from the evidence that intake of alcohol is associated with 
a systemic inflammatory state, which may induce cancer; other mechanisms have been proposed 10,271. The 
primary ethanol metabolite, acetaldehyde, may cause DNA damage 272. However, the evidence is weak 10 
and genetic variation in the aldehyde dehydrogenase gene ADH1C, which causes phenotypic slow ethanol 
oxidation, is associated with high risk of BC, suggesting that ethanol rather than acetaldehyde is 
carcinogenic 273. Alcohol may also acts as a solvent, enhancing penetration of tobacco or dietary 
carcinogens through mucosal cells 274. Indeed, smoking is an important confounder for alcohol-related 
cancer risk 10,271. Moreover, excessive alcohol consumption may lead to deficiency in essential nutrients such 
as folate, vitamin B12 and B6 10,275. The mechanisms discussed above are mostly involved in the 
carcinogenesis of oral cavity, pharynx, larynx, esophagus, colorectal and liver 10,271. For BC, most evidence 
point to a mechanisms involving disruption in steroidogenesis since alcohol consumption is associated with 
increased level of circulating female sex-hormones 276-282. Steroidogenesis is illustrated in Figure 5. Alcohol 
consumption is more strongly associated to hormone-sensitive BCs than hormone-insensitive subtypes 283,284 
and the evidence is strongest among postmenopausal women 10,271. In addition, alcohol is an inhibitor of 
PPARγ activity 285, which leads us to the hypothesis of PPARγ being an important modulator of alcohol-
related BC among postmenopausal women, which will be discussed in the next section. The mechanisms 
explaining the link between alcohol intake and CRC will not be further examined in this PhD thesis. 
1.6.1. Alcohol-related BC among postmenopausal women – a mechanism involving PPARγ 
Estrogens are female steroid hormones controlling uterine and mammary gland development and function, 
external genitalia structure, secondary sex characteristics, sexual behaviour and menstrual cycle. The 
naturally occurring estrogens are estrone, estradiol and estriol, where estradiol is the predominant estrogen 
during reproductive years. During menopause, estrone replaces estradiol as the primary estrogen and 
throughout pregnancy estriol is the predominant circulating estrogen 286-288. Estrogens play a central role in 
the cellular proliferation of both normal and neoplastic breast epithelium 268. Approximately 60% of 
premenopausal and 75% of postmenopausal women with BC have estrogen-dependent carcinomas 289 and 
estradiol is considered the main determinant of proliferation of estrogen-dependent BC cells 290. Moreover, 
estradiol is considered a carcinogen by the International Agency for Research on Cancer 291. Estrogens exert 
their cellular actions by binding to the estrogen receptor (ER). ERs are present in malignant breast epithelial 
tissue at significant higher amounts than in normal breast epithelial cells 292. This binding induces an 
activation of transcription of proliferative signalling and cell cycle progression genes 293, which may induce 
DNA damage 294. Furthermore, BC is strongly associated with prolonged exposure of the breast epithelium to 
estrogens, i.e., early age at menarche, late age at menopause, nulliparity and old age at first birth 222,295, 
which is supported by several observational studies showing a positive correlation between female sex-
hormone levels and risk of BC in postmenopausal women 296-299. Conversely, high level of sex hormone-
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binding globulin (SHBG) is associated with decreased risk due to reduced circulating free estrogen levels 
297,299. Use of HRT is also considered a risk factor for BC 300-302; and has an additive effect when combined 
with intake of alcohol. Thus, women who drink alcohol and use HRT have higher estradiol concentrations 
than expected from use of HRT alone 303. 
 
 
Figure 5. Steroidogenesis. 
 
Both controlled experimental and observational human studies demonstrate that intake of alcohol is 
associated with increased level of female sex-hormone blood levels in pre- and postmenopausal women 276-
282, which could explain the link between BC and alcohol consumption. However, the underlying mechanism 
is not fully understood.  One explanation could be through a disruption in hepatic steroid catabolism. In the 
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liver, the 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) enzyme degrades estradiol into estrone and 
testosterone into androstenedione in an oxidative catalyzed reaction 304 – which is the opposite compared to 
steroidogenesis (see Figure 5). Alcohol consumption increases the nicotinamide adenine dinucleotide 
hydroxide (NADH) to nicotinamide adenine dinucleotide (NAD+) ratio, which leads to a shift in the 17β-HSD2 
catalyzed reaction in favour of reduction of androstendione to testosterone and estrone to estradiol leading 
to accumulation of testosterone and estradiol along with decrease in androstendione and estrone levels 305-
307. Alcohol also stimulates the hypothalamic–pituitary–adrenal axis which could lead to secretion of 
androstenedione and dehydroepiandrosterone 281 and subsequently increase in circulating estrogens. 
Another possible mechanism for the increased sex hormone levels may be through an increase in 
aromatase activity induced by alcohol 308. Aromatase (encoded by CYP19A1) is the rate-limiting enzyme that 
catalyzes the conversion of androstenedione and testosterone to estrone and estradiol, respectively. In 
postmenopausal women, adipose tissue is the primary site for estrogen synthesis catalyzed by aromatase, 
when ovarian production has ceased 309. Indeed, alcohol intake has been demonstrated to increase 
aromatisation 308,310 and hence estrogen levels. Among postmenopausal women, obesity is also a risk factor 
for BC 311 due to increased conversion of androgenic precursors to estrogens. Therefore, several factors 
point to aromatase as a central mediator in alcohol-related postmenopausal breast carcinogenesis through 
increased biosynthesis of estrogens. 
The expression of CYP19A1 is regulated differently in different tissues with hormonally controlled promoters 
using alternative splicing of exon I 288,312. Thus, regulation of aromatase expression varies by tissue site e.g., 
the human ovary synthesizes primarily estradiol, whereas the placenta synthesizes estriol and adipocytes 
synthesize estrone. In the adipose tissue, the major source of substrate is circulating androstenedione 
produced by the adrenal cortex. The aromatase-dependent conversion of androgenic precursors in adipose 
tissue is the main source of estrogens in postmenopausal women. Several mechanisms may be responsible 
for aromatase overexpression in BC: (1) Alteration in cellular composition leads to increase in aromatase-
expressing cell types using different promoters. (2) Favouring of the binding of transcriptional enhancers 
instead of inhibitors due to cellular environmental alterations, which results in increased transcriptional 
activity. (3) Mutations, which cause the aromatase coding region to lie adjacent to constitutively active 
promoters that normally transcribe other genes, resulting in excessive estrogen production. Indeed, 
aromatase inhibitors have proven effective in treating BC supporting the role of aromatase as a key factor in 
carcinogenesis 288,312. 
Several polymorphisms in estrogen metabolizing enzymes have been associated with BC risk 222. Among 
postmenopausal women, aromatase has major impact on endogenous steroid production and, thus, variation 
in CYP19A1 may be of great importance in relation to postmenopausal BC risk. Several studies have 
demonstrated that genetic variation in CYP19A1 is associated with differences in circulating estrogen levels 
313-316. However, these differences in hormone levels do not seem to contribute detectably to BC risk 317-319. If 
alcohol causes BC by increasing aromatase activity it seems reasonably that variations in CYP19A1 that are 
associated with estrogen levels may interact with alcohol intake in relation to BC risk. 
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So, how does alcohol disrupt aromatisation? PPARγ ligands are inhibitors of CYP19A1 via the promotors 
used in both normal 320 and malignant 321 breast adipose stromal cells. A common functional polymorphism 
in PPARG results in a proline to alanine substitution at codon 12 (Pro12Ala) located in Exon B. Exon B is only 
present in the PPARγ2 isoform which is primarily located in adipose tissue  - which was the main site of 
estrogen production in postmenopausal women 163. The variant Ala-allele has a twofold lower affinity to 
PPREs compared to the Pro isoform, and a reduced ability to trans-activate target genes 322. In a Danish 
prospective cohort study, carriers of the variant Ala-allele of the PPARG Pro12Ala polymorphism had a 33% 
lower risk of BC compared to homozygous wild type carriers 323. Consumption of 10 g alcohol per day was 
associated with a 20% increased risk of BC among homozygous Pro-carriers (with a high PPARγ activity), 
whereas alcohol consumption was not associated with BC risk among variant Ala-allele carriers (with a low 
PPARγ activity) 323. Two other studies have investigated the effect of PPARG Pro12Ala in relation to BC with 
null results, but they did not examine for interaction with alcohol 324,325. Alcohol consumption is high in the 
Danish cohort (16.9-18.6 g/day for participants from Aarhus and Copenhagen, respectively) 326, whereas the 
other two cohort studies have low intake of alcohol of 5.8 g/day 327 and 4.7 g/day 328, respectively. This 
indicates that alcohol may modify BC risk through a mechanism involving a specific activation of PPARγ2 
that differs between the two polymorphic forms of PPARγ2. Indeed, perosixome proliferator-activated 
receptor gamma coactivator 1-alpha (PGC-1α), a transcriptional co-activator encoded by PPARGC1A, binds 
to the PPARγ/RXR complex which results in inhibition of transcription of CYP19A1. This complex sequesters 
PGC-1α from forming a complex with liver receptor homolog-1 (LRH-1) 312, which is a specific transcriptional 
activator of aromatase gene expression in human breast adipocytes 329. The PPARγ 12Ala protein is 
defective in the interaction with PGC-1α 330 and ethanol has been shown to inhibit the PPARγ/PGC-1α 
complex in a transient transfection assay using the wild type PPARG Pro-allele, whereas the Ala-allele was 
unaffected due to the defective interaction between PPARG 12Ala and PGC-1α 285. Thus, alcohol may cause 
BC in a PPARγ and PGC-1α dependent manner in postmenopausal women where ethanol abolishes a 
PPARγ-dependent inhibition of adipocyte aromatase expression, due to an inhibition of formation of the 
PPARγ/PGC-1α complex as illustrated in Figure 6. Moreover, functional polymorphisms in PPARGC1A 
interact negatively with PPARG Pro12Ala in relation to alcohol-related BC 285, confirming that the two proteins 
are part of the same pathway linking alcohol intake with BC. Investigating gene-gene interactions between 
functional polymorphisms in PPARG, PPARGCIA and CYP19A1 with BC risk and female sex-hormone level 
would further enlighten this mechanism. 
In addition, NSAID use has been shown to interact with PPARG Pro12Ala in relation to alcohol-related BC so 
that the protective effect of PPARG 12Ala is absent among NSAID users 323. Thus, use of NSAIDs, which are 
known to stimulate PPARγ 175,176, may also interact with PPARG Pro12Ala in relation to alcohol-induced 
increase in female sex-hormone synthesis resulting in differences in circulating estrogen levels. 
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Figure 6. A proposed mechanism for alcohol-related breast cancer (BC). In absence of alcohol, peroxisome proliferator-
activated receptor gamma (PPARγ) binds to perosixome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC-1α) and inhibits transcription of CYP19A1, by sequestering PGC-1α from forming a complex with liver receptor 
homolog-1 (LRH-1) – the co-activator of aromatase transcription. When alcohol is consumed in PPARG Pro12Ala wild 
type carriers, ethanol inhibits the PPARγ/PGC-1α complex resulting in binding of PGC-1α to LRH-1 which activates 
transcription of aromatase. This would increase the risk of BC due to increased level of circulating estrogens. Among 
PPARG Pro12Ala variant carriers, alcohol does not affect transcription of aromatase due to the defective interaction 
between PPARγ 12Ala and PGC-1α. EtOH: ethanol; RXR: Retinoic X-receptor. 
 
1.6.1.1. Occupational exposure to other organic solvents in relation to BC and PPARG Pro12Ala 
As stated above, alcohol consumption is an important isolated risk factor for development of BC, and PPARγ 
may be a central mediator in the process of carcinogenesis. However, the population is also exposed to 
other organic solvents besides alcohol that may act via a similar mechanism. Several occupational studies 
have linked exposure of different chemicals, including organic solvents, to BC 331-335. The largest study to 
date encompasses 15 million people aged 30-64 years with 373,361 cases of incident female BC and shows 
major variation in BC risk related to occupation 332. Differences in birth pattern, education and physical 
activity do not explain these differences in risks. However, some of the variation may be explained by the 
fact that some types of occupations are related to high alcohol consumption, such as among journalists, 
musicians and hotel and restaurant workers. However, the consumption of alcohol should be considerably 
higher in a certain occupational field compared to the average consumption among all employees in a 
population in order for this factor to contribute significantly to an increased risk. Consequently, the 
differences in risk of BC point to exposure in the working environment 331. Consistent with this, working with 
organic solvents for just one year was associated with a 20-70% increased risk of BC in another study 335. 
The risk estimates tended to increase with increasing duration of employment. All analyses were adjusted for 
social class, age at first child, and number of children emphasising the significance of work-related exposure 
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to organic solvents as a risk factor for BC 335. Most mammary carcinogens among organic solvents are 
lipophilic 336-338. They are hypothesised to cause cancer due to their ability to reside in the adipose tissue 
surrounding the breast parenchyma and lobules where the solvents and their bioactivated metabolites may 
exert harmful local effects 336. However, hydrophilic organic solvents may act differently by inhibition of 
PPARγ leading to increased aromatisation followed by increased levels of circulating estrogens. Testing 
hydrophilic organic solvents with known occupational exposure for inhibition of PPARγ in a cell-based 
screening assay would easily identify solvents with breast carcinogenic potential. 
  
26 
 
1.7. List of references 
1. Engholm G, Ferlay J, Christensen N, et al. NORDCAN: Cancer incidence, mortality, prevalence and 
survival in the nordic countries, version 5.1. . Updated 2012. 
2. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008;359(20):2143-2153. 
3. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of 
cancer--analyses of cohorts of twins from sweden, denmark, and finland. N Engl J Med. 2000;343(2):78-85. 
4. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006;11(1093-4715):1388-
1413. 
5. Patel AR, Klein EA. Risk factors for prostate cancer. Nat Clin Pract Urol. 2009;6(1743-4289; 2):87-95. 
6. Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns and breast cancer risk in asian-american 
women. J Natl Cancer Inst. 1993;85(22):1819-1827. 
7. Deapen D, Liu L, Perkins C, Bernstein L, Ross RK. Rapidly rising breast cancer incidence rates among 
asian-american women. Int J Cancer. 2002;99(5):747-750. 
8. Song M, Lee KM, Kang D. Breast cancer prevention based on gene-environment interaction. Mol 
Carcinog. 2011;50(4):280-290. 
9. Singletary KW, Gapstur SM. Alcohol and breast cancer. JAMA: the journal of the American Medical 
Association. 2001;286(17):2143-2151. 
10. Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol. 2006;7(2):149-156. 
11. Pelucchi C, Tramacere I, Boffetta P, Negri E, La VC. Alcohol consumption and cancer risk. Nutr Cancer. 
2011;63(7):983-990. 
12. Durko L, Malecka-Panas E. Lifestyle modifications and colorectal cancer. Curr Colorectal Cancer Rep. 
2014;10:45-54. 
13. Huxley RR, Ansary-Moghaddam A, Clifton P, Czernichow S, Parr CL, Woodward M. The impact of 
dietary and lifestyle risk factors on risk of colorectal cancer: A quantitative overview of the epidemiological 
evidence. Int J Cancer. 2009;125(1):171-180. 
14. Kushi LH, Doyle C, McCullough M, et al. American cancer society guidelines on nutrition and physical 
activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. CA 
Cancer J Clin. 2012;62(1):30-67. 
27 
 
15. Pal S, Bhattacharjee A, Ali A, Mandal NC, Mandal SC, Pal M. Chronic inflammation and cancer: Potential 
chemoprevention through nuclear factor kappa B and p53 mutual antagonism. J Inflamm (Lond). 
2014;11:23-9255-11-23. eCollection 2014. 
16. Aune D, Chan DS, Vieira AR, et al. Red and processed meat intake and risk of colorectal adenomas: A 
systematic review and meta-analysis of epidemiological studies. Cancer Causes Control. 2013;24(4):611-
627. 
17. Ma RW, Chapman K. A systematic review of the effect of diet in prostate cancer prevention and 
treatment. J Hum Nutr Diet. 2009;22(1365-277; 3):187-199. 
18. Aune D, Chan DS, Lau R, et al. Dietary fibre, whole grains, and risk of colorectal cancer: Systematic 
review and dose-response meta-analysis of prospective studies. BMJ. 2011;343:d6617. 
19. Balkwill F, Mantovani A. Inflammation and cancer: Back to virchow? Lancet. 2001;357(0140-6736; 
9255):539-545. 
20. Stein CJ, Colditz GA. Modifiable risk factors for cancer. Br J Cancer. 2004;90(2):299-303. 
21. Clevers H. At the crossroads of inflammation and cancer. Cell. 2004;118(6):671-674. 
22. Yang GY, Taboada S, Liao J. Inflammatory bowel disease: A model of chronic inflammation-induced 
cancer. Methods Mol Biol. 2009;511:193-233. 
23. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(0028-0836; 6917):860-867. 
24. Peddareddigari VG, Wang D, Dubois RN. The tumor microenvironment in colorectal carcinogenesis. 
Cancer Microenviron. 2010;3(1):149-166. 
25. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 
2007;7(1474-175; 4):256-269. 
26. Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of 
acute inflammation. Immunity. 2014;40(3):315-327. 
27. Wang D, DuBois RN. Prostaglandins and cancer. Gut. 2006;55(0017-5749; 1):115-122. 
28. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol. 
1997;39(1054-3589):1-20. 
29. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW,Jr. Aspirin use and risk of fatal cancer. 
Cancer Res. 1993;53(0008-5472; 6):1322-1327. 
30. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: Promise, 
perils and pharmacogenetics. Nat Rev Cancer. 2006;6(1474-175; 2):130-140. 
28 
 
31. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: 
Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94(0027-8874; 4):252-266. 
32. Friis S, Poulsen AH, Sorensen HT, et al. Aspirin and other non-steroidal anti-inflammatory drugs and risk 
of colorectal cancer: A danish cohort study. Cancer Causes Control. 2009;20(5):731-740. 
33. Tinsley HN, Grizzle WE, Abadi A, et al. New NSAID targets and derivatives for colorectal cancer 
chemoprevention. Recent Results Cancer Res. 2013;191:105-120. 
34. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in 
familial adenomatous polyposis. N Engl J Med. 1993;328(18):1313-1316. 
35. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J 
Med. 1995;333(0028-4793; 10):609-614. 
36. Ranger GS. Current concepts in colorectal cancer prevention with cyclooxygenase inhibitors. Anticancer 
Res. 2014;34(11):6277-6282. 
37. Gupta S, Adhami VM, Subbarayan M, et al. Suppression of prostate carcinogenesis by dietary 
supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 
2004;64(0008-5472; 9):3334-3343. 
38. Dandekar DS, Lopez M, Carey RI, Lokeshwar BL. Cyclooxygenase-2 inhibitor celecoxib augments 
chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer 
cells. Int J Cancer. 2005;115(0020-7136; 3):484-492. 
39. Narayanan BA, Narayanan NK, Pttman B, Reddy BS. Adenocarcina of the mouse prostate growth 
inhibition by celecoxib: Downregulation of transcription factors involved in COX-2 inhibition. Prostate. 
2006;66(0270-4137; 3):257-265. 
40. Bieniek J, Childress C, Swatski MD, Yang W. COX-2 inhibitors arrest prostate cancer cell cycle 
progression by down-regulation of kinetochore/centromere proteins. Prostate. 2014;74(10):999-1011. 
41. Garcia Rodriguez LA, Gonzalez-Perez A. Inverse association between nonsteroidal anti-inflammatory 
drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004;13(1055-9965; 4):649-653. 
42. Dasgupta K, Di CD, Ghosn J, Rajan R, Mahmud S, Rahme E. Association between nonsteroidal anti-
inflammatory drugs and prostate cancer occurrence. Cancer J. 2006;12(1528-9117; 2):130-135. 
43. Jacobs EJ, Rodriguez C, Mondul AM, et al. A large cohort study of aspirin and other nonsteroidal anti-
inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst. 2005;97(1460-2105; 13):975-980. 
44. Mahmud SM, Tanguay S, Begin LR, Franco EL, Aprikian AG. Non-steroidal anti-inflammatory drug use 
and prostate cancer in a high-risk population. Eur J Cancer Prev. 2006;15(0959-8278; 2):158-164. 
29 
 
45. Perron L, Bairati I, Moore L, Meyer F. Dosage, duration and timing of nonsteroidal antiinflammatory drug 
use and risk of prostate cancer. Int J Cancer. 2003;106(0020-7136; 3):409-415. 
46. Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer 
progression. Int J Cancer. 1998;77(0020-7136; 4):511-515. 
47. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs 
(NSAIDs): Results of a case-control study. Oncol Rep. 2000;7(1021-335; 1):169-170. 
48. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ. A population-based study of 
daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc. 2002;77(0025-6196; 
3):219-225. 
49. Habel LA, Zhao W, Stanford JL. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in 
the US. Cancer Causes Control. 2002;13(0957-5243; 5):427-434. 
50. Platz EA, Rohrmann S, Pearson JD, et al. Nonsteroidal anti-inflammatory drugs and risk of prostate 
cancer in the baltimore longitudinal study of aging. Cancer Epidemiol Biomarkers Prev. 2005;14(1055-9965; 
2):390-396. 
51. Irani J, Ravery V, Pariente JL, et al. Effect of nonsteroidal anti-inflammatory agents and finasteride on 
prostate cancer risk. J Urol. 2002;168(0022-5347; 5):1985-1988. 
52. Liu X, Plummer SJ, Nock NL, Casey G, Witte JS. Nonsteroidal antiinflammatory drugs and decreased 
risk of advanced prostate cancer: Modification by lymphotoxin alpha. Am J Epidemiol. 2006;164(0002-9262; 
10):984-989. 
53. Veitonmaki T, Murtola TJ, Maattanen L, et al. Prostate cancer risk and nonsteroidal antiinflammatory 
drug use in the finnish prostate cancer screening trial. Br J Cancer. 2014;111(7):1421-1431. 
54. Bosetti C, Rosato V, Gallus S, La Vecchia C. Aspirin and prostate cancer prevention. Recent Results 
Cancer Res. 2014;202:93-100. 
55. Liu Y, Chen JQ, Xie L, et al. Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate 
cancer incidence and mortality: A systematic review and meta-analysis. BMC Med. 2014;12:55-7015-12-55. 
56. Wang X, Lin YW, Wu J, et al. Meta-analysis of nonsteroidal anti-inflammatory drug intake and prostate 
cancer risk. World J Surg Oncol. 2014;12:304-7819-12-304. 
57. Gonda TA, Tu S, Wang TC. Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell 
Cycle. 2009;8(13):2005-2013. 
58. Medvedev AE. Toll-like receptor polymorphisms, inflammatory and infectious diseases, allergies, and 
cancer. J Interferon Cytokine Res. 2013;33(9):467-484. 
30 
 
59. Kutikhin AG. Association of polymorphisms in TLR genes and in genes of the toll-like receptor signaling 
pathway with cancer risk. Hum Immunol. 2011;72(11):1095-1116. 
60. Kutikhin AG, Yuzhalin AE, Volkov AN, Zhivotovskiy AS, Brusina EB. Correlation between genetic 
polymorphisms within IL-1B and TLR4 genes and cancer risk in a russian population: A case-control study. 
Tumour Biol. 2014. 
61. Kutikhin AG. Impact of toll-like receptor 4 polymorphisms on risk of cancer. Hum Immunol. 
2011;72(2):193-206. 
62. Persson C, Canedo P, Machado JC, El-Omar EM, Forman D. Polymorphisms in inflammatory response 
genes and their association with gastric cancer: A HuGE systematic review and meta-analyses. Am J 
Epidemiol. 2011;173(3):259-270. 
63. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia 
in ulcerative colitis. Gastroenterology. 2004;126(2):451-459. 
64. Andersen V, Halfvarson J, Vogel U. Colorectal cancer in patients with inflammatory bowel disease: Can 
we predict risk? World J Gastroenterol. 2012;18(31):4091-4094. 
65. Seril DN, Liao J, Yang GY, Yang CS. Oxidative stress and ulcerative colitis-associated carcinogenesis: 
Studies in humans and animal models. Carcinogenesis. 2003;24(3):353-362. 
66. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. 
Gut. 2001;48(4):526-535. 
67. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New 
Biol. 1971;231(0090-0028; 25):232-235. 
68. Claria J. Cyclooxygenase-2 biology. Curr Pharm Des. 2003;9(1381-6128; 27):2177-2190. 
69. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: Structural, cellular, and molecular biology. Annu 
Rev Biochem. 2000;69(0066-4154):145-182. 
70. Smith WL, Song I. The enzymology of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins 
Other Lipid Mediat. 2002;68-69(1098-8823):115-128. 
71. Singh P, Mittal A. Current status of COX-2 inhibitors. Mini Rev Med Chem. 2008;8(1389-5575; 1):73-90. 
72. Simmons DL, Levy DB, Yannoni Y, Erikson RL. Identification of a phorbol ester-repressible v-src-
inducible gene. Proc Natl Acad Sci U S A. 1989;86(0027-8424; 4):1178-1182. 
73. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-
inducible mRNA from swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. 
J Biol Chem. 1991;266(0021-9258; 20):12866-12872. 
31 
 
74. Vogel LK, Saebo M, Hoyer H, et al. Intestinal PTGS2 mRNA levels, PTGS2 gene polymorphisms, and 
colorectal carcinogenesis. PLoS One. 2014;9(8):e105254. 
75. Fosslien E. Review: Molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin 
Lab Sci. 2001;31(0091-7370; 4):325-348. 
76. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in apc delta716 knockout 
mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996;87(0092-8674; 5):803-809. 
77. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: 
Progress and perspective. Cancer Lett. 2004;215(0304-3835; 1):1-20. 
78. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in 
human prostate adenocarcinoma. Prostate. 2000;42(0270-4137; 1):73-78. 
79. Kirschenbaum A, Klausner AP, Lee R, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in 
the human prostate. Urology. 2000;56(1527-9995; 4):671-676. 
80. Kang YJ, Mbonye UR, DeLong CJ, Wada M, Smith WL. Regulation of intracellular cyclooxygenase levels 
by gene transcription and protein degradation. Prog Lipid Res. 2007;46(0163-7827; 2):108-125. 
81. Ramsay RG, Friend A, Vizantios Y, et al. Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-
inflammatory drug target, is regulated by c-MYB. Cancer Res. 2000;60(0008-5472; 7):1805-1809. 
82. Newton R, Seybold J, Liu SF, Barnes PJ. Alternate COX-2 transcripts are differentially regulated: 
Implications for post-transcriptional control. Biochem Biophys Res Commun. 1997;234(0006-291; 1):85-89. 
83. Kosaka T, Miyata A, Ihara H, et al. Characterization of the human gene (PTGS2) encoding 
prostaglandin-endoperoxide synthase 2. Eur J Biochem. 1994;221(0014-2956; 3):889-897. 
84. Zhang X, Miao X, Tan W, et al. Identification of functional genetic variants in cyclooxygenase-2 and their 
association with risk of esophageal cancer. Gastroenterology. 2005;129(0016-5085; 2):565-576. 
85. Tazawa R, Xu XM, Wu KK, Wang LH. Characterization of the genomic structure, chromosomal location 
and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun. 1994;203(0006-
291; 1):190-199. 
86. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM. Post-transcriptional control of 
cyclooxygenase-2 gene expression. the role of the 3'-untranslated region. J Biol Chem. 2000;275(0021-
9258; 16):11750-11757. 
87. Chen CY, Shyu AB. Selective degradation of early-response-gene mRNAs: Functional analyses of 
sequence features of the AU-rich elements. Mol Cell Biol. 1994;14(0270-7306; 12):8471-8482. 
32 
 
88. Cok SJ, Morrison AR. The 3'-untranslated region of murine cyclooxygenase-2 contains multiple 
regulatory elements that alter message stability and translational efficiency. J Biol Chem. 2001;276(0021-
9258; 25):23179-23185. 
89. Tanabe T, Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. 
Prostaglandins Other Lipid Mediat. 2002;68-69(1098-8823):95-114. 
90. Inoue H, Tanabe T, Umesono K. Feedback control of cyclooxygenase-2 expression through 
PPARgamma. J Biol Chem. 2000;275(0021-9258; 36):28028-28032. 
91. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: 
Inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270(0036-8075; 
5234):286-290. 
92. Subbaramaiah K, Lin DT, Hart JC, Dannenberg AJ. Peroxisome proliferator-activated receptor gamma 
ligands suppress the transcriptional activation of cyclooxygenase-2. evidence for involvement of activator 
protein-1 and CREB-binding protein/p300. J Biol Chem. 2001;276(0021-9258; 15):12440-12448. 
93. Gou Q, Liu CH, Ben-Av P, Hla T. Dissociation of basal turnover and cytokine-induced transcript 
stabilization of the human cyclooxygenase-2 mRNA by mutagenesis of the 3'-untranslated region. Biochem 
Biophys Res Commun. 1998;242(0006-291; 3):508-512. 
94. DuBois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J. 
1998;12(0892-6638; 12):1063-1073. 
95. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the 
intracellular activation of the epidermal growth factor receptor. J Biol Chem. 2003;278(0021-9258; 
37):35451-35457. 
96. Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, Whelan J. Prostaglandin E(2) protects 
intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in apc(min/+) mice. Cancer 
Res. 2002;62(0008-5472; 2):403-408. 
97. Kawamori T, Uchiya N, Sugimura T, Wakabayashi K. Enhancement of colon carcinogenesis by 
prostaglandin E2 administration. Carcinogenesis. 2003;24(0143-3334; 5):985-990. 
98. Wang D, Wang H, Shi Q, et al. Prostaglandin E(2) promotes colorectal adenoma growth via 
transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell. 2004;6(1535-
6108; 3):285-295. 
99. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and bcl-2 
expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998;58(0008-5472; 2):362-366. 
33 
 
100. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of 
colorectal carcinoma cells. J Biol Chem. 2001;276(0021-9258; 21):18075-18081. 
101. Cohen EG, Almahmeed T, Du B, et al. Microsomal prostaglandin E synthase-1 is overexpressed in 
head and neck squamous cell carcinoma. Clin Cancer Res. 2003;9(1078-0432; 9):3425-3430. 
102. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis 
induced by colon cancer cells. Cell. 1998;93(0092-8674; 5):705-716. 
103. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing 
prostaglandin endoperoxide synthase 2. Cell. 1995;83(0092-8674; 3):493-501. 
104. Goodwin JS, Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol. 
1983;3(0271-9142; 4):295-315. 
105. Balch CM, Dougherty PA, Cloud GA, Tilden AB. Prostaglandin E2-mediated suppression of cellular 
immunity in colon cancer patients. Surgery. 1984;95(0039-6060; 1):71-77. 
106. Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent 
regulation of cytokine balance in lymphocytes and macrophages: Up-regulation of interleukin 10 and down-
regulation of interleukin 12 production. Cancer Res. 1998;58(0008-5472; 6):1208-1216. 
107. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by 
altering the balance of IL-10 and IL-12 synthesis. J Immunol. 2000;164(0022-1767; 1):361-370. 
108. Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in 
synovial fibroblasts by prostaglandin E and interleukin-1: A potential mechanism for inflammatory 
angiogenesis. FEBS Lett. 1995;372(0014-5793; 1):83-87. 
109. Jaffe BM, Parker CW, Philpott GW. Immunochemical measurement of prostaglandin or prostaglandin-
like activity from normal and neoplastic cultured tissue. Surg Forum. 1971;22(0071-8041):90-92. 
110. Pradono P, Tazawa R, Maemondo M, et al. Gene transfer of thromboxane A(2) synthase and 
prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res. 
2002;62(0008-5472; 1):63-66. 
111. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and 
epidermal growth factor receptor: Pharmacologic targets for chemoprevention. J Clin Oncol. 2005;23(0732-
183; 2):254-266. 
112. Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxygenase-2: A novel target for cancer 
chemotherapy? J Cancer Res Clin Oncol. 2001;127(0171-5216; 7):411-417. 
34 
 
113. Cha YI, DuBois RN. NSAIDs and cancer prevention: Targets downstream of COX-2. Annu Rev Med. 
2007;58(0066-4219):239-252. 
114. Kelloff GJ, Fay JR, Steele VE, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as 
potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 1996;5(1055-9965; 8):657-666. 
115. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates 
EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat 
Med. 2002;8(1078-8956; 3):289-293. 
116. Crofford LJ. COX-1 and COX-2 tissue expression: Implications and predictions. J Rheumatol Suppl. 
1997;49(0380-0903):15-19. 
117. Beinke S, Ley SC. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J. 
2004;382(Pt 2):393-409. 
118. Inoue J, Gohda J, Akiyama T, Semba K. NF-kappaB activation in development and progression of 
cancer. Cancer Sci. 2007;98(3):268-274. 
119. Prasad S, Ravindran J, Aggarwal BB. NF-kappaB and cancer: How intimate is this relationship. Mol Cell 
Biochem. 2010;336(1-2):25-37. 
120. Balkwill F, Coussens LM. Cancer: An inflammatory link. Nature. 2004;431(7007):405-406. 
121. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin 
Invest. 2007;117(5):1175-1183. 
122. Natarajan V, Komarov AP, Ippolito T, Bonneau K, Chenchik AA, Gudkov AV. Peptides genetically 
selected for NF-kappaB activation cooperate with oncogene ras and model carcinogenic role of 
inflammation. Proc Natl Acad Sci U S A. 2014;111(4):E474-83. 
123. Israel A. The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb Perspect Biol. 
2010;2(3):a000158. 
124. Andersen V, Vogel U, Godiksen S, et al. Low ABCB1 gene expression is an early event in colorectal 
carcinogenesis. PLoS One. 2013;8(8):e72119. 
125. van der Saag PT, Caldenhoven E, van de Stolpe A. Molecular mechanisms of steroid action: A novel 
type of cross-talk between glucocorticoids and NF-kappa B transcription factors. Eur Respir J Suppl. 
1996;22:146s-153s. 
126. Iademarco MF, McQuillan JJ, Rosen GD, Dean DC. Characterization of the promoter for vascular cell 
adhesion molecule-1 (VCAM-1). J Biol Chem. 1992;267(23):16323-16329. 
35 
 
127. Whelan J, Ghersa P, Hooft van Huijsduijnen R, et al. An NF kappa B-like factor is essential but not 
sufficient for cytokine induction of endothelial leukocyte adhesion molecule 1 (ELAM-1) gene transcription. 
Nucleic Acids Res. 1991;19(10):2645-2653. 
128. Chilov D, Kukk E, Taira S, et al. Genomic organization of human and mouse genes for vascular 
endothelial growth factor C. J Biol Chem. 1997;272(40):25176-25183. 
129. Ueda A, Okuda K, Ohno S, et al. NF-kappa B and Sp1 regulate transcription of the human monocyte 
chemoattractant protein-1 gene. J Immunol. 1994;153(5):2052-2063. 
130. Collart MA, Baeuerle P, Vassalli P. Regulation of tumor necrosis factor alpha transcription in 
macrophages: Involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. 
Mol Cell Biol. 1990;10(4):1498-1506. 
131. Crofford LJ, Tan B, McCarthy CJ, Hla T. Involvement of nuclear factor kappa B in the regulation of 
cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes. Arthritis Rheum. 1997;40(2):226-
236. 
132. Noguchi Y, Makino T, Yoshikawa T, et al. The possible role of TNF-alpha and IL-2 in inducing tumor-
associated metabolic alterations. Surg Today. 1996;26(1):36-41. 
133. Tomimatsu S, Ichikura T, Mochizuki H. Significant correlation between expression of interleukin-1alpha 
and liver metastasis in gastric carcinoma. Cancer. 2001;91(7):1272-1276. 
134. Klotz T, Bloch W, Jacobs G, Niggemann S, Engelmann U, Addicks K. Immunolocalization of inducible 
and constitutive nitric oxide synthases in human bladder cancer. Urology. 1999;54(3):416-419. 
135. Dong Z, Nemeth JA, Cher ML, Palmer KC, Bright RC, Fridman R. Differential regulation of matrix 
metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of 
prostate cancer and stromal cells. Int J Cancer. 2001;93(4):507-515. 
136. Pacheco MM, Nishimoto IN, Mourao Neto M, Mantovani EB, Brentani MM. Prognostic significance of 
the combined expression of matrix metalloproteinase-9, urokinase type plasminogen activator and its 
receptor in breast cancer as measured by northern blot analysis. Int J Biol Markers. 2001;16(1):62-68. 
137. Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR. Epithelial cancer cell migration: A role for 
chemokine receptors? Cancer Res. 2001;61(13):4961-4965. 
138. Strieter RM. Mechanisms of pulmonary fibrosis: Conference summary. Chest. 2001;120(1 Suppl):77S-
85S. 
139. Palmer K, Hitt M, Emtage PC, Gyorffy S, Gauldie J. Combined CXC chemokine and interleukin-12 gene 
transfer enhances antitumor immunity. Gene Ther. 2001;8(4):282-290. 
36 
 
140. Qin ZH, Chen RW, Wang Y, Nakai M, Chuang DM, Chase TN. Nuclear factor kappaB nuclear 
translocation upregulates c-myc and p53 expression during NMDA receptor-mediated apoptosis in rat 
striatum. J Neurosci. 1999;19(10):4023-4033. 
141. Chan H, Bartos DP, Owen-Schaub LB. Activation-dependent transcriptional regulation of the human fas 
promoter requires NF-kappaB p50-p65 recruitment. Mol Cell Biol. 1999;19(3):2098-2108. 
142. Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J. Nuclear factor (NF)-kappaB-
regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor 
alpha-induced apoptosis. J Exp Med. 1998;188(1):211-216. 
143. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS,Jr. NF-kappaB controls cell growth and 
differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999;19(8):5785-5799. 
144. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-kappaB function in growth 
control: Regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol. 1999;19(4):2690-
2698. 
145. Bash J, Zong WX, Gelinas C. C-rel arrests the proliferation of HeLa cells and affects critical regulators 
of the G1/S-phase transition. Mol Cell Biol. 1997;17(11):6526-6536. 
146. Cavallini L, Francesconi MA, Zoccarato F, Alexandre A. Involvement of nuclear factor-kappa B (NF-
kappaB) activation in mitogen-induced lymphocyte proliferation: Inhibitory effects of lymphoproliferation by 
salicylates acting as NF-kappaB inhibitors. Biochem Pharmacol. 2001;62(1):141-147. 
147. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87(0006-4971; 6):2095-2147. 
148. Voronov E, Carmi Y, Apte RN. The role IL-1 in tumor-mediated angiogenesis. Front Physiol. 
2014;5:114. 
149. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 
2009;27:519-550. 
150. Stokkers PC, van Aken BE, Basoski N, Reitsma PH, Tytgat GN, van Deventer SJ. Five genetic markers 
in the interleukin 1 family in relation to inflammatory bowel disease. Gut. 1998;43(0017-5749; 1):33-39. 
151. Voronov E, Dotan S, Krelin Y, et al. Unique versus redundant functions of IL-1alpha and IL-1beta in the 
tumor microenvironment. Front Immunol. 2013;4:177. 
152. Krelin Y, Voronov E, Dotan S, et al. Interleukin-1beta-driven inflammation promotes the development 
and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 2007;67(3):1062-1071. 
153. Carmi Y, Dotan S, Rider P, et al. The role of IL-1beta in the early tumor cell-induced angiogenic 
response. J Immunol. 2013;190(7):3500-3509. 
37 
 
154. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: How bacterial recognition shapes 
intestinal function. Nat Rev Immunol. 2010;10(2):131-144. 
155. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499-511. 
156. Fukata M, Vamadevan AS, Abreu MT. Toll-like receptors (TLRs) and nod-like receptors (NLRs) in 
inflammatory disorders. Semin Immunol. 2009;21(4):242-253. 
157. Hornef MW, Normark BH, Vandewalle A, Normark S. Intracellular recognition of lipopolysaccharide by 
toll-like receptor 4 in intestinal epithelial cells. J Exp Med. 2003;198(8):1225-1235. 
158. Fukata M, Chen A, Klepper A, et al. Cox-2 is regulated by toll-like receptor-4 (TLR4) signaling: Role in 
proliferation and apoptosis in the intestine. Gastroenterology. 2006;131(3):862-877. 
159. Fukata M, Hernandez Y, Conduah D, et al. Innate immune signaling by toll-like receptor-4 (TLR4) 
shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis. 2009;15(7):997-
1006. 
160. Fukata M, Chen A, Vamadevan AS, et al. Toll-like receptor-4 promotes the development of colitis-
associated colorectal tumors. Gastroenterology. 2007;133(6):1869-1881. 
161. Garlanda C, Riva F, Veliz T, et al. Increased susceptibility to colitis-associated cancer of mice lacking 
TIR8, an inhibitory member of the interleukin-1 receptor family. Cancer Res. 2007;67(13):6017-6021. 
162. Xiao H, Gulen MF, Qin J, et al. The toll-interleukin-1 receptor member SIGIRR regulates colonic 
epithelial homeostasis, inflammation, and tumorigenesis. Immunity. 2007;26(4):461-475. 
163. Meirhaeghe A, Amouyel P. Impact of genetic variation of PPARgamma in humans. Mol Genet Metab. 
2004;83(1-2):93-102. 
164. Dubuquoy L, Rousseaux C, Thuru X, et al. PPARgamma as a new therapeutic target in inflammatory 
bowel diseases. Gut. 2006;55(9):1341-1349. 
165. Han S, Inoue H, Flowers LC, Sidell N. Control of COX-2 gene expression through peroxisome 
proliferator-activated receptor gamma in human cervical cancer cells. Clin Cancer Res. 2003;9(1078-0432; 
12):4627-4635. 
166. Szanto A, Nagy L. The many faces of PPARgamma: Anti-inflammatory by any means? Immunobiology. 
2008;213(0171-2985; 9-10):789-803. 
167. Sasaki H, Tanahashi M, Yukiue H, et al. Decreased perioxisome proliferator-activated receptor gamma 
gene expression was correlated with poor prognosis in patients with lung cancer. Lung Cancer. 
2002;36(0169-5002; 1):71-76. 
38 
 
168. Jung TI, Baek WK, Suh SI, et al. Down-regulation of peroxisome proliferator-activated receptor gamma 
in human cervical carcinoma. Gynecol Oncol. 2005;97(2):365-373. 
169. He Q, Chen J, Lin HL, Hu PJ, Chen MH. Expression of peroxisome proliferator-activated receptor 
gamma, E-cadherin and matrix metalloproteinases-2 in gastric carcinoma and lymph node metastases. Chin 
Med J (Engl). 2007;120(17):1498-1504. 
170. Aldred MA, Morrison C, Gimm O, et al. Peroxisome proliferator-activated receptor gamma is frequently 
downregulated in a diversity of sporadic nonmedullary thyroid carcinomas. Oncogene. 2003;22(22):3412-
3416. 
171. Terashita Y, Sasaki H, Haruki N, et al. Decreased peroxisome proliferator-activated receptor gamma 
gene expression is correlated with poor prognosis in patients with esophageal cancer. Jpn J Clin Oncol. 
2002;32(7):238-243. 
172. Michael MS, Badr MZ, Badawi AF. Inhibition of cyclooxygenase-2 and activation of peroxisome 
proliferator-activated receptor-gamma synergistically induces apoptosis and inhibits growth of human breast 
cancer cells. Int J Mol Med. 2003;11(6):733-736. 
173. Badawi AF, Badr MZ. Chemoprevention of breast cancer by targeting cyclooxygenase-2 and 
peroxisome proliferator-activated receptor-gamma (review). Int J Oncol. 2002;20(6):1109-1122. 
174. Zhang Z, Xu Y, Xu Q, Hou Y. PPARgamma against tumors by different signaling pathways. Onkologie. 
2013;36(10):598-601. 
175. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase 
inhibitors. FASEB J. 2001;15(12):2057-2072. 
176. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated 
receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. 
J Biol Chem. 1997;272(6):3406-3410. 
177. Ieiri I. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast 
cancer resistance protein (BCRP, ABCG2). Drug Metab Pharmacokinet. 2012;27(1):85-105. 
178. Sissung TM, Troutman SM, Campbell TJ, et al. Transporter pharmacogenetics: Transporter 
polymorphisms affect normal physiology, diseases, and pharmacotherapy. Discov Med. 2012;13(68):19-34. 
179. Jemnitz K, Heredi-Szabo K, Janossy J, Ioja E, Vereczkey L, Krajcsi P. ABCC2/Abcc2: A multispecific 
transporter with dominant excretory functions. Drug Metab Rev. 2010;42(3):402-436. 
180. Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype 
shapes protein function. Biochim Biophys Acta. 2009;1794(5):860-871. 
39 
 
181. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. 
Genome Res. 2001;11(7):1156-1166. 
182. Dean M, Annilo T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. 
Annu Rev Genomics Hum Genet. 2005;6:123-142. 
183. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem. 
2002;71:537-592. 
184. Kerr ID, Haider AJ, Gelissen IC. The ABCG family of membrane-associated transporters: You don't 
have to be big to be mighty. Br J Pharmacol. 2011;164(7):1767-1779. 
185. Johnstone RW, Ruefli AA, Tainton KM, Smyth MJ. A role for P-glycoprotein in regulating cell death. 
Leuk Lymphoma. 2000;38(1-2):1-11. 
186. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human 
"MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A. 
1987;84(9):3004-3008. 
187. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. 
Annu Rev Biochem. 1993;62:385-427. 
188. Mizutani T, Masuda M, Nakai E, et al. Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab. 
2008;9(2):167-174. 
189. Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Kurzawski M, Gawronska-Szklarz B. Involvement of 
C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood 
mononuclear cells treated with methotrexate and dexamethasone. Eur J Pharmacol. 2005;528(1-3):27-36. 
190. Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Safranow K, Gawronska-Szklarz B. Involvement of P-
glycoprotein in the release of cytokines from peripheral blood mononuclear cells treated with methotrexate 
and dexamethasone. J Pharm Pharmacol. 2005;57(11):1421-1425. 
191. McRae MP, Brouwer KL, Kashuba AD. Cytokine regulation of P-glycoprotein. Drug Metab Rev. 
2003;35(1):19-33. 
192. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: Mice deficient for the 
multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol. 1998;161(10):5733-5744. 
193. Englund G, Jacobson A, Rorsman F, Artursson P, Kindmark A, Ronnblom A. Efflux transporters in 
ulcerative colitis: Decreased expression of BCRP (ABCG2) and pgp (ABCB1). Inflamm Bowel Dis. 
2007;13(3):291-297. 
40 
 
194. Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and crohn's disease: Distinctive gene 
expression profiles and novel susceptibility candidate genes. Hum Mol Genet. 2001;10(5):445-456. 
195. Langmann T, Moehle C, Mauerer R, et al. Loss of detoxification in inflammatory bowel disease: 
Dysregulation of pregnane X receptor target genes. Gastroenterology. 2004;127(1):26-40. 
196. Kalitsky-Szirtes J, Shayeganpour A, Brocks DR, Piquette-Miller M. Suppression of drug-metabolizing 
enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab Dispos. 
2004;32(1):20-27. 
197. Ho GT, Nimmo ER, Tenesa A, et al. Allelic variations of the multidrug resistance gene determine 
susceptibility and disease behavior in ulcerative colitis. Gastroenterology. 2005;128(2):288-296. 
198. Ho GT, Soranzo N, Nimmo ER, Tenesa A, Goldstein DB, Satsangi J. ABCB1/MDR1 gene determines 
susceptibility and phenotype in ulcerative colitis: Discrimination of critical variants using a gene-wide 
haplotype tagging approach. Hum Mol Genet. 2006;15(5):797-805. 
199. Schwab M, Schaeffeler E, Marx C, et al. Association between the C3435T MDR1 gene polymorphism 
and susceptibility for ulcerative colitis. Gastroenterology. 2003;124(1):26-33. 
200. De Iudicibus S, De Pellegrin A, Stocco G, Bartoli F, Bussani R, Decorti G. ABCB1 gene polymorphisms 
and expression of P-glycoprotein and long-term prognosis in colorectal cancer. Anticancer Res. 
2008;28(6B):3921-3928. 
201. Zrieki A, Farinotti R, Buyse M. Cyclooxygenase inhibitors down regulate P-glycoprotein in human 
colorectal caco-2 cell line. Pharm Res. 2008;25(9):1991-2001. 
202. Bentires-Alj M, Barbu V, Fillet M, et al. NF-kappaB transcription factor induces drug resistance through 
MDR1 expression in cancer cells. Oncogene. 2003;22(1):90-97. 
203. Aszalos A. Role of ATP-binding cassette (ABC) transporters in interactions between natural products 
and drugs. Curr Drug Metab. 2008;9(10):1010-1018. 
204. Abu-Qare AW, Elmasry E, Abou-Donia MB. A role for P-glycoprotein in environmental toxicology. J 
Toxicol Environ Health B Crit Rev. 2003;6(3):279-288. 
205. Szabady RL, McCormick BA. Control of neutrophil inflammation at mucosal surfaces by secreted 
epithelial products. Front Immunol. 2013;4:220. 
206. Pazos M, Siccardi D, Mumy KL, et al. Multidrug resistance-associated transporter 2 regulates mucosal 
inflammation by facilitating the synthesis of hepoxilin A3. J Immunol. 2008;181(11):8044-8052. 
41 
 
207. Elmorsi YM, El-Haggar SM, Ibrahim OM, Mabrouk MM. Effect of ketoprofen and indomethacin on 
methotrexate pharmacokinetics in mice plasma and tumor tissues. Eur J Drug Metab Pharmacokinet. 
2013;38(1):27-32. 
208. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Interaction of nonsteroidal anti-
inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated 
methotrexate transport. J Pharmacol Exp Ther. 2007;320(1):229-235. 
209. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast 
cancer cells. Proc Natl Acad Sci U S A. 1998;95(26):15665-15670. 
210. Mosaffa F, Kalalinia F, Lage H, Afshari JT, Behravan J. Pro-inflammatory cytokines interleukin-1 beta, 
interleukin 6, and tumor necrosis factor-alpha alter the expression and function of ABCG2 in cervix and 
gastric cancer cells. Mol Cell Biochem. 2012;363(1-2):385-393. 
211. Vlaming ML, Lagas JS, Schinkel AH. Physiological and pharmacological roles of ABCG2 (BCRP): 
Recent findings in Abcg2 knockout mice. Adv Drug Deliv Rev. 2009;61(1):14-25. 
212. Malekshah OM, Bahrami AR, Afshari JT, Mosaffa F, Behravan J. Correlation between PXR and ABCG2 
patterns of mRNA expression in a MCF7 breast carcinoma cell derivative upon induction by proinflammatory 
cytokines. DNA Cell Biol. 2011;30(1):25-31. 
213. Mosaffa F, Lage H, Afshari JT, Behravan J. Interleukin-1 beta and tumor necrosis factor-alpha increase 
ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX. 
Inflamm Res. 2009;58(10):669-676. 
214. Le Vee M, Lecureur V, Stieger B, Fardel O. Regulation of drug transporter expression in human 
hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug 
Metab Dispos. 2009;37(3):685-693. 
215. Gupta N, Martin PM, Miyauchi S, et al. Down-regulation of BCRP/ABCG2 in colorectal and cervical 
cancer. Biochem Biophys Res Commun. 2006;343(2):571-577. 
216. van Herwaarden AE, Wagenaar E, Karnekamp B, Merino G, Jonker JW, Schinkel AH. Breast cancer 
resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and 
trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis. 2006;27(1):123-130. 
217. Ebert B, Seidel A, Lampen A. Identification of BCRP as transporter of benzo[a]pyrene conjugates 
metabolically formed in caco-2 cells and its induction by ah-receptor agonists. Carcinogenesis. 
2005;26(10):1754-1763. 
42 
 
218. Enokizono J, Kusuhara H, Ose A, Schinkel AH, Sugiyama Y. Quantitative investigation of the role of 
breast cancer resistance protein (bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic 
compounds. Drug Metab Dispos. 2008;36(6):995-1002. 
219. van Herwaarden AE, Jonker JW, Wagenaar E, et al. The breast cancer resistance protein 
(Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. 
Cancer Res. 2003;63(19):6447-6452. 
220. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity 
and the prevention of cancer: A global perspective. dietandcancerreport.org Web site. 
http://www.dietandcancerreport.org/index.php. Updated 2014. 
221. Dumitrescu RG, Cotarla I. Understanding breast cancer risk -- where do we stand in 2005? J Cell Mol 
Med. 2005;9(1):208-221. 
222. Mitrunen K, Hirvonen A. Molecular epidemiology of sporadic breast cancer. the role of polymorphic 
genes involved in oestrogen biosynthesis and metabolism. Mutat Res. 2003;544(1):9-41. 
223. Kim E, Coelho D, Blachier F. Review of the association between meat consumption and risk of 
colorectal cancer. Nutr Res. 2013;33(12):983-994. 
224. Santarelli RL, Pierre F, Corpet DE. Processed meat and colorectal cancer: A review of epidemiologic 
and experimental evidence. Nutr Cancer. 2008;60(2):131-144. 
225. IJssennagger N, Rijnierse A, de Wit N, et al. Dietary haem stimulates epithelial cell turnover by 
downregulating feedback inhibitors of proliferation in murine colon. Gut. 2012;61(7):1041-1049. 
226. Oates PS, West AR. Heme in intestinal epithelial cell turnover, differentiation, detoxification, 
inflammation, carcinogenesis, absorption and motility. World J Gastroenterol. 2006;12(27):4281-4295. 
227. Hebels DG, Sveje KM, de Kok MC, et al. Red meat intake-induced increases in fecal water genotoxicity 
correlate with pro-carcinogenic gene expression changes in the human colon. Food Chem Toxicol. 
2012;50(2):95-103. 
228. Jakszyn P, Bingham S, Pera G, et al. Endogenous versus exogenous exposure to N-nitroso 
compounds and gastric cancer risk in the european prospective investigation into cancer and nutrition (EPIC-
EURGAST) study. Carcinogenesis. 2006;27(7):1497-1501. 
229. Santarelli RL, Vendeuvre JL, Naud N, et al. Meat processing and colon carcinogenesis: Cooked, nitrite-
treated, and oxidized high-heme cured meat promotes mucin-depleted foci in rats. Cancer Prev Res (Phila). 
2010;3(7):852-864. 
230. Le Leu RK, Young GP. Fermentation of starch and protein in the colon: Implications for genomic 
instability. Cancer Biol Ther. 2007;6(2):259-260. 
43 
 
231. O'Keefe SJ, Kidd M, Espitalier-Noel G, Owira P. Rarity of colon cancer in africans is associated with low 
animal product consumption, not fiber. Am J Gastroenterol. 1999;94(5):1373-1380. 
232. Sobhani I, Tap J, Roudot-Thoraval F, et al. Microbial dysbiosis in colorectal cancer (CRC) patients. 
PLoS One. 2011;6(1):e16393. 
233. Le Leu RK, Young GP, Hu Y, Winter J, Conlon MA. Dietary red meat aggravates dextran sulfate 
sodium-induced colitis in mice whereas resistant starch attenuates inflammation. Dig Dis Sci. 
2013;58(12):3475-3482. 
234. Joshi AD, Corral R, Catsburg C, et al. Red meat and poultry, cooking practices, genetic susceptibility 
and risk of prostate cancer: Results from a multiethnic case-control study. Carcinogenesis. 
2012;33(11):2108-2118. 
235. Steck SE, Gaudet MM, Eng SM, et al. Cooked meat and risk of breast cancer--lifetime versus recent 
dietary intake. Epidemiology. 2007;18(3):373-382. 
236. Tappel A. Heme of consumed red meat can act as a catalyst of oxidative damage and could initiate 
colon, breast and prostate cancers, heart disease and other diseases. Med Hypotheses. 2007;68(3):562-
564. 
237. Bingham SA. High-meat diets and cancer risk. Proc Nutr Soc. 1999;58(2):243-248. 
238. Young GP, Hu Y, Le Leu RK, Nyskohus L. Dietary fibre and colorectal cancer: A model for 
environment--gene interactions. Mol Nutr Food Res. 2005;49(6):571-584. 
239. Murphy N, Norat T, Ferrari P, et al. Dietary fibre intake and risks of cancers of the colon and rectum in 
the european prospective investigation into cancer and nutrition (EPIC). PLoS One. 2012;7(6):e39361. 
240. Bingham SA, Day NE, Luben R, et al. Dietary fibre in food and protection against colorectal cancer in 
the european prospective investigation into cancer and nutrition (EPIC): An observational study. Lancet. 
2003;361(9368):1496-1501. 
241. Bingham SA. Mechanisms and experimental and epidemiological evidence relating dietary fibre (non-
starch polysaccharides) and starch to protection against large bowel cancer. Proc Nutr Soc. 1990;49(2):153-
171. 
242. De Preter V, Rutgeerts P, Schuit F, Verbeke K, Arijs I. Impaired expression of genes involved in the 
butyrate oxidation pathway in crohn's disease patients. Inflamm Bowel Dis. 2013;19(3):E43-4. 
243. Whitehead RH, Young GP, Bhathal PS. Effects of short chain fatty acids on a new human colon 
carcinoma cell line (LIM1215). Gut. 1986;27(12):1457-1463. 
44 
 
244. Heerdt BG, Houston MA, Augenlicht LH. Short-chain fatty acid-initiated cell cycle arrest and apoptosis 
of colonic epithelial cells is linked to mitochondrial function. Cell Growth Differ. 1997;8(5):523-532. 
245. Segain JP, Raingeard de la Bletiere D, Bourreille A, et al. Butyrate inhibits inflammatory responses 
through NFkappaB inhibition: Implications for crohn's disease. Gut. 2000;47(3):397-403. 
246. Andersen V, Holst R, Kopp TI, Tjonneland A, Vogel U. Interactions between diet, lifestyle and IL10, 
IL1B, and PTGS2/COX-2 gene polymorphisms in relation to risk of colorectal cancer in a prospective danish 
case-cohort study. PLoS One. 2013;8(10):e78366. 
247. Slavin J. Whole grains and human health. Nutr Res Rev. 2004;17(1):99-110. 
248. Wu F, Groopman JD, Pestka JJ. Public health impacts of foodborne mycotoxins. Annu Rev Food Sci 
Technol. 2014;5:351-372. 
249. Ravishankar D, Rajora AK, Greco F, Osborn HM. Flavonoids as prospective compounds for anti-cancer 
therapy. Int J Biochem Cell Biol. 2013;45(12):2821-2831. 
250. McCullough ML, Robertson AS, Chao A, et al. A prospective study of whole grains, fruits, vegetables 
and colon cancer risk. Cancer Causes Control. 2003;14(10):959-970. 
251. Gravaghi C, La Perle KM, Ogrodwski P, et al. Cox-2 expression, PGE(2) and cytokines production are 
inhibited by endogenously synthesized n-3 PUFAs in inflamed colon of fat-1 mice. J Nutr Biochem. 
2011;22(4):360-365. 
252. Whiting CV, Bland PW, Tarlton JF. Dietary n-3 polyunsaturated fatty acids reduce disease and colonic 
proinflammatory cytokines in a mouse model of colitis. Inflamm Bowel Dis. 2005;11(4):340-349. 
253. MacLean CH, Newberry SJ, Mojica WA, et al. Effects of omega-3 fatty acids on cancer risk: A 
systematic review. JAMA. 2006;295(4):403-415. 
254. Gu Z, Suburu J, Chen H, Chen YQ. Mechanisms of omega-3 polyunsaturated fatty acids in prostate 
cancer prevention. Biomed Res Int. 2013;2013:824563. 
255. Chajes V, Bougnoux P. Omega-6/omega-3 polyunsaturated fatty acid ratio and cancer. World Rev Nutr 
Diet. 2003;92:133-151. 
256. Colli JL, Amling CL. Chemoprevention of prostate cancer: What can be recommended to patients? Curr 
Urol Rep. 2009;10(1534-6285; 1527-2737; 3):165-171. 
257. Pericleous M, Mandair D, Caplin ME. Diet and supplements and their impact on colorectal cancer. J 
Gastrointest Oncol. 2013;4(4):409-423. 
258. Ye YN, Liu ES, Shin VY, Wu WK, Cho CH. The modulating role of nuclear factor-kappaB in the action 
of alpha7-nicotinic acetylcholine receptor and cross-talk between 5-lipoxygenase and cyclooxygenase-2 in 
45 
 
colon cancer growth induced by 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone. J Pharmacol Exp 
Ther. 2004;311(1):123-130. 
259. Wong HP, Yu L, Lam EK, Tai EK, Wu WK, Cho CH. Nicotine promotes colon tumor growth and 
angiogenesis through beta-adrenergic activation. Toxicol Sci. 2007;97(2):279-287. 
260. Reynolds P. Smoking and breast cancer. J Mammary Gland Biol Neoplasia. 2013;18(1):15-23. 
261. Cuzick J, Thorat MA, Andriole G, et al. Prevention and early detection of prostate cancer. Lancet Oncol. 
2014;15(11):e484-e492. 
262. Islami F, Moreira DM, Boffetta P, Freedland SJ. A systematic review and meta-analysis of tobacco use 
and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol. 2014. 
263. Leufkens AM, Van Duijnhoven FJ, Siersema PD, et al. Cigarette smoking and colorectal cancer risk in 
the european prospective investigation into cancer and nutrition study. Clin Gastroenterol Hepatol. 
2011;9(2):137-144. 
264. Cook RT. Alcohol abuse, alcoholism, and damage to the immune system--a review. Alcohol Clin Exp 
Res. 1998;22(9):1927-1942. 
265. Wang HJ, Zakhari S, Jung MK. Alcohol, inflammation, and gut-liver-brain interactions in tissue damage 
and disease development. World J Gastroenterol. 2010;16(11):1304-1313. 
266. Haorah J, Ramirez SH, Floreani N, Gorantla S, Morsey B, Persidsky Y. Mechanism of alcohol-induced 
oxidative stress and neuronal injury. Free Radic Biol Med. 2008;45(11):1542-1550. 
267. Fedirko V, Tramacere I, Bagnardi V, et al. Alcohol drinking and colorectal cancer risk: An overall and 
dose-response meta-analysis of published studies. Ann Oncol. 2011;22(9):1958-1972. 
268. Dumitrescu RG, Shields PG. The etiology of alcohol-induced breast cancer. Alcohol. 2005;35(3):213-
225. 
269. Rota M, Scotti L, Turati F, et al. Alcohol consumption and prostate cancer risk: A meta-analysis of the 
dose-risk relation. Eur J Cancer Prev. 2012;21(4):350-359. 
270. Boffetta P, Hashibe M, La VC, Zatonski W, Rehm J. The burden of cancer attributable to alcohol 
drinking. Int J Cancer. 2006;119(4):884-887. 
271. Testino G. The burden of cancer attributable to alcohol consumption. Maedica (Buchar). 2011;6(4):313-
320. 
272. Baan R, Straif K, Grosse Y, et al. Carcinogenicity of alcoholic beverages. Lancet Oncol. 2007;8(4):292-
293. 
46 
 
273. Benzon LS, Vogel U, Christensen J, et al. Interaction between ADH1C arg(272)gln and alcohol intake in 
relation to breast cancer risk suggests that ethanol is the causal factor in alcohol related breast cancer. 
Cancer Lett. 2010;295(2):191-197. 
274. Wight AJ, Ogden GR. Possible mechanisms by which alcohol may influence the development of oral 
cancer--a review. Oral Oncol. 1998;34(6):441-447. 
275. Voigt MD. Alcohol in hepatocellular cancer. Clin Liver Dis. 2005;9(1):151-169. 
276. Rinaldi S, Peeters PH, Bezemer ID, et al. Relationship of alcohol intake and sex steroid concentrations 
in blood in pre- and post-menopausal women: The european prospective investigation into cancer and 
nutrition. Cancer Causes Control. 2006;17(8):1033-1043. 
277. Onland-Moret NC, Peeters PH, van dS, Grobbee DE, van Gils CH. Alcohol and endogenous sex steroid 
levels in postmenopausal women: A cross-sectional study. J Clin Endocrinol Metab. 2005;90(0021-972; 
0021-972; 3):1414-1419. 
278. Hankinson SE, Willett WC, Manson JE, et al. Alcohol, height, and adiposity in relation to estrogen and 
prolactin levels in postmenopausal women. J Natl Cancer Inst. 1995;87(17):1297-1302. 
279. Muti P, Trevisan M, Micheli A, et al. Alcohol consumption and total estradiol in premenopausal women. 
Cancer Epidemiol Biomarkers Prev. 1998;7(3):189-193. 
280. Coutelle C, Hohn B, Benesova M, et al. Risk factors in alcohol associated breast cancer: Alcohol 
dehydrogenase polymorphism and estrogens. Int J Oncol. 2004;25(4):1127-1132. 
281. Dorgan JF, Baer DJ, Albert PS, et al. Serum hormones and the alcohol-breast cancer association in 
postmenopausal women. J Natl Cancer Inst. 2001;93(9):710-715. 
282. Reichman ME, Judd JT, Longcope C, et al. Effects of alcohol consumption on plasma and urinary 
hormone concentrations in premenopausal women. J Natl Cancer Inst. 1993;85(9):722-727. 
283. Li CI, Chlebowski RT, Freiberg M, et al. Alcohol consumption and risk of postmenopausal breast cancer 
by subtype: The women's health initiative observational study. J Natl Cancer Inst. 2010;102(18):1422-1431. 
284. Suzuki R, Orsini N, Mignone L, Saji S, Wolk A. Alcohol intake and risk of breast cancer defined by 
estrogen and progesterone receptor status--a meta-analysis of epidemiological studies. Int J Cancer. 
2008;122(8):1832-1841. 
285. Petersen RK, Larsen SB, Jensen DM, et al. PPARgamma-PGC-1alpha activity is determinant of alcohol 
related breast cancer. Cancer Lett. 2012;315(1):59-68. 
286. Longnecker MP, Tseng M. Alcohol, hormones, and postmenopausal women. Alcohol Health Res World. 
1998;22(3):185-189. 
47 
 
287. Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol. 2003;86(3-5):225-
230. 
288. Bulun SE, Lin Z, Imir G, et al. Regulation of aromatase expression in estrogen-responsive breast and 
uterine disease: From bench to treatment. Pharmacol Rev. 2005;57(3):359-383. 
289. Kinoshita Y, Chen S. Induction of aromatase (CYP19) expression in breast cancer cells through a 
nongenomic action of estrogen receptor alpha. Cancer Res. 2003;63(13):3546-3555. 
290. Russo J, Russo IH. Genotoxicity of steroidal estrogens. Trends Endocrinol Metab. 2004;15(5):211-214. 
291. International Agency for Research on Cancer. Monograph on the evaluation of carcinogenic risks to 
humans. overall evaluations of carcinogenecy: An updating of IARC monographs volumes 1-40<br /> . . 
1987;Suppl 7:280-285. 
292. Russo J, Hu YF, Yang X, Russo IH. Developmental, cellular, and molecular basis of human breast 
cancer. J Natl Cancer Inst Monogr. 2000(27):17-37. 
293. Hamelers IH, Steenbergh PH. Interactions between estrogen and insulin-like growth factor signaling 
pathways in human breast tumor cells. Endocr Relat Cancer. 2003;10(2):331-345. 
294. Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev. 2000;21(0163-769; 0163-769; 
1):40-54. 
295. Hulka BS, Moorman PG. Breast cancer: Hormones and other risk factors. Maturitas. 2008;61(1-2):203-
213. 
296. Kaaks R, Rinaldi S, Key TJ, et al. Postmenopausal serum androgens, oestrogens and breast cancer 
risk: The european prospective investigation into cancer and nutrition. Endocr Relat Cancer. 
2005;12(4):1071-1082. 
297. Woolcott CG, Shvetsov YB, Stanczyk FZ, et al. Plasma sex hormone concentrations and breast cancer 
risk in an ethnically diverse population of postmenopausal women: The multiethnic cohort study. Endocr 
Relat Cancer. 2010;17(1):125-134. 
298. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast 
cancer in postmenopausal women. J Natl Cancer Inst. 1998;90(17):1292-1299. 
299. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in 
postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94(8):606-616. 
300. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement 
therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast 
cancer and 108,411 women without breast cancer. Lancet. 1997;350(9084):1047-1059. 
48 
 
301. Tjonneland A, Christensen J, Thomsen BL, et al. Hormone replacement therapy in relation to breast 
carcinoma incidence rate ratios: A prospective danish cohort study. Cancer. 2004;100(0008-543; 0008-543; 
11):2328-2337. 
302. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different 
types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114(3):448-454. 
303. Ginsburg ES. Estrogen, alcohol and breast cancer risk. J Steroid Biochem Mol Biol. 1999;69(1-6):299-
306. 
304. Labrie F, Luu-The V, Lin SX, et al. The key role of 17 beta-hydroxysteroid dehydrogenases in sex 
steroid biology. Steroids. 1997;62(1):148-158. 
305. Sarkola T, Adlercreutz H, Heinonen S, von Der PB, Eriksson CJ. The role of the liver in the acute effect 
of alcohol on androgens in women. J Clin Endocrinol Metab. 2001;86(0021-972; 0021-972; 5):1981-1985. 
306. Sarkola T, Fukunaga T, Makisalo H, Peter Eriksson CJ. Acute effect of alcohol on androgens in 
premenopausal women. Alcohol Alcohol. 2000;35(1):84-90. 
307. Sarkola T, Makisalo H, Fukunaga T, Eriksson CJ. Acute effect of alcohol on estradiol, estrone, 
progesterone, prolactin, cortisol, and luteinizing hormone in premenopausal women. Alcohol Clin Exp Res. 
1999;23(6):976-982. 
308. Purohit V. Can alcohol promote aromatization of androgens to estrogens? A review. Alcohol. 
2000;22(3):123-127. 
309. Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr. 1987;45(1):277-282. 
310. Monteiro R, Soares R, Guerreiro S, Pestana D, Calhau C, Azevedo I. Red wine increases adipose 
tissue aromatase expression and regulates body weight and adipocyte size. Nutrition. 2009;25(6):699-705. 
311. Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk: Findings from the european 
prospective investigation into cancer and nutrition (EPIC). Int J Cancer. 2004;111(5):762-771. 
312. Chen D, Reierstad S, Lu M, Lin Z, Ishikawa H, Bulun SE. Regulation of breast cancer-associated 
aromatase promoters. Cancer Lett. 2009;273(1):15-27. 
313. Beckmann L, Husing A, Setiawan VW, et al. Comprehensive analysis of hormone and genetic variation 
in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the breast and 
prostate cancer cohort consortium (BPC3). J Clin Endocrinol Metab. 2011;96(0021-972; 2):E360-E367. 
314. Haiman CA, Dossus L, Setiawan VW, et al. Genetic variation at the CYP19A1 locus predicts circulating 
estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res. 2007;67(5):1893-1897. 
49 
 
315. Dunning AM, Dowsett M, Healey CS, et al. Polymorphisms associated with circulating sex hormone 
levels in postmenopausal women. J Natl Cancer Inst. 2004;96(12):936-945. 
316. Straume AH, Knappskog S, Lonning PE. Effect of CYP19 rs6493497 and rs7176005 haplotype status 
on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women. J Steroid 
Biochem Mol Biol. 2012;128(1-2):69-75. 
317. Healey CS, Dunning AM, Durocher F, et al. Polymorphisms in the human aromatase cytochrome P450 
gene (CYP19) and breast cancer risk. Carcinogenesis. 2000;21(2):189-193. 
318. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A systematic review of 
genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1999;8(10):843-854. 
319. Ma X, Qi X, Chen C, et al. Association between CYP19 polymorphisms and breast cancer risk: Results 
from 10,592 cases and 11,720 controls. Breast Cancer Res Treat. 2010;122(2):495-501. 
320. Rubin GL, Zhao Y, Kalus AM, Simpson ER. Peroxisome proliferator-activated receptor gamma ligands 
inhibit estrogen biosynthesis in human breast adipose tissue: Possible implications for breast cancer 
therapy. Cancer Res. 2000;60(6):1604-1608. 
321. Yanase T, Mu YM, Nishi Y, et al. Regulation of aromatase by nuclear receptors. J Steroid Biochem Mol 
Biol. 2001;79(1-5):187-192. 
322. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with 
decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 
1998;20(3):284-287. 
323. Vogel U, Christensen J, Nexo BA, Wallin H, Friis S, Tjonneland A. Peroxisome proliferator-activated 
corrected] receptor-gamma2 corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation 
to risk of breast cancer in a prospective study of danes. Carcinogenesis. 2007;28(2):427-434. 
324. Wang Y, McCullough ML, Stevens VL, et al. Nested case-control study of energy regulation candidate 
gene single nucleotide polymorphisms and breast cancer. Anticancer Res. 2007;27(1):589-593. 
325. Memisoglu A, Hankinson SE, Manson JE, Colditz GA, Hunter DJ. Lack of association of the codon 12 
polymorphism of the peroxisome proliferator-activated receptor gamma gene with breast cancer and body 
mass. Pharmacogenetics. 2002;12(0960-314; 0960-314; 8):597-603. 
326. Sieri S, Agudo A, Kesse E, et al. Patterns of alcohol consumption in 10 european countries participating 
in the european prospective investigation into cancer and nutrition (EPIC) project. Public Health Nutr. 
2002;5(6):1287-1296. 
50 
 
327. Paynter RA, Hankinson SE, Colditz GA, Hunter DJ, De V,I. No evidence of a role for PPARgamma 
Pro12Ala polymorphism in endometrial cancer susceptibility. Pharmacogenetics. 2004;14(0960-314; 0960-
314; 12):851-856. 
328. Calle EE, Rodriguez C, Jacobs EJ, et al. The american cancer society cancer prevention study II 
nutrition cohort: Rationale, study design, and baseline characteristics. Cancer. 2002;94(0008-543; 0008-543; 
9):2490-2501. 
329. Safi R, Kovacic A, Gaillard S, et al. Coactivation of liver receptor homologue-1 by peroxisome 
proliferator-activated receptor gamma coactivator-1alpha on aromatase promoter II and its inhibition by 
activated retinoid X receptor suggest a novel target for breast-specific antiestrogen therapy. Cancer Res. 
2005;65(24):11762-11770. 
330. Heikkinen S, Argmann C, Feige JN, et al. The Pro12Ala PPARgamma2 variant determines metabolism 
at the gene-environment interface. Cell Metab. 2009;9(1):88-98. 
331. Hansen J, Meersohn A. Kræftsygelighed (1970-97) blandt danske l¢nmodtagere fordelt på 
atbejdstilsynets 49 branchegrupper. . 2003. 
332. Pukkala E, Martinsen JI, Lynge E, et al. Occupation and cancer - follow-up of 15 million people in five 
nordic countries. Acta Oncol. 2009;48(1651-226; 0284-186; 5):646-790. 
333. Andersen A, Barlow L, Engeland A, Kjaerheim K, Lynge E, Pukkala E. Work-related cancer in the 
nordic countries. Scand J Work Environ Health. 1999;25 Suppl 2:1-116. 
334. Goldberg MS, Labreche F. Occupational risk factors for female breast cancer: A review. Occup Environ 
Med. 1996;53(3):145-156. 
335. Hansen J. Breast cancer risk among relatively young women employed in solvent-using industries. Am 
J Ind Med. 1999;36(1):43-47. 
336. Labreche FP, Goldberg MS. Exposure to organic solvents and breast cancer in women: A hypothesis. 
Am J Ind Med. 1997;32(1):1-14. 
337. NTP. Report on carcinogens, twelfth edition. . 2011;12th. 
338. IARC. Agents classified by the IARC monographs, vol. 1-107 . Agents classified by the IARC 
Monographs, vol. 1-107 Web site. http://monographs.iarc.fr/ENG/Classification/index.php. Updated 2013. 
Accessed May 13, 2013. 
  
  
51 
 
Chapter 2 
 
The “Diet, Cancer and Health” Cohort & 
Selection of polymorphisms  
52 
 
  
53 
 
2.1. Description of the Danish Diet, Health and Cancer cohort 
The Danish, prospective “Diet, Cancer and Health” (DCH) cohort study was initiated after convincing 
evidence relating lifestyle factors, especially diet, to cancer incidence 1. The overall aim of the cohort study 
was to investigate the relations between dietary and lifestyle factors and the incidence of cancer and other 
chronic diseases, e.g., type 2 diabetes and cardiovascular diseases. Moreover, combining questionnaire 
data and biological samples from participants, would permit the investigator to examine genetic susceptibility 
and the interaction with diet and life style factors in relation to the development of cancer.  
2.1.1. Study population 
Between December 1993 and May 1997, 80,996 men and 79,729 women were invited to participate in the 
DCH study. The criteria for being invited were: 1) age between 50 and 64 years, 2) residency in Copenhagen 
municipality, or Copenhagen or Aarhus counties, 3) born in Denmark and 4) no diagnosis of cancer 
registered in the Danish Cancer Registry. Of 160,725 invited individuals, 57,053 (27,178 men and 29,875 
women) (35.5%) accepted the invitation. All participants completed a mailed, detailed 192-item semi-
quantitative food frequency questionnaire (FFQ) prior to the visit to the study centres. At the study centres, 
the participants filled in a general questionnaire concerning lifestyle habits, social factors and health status 
including medical history and reproductive factors. Anthropometrical measures, including height and weight, 
were obtained by professional staff and biological materials (blood, fat biopsy and toe nails) were collected. 
The DCH study was approved by the regional Ethical Committees on Human Studies in Copenhagen and 
Aarhus [jr.nr.(KF)11-037/01] and [jr.nr.(KF)01-045/93], and by the Danish Data Protection Agency.  
2.1.2. Case ascertainments and selection 
The DCH cohort is annually linked to the Danish Cancer Registry, which has recorded cancer incidences in 
Denmark since 1943 2. Record linkage to the Central Population Register provides information on vital status 
and date of death or emigration. Gleason’s score data was obtained from Hospital records.  Participants 
were followed-up until censoring, which was the date of diagnosis of any cancer (except non-melanoma skin 
cancer), date of death and date of emigration or end of follow-up. PC and BC case were age-matched via 
incidence density sampling, that is, the controls were alive and at risk of cancer at the time the 
corresponding case was diagnosed, but could be subsequently diagnosed as a case. In addition, BC 
controls were matched on use of HRT (current/former/never) and on certainty of postmenopausal status 
(known/probably postmenopausal) at enrolment. CRC controls or sub-cohort members were randomly 
selected, which allows the studying of multiple outcomes. In order to correct for differences in age between 
cases and sub-cohort members, age was used as the underlying time axis in the statistical analyses, which 
ensured that the estimation procedure was based on comparisons of individuals at the same age and the 
analyses were corrected for delayed entry, such that persons were considered under risk only from the age 
at enrolment in the cohort.  
2.1.3. Assessment of questionnaire data  
In the FFQ, participants were asked to report habitual intake of foods and beverages during the last 12 
month in 12 predefined categories ranging from “never” to “eight times or more per day”. Daily intakes of 
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foods and nutrients were then calculated for each participant using FoodCalc 3 which uses standardized 
recipes and portion sizes specifically developed for the DCH cohort population 4,5. The FFQ originally 
included 92 foods and recipes predicting the intake of 19 nutrients considered important in human 
carcinogenesis, and which provided 81% of the average total nutrient supply 6.  Since then, the FFQ was 
expanded to finally include 192 foods and recipes for the main study.The first FFQ with 92 food items was 
validated by comparing the data from the FFQ with two times seven day of weighed diet records assessed in 
a pilot study prior to the DCH study. Correlation between calorie-adjusted intakes from the FFQ and diet 
records ranged from 0.17 to 0.71 7. Red meat was calculated by combining intake of fresh and minced beef, 
veal, pork, lamb, and offal, whereas processed meat combined intake of bacon, smoked or cooked ham, 
other cold cuts, salami, frankfurter, Cumberland sausage, and liver pâté. Total dietary fiber was estimated by 
the method of the Association of Official Analytical Chemists 8, which includes lignin and resistant starch 9. 
Intake of cereals was calculated by adding up intake of wholegrain foods (wholegrain bread, rye bread, 
wholegrain flour, oatmeal, corncobs, müsli, and crispbread) and refined grain foods (white wheat bread, 
wheat flour, rice flour, potato flour, corn flour/starch, pasta, wheat) and was measured in grams per day. 
Intake of fish in grams per day was calculated by adding up intake of fresh and processed fish. For fruit, only 
intake of fresh fruit (as indicated in the FFQ) was examined, whereas intake of vegetables also included 
estimated contributions from food recipes. Alcohol intake was recorded as the average frequency of intake of 
six types of alcoholic beverage over the preceding year: the frequency of consumption of three types of beer 
was recorded in bottles (330 ml), wine in glasses (125 ml), fortified wine in drinks (60 ml) and spirits in drinks 
(30 ml). The predefined responses were in 12 categories, ranging from ‘never’ to ‘8 or more times a day’. 
The alcohol content was calculated as follows: one bottle of light beer, 8.9 g ethanol; one bottle of regular 
beer, 12.2 g ethanol; one bottle of strong beer, 17.5 g ethanol; one glass of wine, 12.2 g ethanol; one drink of 
fortified wine, 9.3 g ethanol; and one drink of spirits, 9.9 g ethanol. Wine included both red and white wine 10. 
Smoking intensity was calculated as gram tobacco smoked per day and included information on cigarettes 
(one cigarette = 1 g tobacco), cigars (one cigar = 4.5 g tobacco), cheroot (one cheroot = 4 g tobacco), and 
pipe (one pipe = 3 g tobacco). Information on food supplements included questions on brand and doses, and 
frequency of intake. Information about the contents of micronutrients was retrieved from producers or 
distributors of the different brands. 
In the lifestyle questionnaire, information on NSAID use, HRT and length of school education was assessed. 
With regards to NSAID use, participants were asked “Have you taken more than one pain relieving pill per 
month during the last year”? If the answer was yes, the participant was asked to record how frequent they 
took each of the following medications: ‘aspirin’, ‘paracetamol’, ‘ibuprofen’, or ‘other pain relievers’. The latter 
category included NSAID preparations other than aspirin and ibuprofen. Based on all records, study subjects 
were classified according to use of ‘any NSAID’ (2 pills per month during one year) at baseline. All women 
were asked about their use of HRT (never received HRT, previously received HRT, or currently receive 
HRT), the age at which they began receiving HRT, the duration (in years) of their HRT use, and the brand of 
HRT product currently used. Time since HRT cessation was calculated using the participant’s age at the start 
of HRT use and the reported duration of use. In order to determine the women’s postmenopausal status at 
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baseline (known/probably post-menopausal) the following criteria were set: “Known” postmenopausal status 
included women that were (1) non-hysterectomized and reporting no menstruation during 12 months before 
inclusion, (2) reporting bilateral oophorectomy, or (3) reporting age at last menstruation lower than age at 
hysterectomy. “Probably” post-menopausal women were either (1) reporting menstruation during the 12 
months prior to inclusion and current use of HRT (the bleeding was assumedly caused by HRT), (2) reporting 
hysterectomy with a unilateral oophorectomy or an oophorectomy of unknown laterality, or (3) reporting last 
menstruation at the same age as age of hysterectomy. The lifestyle questionnaire also provided information 
regarding duration of schooling (short: ≤ 7 years, medium: 8–10 years, or long: >10 years). At the study 
centre, the self-administrated questionnaires were scanned optically and checked for missing values and 
reading errors. Uncertainties were cleared up with the participants by the laboratory technician during the 
visit. 
2.2. Selection of polymorphisms 
In this PhD thesis, 32 polymorphisms have been examined in relation to PC, CRC and/or BC and relevant 
dietary and lifestyle factors. In Table 2, a description of each polymorphism is provided.  
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Table 2. Description of polymorphisms examined in the present PhD thesis. 
SNP  Reference SNP 
ID number 
Location on 
gene 
Paper Function/effect of polymorphism 
COX-2            
-1195 A/G  
(rs689466) Promoter I Loss of a potential c-myb binding site with reduced promoter activity and mRNA levels 11. Associated 
with reduced risk of CRC 12 and basal cell carcinoma 13. Interacts with NSAID use in relation to lung 
cancer 14 and several dietary factors and smoking in relation to CRC 15. 
COX-2 +8473 
T/C 
(rs5275) Exon 10/3’ 
UTR 
I COX-2 +8473 T/C interrupts a predicted stem and creates an additional loop 16, which may alter mRNA 
stability and expression. Haplotype analysis of COX-2 +8473 T/C and -765 G/C (-765 G/C is in LD with 
COX-2 +3496 T/C 17 and used in the present study instead of -765 G/C) reveals an increase in PGE2 
and PGD2 by peripheral blood monocytes among variant carriers of both SNPs 18. The effect is 
suggestively caused by COX-2 +8473 T/C alone, which is supported by studies showing increased risk 
of esophageal adenocarcinoma 19, basal cell carcinoma 13, BC 16 and CRC 15 for variant carriers. COX-
2 +8473 T/C also interacts with dietary factors in relation to CRC 15. 
COX-2 +3496 
T/C 
(rs2066826) Intronic I Please see COX-2 +8473 T/C: Interaction with COX-2 +8473 T/C in haplotype analysis 18. 
COX-2 +202 
G/A  
(rs2745557) Intronic I Interacts with NSAID use in relation to risk of PC 20. 
COX-2 +306 
C/G  
(rs5277) Exon 3 I A suggestive risk haplotype defined by variant carriers of the G allele of COX-2 +306 C/G with the 
above mentioned COX-2 SNPs in Caucasians 20. 
PPARG 
Pro12Ala C/G  
(rs1801282) Exon B in 
PPARγ2 
I, V 
and VI 
Missense mutation. Reduced ability to trans-activate transcription of target genes, e.g., COX-2 21,22. 
This SNP has been extensively studied and has been associated with reduced risk of type 2 diabetes 
23,24, CRC 25 and BC 26,27. The SNP has opposing effects in relation to alcohol consumptions and risk of 
BC and CRC, respectively. WT carriers have increased risk of alcohol-related BC 26,27, whereas variant 
carriers have increased risk of alcohol-related CRC 26. In addition, NSAID use interacts with PPARG 
Pro12Ala and alcohol intake in relation to BC 26. 
NFKB1 -94 
ins/del ATTG 
(rs28362491)*** Promoter I and II The deletion of four amino acids leads to weaker binding of nuclear proteins and decreased promoter 
activity, resulting in lower levels of the p50 subunit 28. NFKB1 -94 ins/del ATTG is associated with 
reduced risk of PC 29, but increased risk of CRC 30-32 and IBD 28,33,34. 
IL1B -31 T/C  (rs1143627) Promoter I and 
III** 
Higher levels of IL-1β and hence, increased stabilizing of COX-2 mRNA 35,36. In a haplotype context 
with the other two IL1B SNPs, variant carriers of the C allele of IL1B -31 T/C has the highest 
transcription level of IL-1β in vitro 35 and homozygous variant carriers had higher mucosal IL-1β levels 
than heterozygous variant carriers and WT carriers in Japanese Helicobacter pylori-infected patients 37. 
Associated with increased risk of lung cancer 14, multiple myeloma 38 and CRC 15. 
IL1B -1464 
G/C  
(rs1143623) Promoter I and 
III** 
High transcriptional level of IL1β in vitro in a haplotype context with the two other IL1B SNPs 35. 
Associated with increased risk of CRC 15. 
IL1B -3737 
G/A  
(rs4848306) Promoter I and 
III** 
Abolishes a binding site for the anti-inflammatory NF-κB subunit p50 and results in lower transcriptional 
activity 35. Associated with reduced risk of CRC and interacts with vegetables and NSAID use 15. 
CYP19A1 
A/G 
(rs10519297) Promoter V Associated with femoral neck-shaft angle in GWAS - a phenotypic trait in osteoporosis 39. SNP tagger – 
force included*. 
CYP19A1 
G/A 
(rs749292) Promoter V Associated with increased estrone and estradiol levels in postmenopausal women 40,41. SNP tagger – 
force included*. 
CYP19A1 (rs1062033) Exon V Increased transcriptional activity by binding of the CCAAT/ enhancer binding protein β 42. Associated 
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C/G I.2/promoter with enhanced bone mineral density in postmenopausal women 42,43 and increased aromatase gene 
expression in adipose tissue 44. SNP tagger – force included*. 
CYP19A1 
3’UTR A/G 
(rs10046) Exon 10/3’ 
UTR 
V Considered a low activity genotype (G-carriers) 45. This SNP has been extensively examined and has 
consistently been associated with decreased levels of circulating estrogens 40,41,46. Some studies have 
found a decreased risk of BC 45,47 and decreased risk of ER positive 48 and HER2 positive BC 49; 
whereas others have not been able to confirm the association between the SNP and BC 41,46,50. SNP 
tagger – force included*. 
CYP19A1 
C/A 
(rs4646) Exon 10/3’ 
UTR 
V Associated with decreased levels of estrogens 40,41 and decreased risk of HER2 positive BC 49. Others 
have not been able to confirm association with BC 41. SNP tagger*. 
CYP19A1 
A/G 
(rs6493487) Intronic V SNP tagger*. 
CYP19A1 
A/G 
(rs2008691) Promoter V Associated with femoral neck-shaft angle in GWAS - a phenotypic trait in osteoporosis 39. SNP tagger*. 
CYP19A1 T/C (rs3751591) Promoter V Associated with age at natural menopause 51; and is placed in a recombination spot. SNP tagger*. 
CYP19A1 T/C (rs2445762) Promoter V Associated with lower estradiol and higher FSH levels in GWAS 52. SNP tagger*. 
 
CYP19A1 C/T (rs11070844) Promoter V SNP tagger*. 
ABCB1  
Ile1145Ile 
+3435 C/T 
 
(rs1045642)*** Exon 26 III Synonymous substitution. Extensively studied SNP. Associated with lower levels of mRNA and protein 
levels 53,54 possibly caused by lower mRNA stability and protein folding 55. It has also been associated 
with altered drug and inhibitor interactions resulting in altered response to pharmacotherapy 53,56-58.  
Several studies have investigated the association with CRC 59-65 and IBD 66, but the results are 
inconsistent. In line with these results, studies on intestinal mRNA levels and protein expression levels 
are not consistent either 53,67-69. The SNP has been found to interact with meat intake and NSAID use 
in relation to CRC 70. 
ABCB1  
Gly412Gly 
1236 C/T 
(rs1128503) Exon 12 III Synonymous substitution. Lowered Pgp/MDR1 activity 58. Associated with decreased risk of IBD 71-73. 
However, these studies were mostly using haplotype combinations with rs1045642 and another SNP 
not examined in this thesis (rs2032582). 
ABCB1 
C/T 
(rs3789243)*** Intronic III Associated with increased risk of IBD 72,74,75 and possibly increased risk of CRC 70. However, other 
studies point to no risk of CRC 60,76. Interacts with intake of meat in relation to CRC 70. 
ABCC2 
Val417Ile 
+1249 G/A or 
+1286 G/A 
(rs2273697) Exon 10 III Missense mutation. High MRP2 activity 77 which is consistent with a study showing increased intestinal 
efflux and, as a consequence, decreased bioavailability of the drug β-blocker talinolol 78. 
 
ABCC2 
Val1188Glu 
+3600 T/A 
(rs17222723) Exon 25 III Missense mutation. High MRP2 expression 79. 
ABCC2  
-24 C/T 
(rs717620) Exon 
1/promoter 
III Decreased mRNA expression 54 and low MRP2 activity 54,77. Associated with response rate to drugs 80-
83. 
ABCG2  
Gln141Lys 
+421 C/A 
(rs2231142)*** Exon 5 III Missense mutation. Decreased expression of BCRP and lower transport activity 69,84,85. Decreased risk 
of chronic lymphocytic leukemia 86; elevated uric acid levels and prevalent gout 87-89. Associated with 
altered pharmacokinetic parameters of BCRP substrates 90. 
ABCG2 
Val12Met 
+34 C/G 
(rs2231137) Exon 2 III Missense mutation. Lower mRNA levels possibly due to polymorphic splicing 91. 
 
ABCG2 (rs2622604) Intronic III Low intestinal BCRP expression 91 
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+1143 G/A 
TLR4 
Asp299Gly 
+896 A/G 
(rs4986790) Exon 4 II Missense mutation. Extensively studied SNP. Loss of a negatively charged area at position 299, 
leading to alteration in the ligand-binding receptor site and decreased sensitivity to Gram-negative LPS 
92. Increased expression and of inflammatory and/or oncological genes and proteins in CRC cells 93. 
Increased NF-κB activity in CRC cells 94. Associated with several diseases e.g., Gram-negative 
bloodstream infections, sepsis, chronic sarcoidosis, haematogenous and chronic osteomyelitis and IBD 
95. The association with risk of CRC is less consistent 95. Some studies point to no effect 96-99, whereas 
others point to increased risk 100-104. Low MAF of ~4% in Caucasians. 
TLR4                   
+385 G/A 
(rs5030728) Intronic II In partially LD with rs4986790 (D’: 1.0; r2: 0.017) and a higher MAF of ~30% in Caucasians. Located 
near exon 3, which makes it likely to affect messenger RNA processing and stability 105. Intake of 
dietary saturated fatty acids is inversely related to blood level of high density lipoprotein cholesterol in 
individuals homozygous for the TLR4/rs5030728 G-allele 105. Associated with response to anti-TNF 
therapy in patients with IBD 34. Not associated with risk of CRC, but associated with increased survival 
after diagnosis of colon cancer 102.  
HMOX1         
-413 A/T  
(rs2071746)*** Upstream of 
gene 5’ 
IV Increased expression of HO-1 due to alteration in promoter activity 106. Associated with beneficial 
outcome in several diseases e.g., ischemic heart disease 106, hypertension in women 107, sepsis 108 and 
cardiac function 109. Additionally, this SNP is in LD with a microsatellite GT-dinucleotide repeat, which 
has also been associated with various diseases 110-112. However, no association with risk of CRC and 
meat intake was found in a sub-cohort DCH study 113. 
* CYP19A1 SNPs are tagged using HapMap 114 genotyping data set from Utah residents with ancestry from Northern and Western Europe (CEU, version 3, release 2) in combination with 
Haploview (version 4.2, Broad Institute, Cambridge USA) 115 in order to evaluate the major variations of CYP19A1. Criteria for SNP inclusion was a minor allele frequency (MAF) of minimum 
5% and an r2 threshold of 0.1.  Tagging of SNPs with an r2 higher than 0.1 resulted in several SNPs being in complete LD.  Four functional polymorphisms were force included in the 
aggressive SNP tagging (rs10046, rs749292, rs1062033 and rs10519297) due to their documented impact on aromatase RNA expression, estrogen levels and/or BC risk (see above). 
** IL1B SNPS were only investigated in relation to CRC for gene-gene interactions, not main effects. 
*** These SNPs have been examined in CRC sub-cohorts of the DCH cohort. 
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Abstract 
The aetiology of prostate cancer (PC) remains mostly unknown, but increasing evidence suggests that 
chronic inflammation in the prostate is associated with an increased risk of PC. Epidemiological 
studies have suggested that use of non-steroidal anti-inflammatory drugs (NSAIDs) may protect 
against PC. Inborn variations in genes involved in the inflammatory response may modulate the risk of 
PC and interact with NSAIDs. The aims of the study were 1) to evaluate whether polymorphisms and 
haplotypes of the inflammation-related genes COX-2, IL1B, NFKB1 and PPARG are associated with 
risk of PC; 2) to investigate gene-environment interactions between polymorphisms, and NSAID use; 
and 3) to examine whether the studied polymorphisms were associated with aggressiveness of PC. 
The study population consisted of 370 cases of PC and 370 risk-set matched (age) controls nested 
within the prospective Danish “Diet, Cancer and Health” cohort. Carriers of the variant del-allele of 
NFKB1 -94ins/delATTG had a tendency towards a reduced risk of PC (incidence rate ratio (IRR) = 
0.73; 95% CI= 0.52-1.04). A lowered risk for PC was also found for variant allele carriers of NFKB1 -
94ins/delATTG among non-users of NSAIDs (IRR= 0.68; 95% CI= 0.47-0.99), for non-aggressive 
disease (IRR= 0.64; 95% CI= 0.42-0.99), and among men with BMI above 30 kg/m2 (IRR= 0.56; 95% 
CI= 0.27-1.16), although the latter estimate was based on small numbers. A similar pattern was seen 
for carriage of the variant C-allele of the COX-2 +8473T→C polymorphism. No apparent associations 
with PC were observed for the other studied polymorphisms. Our study did not indicate that chronic 
inflammation is a major risk factor for aggressive PC.  
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Introduction 
Prostate cancer (PC) is the most frequent non-skin cancer and the second leading cause of cancer-
related deaths among men in the Western world 1,2. The incidence of PC has reached epidemic 
proportions during the past two decades 1,2. In Denmark, 3,900 men were diagnosed with PC in 2009, 
corresponding to an age-standardized incidence rate of 138 per 100,000 persons 3. The steep 
increase in PC incidence is mainly due to increasing use of prostate specific antigen (PSA) testing4. 
Although PSA testing has been employed less frequently in Denmark than in other Western countries, 
the annual number of new cases of PC has doubled from 2000 to 2009 3. The only well-established 
risk factors for PC are increasing age, race, family history, and genetic susceptibility of PC. However, 
studies of migrant populations clearly indicate that environmental factors are important 5-8.  
There is increasing evidence for a role of chronic inflammation in the carcinogenesis of PC 9-13, and 
dysregulation of several inflammatory mediators have been associated with prostate carcinogenesis 14-
19. In addition, epidemiological studies have suggested that use of non-steroidal anti-inflammatory 
drugs (NSAIDs) may protect against PC 20-22.  
Cyclooxygenase-2 (COX-2) is an inducible, pro-inflammatory enzyme that converts arachidonic acid 
(AA) to a range of prostaglandins (PGs) and the enzymatic activity of COX-2 is inhibited by NSAIDs 23-
25. An increased level of prostaglandin E2 (PGE2) has been reported to be involved in cellular 
proliferation, suppression of immune responses, promotion of angiogenesis, inhibition of apoptosis, 
and stimulation of invasion and motility 23-25. COX-2 is expressed at sites of inflammation and 
neoplasia 24,26, and overexpression of the enzyme has been found in several types of cancer, including 
PC 14-16. Thus, COX-2 upregulation may be an important step in prostate carcinogenesis.  
Peroxisome proliferator-activated receptor γ (PPAR-γ) is a member of the nuclear hormone receptor 
super family and is known to possess anti-inflammatory properties 27. In addition, PPAR-γ has 
potential anti-cancer effects, since a lowered expression of the PPARG gene has been correlated with 
a poor prognosis among lung cancer patients 28. PPAR-γ ligands, which form heterodimers with 
PPAR-γ, have been shown to reduce COX-2 expression by interfering with the NF-κB pathway 29 and 
to inhibit the AP-1-mediated transcriptional activation of COX-2 in human epithelial cells 30 and in 
cervical cancer cells 31. Furthermore, COX-2 and PPARG messenger RNA (mRNA) levels are 
inversely regulated 31, which is in agreement with the findings of a study that reported that PPARG 
seems to be regulated by some PGs in a negative feedback mechanism 29.  
The cytokine interleukin 1 (IL-1) is a member of the IL-1 gene family. IL-1β is secreted upon induction 
and is found in pathological fluids 32. Elevated levels of mucosal IL-1β have been detected in animal 
models of intestinal inflammation and in humans with inflammatory bowel disease 33. IL-1α and β 
stabilise the mRNA and induces transcription of COX-234. Upon stimulation, COX-2 production 
remains elevated for several hours and PGE2 concentration increases steeply. Many of the IL-1α- and 
IL-1β-induced changes are mediated by PGE2, and the use of NSAIDs are therefore potent inhibitors 
of IL-1-induced activity 32.  
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Induction of the transcription factor nuclear factor kappa B (NF-κB) is essential for the expression of 
several immune response genes, e.g., COX-2 35 and IL-1 36,37. NF-κB is implicated in carcinogenesis 
due to its regulation of expression of inflammatory proteins, anti-apoptotic proteins and the cell-cycle 
regulator cyclin D1 36,37. NSAIDs have been shown to inhibit NF-κB independently of COX inhibition 38.  
The primary aims of the study were to examine the associations between genetic variations in 
inflammatory genes, including haplotype analyses, and risk of PC in a nested case-control study within 
the prospective, Danish “Diet, Cancer and Health” (DCH) cohort. We selected 10 predominantly 
functional polymorphisms in COX-2, IL1B, NFKB1 and PPARG which allowed us to analyse the 
haplotypes of COX-2 and IL-1B (Table 1). Secondarily, we investigated interactions between genetic 
variations and NSAID use, overall and according to aggressiveness of PC. 
Methods 
Study population 
The study population was drawn from the DCH study that was conducted between December 1993 
and May 1997 and has been described in detail elsewhere 39. Of 160,725 invited individuals, 57,053 
(27,178 men and 29,875 women) (35.5%) agreed to participate in the study. The criteria for being 
invited were: 1) age between 50 and 64 years, 2) residency in one of the two largest cities in 
Denmark, Copenhagen or Aarhus; and 3) no history of cancer. Each participant completed a detailed 
192-item food-frequency questionnaire and a general questionnaire concerning lifestyle, medical 
history and background factors. Anthropometric measures, including height and weight, were obtained 
by professional staff and biological materials, including blood samples, were collected.  
The DCH cohort is annually linked to the Danish Cancer Registry, which has recorded cancer 
incidence in Denmark since 1943 3,40,41. Record linkage to the Central Population Register provides 
information on vital status and date of death or emigration of each participant 39,42.  
We identified 370 patients with a first diagnosis of PC during the period from entry into the DCH until 
December 31, 2003. For each case, we chose one male control matched on year of birth, center, 
length of follow-up, time of blood collection and state of fasting using risk-set sampling; the controls 
were alive and free of cancer at the time the corresponding case was diagnosed (index date), but they 
were subsequently eligible as cases. Thereby, the estimated odds ratios (OR) are unbiased estimates 
of the incidence rate ratio (IRR) 43.  
In total, 7 cases (and their corresponding controls) were excluded because of a previous cancer 
diagnosis, 7 case-control pairs were excluded because of missing information on potential 
confounders, and 22 pairs either failed the genotype analysis or had no buffy-coats available for 
analysis. Thus, a total of 334 case-control pairs were included in our analyses.  
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Exposure variables 
From the general DCH questionnaire, we obtained information on NSAID use, duration of school 
education, history of diabetes, smoking habits, intake of alcohol, red meat, dietary fat, omega-3 fatty 
acids, calcium, vitamin D, vitamin E, selenium, and total calories. Each participant’s body mass index 
(BMI) was computed based on measurements of height and weight obtained at enrolment 6,39,44. 
 
Table 3. Schematic view of the studied single nucleotide polymorphisms (SNPs). 
SNP  Location on the gene Function/effect of polymorphism 
COX-2 -1195A→G 
(rs689466) 
Promoter Loss of a potential c-myb binding site with reduced promoter activity and mRNA 
levels 45. Carriers of the variant G-allele of COX-2 -1195A→G have lower risks of 
colorectal cancer 46 and basal cell carcinoma 47 compared with that of carriers of the 
A-allele. An interaction between COX-2 -1195A→G and NSAIDs was found in a study 
of lung cancer 48. 
COX-2 +8473T→C 
(rs5275) 
Exon 10/3’ 
UTR 
COX-2 +8473T→C interrupts a predicted stem and creates an additional loop 49, 
which may alter mRNA stability and expression.  Haplotypeanalysis of COX-2 
+8473T→C and -765G→C (-765G→C is in LD with COX-2 +3496T→C 50 and used in 
the present study instead of -765G→C) reveals an increase in PGE2 and PGD2 by 
peripheral blood monocytes among variant carriers of both SNPs 51.  The effect is 
suggestively caused by COX-2 +8473T→C alone, which is supported by studies of  
esophageal adenocarcinoma 52, basal cell carcinoma 47 and breast cancer 49, where 
variant carriers of COX-2 +8473T→C were associated with increased risk of disease 
compared with that of WT. 
COX-2 +3496T→C  
(rs2066826) 
Intron 6 Please see COX-2 +8473T→C: Interaction with COX-2 +8473T→C in haplotype 
analysis 51. 
COX-2 +202G→A 
(rs2745557)  
Intron 1 Heterozygous carriers of the A-allele have a lower risk for PC compared with that of 
WT carriers and a lower risk for PC among homozygous carriers of the G-allele who 
use NSAIDs, whereas NSAID use has no impact on risk among men carrying the 
GA/AA genotype 53. 
COX-2 +306C→G 
(rs5277)  
Exon 3 A suggestive risk haplotype defined by variant carriers of the G-allele of COX-2 
+306C→G with the above mentioned COX-2 SNPs has been seen in Caucasians 53.  
PPARG Pro12AlaC→G 
(rs1801282) 
Codon 12 in 
PPARγ-2 
Reduced ability to activate transcription of target genes e.g. COX-2 54,55. Carriers of 
the variant Ala-allele have a reduced risk of breast cancer compared with that of WT 
carriers 56, and weak interactions between alcohol consumption, NSAID use and 
Pro12Ala in relation to breast cancer risk have been seen 57. 
NFKB1 -
94ins/delATTG 
(rs28362491) 
Promoter Weaker binding of nuclear proteins and decreased promoter activity 58, leading to 
lower levels of the p50 subunit. Deletion allele carriers have higher plasma levels of 
CRP, which is transcriptionally regulated by the p50 dimer 59. A reduced risk of PC is 
observed for carriers of the variant deletion allele 60. 
IL-1B -31T→C  
(rs1143627) 
Promoter Higher levels of IL-1β and hence, increased stabilizing of COX-2 mRNA 61,62. In 
haplotype context with the other two IL-1β SNPs, variant carriers of the C-allele of IL-
1β -31T→C has the highest transcription level of IL-1β in vitro 61 and homozygous 
variant carriers had higher mucosal IL-1β levels than heterozygous variant carriers 
and WT carriers in Japanese Helicobacter pylori-infected patients 63. Variant allele 
carriers of IL-1β -31T→C are at increased risk of lung cancer 48 and multiple myeloma 
64. 
Il-1B -1464G→C 
(rs1143623) 
Promoter The variant allele gives lower transcriptional activity. However, a high transcriptional 
level of IL-1β in vitro in a haplotype context with the -31T→C IL-1β SNPs was 
reported among variant carriers of the C-allele 61.   
Il-1B -3737G→A 
(rs4848306) 
Promoter Low transcriptional level of IL-1β in vitro in haplotype context with the two other IL-1β  
SNPs among variant carriers of the C-allele 61.   
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NSAID use 
The general DCH questionnaire asked how frequently aspirin, non-aspirin (NA) NSAID, or 
acetaminophen (paracetamol) had been used during the 12 months prior to enrolment. Frequency of 
use was assessed as number of pills taken per month, week, or day. Indications for use and dosing 
schedule were not assessed. We defined NSAID use as the weekly use of aspirin or an NA-NSAID at 
baseline; this threshold was based on the results of a recent study of colorectal cancer within the DCH 
cohort, which reported that long-term consistent use of aspirin or NA-NSAID appears necessary to 
achieve a protective effect 65. 
BMI 
BMI was incorporated in the gene-environment analyses, since there is accumulating evidence that 
BMI is associated with PC risk 66,67. BMI was classified according to the World Health Oranization 
standard definition of obesity; a BMI of 18-25 kg/m2 was defined as normal weight, 25-30 kg/m2 as 
overweight and above 30 kg/m2 as obesity 68. There were no men with BMI below 18 kg/m2 in the 
present study group. 
Outcome variable 
Aggressiveness of PC 
The purpose of stratifying PC by aggressiveness was to evaluate whether genetic variations in 
inflammatory genes affected the severity of the disease. We hypothesized that the effects of the 
functional polymorphisms would be more pronounced among aggressive PC cases, because 
functional genetic variations could potentially promote carcinogenesis, leading to more severe 
disease. The stratification of PC by aggressiveness was based on the Gleason score 69, which were 
retrieved from the cases’ pathology reports 70. “Non-aggressive” or “low-grade” PC was defined as 
Gleason’s scores of below 7, whereas “aggressive” or “high-grade” PC was defined as Gleason’s 
scores of 7 or more. 
Genotyping 
At DCH enrolment, 30 ml blood was collected from non-fasting participants, and buffy coat samples 
were stored at -150 ˚C in liquid nitrogen. DNA was isolated from frozen lymphocytes as described by 
Miller et al. 71. Genotypes were determined using reverse transcription-polymerase chain reaction (RT-
PCR) and allelic discrimination on Applied Biosystems ABI 7900HT instruments (Applied Biosystems, 
Nærum, Denmark). Generally, 50-300 ng/µl DNA was obtained from 107 lymphocytes, and 20 ng of 
DNA was genotyped in 5 μl solution containing 50% 2 × Mastermix (Applied Biosystems), 100 nM 
probes, and 900 nM primers. Controls were included in each reaction and replication of 10% of the 
samples yielded 100 % identical genotypes. The average genotyping success rate was 99%. Analysis 
of a small sub-cohort ((N=50, aggressive and non-aggressive) and controls (N=58)) using a 
genotyping method that differs from the one used in this study has been published previously 72.  
For COX-2 -1195A→G (rs689466) primers and probes were: primers: 5’-GCA CTA CCC ATG ATA 
GAT GTT AAA CAA A-3’ and 5’-TGG AAC ATA GTT GGA TGA GGA ATT AAT-3’: probes: A-allele: 5’-
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FAM-ATG AAA TTC CAA CTG TCA AAA TCT CCC TT-BHQ-1-3’ and G-allele: 5’-Yakima Yellow-ATG 
AAA TTC CAG CTG TCA AAA TCT CCC T-BHQ-1-3’ 47.  
For COX-2 +8473T→C (rs5275) primers and probes were: primers: 5’-ATG CAC TGA CTG TTT TTG 
TTT G-3’ and 5’-GTT TCC AAT GCA TCT TCC ATG A-3’: probes: T-allele: 5’-VIC-TGA CAG AAA 
AAT AAC CAA AA- MGB-3’ and C-allele: 5’-FAM-TGA CAG AAA AAT GAC CAA A- MGB-3’ 73.  
For COX-2 +3496T→C (rs2066826), we used a TaqMan® predesigned single nucleotide 
polymorphism (SNP) genotyping assay (assay ID: C__11997848_20).  
For COX-2 +306C→G (rs5277), we used a TaqMan® predesigned SNP genotyping assay (assay ID: 
C__7550198_10).  
For COX-2 +202G→A (rs2745557) primers and probes were: primers: 5’-TTG TGG GAA AGC TGG 
AAT ATC C-3’ and 5’-TGA CTT GGG AAA GAG CTT GGA-3’: probes: G-allele: 5’-FAM-CTT TCG 
GAC TCT AGC-MGB-3’ and A-allele: 5’-VIC-CTT TCG AAC TCT AGC G-MGB-3’.  
For PPARG Pro12Ala (rs1801282) primers and probes were: primers: 5’-GTT ATG GGT GAA ACT 
CTG GGA GAT-3’ and 5’-GTT ATG GGT GAA ACT CTG GGA GAT-3’: probes: C-allele: 5’'-FAM-CTC 
CTA TTG ACG CAG AAA GCG ATT C-BHQ-1-3’ and G-allele: 5’-Yakima Yellow-TCC TAT TGA CCC 
AGA AAG CGA TTC C-BHQ-1-3’ 73.  
For IL-1B -31T→C (rs1143627) primers and probes were: primers: 5’-CCC TTT CCT TTA ACT TGA 
TTG TGA-3’ and 5’-GGT TTG GTA TCT GCC AGT TTC TC-3’: probes: T-allele: 5’-Yakima Yellow-
CCT CGC TGT TTT TAT AGC TTT CAA AAG CAG A-BHQ-1-3’ and C-allele: 5’FAM-TCG CTG TTT 
TTA TGG CTT CTT TCA AAA GCA G-BHQ-1-3’ 74.  
For IL-1B -1464G→C (rs1143623) primers and probes were: primers: 5’-CAG TAG AAC CTA TTT 
CCC TCG TGT CT-3’ and 5’- TCA AAT TAG TAT GTG CCA GGT ATC G-3’. Probes: C-allele: 5’-
FAM-CTC CCT TGC ATA ATG-MGB-3’ and G-allele: 5’-VIC- CTC CCT TGG ATA ATG-MGB-3’ 75.  
For IL-1B -3737G→A (rs4848306) primers and probes were: primers: 5’-TGG ATC CAG GTT CTC 
AGA TTG G-3’ and 5’-GCT CAT ATA TCT AAG CCC TCC TTG TT-3’. Probes: A-allele: 5’-FAM-CAA 
GGA ACA TTC C-MGB-3’ and G-allele: 5’-VIC-CCA AGG GAC ATT CC-MGB-3’ 75.  
For NFKB1 -94ins/delATTG (rs28362491) primers and probes were: primers: 5’-CTA TGG ACC GCA 
TGA CTC TAT CAG-3’ and 5’-GGG CTC TGG CTT CCT AGC A-3’;  probes: ins-allele: 5’- FAM-ACC 
ATT GAT TGG GCC CGG-BHQ -1-3’ and del-allele: 5’-Yakima Yellow- CCG ACC ATT GGG CCC G -
BHQ-1-3’ 64. 
Statistical methods 
Descriptive statistics were used to characterize the study population by demographic characteristics 
and baseline levels of potential confounders, including NSAID use and BMI. Conditional logistic 
regression analysis was used to calculate IRRs for the associations between the exposure variables 
and PC 76.  
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Haplotype determination was based on combinatorial analysis. First, all possible haplotypes were 
identified. Second, homozygous haplotypes were included twice, and heterozygous haplotypes were 
only included once. In the haplotype analyses, no adjustment for confounders was performed, since 
the data used in the analysis were not reviewed on a per person level, but on a frequency level. 
Logistic regression analysis was used to calculate ORs. Wild type (WT) was defined as the allele with 
the highest frequency in the general population, because of the assumption that there is a selection 
pressure against the variant carrier. Furthermore, WT was used as reference in all genotype analyses 
(except for the haplotype analysis of COX-2 SNPs, in which the predefined risk haplotype was used as 
reference to compare the results with a similar study by Cheng et al. 53). Heterozygous and 
homozygous variant carriers were combined in the analyses, since no recessive associations were 
observed, to achieve a higher statistical precision.  
Although the associations between BMI or school education and PC risk were weak, all survival 
analyses were adjusted for these two characteristics, since the direction of the associations were 
compatible with the literature 6,66,77. This also allowed us to compare with the crude risk estimates.  
Risk estimates for PC overall applied to the total study population of 334 cases and controls. In the 
analyses by aggressiveness of PC, the risk estimates for aggressive and non-aggressive PC applied 
to subsets of case-control pairs with case type of aggressive (n=113) and non-aggressive (n=221) PC, 
respectively. We used SAS version 9.1 (SAS Institute Inc., Cary, NC, USA) in all statistical analyses. 
Results 
The baseline characteristics of PC cases and matched controls are presented in Table 2. BMI was 
inversely associated with PC risk, in other words, a high BMI was associated with a reduced PC risk 
(IRR=0.90; 95% CI:0.82-1.00; P=0.04). The duration of school education was associated with an 
increased risk of PC, although not statistically significant (IRR=1.42; 95% CI:0.98-2.06; P=0.06 for 
medium, and IRR=1.33; 95% CI:0.85-2.09; P=0.21 for long school education versus short education). 
The risk estimates for NSAID use and the remaining covariates in Table 2 were close to unity.  
SNP analyses and gene-gene interactions 
Among controls, the genotype distributions of all the studied polymorphisms were in Hardy-Weinberg 
equilibrium (data not shown). 
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Table 2. Baseline characteristics of PC cases and controls 
Variable Cases (N = 334) Controls (N = 334) IRRa  (95% CI) 
No. (%) Median (5-95%) No. (%) Median (5-95%) 
Age  59.0 (51.0-64.0)  59.0 (51.0-64.0) 0.95 (0.59-1.53) 
School education 
Short  (≤7 years) 
Medium (8-10 years) 
Long (>10 years) 
 
113 (33.8) 
133 (39.8) 
88 (26.4) 
 
 
 
137 (41.0) 
122 (36.5) 
75 (22.5) 
 
 
1.00 (ref.) 
1.42 (0.98-2.06) 
1.33 (0.85-2.09) 
BMI (kg/m2) overall 
BMI < 25 
BMI 25-30 
BMI > 30 
 
108 (32.3) 
181 (54.2) 
45 (13.5) 
26.1 (21.8-31.9)  
100 (29.9) 
173 (51.8) 
61 (18.3) 
26.8 (21.5-35.2) 0.90 (0.82-1.00)d 
 
Alcohol intake (g/day)  18.3 (1.9-81.3)  19.8 (2.8-67.7) 0.99 (0.90-1.08)e 
Smoking status 
Never 
Past 
Current 
 
86 (25.8) 
128 (38.3) 
120 (35.9) 
 
 
95 (28.4) 
129 (38.6) 
110 (32.9) 
 
 
1.00 (ref.) 
1.07 (0.71-1.61) 
1.25 (0.79-1.98) 
NSAID use  (% ever 
users)b 
56 (16.8) 
 
56 (16.8)  1.17 (0.76-1.80) 
Total energy 
(MJ/day) 
 10.8 (7.2-15.5)  11.0 (7.5-15.1) 0.99 (0.90-1.10)f 
Red meat (g/day)  93.6 (43.7-177.7)  99.5 (54.0-177.7) 0.91 (0.79-1.06)g 
Dietary fat (g/day)  96.3 (54.1-147.9)  97.1 (57.7-145.0) 0.87 (0.61-1.22)h 
Omega-3 fatty acids 
(g/day) 
 0.7 (0.3-1.7)  0.7 (0.3-1.6) 1.02 (0.66-1.58)i 
Calcium (mg/day)  1,132 (512-2,140)  1,063 (538-2,083) 1.16 (0.93-1.45)j 
D vitamin (μg/day)  5.2 (2.6-10.0)  5.0 (2.6-9.8) 1.06 (0.65-1.74)k 
E vitamin (α-TE/day)c  9.5 (5.3-17.1)  9.5 (5.3-16.1) 1.07 (0.77-1.56)l 
Selenium (μg/day)  53.5 (34.3-85.6)  53.4 (35.3-86.6) 1.04 (0.62-1.75)m 
Diabetes Mellitus 
No 
Yes 
 
324 (97.0) 
10 (3.0) 
 
 
325 (97.3) 
9 (2.7) 
 
 
1.00 (ref.) 
1.32 (0.51-3.4) 
Median values with 5th-95th percentiles or fraction of the distribution of potential confounders for PC among PC cases and 
controls. 
a IRR for PC - mutually adjusted  
b NSAID use is defined as ≥ 2 pills per week during the preceding year 
c 1 α-TE equals 1 mg R,R,R-α-tocopherol (the most active form of E vitamin) 
d Risk estimate per 2 kg/m2 increment of BMI 
e Risk estimate for the increment of 10 g alcohol per day 
f Risk estimate for the increment of 500 kJ energy per day 
g Risk estimate for the increment of 25 g red meat per day 
h Risk estimate for the increment of 25 g dietary fat per day 
i Risk estimate for the increment of 0.5 g omega-2 fatty acids per day 
j Risk estimate for the increment of 400 mg calcium per day 
k Risk estimate for the increment of 3 μg D vitamin per day 
l  Risk estimate for the increment of 5 α-TE E vitamin per day 
m Risk estimate for the increment of 20 μg Selenium per day 
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Carriers of the variant deletion allele of NFKB1 -94ins/delATTG had a 27% lowered risk of PC 
compared with WT carriers (95% CI:0.52-1.04; P=0.08) and, similarly, carriers of the variant C-allele of 
COX-2 +8473T→C had a 26% lowered PC risk (95% CI:0.53-1.04; P=0.08) (Table 3).  
Table 3. IRR for PC in relation to the studied polymorphisms 
Genotypes Ncases (%) 
(N=334) 
Ncontrols 
(%) 
(N=334) 
IRR (95% CI)a P-
valuec 
IRR (95% CI)b P-
valuec 
COX-2 -1195A→G 
AA 
AG 
GG 
AG + GG 
 
210 (63) 
111 (33) 
13 (4) 
123 (37) 
 
210 (63) 
112 (33) 
12 (4) 
124 (37) 
 
1.00 (ref.) 
1.02 (0.74-1.42) 
0.85 (0.38-1.91) 
1.00 (0.73-1.37) 
 
 
0.91 
 
1.00 
 
1.00 (ref.) 
1.04 (0.74-1.45) 
0.92 (0.41-2.10) 
1.02 (0.74-1.41) 
 
 
0.96 
 
0.90 
COX-2 +8473T→C 
TT 
TC 
CC 
TC + CC 
 
169 (51) 
130 (39) 
35 (10) 
165 (49) 
 
146 (44) 
154 (46) 
34 (10) 
188 (56) 
 
1.00 (ref.) 
0.74 (0.53-1.05) 
0.92 (0.53-1.60) 
0.77 (0.56-1.07) 
 
 
0.23 
 
0.12 
 
1.00 (ref.) 
0.72 (0.51-1.02) 
0.84 (0.48-1.49) 
0.74 (0.53-1.04) 
 
 
0.18 
 
0.08 
COX-2 +3496T→C 
TT 
TC 
CC 
TC + CC 
 
263 (79) 
67 (20) 
4 (1) 
71 (21) 
 
274 (82) 
53 (16) 
7 (2) 
60 (18) 
 
1.00 (ref.) 
1.37 (0.90-2.06) 
0.62 (0.18-2.13) 
1.28 (0.86-1.91) 
 
 
0.23 
 
0.23 
 
1.00 (ref.) 
1.32 (0.86-2.02) 
0.58 (0.17-2.01) 
1.23 (0.82-1.85) 
 
 
0.28 
 
0.32 
COX-2 +202G→A 
GG 
GA 
AA 
GA + AA 
 
223 (67) 
99 (30) 
12 (3) 
111 (33) 
 
236 (71) 
91 (27) 
7 (2) 
98 (29) 
 
1.00 (ref.) 
1.14 (0.81-1.62) 
1.79 (0.70-4.58) 
1.19 (0.85-1.66) 
 
 
0.40 
 
0.31 
 
1.00 (ref.) 
1.11 (0.80-1.58) 
1.86 (0.72-4.86) 
1.16 (0.83-1.64) 
 
 
0.41 
 
0.38 
COX-2 +306C→G 
CC 
CG 
GG 
CG + GG 
 
227 (68) 
98 (29) 
9 (3) 
107 (32) 
 
228 (68) 
99 (30) 
7 (2) 
106 (32) 
 
1.00 (ref.) 
0.99 (0.70-1.40) 
1.16 (0.39-3.49) 
1.00 (0.72-1.40) 
 
 
0.96 
 
1.00 
 
1.00 (ref.) 
0.96 (0.70-1.41) 
1.22 (0.40-3.73) 
1.01 (0.72-1.42) 
 
 
0.94 
 
0.97 
PPARG Pro12Ala 
CC 
CG 
GG 
CG + GG 
 
241 (72) 
90 (27) 
3 (1) 
93 (28) 
 
245 (73) 
87 (26) 
2 (1) 
89 (27) 
 
1.00 (ref.) 
1.14 (0.78-1.65) 
1.03 (0.15-7.35) 
1.13 (0.78-1.64) 
 
 
0.80 
 
0.51 
 
1.00 (ref.) 
1.10 (0.75-1.60) 
0.91 (0.12-6.74) 
1.09 (0.75-1.59) 
 
 
0.89 
 
0.65 
NFKB1 -94ins/delATTG 
ins/ins 
ins/del 
del/del 
ins/del + del/del 
 
128 (38) 
152 (46) 
54 (16) 
206 (62) 
 
109 (33) 
161 (48) 
64 (19) 
225 (67) 
 
1.00 (ref.) 
0.81 (0.57-1.15) 
0.73 (0.46-1.17) 
0.79 (0.57-1.11) 
 
 
0.36 
 
0.17 
 
1.00 (ref.) 
0.74 (0.52-1.06) 
0.71 (0.44-1.15) 
0.73 (0.52-1.04) 
 
 
0.21 
 
0.08 
IL-1B -31T→C 
TT 
TC 
CC 
TC + CC 
 
134 (40) 
178 (53) 
22 (7) 
200 (60) 
 
148 (44) 
143 (43) 
43 (13) 
186 (56) 
 
1.00 (ref.) 
1.48 (1.06-2.08) 
0.56 (0.30-1.05) 
1.27 (0.92-1.74) 
 
 
0.004 
 
0.15 
 
1.00 (ref.) 
1.58 (1.11-2.24) 
0.56 (0.30-1.07) 
1.32 (0.96-1.84) 
 
 
0.002 
 
0.09 
IL-1B -1464G→C 
GG 
GC 
CC 
GC + CC 
 
170 (51) 
149 (45) 
15 (4) 
164 (49) 
 
179 (54) 
130 (39) 
25 (7) 
155 (46) 
 
1.00 (ref.) 
1.27 (0.92-1.76) 
0.69 (0.34-1.41) 
1.18 (0.86-1.62) 
 
 
0.14 
 
0.30 
 
1.00 (ref.) 
1.30 (0.93-1.81) 
0.72 (0.35-1.48) 
1.21 (0.88-1.67) 
 
 
0.14 
 
0.24 
IL-1B -3737G→A 
GG 
GA 
AA 
GA + AA 
 
107 (32) 
162 (49) 
65 (19) 
227 (68) 
 
106 (32) 
172 (51) 
56 (17) 
228 (68) 
 
1.0 (ref.) 
0.88 (0.62-1.26) 
1.08 (0.68-1.72) 
0.92 (0.66-1.30) 
 
 
0.60 
 
0.67 
 
1.00 (ref.) 
0.87 (0.30-1.25) 
0.99 (0.62-1.60) 
0.90 (0.63-1.27) 
 
 
0.69 
 
0.54 
a Crude 
b Adjusted for BMI and school education at baseline 
c P-value for trend  
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Heterozygous variant carriers of IL-1B -31T→C had a 1.6-fold higher PC risk (95% CI:1.11-2.24; 
P=0.002) than homozygous WT carriers, whereas homozygous variant carriers had a 44% lowered 
risk (95% CI:0.30-1.07; P=0.002). In combined analysis of heterozygous and homozygous variant 
carriers, there was no association between IL-1B -31T→C and risk of PC (IRR=1.32; 95% CI:0.96-
1.84; P=0.09). 
Haplotype analysis of the five COX-2 SNPs identified six haplotypes covering 88% of the variation 
among cases and controls (Table 4). No statistically significant associations with risk of PC were 
observed. A predefined risk haplotype defined by the variant G-allele of COX-2 +306C→G 53 was not 
associated with risk of PC.  
Table 4. Association between COX-2 haplotypes and PC risk 
-1195A→G +202G→A +306C→G +3496T→C +8473T→C Nhaplotype in case/controls (%) OR (95% CI) 
A A C T T (18) 123/103 (15) 1.00 (ref.) 
A G C T T  (14) 92/90 (13) 0.86 (0.58-1.27) 
G G C T T (17) 111/101 (15) 0.92 (0.63-1.34) 
A G C T C (15) 103/122 (18) 0.71 (0.49-1.02) 
A G G T T (17) 116/112 (17) 0.87 (0.60-1.25) 
A G C C C (9) 57/52 (8) 0.92 (0.58-1.45) 
Bold letters indicate the polymorphic bases. The reference haplotype is defined as the AACTT similar to the study by Cheng et al. 
53.  
 
Haplotype analysis of the IL-1B SNPs identified four haplotypes covering 99% of the variation among 
cases and controls (Table 5). No associations were found between these haplotypes and PC risk. 
Stratification according to aggressiveness of PC (Table 6) showed that carriers of the variant deletion 
allele of NFKB1 -94ins/delATTG had a lowered risk of non-aggressive PC (IRR=0.64; 95% CI:0.42-
0.99; P=0.05), but not of aggressive PC (IRR=0.93; 95% CI:0.52-1.67; P=0.81). 
 
Table 5. Association between IL-1B haplotypes and PC risk 
-3737G→A -1464G→C -31T→C Nhaplotype in case/controls (%) OR (95% CI) 
G G T (23) 156/157 (24) 1.00 (ref.) 
G C C (27) 178/175 (26) 1.02 (0.76-1.39) 
A G T (34) 288/281 (42) 1.03 (0.78-1.36) 
G G C (6) 42/49 (7) 0.86 (0.54-1.38) 
Bold letters indicate the polymorphic bases. The reference haplotype is defined as the WT haplotype. 
 
Presence of the NFKB1 -94/ins/delATTG polymorphism was consistently, although only borderline 
statistically significantly associated with a reduced risk of PC. A similar pattern was seen for COX-2 
+8473T→C. An interaction analysis revealed an additive effect between NFKB1 -94ins/delATTG and 
COX-2 8473T→C, resulting in an additionally lowered risk of PC of 46% (95% CI:0.33-0.88) (data not 
shown), compared with individual risk estimates of 30% for NFKB1 -94ins/delATTG (95% CI:0.43-
1.14) and 30% for COX-2 +8473T→C (95% CI:0.40-1.21; P for interaction=0.77).  
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Gene-environment analyses 
We found no interaction between the studied polymorphisms and NSAID use (Table 7). Carriers of the 
variant allele of NFKB1 -94ins/delATTG had a lowered risk of PC among non-users of NSAIDs 
(IRR=0.68; 95% CI:0.47-0.99; P for interaction=0.30) only. Moreover, NSAID use was not associated 
with risk of total PC or non-aggressive PC, whereas a borderline statistically significantly increased 
risk was observed for aggressive PC (IRR=2.08; 95% CI:0.96-4.52; P=0.06) compared with non-use of 
NSAIDs (data not shown). 
Table 6. The studied polymorphisms in relation to aggressiveness 
a Crude.  
b Adjusted for BMI and school education at baseline. 
c P = 0.05 
 
There was a trend towards a reduced risk of PC among obese men (Table 8). For both NFKB1 -
94ins/delATTG and COX-2 +8473T→C, there seemed to be a consistent additive effect between BMI 
and genotype (Table 8). Obese carriers of the WT of both polymorphisms exhibited a reduced risk of 
PC, whereas all men carrying the variant deletion or C-allele experienced a reduced risk. The risk 
decrease was most pronounced among the obese, albeit this finding was not statistically significant. 
BMI was also associated with severity of PC (data not shown). Among obese men, the lower risk of 
total PC was due to a reduction in risk of non-aggressive PC (IRR=0.64; 95% CI:0.35-1.17; P=0.12), 
whereas a risk estimate above unity, although based on small numbers, was observed for aggressive 
PC (IRR=1.20; 95% CI:0.45-3.19; P=0.57). 
Genotypes Naggr. 
(%) 
(N=113) 
Nnon-aggr. 
(%) 
(N=221) 
Aggressive PC  Non-aggressive PC 
IRR (95% CI)a IRR (95% CI)b  IRR (95% CI)a IRR (95% CI)b 
COX-2 -1195A→G 
AA 
AG + GG 
 
72 (64) 
41 (36) 
 
138 (62) 
83 (38) 
 
1.00 (ref.) 
0.92 (0.53-1.61) 
 
1.00 (ref.) 
0.96 (0.55-1.70) 
  
1.00 (ref.) 
1.04 (0.71-1.52) 
 
1.00 (ref.) 
1.04 (0.71-1.54) 
COX-2 +8473T→C 
TT 
TC + CC 
 
56 (50) 
57 (50) 
 
113 (51) 
108 (49) 
 
1.00 (ref.) 
0.90 (0.54-1.51) 
 
1.00 (ref.) 
0.88 (0.51-1.50) 
  
1.00 (ref.) 
0.70 (0.47-1.07) 
 
1.00 (ref.) 
0.68 (0.44-1.05) 
COX-2 +3496T→C 
TT 
TC + CC 
 
88 (78) 
25 (22) 
 
175 (79) 
46 (21) 
 
1.00 (ref.) 
1.82 (0.87-3.79) 
 
1.00 (ref.) 
1.66 (0.78-3.52) 
  
1.00 (ref.) 
1.09 (0.68-1.77) 
 
1.00 (ref.) 
1.08 (0.66-1.78) 
COX-2 +202G→A 
GG 
GA + AA 
 
77 (68) 
36 (32) 
 
146 (66) 
75 (34) 
 
1.00 (ref.) 
1.04 (0.60-1.80) 
 
1.00 (ref.) 
0.96 (0.54-1.70) 
  
1.00 (ref.) 
1.29 (0.84-1.97) 
 
1.00 (ref.) 
1.27 (0.83-1.96) 
COX-2 +306C→G 
CC 
CG + GG 
 
79 (70) 
34 (30) 
 
148 (67) 
73 (33) 
 
1.00 (ref.) 
0.80 (0.44-1.44) 
 
1.00 (ref.) 
0.85 (0.47-1.56) 
  
1.00 (ref.) 
1.12 (0.74-1.68) 
 
1.00 (ref.) 
1.13 (0.74-1.72) 
PPARG Pro12Ala 
CC 
CG + GG 
 
76 (67) 
37 (33) 
 
165 (75) 
56 (25) 
 
1.00 (ref.) 
1.22 (0.66-2.28) 
 
1.00 (ref.) 
1.18 (0.62-2.24) 
  
1.00 (ref.) 
1.09 (0.69-1.72) 
 
1.00 (ref.) 
1.07 (0.67-1.72) 
NFKB194ins/delATTG 
ins/ins 
ins/del + del/del 
 
43 (38) 
70 (62) 
 
85 (38) 
136 (62) 
 
1.00 (ref.) 
1.00 (0.57-1.76) 
 
1.00 (ref.) 
0.93 (0.52-1.67) 
  
1.00 (ref.) 
0.69 (0.46-1.06) 
 
1.00 (ref.) 
0.64c (0.42-0.99) 
IL-1B -31T→C 
TT 
TC + CC 
 
44 (39) 
69 (61) 
 
90 (41) 
125 (59) 
 
1.00 (ref.) 
1.30 (0.76-2.25) 
 
1.00 (ref.) 
1.36 (0.78-2.36) 
  
1.00 (ref.) 
1.24 (0.84-1.84) 
 
1.00 (ref.) 
1.35 (0.90-2.03) 
IL-1B -1464G→C 
GG 
GC + CC 
 
54 (48) 
59 (52) 
 
116 (52) 
105 (48) 
 
1.00 (ref.) 
1.29 (0.76-2.20) 
 
1.00 (ref.) 
1.31 (0.76-2.26) 
  
1.00 (ref.) 
1.13 (0.76-1.67) 
 
1.00 (ref.) 
1.21 (0.81-1.81) 
IL-1B -3737G→A 
GG 
GA + AA 
 
39 (35) 
74 (65) 
 
68 (31) 
153 (69) 
 
1.00 (ref.) 
0.83 (0.46-1.51) 
 
1.00 (ref.) 
0.76 (0.41-1.41) 
  
1.00 (ref.) 
0.98 (0.65-1.48) 
 
1.00 (ref.) 
0.94 (0.62-1.44) 
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Table 7. Interaction between the studied genotypes and NSAID use in relation to the risk of PC 
Genotypes NSAID use 
Ncases/Ncontrols 
NSAID use 
IRR (95% CI)a 
Pc NSAID use 
(IRR 95% CI)b 
Pc 
No Yes No Yes  No Yes  
COX-2 -1195A→G 
AA 
AG + GG 
 
172/172 
106/106 
 
38/38 
18/18 
 
1.00 (ref.) 
1.01 (0.72-1.43) 
 
1.10 (0.67-1.79) 
1.02 (0.52-1.98) 
0.83 
 
1.00 (ref.) 
1.03 (0.72-1.45) 
 
1.10 (0.67-1.80) 
1.11 (0.56-2.20) 
0.97 
COX-2 +8473T→C 
TT 
TC + CC 
 
146/127 
132/151 
 
23/19 
33/37 
 
1.00 (ref.) 
0.78 (0.54-1.11) 
 
1.13 (0.59-2.19) 
0.83 (0.49-1.43) 
0.91 
 
1.00 (ref.) 
0.74 (0.51-1.07) 
 
1.15 (0.59-2.26) 
0.83 (0.48-1.43) 
0.96 
COX-2 +3496T→C 
TT 
TC + CC 
 
224/227 
54/51 
 
39/47 
17/9 
 
1.00 (ref.) 
1.11 (0.72-1.71) 
 
0.88 (0.56-1.40) 
2.31 (0.95-5.66) 
0.10 
 
1.00 (ref.) 
1.04 (0.67-1.64) 
 
0.89 (0.56-1.43) 
2.36 (0.95-5.85) 
0.08 
COX-2 +202G→A 
GG 
GA + AA 
 
181/193 
97/85 
 
42/43 
14/13 
 
1.00 (ref.) 
1.17 (0.82-1.68) 
 
1.04 (0.64-1.67) 
1.50 (0.66-3.43) 
0.67 
 
1.00 (ref.) 
1.15 (0.79-1.66) 
 
1.06 (0.65-1.73) 
1.52 (0.65-3.53) 
0.66 
COX-2 +306C→G 
CC 
CG + GG 
 
188/188 
90/90 
 
39/40 
17/16 
 
1.00 (ref.) 
1.00 (0.70-1.43) 
 
1.06 (0.66-1.72) 
1.08 (0.51-2.26) 
0.97 
 
1.00 (ref.) 
1.02 (0.71-1.48) 
 
1.12 (0.69-1.83) 
1.05 (0.49-2.23) 
0.85 
PPARG Pro12Ala 
CC 
CG + GG 
 
198/204 
80/74 
 
43/41 
13/15 
 
1.00 (ref.) 
1.18 (0.79-1.77) 
 
1.13 (0.71-1.80) 
1.05 (0.48-2.28) 
0.63 
 
1.00 (ref.) 
1.13 (0.75-1.71) 
 
1.15 (0.72-1.86) 
1.03 (0.47-2.29) 
0.64 
NFKB194ins/delATTG 
ins/ins 
ins/del + del/del 
 
107/86 
171/192 
 
21/23 
35/33 
 
1.00 (ref.) 
0.75 (0.52-1.08) 
 
0.84 (0.43-1.63) 
0.89 (0.50-1.56) 
0.41 
 
1.00 (ref.) 
0.68 (0.47-0.99) 
 
0.80 (0.40-1.58) 
0.85 (0.48-1.52) 
0.30 
IL-1B -31T→C 
TT 
TC + CC 
 
112/127 
166/151 
 
22/21 
34/35 
 
1.00 (ref.) 
1.35 (0.96-1.91) 
 
1.38 (0.72-2.65) 
1.23 (0.71-2.15) 
0.33 
 
1.00 (ref.) 
1.41 (0.99-2.00) 
 
1.38 (0.71-2.67) 
1.35 (0.76-2.40) 
0.41 
IL-1B -1464G→C 
GG 
GC + CC  
 
141/154 
137/124 
 
29/25 
27/31 
 
1.00 (ref.) 
1.32 (0.93-1.87) 
 
1.45 (0.80-2.60) 
1.06 (0.60-1.85) 
0.15 
 
1.00 (ref.) 
1.35 (0.95-1.93) 
 
1.50 (0.82-2.72) 
1.10 (0.62-1.96) 
0.15 
IL-1B -3737G→A 
GG 
GA + AA  
 
88/86 
190/192 
 
19/20 
37/36 
 
1.00 (ref.) 
0.91 (0.62-1.33) 
 
1.00 (0.49-2.04) 
1.00 (0.59-1.71) 
0.83 
 
1.00 (ref.) 
0.87 (0.59-1.29) 
 
1.00 (0.48-2.06) 
1.00 (0.58-1.72) 
0.75 
a Crude 
b Adjusted for BMI  and school education at baseline 
c P-value for interaction on a multiple scale 
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Discussion 
We evaluated whether inflammation is a risk factor for PC by assessing whether genetically 
determined differences in the inflammatory response were associated with the development of PC. 
Specifically, we examined associations between polymorphisms in selected inflammatory genes and 
risk of PC. Analyses of baseline characteristics indicated an inverse association between BMI and risk 
of PC and a tendency toward and increasing PC risk with increasing length of education. We found no 
association between the weekly use of NSAID and the risk of PC. 
If inflammation is a risk factor for PC, a genetically determined high inflammatory response should be 
associated with PC, and vice versa. We found that none of the studied polymorphisms were 
associated with PC risk; however, at tendency toward an associated with PC risk was seen for one 
polymorphism. Carriers of the variant deletion allele of NFKB1 -94ins/delATTG had a marginal and not 
statistically significant 27% reduced risk of PC. Risk reductions were seen for variant carriers of 
NFKB1 -94ins/delATTG among non-users of NSAIDs (32%), for non-aggressive PC cases (36%), and 
among men with a BMI above 30 kg/m2 (44%). Moreover, an additive effect between NFKB1 -
94ins/delATTG and COX-2 +8473T→C was observed. Carriers of variant alleles of both 
polymorphisms had a 46% reduced risk of PC. These risk reductions only showed a tendency and 
were not statistically significant (except for the interaction between NFKB1 -94ins/delATTG and non-
aggressive PC cases), which could be due to the low number of persons in each strata or it could be 
attributable to chance findings.  
An association between NFKB1 -94ins/delATTG and PC has previously been observed by Zhang et 
al., who reported an 1.5-fold increased risk for PC among WT carriers of NFKB1 -94ins/delATTG (95% 
CI:1.03-2.08) compared with variant allele carriers 60. This finding is compatible with the reduced risk 
for PC observed among variant carriers in our study. The ins/del NFKB1 polymorphism was included 
because of its proven functionality and biological effects 58,59. Deletion of an ATTG repeat in the 
promoter region of NFKB1 abolishes the binding of a nuclear factor and leads to less promoter 
transcriptional activity and less p50 biosynthesis 58. The NF-κB p50 dimer activates transcription of C-
reactive protein (CRP) with IL-6 and IL-1β,  and deletion allele carriers of the NFKB1 polymorphism 
have lower baseline plasma CRP levels in an allele-dose-dependent manner 59.  
NF-κB is a transcription factor that is a homo- or heterodimer consisting of a number of different 
subunits p65, p50, p105, C-rel and relB 78,79, and the target gene specificity of NF-κB is determined by 
the subunits. The p50 subunit encoded by NFKB1 has both pro- and anti-inflammatory properties. The 
p65/p50 NF-κB transcription factor complex is pro-inflammatory, controlling transcription of pro-
inflammatory cytokines, such as tumor necrosis factor (TNF) and IL-1β 79. Conversely, p50 has anti-
inflammatory properties in the p50 homodimer, which represses transcription of pro-inflammatory 
cytokines such as TNF and IL-12 and stimulates transcription of the anti-inflammatory cytokine IL-10 
and the acute phase protein CRP 59,78,80,81.  The relative abundance of p50/p65 heterodimers and p50 
homodimers will therefore determine the magnitude of inflammation by balancing the pro-inflammatory 
and anti-inflammatory response 78. We therefore believe that partial depletion of p50 will disfavour the 
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anti-inflammatory response, because the formation of the pro-inflammatory p65/p50 heterodimer 
depends on the concentration of p50, whereas the formation of the anti-inflammatory p50 homodimer 
depends on the concentration of p50 squared 59.  
Consequently, the anti-inflammatory response is more affected by the genetically determined partial 
p50 depletion of the deletion allele than the pro-inflammatory response. Thus, the pro-inflammatory 
allele (deletion allele) appears to be associated with a lower PC risk. 
One might assume that NFKB1 -94ins/delATTG would be more strongly associated with aggressive 
PC. However, we found that carriers of the variant deletion allele of NFKB1 -94ins/delATTG had a 
lower risk of non-aggressive PC, but not of aggressive PC. Zhang et al. found no difference between 
low-grade (non-aggressive) and high-grade (aggressive) PC. Furthermore, Zhang et al., found no 
difference between localized (low TNM stage) and advanced (high TNM stage) PC.  
In the haplotype analyses of the COX-2 SNPs, the haplotype frequencies were comparable to similar 
analyses in the study by Cheng et al. 53. We were not able to reproduce the findings regarding the 
previously found risk haplotype defined by the variant allele of the G-allele of COX-2 +306C→G. In 
fact, all the risk estimates in our study were less than unity, in contrast to the estimates by Cheng et al. 
who were above unity.  
NFKB1 -94ins/delATTG may be associated with the risk of non-aggressive PC. However, our results 
imply that genetically determined low NFKB1-mediated anti-inflammatory response in the prostate 
lowers the risk of non-aggressive PC, but not of aggressive PC.  
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Table 8. Interaction between the studied polymorphisms and BMI in relation to the risk of PC 
Genotypes BMI (kg/m)2 
Ncases/Ncontrols  
BMI (kg/m2) 
IRR (95% CI)a 
P-valuec BMI (kg/m2) 
IRR (95% CI)b 
P-valuec 
< 25 25-30 > 30 < 25 25-30 > 30 < 25 25-30 > 30 
COX-2 -1195A→G 
AA 
AG + GG 
 
70/63 
38/37 
 
113/110 
68/63 
 
27/37 
18/24 
  
1.00 (ref.) 
0.92 (0.51-1.66) 
 
0.90 (0.57-1.41) 
0.94 (0.58-1.53) 
 
0.66 (0.35-1.22) 
0.72 (0.35-1.49) 
0.92 
 
1.00 (ref.) 
0.90 (0.49-1.64) 
 
0.93 (0.59-1.47) 
1.01 (0.62-1.65) 
 
0.69 (0.37-1.30) 
0.77 (0.37-1.61) 
0.88 
COX-2 +8473T→C 
TT 
TC + CC 
 
49/35 
59/65 
 
95/82 
86/91 
 
25/29 
20/32 
  
1.00 (ref.) 
0.75 (0.43-1.32) 
 
0.89 (0.52-1.52) 
0.72 (0.42-1.23) 
 
0.71 (0.35-1.47) 
0.51 (0.25-1.03) 
0.96 
 
1.00 (ref.) 
0.76 (0.43-1.34) 
 
0.96 (0.56-1.66) 
0.75 (0.43-1.31) 
 
0.77 (0.37-1.62) 
0.54 (0.26-1.11) 
0.97 
COX-2 +3496T→C 
TT 
TC + CC 
 
86/81 
22/19 
 
140/145 
41/28 
 
37/48 
8/13 
  
1.00 (ref.) 
1.24 (0.61-2.52) 
 
0.89 (0.60-1.32) 
1.40 (0.78-2.51) 
 
0.77 (0.44-1.34) 
0.59 (0.23-1.51) 
0.45 
 
1.00 (ref.) 
1.22 (0.59-2.51) 
 
0.95 (0.64-1.42) 
1.41 (0.78-2.55) 
 
0.83 (0.47-1.47) 
0.60 (0.23-1.53) 
0.44 
COX-2 +202G→A 
GG 
GA + AA 
 
78/74 
30/26 
 
119/119 
62/54 
 
26/43 
19/18 
  
1.00 (ref.) 
1.06 (0.58-1.96) 
 
0.91 (0.60-1.38) 
1.07 (0.65-1.75) 
 
0.61 (0.34-1.08) 
1.00 (0.47-2.12) 
0.66 
 
1.00 (ref.) 
1.00 (0.54-1.87) 
 
0.96 (0.63-1.47) 
1.08 (0.66-1.77) 
 
0.64 (0.36-1.16) 
1.03 (0.48-2.20) 
0.64 
COX-2 +306C→G 
CC 
CG + GG 
 
80/77 
28/23 
 
115/116 
66/57 
 
32/35 
13/26 
  
1.00 (ref.) 
1.08 (0.55-2.14) 
 
0.92 (0.60-1.41) 
1.06 (0.65-1.73) 
 
0.89 (0.48-1.65) 
0.51 (0.24-1.08) 
0.35 
 
1.00 (ref.) 
1.20 (0.60-2.40) 
 
1.02 (0.66-1.58) 
1.11 (0.68-1.81) 
 
0.98 (0.52-1.83) 
0.55 (0.26-1.17) 
0.35 
PPARG Pro12Ala 
CC 
CG + GG 
 
78/75 
30/26 
 
129/131 
52/42 
 
34/40 
11/21 
  
1.00 (ref.) 
1.24 (0.65-2.35) 
 
0.93 (0.62-1.40) 
1.22 (0.70-2.14) 
 
0.87 (0.49-1.54) 
0.53 (0.23-1.23) 
0.32 
 
1.00 (ref.) 
1.23 (0.64-2.34) 
 
0.98 (0.65-1.48) 
1.29 (0.73-2.29) 
 
0.94 (0.52-1.71) 
0.55 (0.24-1.27) 
0.27 
NFKB1 -94ins/delATTG 
ins/ins 
ins/del + del/del 
 
43/37 
65/63 
 
66/50 
115/123 
 
19/22 
26/39 
  
1.00 (ref.) 
0.90 (0.49-1.66) 
 
1.07 (0.59-1-97) 
0.78 (0.45-1.35) 
 
0.79 (0.35-1.78) 
0.57 (0.28-1.18) 
0.85 
 
1.00 (ref.) 
0.84 (0.45-1.57) 
 
1.11 (0.60-2.04) 
0.79 (0.45-1.37) 
 
0.86 (0.38-1.97) 
0.56 (0.27-1.16) 
0.87 
IL-1B -31T→C 
TT 
TC + CC 
 
45/49 
63/51 
 
72/72 
109/101 
 
17/27 
28/34 
  
1.00 (ref.) 
1.43 (0.82-2.51) 
 
1.05 (0.61-1.81) 
1.22 (0.74-2.02) 
 
0.64 (0.29-1.41) 
0.98 (0.52-1.88) 
0.78 
 
1.00 (ref.) 
1.55 (0.88-2.75) 
 
1.18 (0.68-2.07) 
1.34 (0.80-2.24) 
 
0.72 (0.32-1.61) 
1.10 (0.57-2.12) 
0.64 
IL-1B -1464G→C 
GG 
GC + CC 
 
57/57 
51/43 
 
90/87 
91/86 
 
23/35 
22/26 
  
1.00 (ref.) 
1.27 (0.72-2.25) 
 
1.00 (0.61-1.64) 
1.11 (0.68-1.79) 
 
0.67 (0.34-1.29) 
0.93 (0.46-1.89) 
0.85 
 
1.00 (ref.) 
1.32 (0.74-2.35) 
 
1.08 (0.66-1.79) 
1.19 (0.73-1.94) 
 
0.71 (0.36-1.41) 
1.03 (0.50-2.11) 
0.80 
IL-1B -3737G→A 
GG 
GA + AA 
 
35/22 
73/78 
 
57/62 
124/111 
 
15/22 
30/39 
  
1.00 (ref.) 
0.50 (0.26-0.97) 
 
0.52 (0.27-1.02) 
0.59 (0.32-1.10) 
 
0.39 (0.16-0.95) 
0.44 (0.21-1.95) 
0.10 
 
1.00 (ref.) 
0.48 (0.24-0.93) 
 
0.53 (0.27-1.05) 
0.61 (0.33-1.14) 
 
0.42 (0.17-1.02) 
0.46 (0.21-0.99) 
0.08 
a Crude 
b Adjusted for school education at baseline 
c P-value for interaction on a multiple scale 
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We found a statistically significantly increased risk of PC among heterozygous carriers of the variant allele of 
IL1B T-31C, whereas a reduced risk of PC was seen among homozygous carriers of the variant allele. A 
combined analysis of heterozygous and homozygous variant carriers did not reveal an association between 
IL-1B -31T→C and the risk of PC. However, the discrepant findings could be due to other functional SNPs 
near the IL-1B -31T→C polymorphism. A haplotype analysis with other functional polymorphisms in the IL-1B 
gene might reveal such effects, and we therefore conducted a haplotype analysis with three SNPs in IL1B, 
all with proven functionality 61. Previous studies have found associations between IL-1β -31T→C 
polymorphism and risk of lung cancer 48 and multiple myeloma 64; these findings are in agreement with the 
biological function of the SNP (higher transcriptional levels of IL-1β and, hence, a more aggressive 
inflammatory state). However, the haplotypes defined by the variant C-allele of IL-1β -31T→C (GGC) and by 
the variant C-allele of both IL-1β -31T→C and IL-1β -1464G→C (GCC) were not associated with increased 
risk of PC, even though these two haplotypes leads to increased transcriptional levels of IL-1β 61. Therefore, 
based on the results from our study, there is no indication that a high IL-1β expression is a risk factor for PC, 
and, hence, the discrepant findings for the association between IL-1B -31T→C and PC were likely due to 
chance. 
NSAID inhibits inflammation and specifically COX-2 25. If inflammation is a risk factor for PC, we would 
expect that genetically determined differences in inflammatory response would be associated with PC in the 
absence of NSAID use, but not in the presence of NSAID use. However, no overall association with NSAID 
use was seen in relation to risk of PC. When stratifying by genotype, we found no apparent interactions 
between the selected polymorphisms and NSAID use. An interaction between COX-2 -1195A→G and 
NSAIDs has been found in relation to breast and lung cancer risk 47,48. The fact that NSAID use did not 
protect against PC is consistent with lack of association with PC risk for the functional COX-2 SNPs. 
Consistent with this result, a recent study 82 was not able to find associations between CRP and other 
commonly used markers of inflammation and risk of PC, again indicating that inflammation is not a strong 
risk factor for PC. 
Two recent studies also found an apparent modifying effect of obesity for PC among carriers of certain SNPs 
of inflammatory genes, including COX-2 72,83. However, the study by Allott et al. 66 suggests that the 
associations between obesity and PC could be partly due to detection bias. The authors argue that digital 
rectal examination is more difficult and PSA levels are lower in obese men and that obesity therefore may be 
associated with an impaired detection of PC 66. In Denmark, however, PSA testing is not used nearly as 
frequently as in other Western countries, but it remains a possibility that our findings on obesity and PC are 
biased due to increasing use of PSA tests.  
We observed a tendency towards elevated risk estimates for PC among men with eight or more years of 
formal education. A similar pattern has been reported for women with breast cancer 57. It is possible that 
people with a higher educational background have a higher risk of PC and breast cancer. However, these 
findings may also be the result of a detection bias; individuals with higher education may visit the doctor 
more often and insist on participation in screening measures. For PC, PSA has been implemented as a 
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screening test in several countries, resulting in an increased incidence of PC, but with little impact on PC 
mortality 4.  
Our cases and controls were selected from the same population-based cohort, all with almost complete 
follow-up of the participants, which should minimize the risk for selection bias. For all participants, 
information on lifestyle factors was collected at enrolment, which minimized the risk for differential exposure 
misclassification between the cases and controls.  
Our study group has limited statistical power, with only 334 matched cases and controls. However, we have 
previously found associations between the polymorphisms we investigated and risk of cancer in similarly 
powered studies nested within the DCH cohort. For example, among 304 basal cell carcinoma (BCC) case-
control pairs, variant allele carriers of COX-2 A11905G with genetically determined low COX-2 activity had a 
reduced risk of BCC (IRR=0.65; 95% CI:0.47-0.89), and homozygous carriers of COX-2 T8473C, with 
genetically determined high COX-2 activity, were at increased risk of BCC (IRR=2.27; 95% CI:1.31-3.92) 47. 
Assuming Hardy–Weinberg equilibrium and the allele frequency of the control group of IL-1β -31T→C, we 
had an 84% chance of detecting an OR of 1.6 for variant allele carriers at a 5% significance level. Similarly, 
we had 87% chance of detecting an OR of 1.7 for variant allele carriers of Il-1β -3737G→A. However, 
considering the number of statistical tests and the obtained P values, chance also remains a possible 
explanation for our findings. 
Another limitation of our study is that we relied solely on Gleason scores in the categorization of PC 
aggressiveness. Recent evidence indicates that intermediate PC risk 84 - for example, PC with Gleason 
score 7 - has increasing aggressive potential with increasing quantities of Gleason score 4 components, in 
other words, from 3+4 to 4+3 85. Unfortunately, we did not have access to these pathological details. Further, 
we were not able to supplement the Gleason scores with data on clinical stage from the Cancer Registry 
because of the heavy underreporting of this information 86.  
In conclusion, this study did not indicate that inflammation is a major risk factor for aggressive PC.  
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Abstract 
Maintenance of a balance between commensal bacteria and the mucosal immune system is crucial and 
intestinal dysbiosis may be a key event in the pathogenesis of colorectal cancer (CRC). The toll-like receptor 
4 (TLR4) is an important pattern-recognition receptor that regulates inflammation and barrier function in the 
gut by a mechanism that involves activation of the nuclear factor–κB (NF-κB) transcription factor. Dietary and 
life style factors may impact these functions. We therefore used a Danish prospective case-cohort study of 
1010 CRC cases and 1829 randomly selected participants from the Danish Diet, Cancer and Health cohort 
to investigate three polymorphisms in NFKB1 and TLR4 and their possible interactions with diet and life style 
factors in relation to risk of CRC. Homozygous carriage of the variant allele of the TLR4/rs5030728 
polymorphism was associated with increased risk of CRC (incidence rate ratio (IRR)=1.30; 95% confidence 
interval (CI): 1.05-1.60; P=0.02 (gene-dose model); IRR=1.24; 95%CI: 1.01-1.51; P=0.04 (recessive model)). 
Del-carriers of the NFKB1/rs28362491 polymorphism had a 17% (95%CI: 1.03-1.34; P=0.02) increased risk 
of CRC compared to homozygous carriers of the ins-allele. However, none of these risk estimates withstood 
adjustment for multiple comparisons. We found no strong gene-environment interactions between the 
examined polymorphism and diet and life style factors in relation to CRC risk.   
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Introduction 
Colorectal cancer (CRC) is the third most common cancer type in men and the second in women worldwide 
1. Hereditary factors are estimated to contribute to only 35% of the risk 2 emphasizing the importance of 
environmental factors in the etiology of CRC. Indeed, dietary and lifestyle factors have been intensively 
studied for their role in colorectal carcinogenesis; and alcohol, smoking, obesity and high meat intake are 
now established risk factors for CRC 3-5. Intake of red and processed meat has the potential of inducing 
cancer by chemical carcinogens formed during cooking of meat at high temperatures 6, production of toxic 
fermentation compounds 7-9 or by inducing inflammation due to changes in bacterial composition 10. 
Conversely, fibre, fruit and vegetables provide short-chain fatty acids (SCFAs) to the colonic epithelium by 
fermentation of unabsorbed dietary fibre and starch 11-15. The SCFA butyrate is important for colonic integrity 
14, inhibits growth of cancer cells in vitro 16,17 and has anti-inflammatory properties mainly by the inhibition of 
nuclear factor–κB (NF-κB) activation 18. 
Toll-like receptors (TLR) are important pattern-recognition receptors that regulate inflammation and barrier 
function in the gut thereby maintaining a balance between commensal bacteria and the mucosal immune 
system 19,20. The receptor for gram-negative bacterial lipopolysaccharide (LPS), TLR4, regulates cell 
proliferation in response to cell injury through induction of cyclooxygenase 2 expression 21 in a cascade that 
involves activation of NF-κB and epidermal growth factor 22 suggesting that TLR4 is an important element in 
the transition from inflammation to neoplasia 19. Indeed, increased expression of TLR4 has been linked to 
development of inflammation-associated neoplasia 23-26. In addition, we have previously found evidence that 
inflammation may contribute to CRC carcinogenesis. Thus, genetically determined high IL-1β and COX-2 
levels were associated with increased risk of CRC 27. 
Dysbiosis in the gut may be a key event in the pathogenesis of both inflammatory bowel diseases (IBD) and 
CRC. Using functional single nucleotide polymorphisms (SNPs) and their interaction with diet and life style 
may reveal important pathways for colorectal carcinogenesis 28. Since TLR polymorphisms have been 
associated with IBD 29, we aimed to examine a possible mutual mechanism for IBD and CRC.   
We have previously shown that carriage of the variant del-allele of the functional ins/del NFKB1/rs28362491 
polymorphism is associated with increased risk of CRC and interacted with meat intake in a subset of the 
current study group 30 in agreement with results from two other studies also reporting increased risk of CRC 
among variant carriers of the polymorphism among a Malaysian 31 and a Swedish population 32, but not a 
Chinese study group 32. A functional SNP in TLR4 (rs4986790) has been extensively studied and has been 
associated with neoplastic progression in vitro 33, aggressive human colon cancer 33, IBD 34-37 and CRC 38-40. 
However others were not able to find an association between CRC and the SNP 41-43. In a Canadian study 44, 
intake of dietary saturated fatty acids was inversely related to blood level of high density lipoprotein 
cholesterol in individuals homozygous for the TLR4/rs5030728 G-allele. TLR4/rs5030728 may therefore 
interact with dietary components in the gut.  
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Thus, we expected that inflammation is an important factor in colorectal carcinogenesis and thus examined 
whether diet and life style factors (non-steroidal anti-inflammatory drugs (NSAID) and smoking) modify CRC 
risk by altering the mucosal immune response in the gut via interacting with TLR4 and NF-κB. We therefore 
evaluated three polymorphisms in NFKB1 and TLR4 and their possible interaction with diet and life style 
factors in a prospective cohort of 1010 CRC cases and 1829 randomly selected participants from the Danish 
Diet, Cancer and Health Study. 
Methods 
Studied subjects 
The Diet, Cancer and Health study is an ongoing Danish cohort study designed to investigate the relation 
between diet, lifestyle and cancer risk 45. The cohort consists of 57,053 persons, recruited between 
December 1993 and May 1997. All the subjects were born in Denmark, and the individuals were 50 to 64 
years of age and had no previous cancers at study entry. Blood samples and questionnaire data on diet and 
lifestyle were collected at study entry. 
Follow-up and endpoints 
Follow-up was based on population-based cancer registries. Between 1994 and 31th December 2009, 1010 
CRC cases were diagnosed. A sub-cohort of 1829 persons was randomly selected within the cohort. 28 
persons were both cases and sub-cohort due to the used study design 46. 245 with missing genotype data 
and 16 with missing data on risk factors were excluded. All information on genotypes and diet and lifestyle 
factors was available for 915 CRC cases and 1719 sub-cohort members. 
Dietary and lifestyle questionnaire 
Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-
economic factors were collected at enrolment using questionnaires and interviews and has been described 
in details elsewhere 27,47-49. In short, the food-frequency questionnaire, diet consumption was assessed in 12 
categories of predefined responses, ranking from ‘never’ to ‘eight times or more per day’. The daily intake 
was then calculated by FoodCalc 45. Smoking status was classified as never, past or current. Persons 
smoking at least 1 cigarette daily during the last year were classified as smokers. NSAID use (“Aspirin”, 
“Paracetamol”, “Ibuprofen”, or “Other pain relievers) was assessed as ≥ 2 pills per month during one year at 
baseline.  
Genotyping 
Buffy coat preparations were stored at minus 150°C until use. DNA was extracted as described 50. The DNA 
was genotyped by LGC KBioscience (LGC KBioscience, Hoddesdon, United Kingdom) by PCR-based 
KASP™ genotyping assay (http:// www.lgcgenomics.com/). NFKB1/rs28362491 was analysed and reported 
for a subset of the current study group 30. Two of the polymorphisms (NFKB1/rs28362491 and 
TLR4/rs4986790) were chosen based on known functionality and their association with CRC 30-33 and IBD 34-
37 from a literature search. The TLR4/rs5030728 polymorphism, on the other hand, has no known 
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functionality. However, TLR4/rs4986790 is tightly linked with TLR4/rs5030728 (D’: 1.0; r2: 0.017) using 
Haploview version 4.2 (Broad Institute of MIT and Harvard, Cambridge) 51 with HapMap3 Genome Browser 
release #2 (Phase 3) 52; and since TLR4/rs5030728 has a higher minor allele frequency in Caucasians than 
TLR4/rs4986790 (0.305 vs. 0.035), this polymorphism is more suitable for gene-environment interaction 
analyses. To confirm reproducibility, genotyping was repeated for 10% of the samples yielding 100% identity. 
Statistical analysis 
Deviation from Hardy-Weinberg equilibrium was assessed using a Chi-square test.  
Incidence rate ratios (IRR) and 95% Confidence Interval (CI) were calculated according to the principles for 
analysis of case-cohort studies using an un-weighted approach 46. Age was used as the time scale in the 
Cox regression models. Tests and confidence intervals were based on Wald’s tests using the robust 
estimate of the variance-covariance matrix for the regression parameters in the Cox regression models 53 as 
previously described 27,46,48,54-61. 
All models were adjusted for baseline values of risk factors for colorectal cancer such as body mass index 
(BMI) (kg/m2, continuous),  use of hormone replacement therapy (HRT) (never/past/current, among women),  
intake of dietary fibre (g/day, continuous), and red meat and processed meat (g/day, continuous) and in 
addition to suspected risk factors such as NSAID use (yes/no) and smoking status (never/past/current). 
Cereals, fibre, fruit and vegetables were also entered linearly. All analyses were stratified by gender, so that 
the basic (underlying) hazards were gender specific. For all the polymorphisms, IRR was calculated 
separately for heterozygous and homozygous variant allele carriers. For TLR4/rs4986790 and 
NFKB1/rs28362491, variant allele carriers were subsequently grouped for interaction analyses since no 
recessive effects were observed. TLR4/rs5030728 was inferred both in a gene-dose and a recessive mode 
in the subsequent analyses.  
Moreover, we assessed weekly use of NSAID based on the results of a study of colorectal cancer within the 
Diet, Cancer and Health cohort 62 reporting that long-term consistent use of Aspirin or Non-Aspirin NSAID 
appears necessary to achieve a protective effect. However, there were no differences in risk estimates 
between monthly or weekly use, consequently, to maintain the statistical power in the strata; we used 
monthly NSAID use in the analyses. 
The likelihood ratio test was used for interaction analyses between the studied polymorphisms and intake of 
red and processed meat, dietary fibre, cereals, fish, fruits, vegetables, alcohol intake, smoking status and 
NSAID use. In interaction analyses where the dietary factors were entered as categorical variables, tertile 
cutpoints were based on the empirical distribution among male and female cases, respectively. The possible 
interactions were investigated using the likelihood ratio test.  
All analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC). A p<0.05 was considered 
to be significant. Moreover, to test for multiple comparisons, Bonferroni correction was used. 
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Ethics statement 
All participants gave verbal and written informed consent. The Diet, Cancer and Health study was approved 
by the National Committee on Health Research Ethics (journal nr. (KF) 01-345/93) and the Danish Data 
Protection Agency. 
Results 
Baseline characteristics of the study population are presented in Table 1. Among sub-cohort members, the 
genotype distribution of the SNPs did not deviate from Hardy-Weinberg equilibrium (results not shown).  
Table 1. Baseline characteristics of the study participants by selected demographic and established 
CRC risk factors. 
Variable Cases Sub-cohort IRRa (95% CI) 
n (%) Median (5-95%) n (%) Median (5-95%)  
Total 915 (100)  1719 (100)   
Sex      
Men 515 (56)  920 (54)   
Women 400 (44)  799 (46)   
Age at inclusion (years)  58 (51-64)  56 (50-64)  
BMI (kg/m2)  26.3 (20.7-34.3)  25.6 (20.5-33.0) 1.03 (1.00-1.06)d 
Food intake (g/day)      
Alcoholb  15.1 (1.0-71.6)  14.2 (1.2-65.3) 1.03 (1.00-1.07)e 
Dietary fibre  19.9 (10.8-32.9)  20.7 (10.7-34.2) 0.88 (0.80-0.97)f 
Red and processed meat  113.1 (47.4-233.4)  108.9 (41.5-235.4) 1.03 (1.00-1.06)g 
Smoking status      
Never 274 (30)  572 (33)  1.00 (ref.) 
Past 280 (31)  513 (30)  1.04 (0.88-1.23) 
Current 361 (39)  634 (37)  1.11 (0.94-1.30) 
NSAID usec      
No 632 (69)  1174 (68)  1.00 (ref.) 
Yes 283 (31)  545 (32)  0.99 (0.86-1.14) 
HRT use among women      
Never 246 (62)  418 (52)  1.00 (ref.) 
Past 50  (13)  126 (16)  0.66 (0.49-0.90) 
Current 104 (26)  255 (32)  0.74 (0.59-0.93) 
Values are expressed as medians (5th and 95th percentiles) or as fractions (%).  
aIRRs for CRC – mutually adjusted. 
bAmong current drinkers. 
cNSAID use is defined as  ≥ 2 pills per month during one year. 
dRisk estimate per 2 kg/m2 increment of BMI. 
eRisk estimate for the increment of 10 g alcohol per day. 
fRisk estimate for the increment of 10 g dietary fibres per day. 
gRisk estimate for the increment of 25 g red and processed meat per day. 
 
Associations between polymorphisms and CRC 
Homozygous variant carriers of the TLR4/rs5030728 polymorphism were at 1.30-fold (95%CI: 1.05-1.60) 
increased risk of CRC in a gene-dose model and at 1.24-fold (95%CI: 1.01-1.51) increased risk of CRC 
compared to wild type and heterozygous carriers in a recessive model (Table 2). Moreover, carriers of the 
NFKB1 del-allele had a 17% (95%CI: 1.03-1.34) increased risk of CRC compared to homozygous carriers of 
the ins-allele (Table 2). These risk estimates did not, however, reach statistically significance after Bonferroni 
correction. There was no interaction between the two risk genotypes TLR4/rs5030728 and 
NFKB1/rs28362491 but on the other hand, there was no additive effect of being homozygous carrier of both 
variant alleles (Table S1). 
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Table 2. IRR for CRC in relation to the studied polymorphisms. 
  ncases (%) nsub-cohort (%) IRR
a (95% CI) IRRb (95% CI) P-valuec 
TLR4 rs4986790  
AA 
GA 
GG 
GA+GG 
 
839 (92) 
76 (8) 
0 (0) 
76 (8) 
 
1577 (92) 
141 (8) 
1 (0) 
142 (8) 
 
1.00 (ref.) 
0.99 (0.79-1.25) 
- 
0.99 (0.79-1.25) 
 
1.00 (ref.) 
1.00 (0.79-1.26) 
- 
1.00 (0.79-1.26) 
 
- 
0.98 
- 
0.97 
 rs5030728  
GG 
GA 
AA 
GA+AA 
AA vs. GG+GA 
 
405 (44) 
399 (44) 
111 (12) 
510 (56) 
111 (12) 
 
826 (48) 
731 (43) 
162 (9) 
398 (23) 
162 (9) 
 
1.00 (ref.) 
1.10 (0.96-1.26) 
1.30 (1.06-1.61) 
1.14 (1.00-1.30) 
1.24 (1.02-1.52) 
 
1.00 (ref.) 
1.11 (0.96-1.27) 
1.30 (1.05-1.60) 
1.14 (1.00-1.30) 
1.24 (1.01-1.51) 
 
- 
0.16 
0.02 
0.05 
0.04 
NFKB1 rs28362491 
Ins/Ins 
Ins/Del 
Del/Del 
Ins/Del+Del/Del 
 
320 (35) 
449 (49) 
146 (16) 
595 (65) 
 
679 (60) 
787 (46) 
253 (15) 
1040 (61) 
 
1.00 (ref.) 
1.19 (1.03-1.37) 
1.13 (0.93-1.37) 
1.17 (1.02-1.34) 
 
1.00 (ref.) 
1.19 (1.03-1.37) 
1.14 (0.94-1.38) 
1.17 (1.03-1.34) 
 
- 
0.02 
0.18 
0.02 
a Crude – adjusted for age and sex. 
b In addition, adjusted for smoking status, alcohol intake , HRT status (women only), BMI, use of NSAID, intake of red and processed 
meat, and dietary fibre. 
c P-value for the adjusted estimate 
 
 
Gene-environment analyses 
We found no interaction between any of the dietary factors and the studied polymorphisms in relation to risk 
of CRC in the linear analyses (Table S2). In the tertile analyses, there was weak interaction between 
TLR4/rs5030728 and intake of vegetables (Gene-dose model: P-value for interaction (Pint)=0.05; Recessive 
model: Pint=0.03) (Table 3). Moreover, a borderline statistically significant interaction between meat intake 
and the NFKB1/rs28362491 polymorphism (Pint=0.06) was found (Table 3). For ins-carriers, risk estimates 
were comparable across tertiles of meat intake. Conversely, among del-carriers, intake of meat in the second 
(IRR=1.46; 95%CI: 1.17-1.83) and third tertile (IRR=1.24; 95%CI: 0.99-1.56) was associated with risk of 
CRC, whereas del-allele carriers were not at risk in the first tertile with low meat intake (IRR=0.98; 95%CI: 
0.78-1.23). With regard to alcohol, variant carriers of NFKB1/rs28362491 and homozygous A-allele carriers 
of TLR4/rs5030728 were associated with CRC risk compared to the homozygous wild type carriers among 
participants with a low intake of alcohol. Furthermore, for variant carriers of all three polymorphisms, a low 
intake (first tertile) of alcohol was associated with the highest CRC risk compared with moderate (second 
tertile) intake - which was associated with the lowest risk - and high alcohol intake (third tertile) (Table 3).  
 
 
 
Table 3. IRR for CRC for tertiles of intake of dietary factors for the studied polymorphisms. 
 1.tertile 2.tertile 3.tertile 1.tertile 2.tertile 3.tertile P-value
b 1.tertile 2.tertile 3.tertile 1.tertile 2.tertile 3.tertile P-valueb 
 Nc Ns Nc Ns Nc Ns IRR (95%CI)
a IRR (95%CI)a IRR (95%CI)a  Nc Ns Nc Ns Nc Ns IRR (95%CI)
a IRR (95%CI)a IRR (95%CI)a  
TLR4/rs4986790 Red and processed meat        Fish  
AA 273 598 248 457 288 522 1.00 (ref.) 1.31 (1.11-1.55) 1.22 (1.04-1.54)  279 534 286 496 274 547 1.00 (ref.) 1.02 (0.86-1.20) 0.92 (0.77-1.10)  
GA+GG 29 49 27 48 20 45 1.15 (0.77-1.72) 1.22 (0.85-1.76) 0.98 (0.62-1.55) 0.49 27 48 21 46 28 48 1.06 (0.70-1.60) 0.85 (0.55-1.32) 0.93 (0.63-1.37) 0.72 
       Dietary cereal        Dietary fibre  
AA 282 445 277 534 280 598 1.00 (ref.) 0.88 (0.74-1.05) 0.94 (0.75-1.17)  279 479 277 464 283 634 1.00 (ref.) 0.99 (0.84-1.16) 0.81 (0.69-0.96)  
GA+GG 19 44 30 42 27 56 0.74 (0.46-1.19) 1.01 (0.69-1.47) 0.96 (0.64-1.46) 0.33 21 48 29 36 26 58 0.78 (0.49-1.22) 1.29 (0.88-1.90) 0.72 (0.49-1.07) 0.19 
       Fruit        Vegetables  
AA 275 487 287 535 277 555 1.00 (ref.) 0.96 (0.81-1.14) 0.95 (0.77-1.16)  275 466 278 549 286 562 1.00 (ref.) 1.02 (0.86-1.21) 1.08 (0.89-1.32)  
GA+GG 25 39 22 52 29 51 1.04 (0.69-1.56) 0.81 (0.52-1.27) 0.97 (0.66-1.44) 0.75 28 34 26 59 22 49 1.17 (0.79-1.72) 0.91 (0.60-1.38) 0.95 (0.62-1.47) 0.55 
       Alcohol          
AA 288 517 277 578 274 482 1.00 (ref.) 0.92 (0.78-1.08) 1.10 (0.93-1.31)            
GA+GG 33 42 22 53 21 47 1.23 (0.86-1.78) 0.80 (0.52-1.22) 0.89 (0.57-1.40) 0.28           
TLR4/rs5030728 Red and processed meat        Fish  
GG 134 295 134 255 137 276 1.00 (ref.) 1.19 (0.94-1.51) 1.08 (0.86-1.36)  127 284 139 262 139 280 1.00 (ref.) 1.08 (0.86-1.37) 1.00 (0.78-1.27)  
GA 133 284 134 210 132 237 1.00 (0.79-1.27) 1.34 (1.06-1.69) 1.26 (1.00-1.60)  137 240 131 227 131 264 1.21 (0.94-1.54) 1.13 (0.89-1.44) 1.03 (0.81-1.32)  
AA 35 68 37 40 39 54 1.06 (0.73-1.55) 1.70 (1.19-2.43) 1.54 (1.09-2.17) 0.73 42 58 37 53 32 51 1.39 (0.99-1.96) 1.32 (0.92-1.90) 1.23 (0.83-1.81) 0.90 
                     
GG+GA 267 579 268 465 269 513 1.00 (ref.) 1.26 (1.06-1.49) 1.16 (0.98-1.37)  264 524 270 489 270 544 1.00 (ref.) 1.01 (0.85-1.20) 0.93 (0.78-1.11)  
AA 35 68 37 40 39 54 1.06 (0.74-1.52) 1.70 (1.21-2.38) 1.54 (1.11-2.13) 0.55 42 58 37 53 32 51 1.27 (0.92-1.75) 1.20 (0.85-1.70) 1.12 (0.77-1.63) 0.96 
       Dietary cereal        Dietary fibre  
GG 125 233 136 275 144 318 1.00 (ref.) 0.97 (0.76-1.24) 1.00 (0.76-1.31)  130 254 131 234 144 338 1.00 (ref.) 1.05 (0.83-1.33) 0.83 (0.66-1.05)  
GA 126 211 145 244 128 276 1.10 (0.85-1.41) 1.07 (0.84-1.37) 1.07 (0.81-1.42)  126 223 142 217 131 291 1.10 (0.86-1.40) 1.14 (0.91-1.44) 0.89 (0.70-1.14)  
AA 50 45 26 57 35 60 1.54 (1.12-2.13) 0.89 (0.58-1.36) 1.34 (0.90-2.00) 0.34 44 50 33 49 34 63 1.35 (0.96-1.90) 1.22 (0.84-1.78) 1.11 (0.76-1.62) 0.98 
                     
GG+GA 251 444 281 519 272 594 1.00 (ref.) 0.97 (0.81-1.17) 0.99 (0.79-1.23)  256 477 273 451 275 629 1.00 (ref.) 1.05 (0.89-1.24) 0.82 (0.69-0.98)  
AA 50 45 26 57 35 60 1.48 (1.09-1.99) 0.85 (0.57-1.28) 1.28 (0.88-1.87) 0.10 44 50 33 49 34 63 1.30 (0.94-1.78) 1.17 (0.82-1.67) 1.06 (0.74-1.52) 0.79 
       Fruit        Vegetables  
GG 139 264 135 275 131 287 1.00 (ref.) 0.98 (0.77-1.24) 0.91 (0.70-1.18)  132 250 130 289 143 287 1.00 (ref.) 1.03 (0.80-1.31) 1.16 (0.90-1.50)  
GA 126 212 136 260 137 259 1.10 (0.87-1.40) 0.98 (0.78-1.25) 1.07 (0.83-1.39)  136 187 129 269 134 275 1.28 (1.01-1.62) 1.06 (0.83-1.35) 1.15 (0.88-1.50)  
AA 35 50 38 52 38 60 1.26 (0.88-1.82) 1.24 (0.87-1.76) 1.21 (0.83-1.75) 0.92 35 63 45 50 31 49 1.02 (0.70-1.47) 1.75 (1.26-2.44) 1.44 (0.96-2.15) 0.05 
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GG+GA 265 476 271 353 268 546 1.00 (ref.) 0.94 (0.79-1.12) 0.94 (0.77-1.15)  268 437 259 558 277 562 1.00 (ref.) 0.93 (0.78-1.11) 1.03 (0.84-1.26)  
AA 35 50 38 52 38 60 1.21 (0.85-1.71) 1.18 (0.85-1.65) 1.15 (0.81-1.65) 0.98 35 63 45 50 31 49 0.90 (0.64-1.28) 1.56 (1.15-2.13) 1.28 (0.88-1.88) 0.03 
       Alcohol          
GG 133 267 135 306 137 253 1.00 (ref.) 0.98 (0.78-1.25) 1.23 (0.97-1.57)            
GA 150 246 128 261 121 224 1.23 (0.97-1.54) 1.07 (0.84-1.36) 1.21 (0.94-1.55)            
AA 38 46 36 64 37 52 1.70 (1.19-2.42) 1.14 (0.79-1.65) 1.37 (0.95-1.98) 0.41           
                     
GG+GA 283 513 263 567 258 477 1.00 (ref.) 0.92 (0.78-1.09) 1.10 (0.93-1.31)            
AA 38 46 36 64 37 52 1.53 (1.10-2.14) 1.03 (0.73-1.46) 1.24 (0.88-1.75) 0.33           
NFKB1/rs28362491  Red and processed meat        Fish  
I/I 112 238 102 225 106 216 1.00 (ref.) 1.01 (0.78-1.31) 1.06 (0.82-1.37)  99 228 116 214 105 237 1.00 (ref.) 1.09 (0.84-1.41) 0.95 (0.72-1.26)  
I/D+D/D 190 409 203 280 202 351 0.98 (0.78-1.23) 1.46 (1.17-1.83) 1.24 (0.99-1.56) 0.06 207 354 191 328 197 358 1.25 (0.98-1.58) 1.20 (0.94-1.53) 1.13 (0.88-1.44) 0.76 
       Dietary cereal        Dietary fibre  
I/I 105 187 101 212 114 280 1.00 (ref.) 0.87 (0.66-1.15) 0.91 (0.68-1.22)  104 202 112 201 104 276 1.00 (ref.) 1.05 (0.81-1.36) 0.75 (0.58-0.99)  
I/D+D/D 196 302 206 364 193 374 1.10 (0.87-1.39) 1.04 (0.81-1.32) 1.13 (0.85-1.50) 0.76 196 325 194 299 205 416 1.14 (0.90-1.44) 1.16 (0.92-1.46) 0.97 (0.77-1.23) 0.66 
       Fruit        Vegetables  
I/I 113 218 107 216 100 245 1.00 (ref.) 0.96 (0.74-1.25) 0.88 (0.66-1.17)  105 199 114 240 101 240 1.00 (ref.) 1.16 (0.89-1.50) 1.11 (0.83-1.49)  
I/D+D/D 187 308 202 371 206 361 1.15 (0.91-1.45) 1.07 (0.85-1.35) 1.12 (0.87-1.45) 0.70 198 301 190 368 207 371 1.31 (1.04-1.65) 1.19 (0.94-1.52) 1.33 (1.03-1.71) 0.37 
       Alcohol          
I/I 104 230 111 254 105 195 1.00 (ref.) 1.08 (0.83-1.40) 1.32 (1.01-1.73)            
I/D+D/D 217 329 188 377 190 334 1.45 (1.15-1.83) 1.16 (0.92-1.48) 1.36 (1.08-1.73) 0.09           
a Analysis adjusted for smoking status, alcohol intake, HRT status (women only), BMI, use of NSAID, intake of red and processed meat, and dietary fibre. 
b P-value for interaction between polymorphisms and dietary factors for the adjusted estimates 
Women: Tertiles of red and processed meat (<74.7773 g, 74.7773 g <  and < 102.086 g, >102.086 g), fish (<27.2196 g, 27.2196 g <  and < 43.6676 g, > 43.6676 g), dietary fibre (<16.9701 
g, 16.9701 g <  and < 22.0983 g, > 22.0983 g), cereals (<135.539 g, 135.539 g <  and < 190.481 g, > 190.481 g), fruit (<141.858 g, 141.858 g <  and < 266.488 g, > 266.488 g), vegetables 
(<121.870 g, 121.870 g <  and < 213.721 g, > 213.721 g), laktose (<7.54871 g, 7.54871 g <  and < 17.1355 g, > 17.1355 g), dairy products (<218.144 g, 218.144 g <  and < 454.235 g, > 
454.235 g), alcohol (<4.31931 g, 4.31931 g <  and < 12.9957 g, > 12.9957 g). 
Men: Tertiles of red and processed meat (<116.935 g, 116.935 g <  and < 159.387 g, >159.387 g), fish (<33.3477 g, 33.3477 g <  and < 52.7767 g, > 52.7767 g), dietary fibre (<17.5748 g, 
17.5748 g <  and < 22.4931 g, > 22.4931 g), cereals (<166.378 g, 166.378 g <  and < 233.859 g, > 233.859 g), fruit (<90.9913 g, 90.9913 g <  and < 193.509 g, > 193.509 g), vegetables 
(<105.532 g, 105.532 g <  and < 186.459 g, > 186.459 g), laktose (<7.93777 g, 7.93777 g <  and < 17.2082 g, > 17.2082 g), dairy products (<217.360 g, 217.360 g <  and < 461.449 g, > 
461.449 g), alcohol (<14.4960 g, 14.4960 g <  and < 37.1134 g, > 37.1134 g). 
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There was no interaction between NSAID use or smoking status and the studied genotypes (Table S3 and 
S4). Among non-smokers (Table S4), however, the TLR4/rs5030728 polymorphism demonstrated gene-
dose effect which is comparable with the results seen among participants with low intake of alcohol (Table 
3). In a model where the risk of CRC was inferred per 25 g intake of meat per day subdivided by NSAID use, 
the risk of CRC by meat intake increased in a dose-dependent manner among variant allele carriers of 
TLR4/rs5030728 in the absence of NSAID use, but not among NSAID-users (Table S5). Thus, meat intake 
was not associated with risk among homozygous carriers of the wild type allele, whereas meat intake was 
associated with a 4% increased risk per 25 g meat/day (95%CI: 1.00-1.09) among heterozygotes and 11% 
increased risk among homozygous variant allele carriers (95%CI: 1.02-1.22). However, there were no 
statistically significant interactions (Table S5). 
Discussion  
In the present study, we found that homozygous variant carriage of TLR4/rs5030728 and variant carriage of 
the NFKB1/rs28362491 polymorphism were associated with increased risk of CRC, but not after correction 
for multiple testing. We only found weak interactions with a few dietary factors and, thus, we were not able to 
reproduce the previously found interaction between the NFKB1/rs28362491 polymorphism and meat intake. 
The lack of association between TLR4/rs4986790 and CRC found in the present study could possibly be due 
to the very low variant allele frequency in the Danish population. Only one person was homozygous variant 
allele carrier. We therefore cannot exclude that the functional effect of this SNP affects colorectal 
carcinogenesis. 
The NFKB1/rs28362491 polymorphism has rather consistently been associated with CRC risk 30-32, and to 
some extend also IBD 29,63,64. As previously described 65,66, NFKB1 encodes the p50/p105 subunits of the 
transcription factor NF-κB.  NF-κB consists of homo- or heterodimers of a number of different subunits p65, 
p50, p105, C-rel and relB 67,68 and the combination determines target gene specificity. As a p65/p50 
heterodimer, the complex is pro-inflammatory 68, whereas the p50 homodimer has anti-inflammatory 
properties 65,67,69,70. The relative abundance of p50/p65 heterodimers and p50 homodimers will therefore 
determine the magnitude of inflammation by balancing the pro-inflammatory and anti-inflammatory response 
67. The NFKB1/rs28362491 polymorphism generates a deletion of four nucleotides in the promoter region 
causing lowered transcription levels and consequently partial depletion of p50 63. In agreement with this, it 
was found that the mRNA levels of NFKB1 were lower in colon biopsies of healthy tissue from homozygous 
del-carriers compared to heterozygotes 71. This disfavours the anti-inflammatory response since the 
formation of the pro-inflammatory p65/p50 heterodimer depends on the concentration of p50, whereas the 
formation of the anti-inflammatory p50 homodimer depends on the concentration of p50 squared 65.  
The TLR4/rs5030728 polymorphism has not yet been linked to CRC 20 and its function is unknown 72. 
TLR4/rs4986790, which has been associated with IBD and CRC, is tightly linked with TLR4/rs5030728. It is 
therefore not clear which of the two polymorphisms is the biologically relevant one. However, our results 
indicate that carriage of TLR4/rs4986790 was not associated with risk of CRC, whereas carriage of 
TLR4/rs5030728 was associated with risk. This suggests that the risk conferred by TLR4/rs5030728 carriage 
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was not caused by linkage with TLR4/rs4986790. Interestingly, variant carriage of the TLR4/rs5030728 A-
allele has been associated with beneficial response to anti-TNF therapy among patients with IBD 73, implying 
that these patients may have a higher baseline activity or expression of TLR4.  
The two TLR4 SNP are present on several commonly used GWAS arrays 
(https://www.broadinstitute.org/mpg/snap/ldsearch.php) whereas the ins/del NFKB1/rs28362491 
polymorphism is not monitored linkage in GWAS 65. None of the two TLR4 SNPs were associated with CRC 
in GWAS. However, our main focus was to search for gene-environment interactions, rather than identifying 
loci with strong associations to CRC. Gene-environment interactions are rarely assessed in GWAS. 
We did not find any strong indications of gene-environment interactions. For variant carriers of 
NFKB1/rs28362491 and homozygous A-allele carriers of TLR4/rs5030728, risk of CRC among low meat 
consumers was lower compared to medium and high meat consumers, who had risk estimates between 1.24 
and 1.70 indicating a stronger role of meat in colorectal carcinogenesis among subjects with genetically 
determined high inflammatory response. Alternatively, meat intake covaries with other life style factors that 
per se induce an inflammatory response that we have not been able to adjust for.  
The found interaction with vegetables and TLR4/rs5030728 in the present study is not directly interpretable 
and could be due to small groups in the tertiles. However, vegetables seemed to slightly increase the risk of 
CRC in the present study, which should be addressed in other prospective studies. 
We had limited statistical power to detect gene-environment interactions. However, the prospective study 
design used in this study is well suited for gene-environment interaction analyses due to the collection of 
dietary and life style factors before diagnosis, eliminating the risk of recall bias. Changing in dietary and life 
style habits during follow-up is, however, possible, but is not expected to result in differential misclassification 
between cases and the comparison group. In addition, the present study group is homogenous consisting of 
Danes and two of the studied polymorphisms have high allele frequencies. Using the present study group, 
we have previously found gene-environment interactions between diet and IL10 rs3024505 (Pint;meat=0.04, 
fish=0.007, fibre=0.0008, vegetables=0.0005), IL1B C-3737T (Pint; NSAID use=0.040), PTGS2 G-765C (Pint; 
meat=0.006, fibre=0.0003, fruit 0.004), and PTGS2 T8473C (Pint; fruit=0.03) and PTGS2 A-1195G (Pint;fibre 
0.020 and current smoking=0.046) 27. We adjusted risk estimates for suspected risk factors and carefully 
selected the polymorphisms based on function and/or previously findings on association with dietary factors, 
CRC or IBD. However, none of the analyses withstood adjusting for multiple testing. Thus, we cannot rule 
out that our findings are due to chance and they should therefore not be considered as significant 
associations. 
In conclusion, this study was not able to demonstrate associations between the studied polymorphisms in 
the inflammatory mediator genes NFKB1 and TLR4 as none of the found associations withstood adjustment 
for multiple comparisons. We found no strong gene-environment interactions between the examined 
polymorphism and diet and life style factors in relation to CRC risk.   
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Abstract 
The ATP-binding cassette (ABC) transporter family transports various molecules across the enterocytes in 
the gut protecting the intestine against potentially harmful substances. Moreover, ABC transporters are 
involved in mucosal immune defence through the control of ABC transporter expression by cytokines. We 
used a Danish prospective case-cohort study of 1010 CRC cases and 1829 randomly selected participants 
from the Danish Diet, Cancer and Health cohort to 1) examine whether polymorphisms in ABCB1, ABCC2 
and ABCG2 were associated with risk of CRC; 2) investigate possible interactions with diet and life style 
factors (smoking and use of non-steroidal anti-inflammatory drugs (NSAIDs)) in relation to CRC risk; and 3) 
examine interactions between ABC gene, IL10 and IL1B polymorphisms in relation to CRC risk (retrieved 
from Andersen et al.; PLoS One 2013; 8(10):e78366). None of the polymorphisms were associated with 
CRC per se. Cereals and fibre interacted with ABCB1/rs1045642 (P-value for interaction (Pint)=0.001 and 
0.01, respectively) and fruit interacted with ABCC2/rs2273697 (Pint=0.01). Combinations of ABC transporter 
gene polymorphisms and IL10 polymorphisms interacted with intake of fibre (Pint=0.0007 and 0.009). A 
pattern where NSAID use was associated with decreased risk of CRC among carriers of low activity variants 
of the three ABC transporter genes was seen. Additionally, interaction with NSAID use was found for 
combinations of ABCB1/rs1045642, ABCG2/rs2231137 and IL10/rs3024505 (Pint=0.007 and 0.02, 
respectively). In conclusion, we found indication of interaction between ABC transporter polymorphisms and 
intake of fibre, cereals, fruit and NSAID use in relation to CRC risk suggesting that these factors may affect 
CRC risk by a mechanism involving the ABC transporters. We also found indication of involvement of the 
immune defence system in this mechanism. These results should be replicated in other cohorts to rule out 
chance findings.  
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Introduction 
Colorectal cancer (CRC) is one of the most frequent cancer types in the world. Environmental factors, such 
as alcohol, smoking, obesity and high meat intake have major impact on the carcinogenesis in combination 
with inheritable genetic factors 1-3. Modulation of the exposure to food carcinogens in the intestines by 
enzymes involved in transport or metabolism of the carcinogenic substances may modify risk of CRC. 
Identifying gene-environment interactions may provide insight into the underlying mechanism of action 
because an interaction places gene or pathways and environmental factors in the same carcinogenic 
pathway 4. 
The ATP-binding cassette transporter family (ABCs) transports various molecules across extra- and intra-
cellular membranes controlling absorption, distribution, metabolism and excretion of a wide variety of 
exogenous and endogenous substrates including numerous drugs, but also natural food constituents such 
as flavonoids, lipids and mycotoxins 5-8 and “human-made” food constituents like pesticides 9, insecticides 9, 
the carcinogens polycyclic aromatic hydrocarbons (PAHs) 10 and heterocyclic amines (HCAs) 11-13 including 
2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIPs) 10,11,14. Moreover, the ABC transporters are 
implicated in mucosal immune defence by the modulating of expression of the ABC transporters by several 
cytokines 15-18 suggesting a mechanism involving inflammation. Indeed, mdr1a -/- mice develop colitis 
spontaneously due to a defective intestinal epithelial barrier 19. Some studies also suggest that cytokines are 
substrates for the ABC transporters 20-22.  
The three ABC transporter proteins P-glycoprotein (Pgp)/multidrug resistance 1 (MDR1) (encoded by 
ABCB1), multidrug-resistance-associated protein 2 (MRP2) (encoded by ABCC2) and breast cancer 
resistance protein (BCRP) (encoded by ABCG2) are all efflux transporters. They are expressed in various 
tissues including the apical surface of enterocytes where they serve to restrict the body from exposure to 
potentially harmful substances 5,7,8,23. Genetic variations in these ABC transporters have various effects on 
their expression, mRNA stability, protein folding, intracellular localization, degradation, substrate binding, 
and/or transport kinetics 5,8,24,25, resulting in variation in the exposure of the intestinal epithelial barrier to 
these substances. 
The formation of PAHs and HCAs during cooking of meat at high temperatures could explain the higher risk 
of CRC associated with red meat consumption 2,3,26. We have previously found interaction between two 
polymorphisms in ABCB1 and red meat intake in relation to risk of CRC 27 which could be caused by a 
change in binding affinity or transport activity for PAHs and HCAs. Moreover, we found interaction between 
use of non-steroidal anti-inflammatory drugs (NSAID) and an ABCB1 polymorphism which is in line with 
studies showing that several NSAIDs modulate expression of ABC transporters 28-33 or function as substrates 
for the ABC transporters 28. In another study using the same study group as the present, we found 
interaction between several dietary factors and polymorphisms in genes encoding the cytokines interleukin 
(IL) 1β and IL-10 in relation to CRC risk 34. Since cytokines control expression of the ABC transporters, 
examination of gene-gene and gene-environment interactions may reveal important pathways implicated in 
colorectal carcinogenesis. 
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In the present study, we aimed to update our findings on meat intake, use of NSAID and ABCB1 
polymorphisms in relation to CRC in a prospective cohort of 1010 CRC cases and 1829 randomly selected 
participants from the Danish Diet, Cancer and Health Study. Additionally, we wanted to investigate whether 
other dietary and life style factors interact with other ABC transporter polymorphisms in relation to CRC risk; 
and to investigate gene-gene interactions between the previously studied polymorphisms in IL1B and IL10 
and ABC transporter genes in relation to different dietary factors and CRC risk. 
Methods 
Studied subjects 
The Diet, Cancer and Health Study is an ongoing Danish cohort study designed to investigate the relation 
between diet, lifestyle and cancer risk 35. The cohort consists of 57,053 persons, recruited between 
December 1993 and May 1997. All the subjects were born in Denmark, and the individuals were 50 to 64 
years of age and had no previous cancers at study entry. Blood samples and questionnaire data on diet and 
lifestyle were collected at study entry. Informed consent was obtained from all patients for being included in 
the study. The Diet, Cancer and Health study was approved by the National Committee on Health Research 
Ethics (journal no (KF) 01-345/93), and the Danish Data Protection Agency. 
Follow-up and endpoints 
Follow-up was based on population-based cancer registries. Between 1994 and 31th December 2009, 1010 
CRC cases were diagnosed. A sub-cohort of 1829 persons was randomly selected within the cohort. 28 
persons were both cases and sub-cohort due to the used study design 36. In total, 120 with missing genotype 
data were excluded. All information on genotypes and diet and lifestyle factors was available for 959 CRC 
cases and 1799 sub-cohort members. The present study group was previously described 34. 
Dietary and lifestyle questionnaire 
Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-
economic factors were collected at enrolment using questionnaires and interviews and has been described 
in details elsewhere 34,37-39. In short, the food-frequency questionnaire, diet consumption was assessed in 12 
categories of predefined responses, ranking from ‘never’ to ‘eight times or more per day’. The daily intake 
was then calculated by using FoodCalc 35. Smoking status was classified as never, past or current. Persons 
smoking at least 1 cigarette daily during the last year were classified as smokers. NSAID use (“Aspirin”, 
“Paracetamol”, “Ibuprofen”, or “Other pain relievers) was assessed as ≥ 2 pills per month during one year at 
baseline.  
Genotyping 
Buffy coat preparations were stored at minus 150°C until use. DNA was extracted as described 40. The DNA 
was genotyped by LGC KBioscience (LGC KBioscience, Hoddesdon, United Kingdom) by PCR-based 
KASP™ genotyping assay (http:// www.lgcgenomics.com/). To confirm reproducibility, genotyping was 
repeated for 10 % of the samples yielding 100% identity. 
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ABCB1/rs1045652 41-44, ABCB1/rs1128503 45, ABCG2/rs2231142 46-48, ABCG2/rs2231137 49, 
ABCG2/rs2622604 49, ABCC2/rs2273697 50, ABCC2/17222723 51 and ABCC2/rs717620 50 were all selected 
based on their documented functionality from a literature search; and ABCG2/rs3789243 was chosen based 
on its association with inflammatory bowel disease 52, CRC 27 and low mRNA levels in morphologically 
normal intestinal tissue from patients with adenoma 53.  
ABCB1/rs1045652, ABCB1/rs3789243, ABCG2/rs2231142, ABCC2/rs2273697 and ABCC2/rs717620 have 
been studied previously in a subset of the present cohort 27,54. IL10/rs1800872, IL10/rs3024505, 
IL1B/rs4848306, IL1B/rs1143623 and IL1B/rs1143627 have also been determined and reported in the same 
cohort as the present 34 and were only included in interaction analyses with ABC transporter polymorphisms 
based on findings from the study by Andersen et al., 2013a.  
Statistical analysis 
Deviation from Hardy-Weinberg equilibrium was assessed using a Chi-square test.  
The data were sampled according to the case-cohort design and the unweighted case-cohort approach was 
used for analyses 36 Incidence rate ratios (IRR) for CRC were estimated by the Cox proportional hazards 
model. Age was used as the underlying time axis, which ensured that the estimation procedure was based 
on comparisons of individuals at the same age and the analyses were corrected for delayed entry, such that 
persons were considered under risk only from the age at enrolment in the cohort. Tests and  95% confidence 
intervals (CI) were based on Wald’s tests using the robust estimate of the variance-covariance matrix for the 
regression parameters in the Cox regression models 55 as previously described 27,34,37,54,56-62. 
All models were adjusted for baseline values of suspected risk factors for colorectal cancer such as body 
mass index (BMI) (kg/m2, continuous), NSAID use (yes/no), use of hormone replacement therapy (HRT) 
(never/past/current, among women), smoking status (never/past/current), intake of dietary fibre (g/day, 
continuous), and red meat and processed meat (g/day, continuous). Cereals, fibre, fruit and vegetables were 
also entered linearly. All analyses were stratified by gender, so that the basic (underlying) hazards were 
gender specific. For all the polymorphisms, IRR was calculated separately for heterozygous and 
homozygous variant allele carriers. For all the single nucleotide polymorphisms (SNP) except for 
ABCG2/rs2622604, ABCC2/rs2273697 and ABCB1/rs1045642, all variant allele carriers were subsequently 
grouped for interaction analyses since no recessive effects were observed. For ABCG2/rs2622604 and 
ABCC2/rs2273697, a recessive mode was used in the subsequent analyses. The frequencies of the 
ABCB1/rs1045642 polymorphism vary across ethnical populations 63. Mostly, the T-allele has been 
considered as the variant allele. In this study population, however, the T-allele is the most frequent and 
should therefore be considered as the wild type.  However, we found different effects in the interaction 
analyses. Therefore, we analysed the ABCB1/rs1045642 polymorphism in three different ways by analysing 
all three genotypes separately; by grouping T-allele carriers; and by grouping C-allele carriers.  
We also assessed weekly use of NSAID based on the results of a study of colorectal cancer within the Diet, 
Cancer and Health cohort 64 reporting that regular use of Aspirin or Non-Aspirin NSAID appears necessary to 
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achieve a protective effect. However, there were no differences in risk estimates between monthly or weekly 
use, consequently, to maintain the statistical power in the strata; we used monthly NSAID use in the 
analyses. 
Haplotypes of ABCB1 and ABCG2 were inferred manually as done previously 27,34,65,66. 
The likelihood ratio test was used for interaction analyses between the studied polymorphisms and intake of 
meat, dietary fibre, cereals, fish, fruits, vegetables, alcohol, smoking status and NSAID use. In interaction 
analyses where the dietary factors were entered as categorical variables, tertile cutpoints were based on the 
empirical distribution among cases divided by gender. The possible interactions were investigated using the 
likelihood ratio test. 
All analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC). A P<0.05 was considered 
to be significant. Moreover, to test for multiple comparisons, Bonferroni correction was used. 
Ethics statement 
All participants gave verbal and written informed consent. The Diet, Cancer and Health study was approved 
by the National Committee on Health Research Ethics (journal nr. (KF) 01-345/93) and the Danish Data 
Protection Agency. 
Results 
Baseline characteristics of CRC cases and sub-cohort members are presented in Table 1 as published 
previously 34. Among sub-cohort members, the genotype distribution of the SNPs did not deviate from Hardy-
Weinberg equilibrium (results not shown), except for the ABCC2/rs17222723 which was therefore excluded 
from further analyses. 
Associations between polymorphisms and CRC 
Risk estimates for the association between the studied SNPs and risk of CRC are presented in Table 2. No 
statistically significant associations between genotype distribution and risk of CRC were found. Haplotype 
analysis of the three ABCB1 polymorphisms revealed that the CCC/TCT combination (T-rs1045642C, C-
rs1128503T, C-rs3789243T) was associated with a 41% increased risk of CRC (95%CI: 1.01-1.95; P=0.04) 
compared to the reference haplotype TTC/TTC (Table S1). Having two copies of the CCC haplotype was 
associated with a 1.77-fold increased risk of CRC (95%CI: 1.00-3.13; P=0.05) (Table S1). Conversely, 
having a GTC/GGT combination of the three ABCG2 polymorphisms (G-rs2231137A, G-rs2231142T, C-
rs2622604T) was associated with a 39% decreased risk of CRC (IRR=0.61; 95%CI: 0.44-0.86; P=0.004) 
compared to the reference haplotype GGC (Table S2). We found no interaction with ABC transporter 
polymorphisms and IL1B or IL10 SNPs in relation to CRC (results not shown). 
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Table 1: Baseline characteristics of the study participants by selected demographic and established 
CRC risk factors. 
Variable Cases Sub-cohort IRRa (95% CI) 
n (%) Median (5-95%) n (%) Median (5-95%)  
Total 959 (100)  1799 (100)   
Sex      
Men 539 (56)  967 (54)   
Women 420 (44)  832 (46)   
Age at inclusion (years)  58 (51-64)  56 (50-64)  
BMI (kg/m2)  26.3 (20.6-34.4)  25.6 (20.5-33.0) 1.03 (1.00-1.06)d 
Food intake (g/day)      
Alcoholb  15.0 (1.2-71.4)  14.1 (1.1-66.1) 1.03 (1.00-1.06)e 
Dietary fibre  20.0 (10.6-32.9)  20.6 (10.8-34.2) 0.88 (0.80-0.97)f 
Red and processed meat  113.0 (47.1-233.4)  109.2 (41.5-237.2) 1.02 (1.00-1.05)g 
Smoking status      
Never 286 (30)  599 (33)  1.00 (ref.) 
Past 295 (31)  528 (29)  1.05 (0.89-1.24) 
Current 378 (39)  672 (37)  1.10 (0.94-1.28) 
NSAID usec      
No 667 (70)  1239 (69)  1.00 (ref.) 
Yes 292 (30)  560 (31)  0.99 (0.87-1.14) 
HRT use among women      
Never 256 (61)  437 (53)  1.00 (ref.) 
Past 54  (12)  131 (16)  0.68 (0.50-0.91) 
Current 110 (26)  264 (32)  0.76 (0.60-0.95) 
Values are expressed as medians (5th and 95th percentiles) or as fractions (%).  
aIRRs for CRC – mutually adjusted. 
bAmong current drinkers. 
cNSAID use is defined as  ≥ 2 pills per month during one year. 
dRisk estimate per 2 kg/m2 increment of BMI. 
eRisk estimate for the increment of 10 g alcohol per day. 
fRisk estimate for the increment of 10 g dietary fibres per day. 
gRisk estimate for the increment of 25 g red and processed meat per day. 
 
Gene-environment analyses 
Meat, fish, vegetables and alcohol: We found no associations between ABC transporter SNPs and meat, 
fish, vegetables and alcohol intake (Table 3). 
Cereals, fruits and fibre: ABCB1 rs1045642 C-allele carriers were at 13% increased risk of CRC per 50 g 
cereals per day (95%CI: 1.03-1.25) whereas TT carriers had a slightly non-significantly reduced risk (P-value 
for interaction (Pint)=0.001) (Table 3). These findings were supported by the tertile analyses (Table S3), 
where the risk of CRC increased with increasing intake of cereals, whereas the opposite effect was found for 
C-allele carriers (Pint=0.01) (Table S3). A diet low in cereals was associated with a 1.37 increased risk of 
CRC among carriers of the C-allele (95%CI: 1.06-1.79). Furthermore, intake of 10 g fibre per day decreased 
the risk of CRC with 20% among those carrying the ABCB1/rs1045642 C-allele (IRR=0.80; 95%CI: 0.71-
0.90; Pint=0.01) whereas TT-carriers had no risk reduction for similar intake (Table 3). In the tertile analyses, 
a high intake of fibre was only associated with a protective effect against CRC among C-allele carriers, 
whereas absence of fibre was associated with increased risk of CRC (Pint=0.006) (Table S3).  
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Table 2: IRR for CRC in relation to the studied polymorphisms. 
  ncases (%) nsub-cohort (%) IRR
a (95% CI) IRRb (95% CI) P-valuec 
ABCB1 rs1045642 
TT 
TC 
CC 
TC+CC 
 
CC 
TC 
TT 
TC+TT 
 
300 (32) 
457 (49) 
178 (19) 
635 (68) 
 
178 (19) 
457 (49) 
300 (32) 
757 (81) 
 
563 (32) 
855 (49) 
320 (18) 
1175 (68) 
 
320 (18) 
855 (49) 
563 (32) 
1418 (81) 
 
1.00 (ref.) 
1.01 (0.87-1.16) 
1.07 (0.89-1.29) 
1.02 (0.89-1.17) 
 
1.00 (ref.) 
0.94 (0.79-1.12) 
0.94 (0.78-1.13) 
0.94 (0.80-1.11) 
 
1.00 (ref.) 
1.02 (0.88-1.18) 
1.05 (0.87-1.27) 
1.03 (0.90-1.28) 
 
1.00 (ref.) 
0.97 (0.81-1.15) 
0.95 (0.79-1.14) 
0.96 (0.82-1.13) 
 
- 
0.82 
0.59 
0.70 
 
- 
0.71 
0.59 
0.63 
rs1128503 
CC 
CT 
TT 
CT+TT 
 
300 (32) 
460 (49) 
176 (19) 
636 (68) 
 
573 (33) 
840 (48) 
343 (20) 
1183 (67) 
 
1.00 (ref.) 
1.00 (0.86-1.16) 
0.96 (0.80-1.15) 
0.99 (0.86-1.13) 
 
1.00 (ref.) 
1.00 (0.87-1.16) 
0.95 (0.80-1.15) 
0.99 (0.86-1.14) 
 
- 
0.96 
0.62 
0.88 
rs3789243 
CC 
CT 
TT 
CT+TT 
 
239 (26) 
485 (52) 
206 (22) 
691 (74) 
 
482 (28) 
836 (48) 
434 (25) 
1270 (72) 
 
1.00 (ref.) 
1.14 (0.98-1.33) 
0.99 (0.82-1.20) 
1.09 (0.94-1.26) 
 
1.00 (ref.) 
1.14 (0.98-1.33) 
1.00 (0.83-1.20) 
1.10 (0.95-1.27) 
 
- 
0.09 
0.99 
0.22 
ABCG2 rs2231142 
GG 
TG 
TT 
TG+TT 
 
747 (80) 
172 (18) 
15 (2) 
187 (20) 
 
1368 (78) 
373 (21) 
24 (1) 
397 (22) 
 
1.00 (ref.) 
0.88 (0.74-1.03) 
1.24 (0.77-2.00) 
0.90 (0.77-1.05) 
 
1.00 (ref.) 
0.88 (0.75-1.04) 
1.27 (0.78-2.06) 
0.91 (0.77-1.06) 
 
- 
0.14 
0.33 
0.22 
rs2231137 
GG 
GA 
AA 
GA+AA 
 
872 (93) 
62 (7) 
1 (0) 
63 (7) 
 
1641 (93) 
121 (7) 
2 (0) 
123 (7) 
 
1.00 (ref.) 
0.99 (0.76-1.29) 
1.23 (0.18-8.34) 
0.99 (0.76-1.29) 
 
1.00 (ref.) 
1.01 (0.77-1.31) 
1.13 (0.16-8.10) 
1.01 (0.78-1.31) 
 
- 
0.97 
0.90 
0.96 
rs2622604 
CC 
TC 
TT 
TC+TT 
TT vs. CC+TC 
 
514 (55) 
364 (39) 
53 (6) 
417 (45) 
53 (6) 
 
921 (53) 
707 (40) 
125 (7) 
832 (47) 
125 (7) 
 
1.00 (ref.) 
0.96 (0.84-1.10) 
0.79 (0.59-1.06) 
0.94 (0.82-1.07) 
0.80 (0.60-1.07) 
 
1.00 (ref.) 
0.98 (0.86-1.12) 
0.81 (0.61-1.09) 
0.96 (0.84-1.09) 
0.82 (0.62-1.09) 
 
- 
0.78 
0.16 
0.50 
0.17 
ABCC2 rs2273697 
GG 
AG 
AA 
AG+AA 
AA vs. GG+AG 
 
592 (63) 
297 (32) 
46 (5) 
343 (37) 
46 (5) 
 
1130 (65) 
557 (32) 
61 (3) 
618 (35) 
61 (3) 
 
1.00 (ref.) 
1.01 (0.88-1.16) 
1.27 (0.96-1.68) 
1.04 (0.91-1.18) 
1.26 (0.96-1.66) 
 
1.00 (ref.) 
1.00 (0.87-1.15) 
1.23 (0.93-1.64) 
1.03 (0.90-1.17) 
1.23 (0.93-1.63) 
 
- 
0.97 
0.15 
0.68 
0.14 
rs17222723 
TT 
AT 
AA 
AT+AA 
 
877 (93) 
63 (7) 
3 (0) 
66 (7) 
 
1645 (93) 
112 (6) 
7 (0) 
119 (7) 
 
1.00 (ref.) 
1.06 (0.82-1.38) 
0.82 (0.26-2.56) 
1.05 (0.81-1.35) 
 
1.00 (ref.) 
1.05 (0.81-1.36) 
0.79 (0.25-2.49) 
1.03 (0.80-1.33) 
 
- 
0.73 
0.69 
0.80 
rs717620 
GG 
AG 
AA 
AG+AA 
 
626 (67) 
270 (29) 
37 (4) 
307 (33) 
 
1137 (65) 
542 (31) 
67 (4) 
609 (35) 
 
1.00 (ref.) 
0.93 (0.81-1.07) 
1.08 (0.77-1.51) 
0.95 (0.83-1.09) 
 
1.00 (ref.) 
0.93 (0.80-1.07) 
1.05 (0.75-1.47) 
0.94 (0.82-1.08) 
 
- 
0.28 
0.78 
0.36 
a Crude – adjusted for age and sex. 
b In addition, adjusted for smoking status, alcohol, HRT status (women only), BMI, use of NSAID, intake of red and processed meat, and 
dietary fibre. 
c P-value for the adjusted estimates. 
 
 
Intake of fruit interacted with the ABCC2/rs2273697 polymorphism (Pint=0.01) so that heterozygous carriers 
of the G-allele had a 2% decreased risk of CRC per 50 gram per day (IRR=0.98; 95%CI: 0.95-1.01), 
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whereas homozygous variant carriers of the A-allele had a 5% increased risk of CRC per 50 gram fruit per 
day (IRR=1.05; 95%CI: 0.99-1.11). 
Carriers of different combinations of polymorphisms in ABC transporter genes and IL10 interacted with fibre 
intake (Table 4 and 5). Homozygous carriers of the ABCB1/rs1045642 T-allele, who were also heterozygous 
carriers of the IL10/rs3024505 T-allele had a 1.31-fold increased risk of CRC per 10 gram fibre per day 
(95%CI: 1.04-1.65), whereas heterozygous carriers of the ABCB1/rs1045642 C-allele, who were also wild 
type carriers of the IL10/rs3024505 C-allele, had a 25% reduced risk of CRC for similar fibre intake 
(IRR=0.75; 95%CI: 0.65-0-87) (Pint=0.0007) (Table 4). Wild type carriers of both the IL10/rs3024505 and the 
ABCG2/rs2231137 polymorphism had an 18% decreased risk of CRC per 10 gram fibre per day (IRR=0.82; 
95%CI: 0.72-0.92). If the CC-carriers of the IL10/rs3024505 polymorphism also were heterozygous carriers 
of the variant ABCG2/rs2231137 A-allele, the risk of CRC was additionally reduced for identical fibre intake 
(IRR=0.51; 95%CI: 0.30-0.86) (Pint=0.009) (Table 5).  
NSAID use: Generally, a pattern of intake of NSAIDs associated with decreased risk of CRC among carriers 
of low activity variants of the ABC transporter genes was seen (Table 6). Increased risk of CRC was found 
among users of NSAID, who were homozygous carriers of either ABCB1/rs1045642 C-allele (IRR=1.39; 
95%CI: 1.03-1.87; Pint=0.02), ABCB1/rs1128503 C-allele (IRR=1.21; 95%CI: 0.96-1.52; Pint=0.04) or 
ABCC2/rs2273697 A-allele (IRR=1.75; 95%CI: 1.12-2.72; Pint=0.06), whereas risk reduction was found for 
variant T-allele carriers of the ABCG2/rs2231142 polymorphism among NSAID users (IRR=0.74; 95%CI: 
0.55-1.00; Pint=0.03) (Table 6). Carrying two of either of these polymorphisms did not increase or decrease 
risk of CRC significantly (results not shown). Interaction with NSAID use was found for combinations of 
ABCB1/rs1045642, ABCG2/rs2231137 and IL10/rs3024505 polymorphisms (Table S4 and S5). 
Homozygous carriers of the ABCB1/rs1045642 C-allele, who were also wild type carriers of the 
IL10/rs3024505 polymorphisms, had a 77% increased risk of CRC if they used NSAIDs (95%CI: 1.27-1.48; 
Pint=0.007) (Table S4). Interaction with ABCG2/rs2231137 and IL10/rs3024505 was also found (Pint=0.02), 
but none of the risk estimates were statistically significant (Table S5). 
Smoking: There was no interaction with smoking status and any of the ABC transporter polymorphisms in 
relation to CRC risk (Table S6). 
Discussion 
In the present study, we show that none of the ABC transporter polymorphisms per se are associated with 
CRC risk. In the haplotype analysis of ABCB1, the CCC/TCT combination was associated with a 41% 
increased risk of CRC; and carriage of two copies of the ABCB1 CCC haplotype further increased the risk. 
The opposite association was found for ABCG2 where a GTC/GGT haplotype combination was associated 
with reduced risk of CRC.  
 
 
Table 3. Interaction between dietary factors and the studied polymorphisms in relation to CRC risk. 
  IRRa (95% CI) IRRb (95% CI) Pc IRRa (95% CI) IRRb (95% CI) Pc IRRa (95% CI) IRRb (95% CI) Pc IRRa (95% CI) IRRb (95% CI) Pc 
  Red and processed meat per 25 g/day Fish per 25 g/day Dietary cereal per 50 g/day Alcohol per 10 g/dayd  
ABCB1 
 
rs1045642 
TT 
TC+CC 
 
TT 
TC 
CC 
 
CC 
TC+TT 
 
1.01 (0.97-1.05) 
1.04 (1.00-1.07) 
 
1.01 (0.97-1.05) 
1.04 (1.01-1.08) 
1.02 (0.96-1.09) 
 
1.02 (0.96-1.09) 
1.03 (1.00-1.06) 
 
1.01 (0.96-1.05) 
1.04 (1.01-1.08) 
 
1.01 (0.96-1.05) 
1.04 (1.01-1.08) 
1.03 (0.97-1.11) 
 
1.03 (0.97-1.11) 
1.03 (1.00-1.06) 
 
0.19 
 
 
 
0.40 
 
 
0.85 
 
0.91 (0.82-1.01) 
0.96 (0.90-1.04) 
 
0.91 (0.82-1.01) 
0.96 (0.88-1.05) 
0.98 (0.86-1.11) 
 
0.98 (0.86-1.11) 
0.94 (0.88-1.01) 
 
0.92 (0.82-1.03) 
0.97 (0.90-1.05) 
 
0.92 (0.82-1.03) 
0.96 (0.88-1.05) 
1.00 (0.88-1.13) 
 
1.00 (0.88-1.13) 
0.95 (0.88-1.02) 
 
0.41 
 
 
 
0.63 
 
 
0.46 
 
1.05 (0.97-1.13) 
0.91 (0.86-0.96) 
 
1.05 (0.97-1.13) 
0.92 (0.86-0.98) 
0.88 (0.79-0.98) 
 
0.88 (0.79-0.98) 
0.97 (0.92-1.01) 
 
1.13 (1.03-1.25) 
0.97 (0.90-1.05) 
 
1.13 (1.03-1.25) 
0.98 (0.90-1.07) 
0.95 (0.84-1.07) 
 
0.95 (0.83-1.07) 
1.04 (0.96-1.11) 
 
0.001 
 
 
 
0.006 
 
 
0.13 
 
1.02 (0.97-1.07) 
1.05 (1.01-1.09) 
 
1.02 (0.97-1.07) 
1.06 (1.02-1.10) 
1.01 (0.94-1.08) 
 
1.01 (0.94-1.08) 
1.04 (1.01-1.08) 
 
1.01 (0.96-1.06) 
1.04 (1.01-1.08) 
 
1.01 (0.96-1.06) 
1.06 (1.02-1.10) 
1.01 (0.94-1.08) 
 
1.01 (0.94-1.08) 
1.04 (1.00-1.07) 
 
0.25 
 
 
 
0.24 
 
 
0.47 
rs1128503 
CC 
CT+TT 
 
1.01 (0.96-1.06) 
1.03 (1.00-1.06) 
 
1.02 (0.97-1.08) 
1.03 (1.00-1.06) 
 
0.83 
 
0.96 (0.87-1.07) 
0.93 (0.86-1.00) 
 
0.97 (0.87-1.08) 
0.94 (0.87-1.02) 
 
0.61 
 
0.94 (0.87-1.02) 
0.97 (0.92-1.02) 
 
1.01 (0.92-1.11) 
1.04 (0.96-1.12) 
 
0.57 
 
1.06 (1.01-1.12) 
1.03 (0.99-1.06) 
 
1.06 (1.00-1.11) 
1.02 (0.98-1.05) 
 
0.20 
rs3789243 
CC 
CT+TT 
 
1.00 (0.96-1.04) 
1.03 (1.00-1.06) 
 
1.00 (0.96-1.05) 
1.03 (1.00-1.06) 
 
0.33 
 
0.91 (0.81-1.01) 
0.95 (0.88-1.02) 
 
0.91 (0.82-1.02) 
0.96 (0.89-1.03) 
 
0.47 
 
0.96 (0.90-1.03) 
0.95 (0.90-1.00) 
 
1.00 (0.93-1.07) 
1.00 (0.93-1.08) 
 
0.95 
 
1.03 (0.97-1.08) 
1.05 (1.01-1.08) 
 
1.01 (0.96-1.07) 
1.04 (1.01-1.08) 
 
0.44 
ABCG2 
 
rs2231142 
GG 
TG+TT 
 
1.01 (0.98-1.04) 
1.04 (0.98-1.10) 
 
1.01 (0.98-1.04) 
1.04 (0.98-1.10) 
 
0.45 
 
0.91 (0.86-0.98) 
1.04 (0.90-1.20) 
 
0.92 (0.85-0.98) 
1.06 (0.92-1.23) 
 
0.07 
 
0.94 (0.90-0.99) 
0.98 (0.89-1.08) 
 
0.99 (0.93-1.05) 
1.03 (0.93-1.14) 
 
0.40 
 
1.03 (1.00-1.06) 
1.07 (1.01-1.14) 
 
1.02 (0.99-1.06) 
1.07 (1.01-1.13) 
 
0.17 
rs2231137 
GG 
GA+AA 
 
1.02 (1.00-1.05) 
1.02 (0.92-1.14) 
 
1.03 (1.00-1.06) 
1.02 (0.92-1.13) 
 
0.90 
 
0.94 (0.88-1.00) 
1.02 (0.88-1.19) 
 
0.94 (0.88-1.01) 
1.04 (0.93-1.17) 
 
0.13 
 
0.97 (0.92-1.01) 
0.84 (0.72-0.99) 
 
1.04 (0.97-1.11) 
0.91 (0.77-1.09) 
 
0.14 
 
1.03 (1.00-1.07) 
1.13 (1.00-1.27) 
 
1.03 (1.00-1.06) 
1.11 (0.98-1.25) 
 
0.21 
rs2622604 
CC+TC  
TT 
 
1.02 (0.99-1.05) 
1.05 (0.96-1.16) 
 
1.02 (0.99-1.05) 
1.06 (0.97-1.17) 
 
0.39 
 
0.95 (0.89-1.01) 
0.94 (0.75-1.17) 
 
0.96 (0.90-1.02) 
0.91 (0.72-1.14) 
 
0.66 
 
0.96 (0.92-1.00) 
0.90 (0.75-1.07) 
 
1.01 (0.95-1.07) 
0.96 (0.80-1.14) 
 
0.56 
 
1.03 (1.00-1.06) 
1.16 (1.01-1.32) 
 
1.03 (1.00-1.06) 
1.16 (1.01-1.33) 
 
0.08 
ABCC2 
 
rs2273697 
GG+AG  
AA  
 
1.03 (1.00-1.05) 
1.04 (0.92-1.17) 
 
1.03 (1.00-1.06) 
1.04 (0.92-1.17) 
 
0.91 
 
0.95 (0.89-1.01) 
1.04 (0.75-1.43) 
 
0.96 (0.90-1.02) 
1.06 (0.77-1.47) 
 
0.53 
 
0.97 (0.93-1.01) 
0.91 (0.71-1.16) 
 
1.02 (0.96-1.08) 
0.95 (0.73-1.24) 
 
0.62 
 
1.04 (1.01-1.07) 
1.05 (0.94-1.18) 
 
1.03 (1.00-1.06) 
1.04 (0.93-1.17) 
 
0.84 
rs717620 
GG 
AG+AA 
 
1.03 (1.00-1.06) 
1.01 (0.96-1.06) 
 
1.03 (1.00-1.07) 
1.01 (0.97-1.07) 
 
0.47 
 
0.98 (0.91-1.05) 
0.87 (0.78-0.97) 
 
0.99 (0.91-1.06) 
0.89 (0.79-0.99) 
 
0.12 
 
0.94 (0.89-1.00) 
0.97 (0.90-1.05) 
 
1.01 (0.94-1.09) 
1.04 (0.95-1.15) 
 
0.53 
 
1.05 (1.02-1.09) 
1.02 (0.97-1.07) 
 
1.05 (1.01-1.08) 
1.01 (0.96-1.07) 
 
0.31 
  Dietary fibre per 10 g/day Fruit per 50 g/day Vegetables per 50 g/day    
ABCB1 
 
rs1045642 
TT 
TC+CC 
 
TT 
TC 
CC 
 
CC 
TC+TT 
 
0.99 (0.85-1.15) 
0.79 (0.70-0.88) 
 
0.99 (0.85-1.15) 
0.77 (0.67-0.88) 
0.84 (0.68-1.04) 
 
0.84 (0.68-1.04) 
0.85 (0.77-0.95) 
 
1.01 (0.87-1.18) 
0.80 (0.71-0.90) 
 
1.01 (0.87-1.18) 
0.77 (0.67-0.89) 
0.86 (0.69-1.07) 
 
0.86 (0.69-1.07) 
0.87 (0.78-0.96) 
 
0.01 
 
 
 
0.04 
 
 
0.95 
 
0.98 (0.95-1.01) 
0.96 (0.93-0.99) 
 
0.98 (0.95-1.01) 
0.94 (0.91-0.97) 
1.00 (0.95-1.05) 
 
1.00 (0.95-1.05) 
0.96 (0.94-0.98) 
 
0.99 (0.96-1.03) 
0.97 (0.94-1.00) 
 
0.99 (0.96-1.03) 
0.95 (0.92-0.99) 
1.01 (0.96-1.06) 
 
1.01 (0.96-1.06) 
0.97 (0.94-1.00) 
 
0.28 
 
 
 
0.08 
 
 
0.15 
 
0.98 (0.92-1.04) 
0.98 (0.95-1.02) 
 
0.98 (0.92-1.04) 
0.98 (0.94-1.03) 
0.99 (0.92-1.06) 
 
0.99 (0.92-1.06) 
0.98 (0.95-1.02) 
 
1.01 (0.95-1.09) 
1.02 (0.98-1.07) 
 
1.01 (0.95-1.09) 
1.02 (0.97-1.07) 
1.03 (0.95-1.11) 
 
1.03 (0.95-1.11) 
1.02 (0.97-1.06) 
 
0.84 
 
 
 
0.95 
 
 
0.77 
   
rs1128503 
CC 
CT+TT 
 
0.81 (0.68-0.95) 
0.89 (0.80-1.00) 
 
0.82 (0.70-0.97) 
0.90 (0.81-1.01) 
 
0.35 
 
0.97 (0.93-1.00) 
0.97 (0.94-0.99) 
 
0.98 (0.94-1.02) 
0.98 (0.95-1.01) 
 
0.92 
 
0.99 (0.94-1.05) 
0.98 (0.94-1.02) 
 
1.03 (0.97-1.10) 
1.01 (0.97-1.06) 
 
0.63 
   
rs3789243 
CC 
CT+TT 
 
0.95 (0.84-1.07) 
0.82 (0.73-0.91) 
 
0.95 (0.84-1.08) 
0.83 (0.74-0.93) 
 
0.12 
 
0.99 (0.95-1.02) 
0.96 (0.93-0.98) 
 
0.99 (0.96-1.03) 
0.97 (0.94-1.00) 
 
0.22 
 
1.01 (0.95-1.07) 
0.97 (0.93-1.01) 
 
1.03 (0.97-1.10) 
1.00 (0.96-1.05) 
 
0.38 
   
ABCG2 
 
rs2231142 
GG 
TG+TT 
 
0.86 (0.78-0.94) 
0.90 (0.74-1.09) 
 
0.87 (0.79-0.95) 
0.90 (0.74-1.10) 
 
0.70 
 
0.97 (0.94-0.99) 
0.96 (0.92-1.01) 
 
0.98 (0.95-1.00) 
0.97 (0.92-1.01) 
 
0.74 
 
0.98 (0.95-1.02) 
0.96 (0.90-1.03) 
 
1.01 (0.97-1.06) 
0.99 (0.92-1.06) 
 
0.55 
   
rs2231137 
GG 
GA+AA 
 
0.89 (0.81-0.98) 
0.59 (0.41-0.85) 
 
0.90 (0.82-0.99) 
0.63 (0.44-0.90) 
 
0.06 
 
0.97 (0.95-0.99) 
0.92 (0.85-1.01) 
 
0.98 (0.96-1.01) 
0.95 (0.87-1.03) 
 
0.40 
 
0.99 (0.96-1.02) 
0.92 (0.81-1.04) 
 
1.02 (0.98-1.07) 
0.96 (0.84-1.09) 
 
0.32 
   
rs2622604             
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CC+TC  
TT 
0.89 (0.82-0.97) 
0.77 (0.53-1.12) 
0.90 (0.83-0.98) 
0.78 (0.53-1.13) 
0.44 0.97 (0.95-0.99) 
0.95 (0.88-1.03) 
0.98 (0.95-1.00) 
0.95 (0.88-1.03) 
0.54 0.98 (0.95-1.02) 
0.97 (0.85-1.11) 
1.01 (0.98-1.05) 
1.00 (0.87-1.15) 
0.84 
ABCC2 
 
rs2273697 
GG+AG  
AA  
 
0.90 (0.83-0.98) 
0.90 (0.61-1.32) 
 
0.91 (0.84-0.99) 
0.90 (0.60-1.34) 
 
0.94 
 
0.97 (0.95-0.99) 
1.04 (0.98-1.09) 
 
0.98 (0.95-1.01) 
1.05 (0.99-1.11) 
 
0.01 
 
0.99 (0.96-1.02) 
0.95 (0.82-1.09) 
 
1.02 (0.98-1.06) 
0.99 (0.85-1.15) 
 
0.63 
   
rs717620 
GG 
AG+AA 
 
0.84 (0.75-0.94) 
0.89 (0.76-1.04) 
 
0.85 (0.76-0.96) 
0.91 (0.78-1.06) 
 
0.54 
 
0.97 (0.95-1.00) 
0.96 (0.93-1.00) 
 
0.99 (0.96-1.02) 
0.97 (0.93-1.01) 
 
0.51 
 
0.97 (0.93-1.01) 
1.00 (0.95-1.05) 
 
1.00 (0.96-1.05) 
1.04 (0.98-1.10) 
 
0.30 
   
a Crude – adjusted for age and sex. 
b In addition, adjusted for smoking status, alcohol intake, HRT status (women only), BMI, use of NSAID, intake of red and processed meat, and dietary fibre. 
c P-value for interaction for the adjusted estimates. 
d Among current drinkers only 
 
Table 4: IRR for CRC in relation to combinations of ABCB1/rs1045642 and IL10/rs3024505 genotypes per 10 g fibre per day 
Genotype  IL10/rs3024505 IL10/rs3024505 IL10/rs3024505 P-valuec  
CC 
ncases/nsub-cohort  
CT+TT 
ncases/nsub-cohort 
CC 
IRR (95% CI)a 
CT+TT 
IRR (95% CI) a 
CC 
IRR (95% CI)b  
 
CT+TT 
IRR (95% CI)b 
ABCB1/rs1045642 
TT 
TC+CC 
 
202/382 
430/789 
 
93/178 
198/383 
 
0.83 (0.69-1.01) 
0.74 (0.64-0.86) 
 
1.28 (1.02-1.61) 
0.89 (0.74-1.08) 
 
0.85 (0.70-1.03) 
0.75 (0.65-0.87) 
 
1.31 (1.04-1.65) 
0.90 (0.75-1.10) 
 
0.0007 
a Crude – adjusted for age and sex. 
b In addition, adjusted for smoking status, alcohol intake, HRT status (women only), BMI, use of NSAID and  intake of red and processed meat. 
c P-value for comparison of the adjusted risk estimates. 
 
 
Table 5: IRR for CRC in relation to combinations of ABCG2/rs2231137 and IL10/rs3024505 genotypes per 10 g fibre per day 
Genotype  IL10/rs3024505 IL10/rs3024505 IL10/rs3024505 P-valuec  
CC 
ncases/nsub-cohort  
CT+TT 
ncases/nsub-cohort 
CC 
IRR (95% CI)a 
CT+TT 
IRR (95% CI) a 
CC 
IRR (95% CI)b  
 
CT+TT 
IRR (95% CI)b 
ABCG2/rs2231137  
GG 
GA+AA 
 
587/1108 
42/82 
 
269/528 
21/40 
 
0.81 (0.71-0.91) 
0.48 (0.28-0.81) 
 
1.05 (0.50-1.23) 
0.78 (0.48-1.26) 
 
0.82 (0.72-0.92) 
0.51 (0.30-0.86) 
 
1.06 (0.91-1.24) 
0.82 (0.49-1.35) 
 
0.009 
a Crude – adjusted for age and sex. 
b In addition, adjusted for smoking status, alcohol intake, HRT status (women only), BMI, use of NSAID and  intake of red and processed meat. 
c P-value for comparison of the adjusted risk estimates. 
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Cereals and fibre interacted with the ABCB1/rs1045642 polymorphism and fruit interacted with 
ABCC2/rs2273697. Moreover, different combinations of ABC transporter and IL10 polymorphisms interacted 
with fibre intake. Use of NSAID changed the risk estimates in four of the nine studied ABC SNPs. Combining 
the ABCB1/rs1045642 and ABCG2/rs2231137 polymorphisms with IL10/rs3024505 increased the 
differences in risk estimates for NSAID intake. However, none of the associations withstood adjustment for 
multiple testing. We found no interaction with intake of meat, fish, vegetables, alcohol or smoking status for 
the studied genotypes.  
The risk ABCB1 haplotype (CCC) encompasses two high activity alleles (T-rs1045642C and C-rs1128503T), 
whereas the third (C-rs3789243T) has no known functionality, suggesting that inherent high activity of 
Pgp/MDR1 is associated with increased risk of CRC. The biological effect of the ABCG2 haplotype with the 
GTC/GGT combination is less clear. The reference ABCG2 haplotype (GGC) consists of three high activity 
alleles (G-rs2231137A, G-rs2231142T, C-rs2622604T), whereas the protective haplotype combination 
encompasses a combination of both high and low activity alleles. The found associations could thus be 
caused by LD with other neighbouring functional SNPs. 
We were not able to reproduce our previous findings on interaction between ABCB1/rs1045642 and 
ABCB1/rs3789243 and meat intake in this updated study. We hypothesized that difference in Pgp/MDR1 
activity would influence the transport of meat carcinogens across the intestinal barrier and hence the 
exposure to these carcinogens which again would increase risk of CRC. We used a combination of red meat 
and processed meat intake as a proxy for intake of meat carcinogens. However, meat is prepared in many 
different methods resulting in varying amounts of carcinogens, such as HCAs, and PAHs. Variables that 
could more accurately estimate the intake of these carcinogens could elucidate a possible mechanism 
involving Pgp/MDR1.  
It is well documented that dietary fibre protects against CRC 67. In the intestines, plant polysaccharides from 
ingested fibres increase stool mass which lower the exposure of the enterocytes to carcinogens through 
reduction in transit time 68. Moreover, dietary fibres are fermented by the commensal bacteria to short-chain 
fatty acids (SCFAs), which are important for the colonic integrity and for its anti-tumorigenic and anti-
inflammatory properties 68. Butyrate is one of the most important SCFAs since it is the primary colonic energy 
source 69,70.  Butyrate has been shown to induce Pgp/MDR1 expression 71 and is used as a substrate for 
BCRP 72. We have previously found interaction between dietary fibre and two polymorphisms in IL10 34,37 
suggesting a role of anti-inflammatory cytokines in the protective effect of dietary fibre. In the present study, 
we now extend this mechanism to include some of the ABC efflux transporters. Cytokines have been shown 
to modulate expression of ABC transporter genes 15-18 and also suggested to function as substrates 21,22. 
Interestingly, the release of several cytokines from peripheral blood mononuclear cells was significantly 
decreased for cells with a haplotype encompassing the T-allele of the ABCB1/rs1045642 polymorphism, 
although this was not observed for IL-10 20. However, the present study does not clarify how the exact 
underlying mechanism is; only that IL-10, Pgp/MDR1 and BCRP are part of the same biological mechanism 
underlying the protective effect of dietary fibre on CRC risk. 
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Table 6: Interaction between NSAID use and the studied polymorphisms in relation to CRC risk. 
  NSAID use 
ncases/nsub-cohort 
NSAID use 
IRR (95% CI)a 
NSAID use 
IRR (95% CI)b 
P-valuec Activity (references) 
No Yes No Yes No Yes 
ABCB1 
 
rs1045642 
TT 
TC+CC 
 
TT 
TC 
CC 
 
CC 
TC+TT 
 
215/391 
435/804 
 
215/391 
329/593 
106/211 
 
106/211 
435/804 
 
85/172 
200/371 
 
85/172 
128/262 
72/109 
 
72/109 
200/371 
 
1.00 (ref.) 
0.97 (0.83-1.14) 
 
1.00 (ref.) 
0.99 (0.83-1.17) 
0.92 (0.73-1.16) 
 
1.00 (ref.) 
1.08 (0.88-1.33) 
 
0.89 (0.70-1.14) 
1.03 (0.86-1.25) 
 
0.89 (0.70-1.14) 
0.94 (0.76-1.16) 
1.27 (0.98-1.65) 
 
1.38 (1.03-1.86) 
1.00 (0-79-1.26) 
 
1.00 (ref.) 
0.97 (0.83-1.15) 
 
1.00 (ref.) 
1.00 (0.84-1.19) 
0.90 (0.71-1.14) 
 
1.00 (ref.) 
1.11 (0.90-1.38) 
 
0.88 (0.69-1.13) 
1.03 (0.85-1.24) 
 
0.88 (0.69-1.13) 
0.93 (0.75-1.16) 
1.25 (0.96-1.62) 
 
1.39 (1.03-1.87) 
1.01 (0.80-1.28) 
 
0.25 
 
 
 
0.05 
 
 
0.02 
 
T=↓ 41-44 
 rs1128503 
CC 
CT+TT 
 
192/384 
458/819 
 
108/189 
178/364 
 
1.00 (ref.) 
1.08 (0.92-1.28) 
 
1.21 (0.96-1.52) 
0.98 (0.80-1.20) 
 
1.00 (ref.) 
1.09 (0.92-1.30) 
 
1.21 (0.96-1.52) 
0.97 (0.79-1.19) 
 
0.04 
 
T=↓ 45 
 rs3789243 
CC 
CT+TT 
 
162/333 
481/879 
 
77/149 
210/400 
 
1.00 (ref.) 
1.12 (0.94-1.33) 
 
1.07 (0.82-1.41) 
1.11 (0.91-1.36) 
 
1.00 (ref.) 
1.12 (0.94-1.33) 
 
1.05 (0.80-1.38) 
1.10 (0.90-1.35) 
 
0.70 
 
unknown 
ABCG2 
 
rs2231142 
GG 
TG+TT 
 
503/943 
142/272 
 
244/425 
45/125 
 
1.00 (ref.) 
1.01 (0.84-1.22) 
 
1.10 (0.95-1.29) 
0.73 (0.55-0.99) 
 
1.00 (ref.) 
1.01 (0.84-1.22) 
 
1.09 (0.93-1.27) 
0.74 (0.55-1.00) 
 
0.03 
T=↓ 46-48 
 rs2231137 
GG 
GA+AA 
 
601/1125 
46/85 
 
271/516 
17/38 
 
1.00 (ref.) 
1.07 (0.79-1.46) 
 
1.03 (0.89-1.18) 
0.85 (0.52-1.38) 
 
1.00 (ref.) 
1.10 (0.81-1.50) 
 
1.02 (0.88-1.17) 
0.83 (0.51-1.35) 
 
0.30 
 
A=↓ 49 
 rs2622604 
CC+TC  
TT 
 
608/1119 
37/86 
 
270/509 
16/39 
 
1.00 (ref.) 
0.82 (0.58-1.17) 
 
1.01 (0.88-1.17) 
0.78 (0.48-1.26) 
 
1.00 (ref.) 
0.85 (0.60-1.21) 
 
1.00 (0.87-1.15) 
0.76 (0.47-1.23) 
 
0.70 
 
T=↓ 49 
ABCC2 
 
rs2273697 
GG+AG  
AA  
 
625/1159 
27/45 
 
264/528 
19/16 
 
1.00 (ref.) 
1.04 (0.73-1.49) 
 
0.98 (0.85-1.13) 
1.77 (1.15-2.72) 
 
1.00 (ref.) 
1.01 (0.70-1.44) 
 
0.96 (0.83-1.11) 
1.75 (1.12-2.72) 
 
0.06 
 
A=↑ 50 
 rs717620 
GG 
AG+AA 
 
427/776 
222/427 
 
199/361 
85/182 
 
1.00 (ref.) 
0.98 (0.84-1.16) 
 
1.05 (0.89-1.24) 
0.90 (0.72-1.13) 
 
1.00 (ref.) 
0.98 (0.83-1.15) 
 
1.04 (0.88-1.23) 
0.88 (0.70-1.11) 
 
0.35 
 
A=↓ 50 
a Crude – adjusted for age and sex. 
b In addition, adjusted for smoking status, alcohol intake, HRT status (women only), BMI, intake of red and processed meat, and dietary fibre. 
c P-value for interaction for the adjusted estimates. 
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Consumption of cereals has also been associated with a protective effect in relation to CRC, mostly due to 
the high content of fibre 73. However, in this study, T-allele carriers of the ABCB1/rs1045642 polymorphism 
were at an increased risk of CRC per 50 gram intake of cereal per day. Cereals are often contaminated with 
mycotoxins produced by fungi of the genera Aspergillus, Fusarium, and Penicillium that grow on food crops 
74. These mycotoxins are very toxic and carcinogenic 74. Mycotoxins or their metabolites are substrates to 
Pgp/MDR1 75-77 and other ABC transporters 78,79 and are known to interact with several drugs 6. It is possible 
that carriage of the low activity T-allele of ABCB1/rs1045642 causes detrimental enterocytic accumulation of 
mycotoxins from cereals. 
As with mycotoxins, flavoniods from fruits are substrates for and modulate the function of the ABC 
transporters 5-7 which could explain the differences in risk estimates for the ABCC2/rs2273697 polymorphism 
seen in the present study. The flavonoids are also well-known for interaction with several drugs due to their 
binding to the ABC transporters; and for their anticancer, anti-inflammatory, antioxidant, anti-angiogenic and 
free radical scavenger properties 6. The increased risk of CRC per 50 gram of fruits for carriers of the high 
activity A-allele of the ABCC2/rs2273697 polymorphism could be a result of the flavonoids not being able to 
exert their beneficial effect due to the high efflux activity of the MRP2 transporter. 
Several studies have shown that NSAID modulate expression of the ABC transporters 28-33 and possibly 
function as substrates 28. The present study supports these findings and suggests that carriers of 
polymorphisms that are associated with lower ABC transport activity benefit from the anti-inflammatory effect 
of the NSAIDs. Conversely, carriers of high activity ABC transporter polymorphisms, have a tendency 
towards increased risk of CRC if they use NSAID, which indicates that the drugs do not exert their anti-
inflammatory effect in these persons due to enhanced efflux of the drugs. Indeed, several clinical studies 
rapport that drug resistance is caused by high activity variants of these transporter genes 24,42,80-82. We also 
found indications of involvement of IL-10 in this mechanism, however since the IL10/rs3024505 
polymorphisms is a marker polymorphisms, which is strongly associated with inflammatory bowel disease 
83,84 but with no known biological function, it is difficult to elucidate the underlying mechanism.  
This prospective cohort has limited statistical power for studying gene-environment interactions. On the other 
hand, the study design has some advantages. Study participants were middle age (50-64 years) at entry 
which reduces the likely-hood of substantial change in dietary patterns during follow up. However, if it 
happens, it is not expected to result in differential misclassification. The Danish cohort is very homogenous 
eliminating population specific genetics and dietary patterns seen in larger multicentre studies. Intake of 
meat in this cohort is very high, which makes it suitable for testing the effect of meat on colorectal 
carcinogenesis. Consumption of alcohol among women is the highest in Europe 85, which also makes it 
suitable for mechanistic investigating. We are well aware of the risk of change findings due to the large 
number of tests. None of the results withstood Bonferroni correction and could therefore theoretically be due 
to change. However, since all our tests are based on a priori hypotheses and previous findings, we believe 
that the risk of chance findings is reduced 86.  
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In conclusion, we found indication of interaction between ABC transporter polymorphisms and intake of fibre, 
cereals, fruit and NSAID use in relation to CRC risk suggesting that these dietary and lifestyle factors affect 
CRC risk by a mechanism involving ABC transporters. We also found interaction with polymorphisms in IL10 
suggesting that the immune system is involved supporting the theory of inflammation as an important risk 
factor for CRC. These proposed mechanisms need to be replicated in other cohorts. 
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Abstract 
Red meat is a risk factor for colorectal cancer (CRC). We wanted to evaluate whether a functional 
polymorphism in the HMOX1 gene encoding heme oxygenase modifies risk of CRC or interacts with diet or 
lifestyle factors because this would identify heme or heme iron as a risk factor of CRC. The HMOX1 A-413T 
(rs2071746) was assessed in relation to risk of CRC and interactions with diet (red meat, fish, fibre, cereals, 
fruit and vegetables) and lifestyle (use of non-steroidal anti-inflammatory drug and smoking status) were 
assessed in a case-cohort study of 928 CRC cases and a comparison group of 1726 randomly selected 
participants from a prospective study of 57,053 persons. No association between HMOX1 A-413T and CRC 
risk was found (TT vs AA+TA; IRR=1.15, 95%CI: 0.98-1.36, P=0.10 for the adjusted estimate). No 
interactions were found between diet or lifestyle and HMOX1 A-413T. HMOX1 A-413T was not associated 
with CRC risk and no interactions with diet or lifestyle were identified in this large, prospective cohort with 
high meat intake. The results reproduced the previous findings from the same cohort and did not support a 
link between heme or heme iron and CRC. These results should be sought replicated in other well-
characterized cohorts with high meat intake.  
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Introduction 
Heme oxygenase (HO-1, encoded by HMOX1) is the inducible, rate-limiting enzyme converting heme to iron, 
carbon monoxide (CO) and biliverdin which is subsequently converted into bilirubin. HO-1 activity reduces 
cellular oxidative stress by removing the pro-oxidant heme and at the same time produces pro-inflammatory 
iron. Thus, HO-1 activity may help discriminate the underlying mechanisms involved in meat-related 
colorectal cancer (CRC) carcinogenesis. The HMOX1 A-413T and a microsatellite GT-dinucleotide repeat 
(GT)n polymorphisms are in strong linkage and haplotype analyses indicated that the HMOX1 A-413T 
genotype was likely to be the biologically functional polymorphism by modifying the promoter activity 1. 
HMOX1 polymorphisms have been found to be associated with various diseases and interaction with diet 
has been suggested 2. We have previously evaluated the HMOX1 A-413T polymorphism in a prospective 
Danish study of 383 cases of CRC and a sub-cohort of 763 participants 3. We now extended this study in a 
larger cohort with power to assess gene-environment interaction. The aim of the present study was to 
evaluate whether the HMOX1 polymorphism modifies risk of CRC or interacts with diet or lifestyle factors in a 
larger updated study from the same cohort because this would identify heme or heme iron as risk factors for 
CRC.  
Methods 
Studied Subjects  
The Diet, Cancer and Health Study is an ongoing Danish cohort study designed to investigate the relation 
between diet, lifestyle and cancer risk 4. The cohort consists of 57,053 persons, recruited between December 
1993 and May 1997. All the subjects were born in Denmark, and the individuals were 50 to 64 years of age 
and had no previous cancers at study entry. Blood samples and questionnaire data on diet and lifestyle were 
collected at study entry.  
Follow-up and endpoints  
Follow-up was based on population-based cancer registries. Between 1994 and 31th December 2009, 970 
CRC cases were diagnosed. A sub-cohort of 1897 persons was randomly selected within the cohort. Of 
these, 213 with missing genotype data were excluded. 28 sub-cohort members developed CRC during 
follow-up and they are thus both sub-cohort members (prior to the diagnosis) and cases (after diagnosis) as 
a consequence of the case-cohort design. All information on genotypes and diet and lifestyle factors was 
available for 928 CRC cases and 1726 sub-cohort members.  
Dietary and lifestyle questionnaire 
Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-
economic factors were collected at enrolment using questionnaires and interviews. In the food-frequency 
questionnaire, diet consumption was assessed in 12 categories of predefined responses, ranking from 
’never’ to ’eight times or more per day’. The daily intake was then calculated by using FoodCalc 4. The study 
has been described in details elsewhere 3-14.  
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Smoking status was classified as never, past or current. Persons smoking at least 1 cigarette daily during the 
last year were classified as smokers. 
The lifestyle questionnaire included information on the frequency regarding of use of “Aspirin”, 
“Paracetamol”, “Ibuprofen”, or “Other pain relievers”). Based on all records, we classified study subjects 
according to use of “any NSAID” (≥ 2 pills per month during one year) at baseline.   
Genotyping  
Buffy coat preparations were stored at minus 1500C until use. DNA was extracted as described 15. HMOX1 
A-413T (rs2071746) was genotyped by KBioscience (KBioscience, Hoddesdon, United Kingdom) by PCR-
based KASP™ genotyping assay (http://www.lgcgenomics.com/). To confirm reproducibility, genotyping was 
repeated for 10% of the samples yielding 100% identity.  Laboratory staff was blinded for the status of the 
samples. 
Statistical Analysis  
Deviation from Hardy-Weinberg equilibrium was assessed using a Chi square test. 
Incidence rate ratios (IRR) and 95% Confidence Interval (95%CI) were calculated according to the principles 
for analysis of case-cohort studies using an un-weighted approach 16. Age was used as the time scale in the 
Cox regression models. Tests and confidence intervals were based on Wald’s tests using the robust 
estimate of the variance-covariance matrix for the regression parameters in the Cox regression models 17 as 
previously described in 3-14. 
All models were adjusted for baseline values of suspected risk factors for CRC such as body mass index 
(BMI) (kg/m2, continuous), NSAID (yes/no), use of hormone replacement therapy (HRT) (never/past/current, 
among women), smoking status (never/past/current), intake of dietary fibre (g/day, continuous), and red meat 
and processed meat (g/day, continuous). Cereals, fibre, fruit and vegetables were also entered linearly. All 
analyses were stratified by gender, so that the basic (underlying) hazards were gender specific. IRR was 
calculated separately for heterozygous and homozygous variant allele carriers. Since recessive effects were 
observed a recessive mode was used in the subsequent analyses. 
We investigated possible interactions between the polymorphism and intake of meat, dietary fibre, cereals, 
fish, fruit, vegetables, smoking status and use of non-steroid anti-inflammatory drug (NSAID) using the 
likelihood ratio test 3,5-9,14. 
In another set of interaction analyses between the polymorphism and the dietary intake subdivided in tertiles, 
dietary intake was entered as a categorical variable. Tertile cut-points were based on the empirical 
distribution among cases. The possible interactions were investigated using the likelihood ratio test.  
The procedure PHREG in SAS (release 9.3; SAS Institute., Cary, NC, USA) was used for the statistical 
analyses. A P<0.05 was considered to be significant.  
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The power to detect a dominant effect with an odds ratio of 1.5 and 1.4 was more than 98% and more than 
92%, respectively 18. 
The power to detect interaction was calculated. The average meat intake among controls was 109 g/day in 
the present study group, which is associated with a 10% increased risk of CRC. The power was 80% to 
detect a 3-fold difference in effect of meat intake with a primary effect of meat intake of 0.1 and an allele 
frequency of 0.41 19. 
Ethics Statement 
All participants gave verbal and written informed consent. The Diet, Cancer and Health study was approved 
by the National Committee on Health Research Ethics (journal nr. (KF) 01-345/93) and the Danish Data 
Protection Agency. 
 
Table 1: Baseline characteristics of the study participants by selected demographic and established 
CRC risk factors. 
Variable Cases Sub-cohort IRRa (95% CI) 
n (%) Median (5-95%) n (%) Median (5-95%)  
Total 928 (100)  1726 (100)   
Sex      
Men 521 (56)  922 (53)   
Women 407 (44)  804 (47)   
Age at inclusion (years)  58 (51-64)  56 (50-64)  
BMI (kg/m2)  26.3 (20.7-34.0)  25.6 (20.5-32.9) 1.03 (1.00-1.06)d 
Food intake (g/day)      
Alcoholb  15.0 (1.2-71.6)  14.0 (1.1-65.3) 1.04 (1.01-1.07)e 
Dietary fibre  19.9 (10.6-32.7)  20.6 (10.7-34.1) 0.87 (0.80-0.97)f 
Red and processed meat  113.0 (47.1-233.4)  109.2 (41.7-236.1) 1.02 (0.99-1.05)g 
Smoking status      
Never 277 (30)  571 (33)  1.00 (ref.) 
Past 284 (31)  508 (29)  1.03 (0.87-1.22) 
Current 367 (39)  647 (37)  1.08 (0.92-1.27) 
NSAID usec      
No 643 (69)  1185 (69)  1.00 (ref.) 
Yes 285 (31)  541 (31)  1.00 (0.87-1.15) 
HRT use among women      
Never 250 (61)  425 (53)  1.00 (ref.) 
Past 50  (13)  124 (15)  0.68 (0.50-0.93) 
Current 107 (26)  255 (32)  0.76 (0.61-0.96) 
Values are expressed as medians (5th and 95th percentiles) or as fractions (%).  
aIRRs for CRC – mutually adjusted. 
bAmong current drinkers. 
cNSAID use is defined as  ≥ 2 pills per month during one year. 
dRisk estimate per 2 kg/m2 increment of BMI. 
eRisk estimate for the increment of 10 g alcohol per day. 
fRisk estimate for the increment of 10 g dietary fibres per day. 
gRisk estimate for the increment of 25 g red and processed meat per day. 
 
Results 
Baseline characteristics of the study participants are shown in Table 1. Median intake of fiber was statistically 
significantly lower and median intake of alcohol was statistically higher among cases compared to members 
of the sub-cohort. Also, a significantly lower proportion of the cases were past or current users of hormone 
142 
 
replacement therapy compared to the members of the sub-cohort. The genotype distribution of the 
polymorphisms in the comparison group did not deviate from Hardy-Weinberg equilibrium (results not 
shown). The variant allele frequency in the sub-cohort was 0.41.  
Table 2: IRR for CRC in relation to HMOX1 A-413T (rs2071746). 
  ncases (%) nsub-cohort (%) IRR
a (95% CI) IRRb (95% CI) P-valuec 
HMOX1 rs2071746  
AA 
TA 
TT 
 
TA+TT 
TT vs. AA+TA 
 
310 (33) 
446 (40) 
172 (19) 
 
618 (67) 
172 (19) 
 
587 (34) 
864 (50) 
275 (16) 
 
1139 (66) 
275 (16) 
 
1.00 (ref.) 
1.01 (0.87-1.16) 
1.16 (0.97-1.40) 
 
1.04 (0.91-1.20) 
1.16 (0.98-1.37) 
 
1.00 (ref.) 
1.00 (0.86-1.15) 
1.15 (0.95-1.38) 
 
1.03 (0.90-1.18) 
1.15 (0.98-1.36) 
 
- 
0.94 
0.15 
 
0.64 
0.10 
a Crude – adjusted for age and sex. 
b In addition, adjusted for smoking status, alcohol, HRT status (women only), BMI, use of NSAID, intake of red and processed meat, and 
dietary fibre. 
c P-value for the adjusted estimates. 
 
As shown in Table 2, no association between HMOX1 A-413T and CRC risk was found (TA vs AA; IRR=1.00 
and 95%CI: 0.86-1.15, P=0.94, TT vs AA; IRR=1.15, 95%CI: 0.95-1.38, P=0.15, and TT vs AA+TA; 
IRR=1.15, 95%CI: 0.98-1.36, P=0.10, respectively, for the fully adjusted estimates (Table 2).  A potential 
recessive effect was found and therefore AA and AT carriers were grouped versus TT carriers to maximize 
the statistical power. 
Table 3. Interaction between dietary factors and HMOX1 A-413T (rs2071746) in relation to CRC risk. 
HMOX1/ 
rs2071746 
IRRa (95% CI) IRRb (95% CI) P-
valuec 
IRRa (95% CI) IRRb (95% CI) P-
valuec 
 Red and processed meat per 25 g/day Fish per 25 g/day 
 
AA+TA  
TT 
 
1.02 (0.99-1.05) 
1.02 (0.96-1.09) 
 
1.02 (0.99-1.05) 
1.02 (0.96-1.09) 
 
0.97 
 
0.96 (0.90-1.03) 
0.85 (0.72-1.00) 
 
0.97 (0.91-1.04) 
0.86 (0.73-1.02) 
 
0.18 
 Dietary fibre per 10 g/day Fruit per 50 g/day 
 
AA+TA  
TT 
 
0.87 (0.79-0.97) 
0.84 (0.68-1.04) 
 
0.89 (0.80-0.99) 
0.85 (0.69-1.05) 
 
0.69 
 
0.97 (0.95-1.00) 
0.96 (0.92-1.01) 
 
0.98 (0.96-1.01) 
0.97 (0.93-1.02) 
 
0.57 
 Dietary cereal per 50 g/day Vegetables per 50 g/day 
 
AA+TA  
TT 
 
0.95 (0.90-1.00) 
0.98 (0.89-1.09) 
 
1.01 (0.94-1.09) 
1.04 (0.93-1.17) 
 
0.58 
 
1.00 (0.96-1.04) 
0.93 (0.85-1.02) 
 
1.04 (0.99-1.08) 
0.97 (0.88-1.06) 
 
0.14 
a Crude – adjusted for age and sex. 
b In addition, adjusted for smoking status, alcohol, HRT status (women only), BMI, use of NSAID, intake of red and processed meat, and 
dietary fibre. 
c P-value for interaction for adjusted risk estimates. 
 
No interactions were found between diet and HMOX1 A-413T using the continuous scale (P-value for 
interaction (Pint); meat=0.97, fish=0.18, cereal=0.58, fibre=0.69, fruit=0.57, vegetables=0.14) (Table 3). This 
analysis describes the increased risk per 25 gram meat per day (Table 3, footnotes). Similarly, no 
interactions with diet were found using the tertile analysis (Table 4). No interactions were found between life 
style and HMOX1 A-413T (use of NSAID P=0.11, smoking status P=0.75) (TT vs AA+TA; IRR=1.15, 95%CI: 
0.98-1.36, P=0.10 for the adjusted estimate) (Table 5-6).   
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Table 4. IRR for CRC for tertiles of intake of dietary factors for HMOX1 A-413T (rs2071746). 
 1.tertile 2.tertile 3.tertile 1.tertile 2.tertile 3.tertile P-value
b 
 Nc
c Nsc Ncc Nsc Ncc Nsc IRR (95%CI)a IRR (95%CI)a IRR (95%CI)a  
Red and processed meat 
AA+TA 251 548 257 462 248 441 1.00 (ref.) 1.25 (1.05-1.50) 1.28 (1.06-1.56)  
TT 57 98 55 101 60 76 1.32 (0.98-1.78) 1.21 (0.92-1.61) 1.52 (1.13-2.04) 0.33 
Dietary cereal 
AA+TA 252 421 259 514 245 516 1.00 (ref.) 0.91 (0.76-1.10) 0.96 (0.76-1.21)  
TT 61 97 52 91 59 87 1.07 (0.80-1.42) 0.99 (0.72-1.35) 1.27 (0.92-1.75) 0.51 
Fruit 
AA+TA 253 452 252 460 251 539 1.00 (ref.) 1.00 (0.83-1.20) 0.92 (0.74-1.13)  
TT 60 90 59 89 53 96 1.20 (0.90-1.60) 1.13 (0.85-1.50) 1.02 (0.74-1.51) 0.93 
Fish 
AA+TA 257 528 255 417 244 506 1.00 (ref.) 1.12 (0.94-1.33) 0.93 (0.77-1.12)  
TT 58 87 55 86 59 102 1.32 (0.98-1.78) 1.21 (0.91-1.61) 1.01 (0.76-1.34) 0.57 
Dietary fibre 
AA+TA 253 436 253 437 250 578 1.00 (ref.) 0.97 (0.82-1.16) 0.81 (0.68-0.97)  
TT 60 98 59 75 53 102 1.05 (0.79-1.40) 1.33 (1.01-1.76) 0.89 (0.65-1.18) 0.37 
Vegetables 
AA+TA 249 439 252 501 255 511 1.00 (ref.) 1.06 (0.88-1.27) 1.12 (0.91-1.37)  
TT 64 78 57 97 51 100 1.35 (1.02-1.80) 1.21 (0.90-1.62) 1.09 (0.79-1.49) 0.28 
a Analysis adjusted for smoking status, alcohol, HRT status (women only), BMI, use of NSAID, intake of red and processed meat, and 
dietary fibre. 
b P-value for interaction between polymorphisms and dietary factors for the adjusted estimates. 
cc: cases, s: sub-cohort 
Tertiles of red and processed meat (<94.2266 g, 94.2266 g <  and < 139.266  g, >139.266 g), fish (<30.0189 g, 30.0189 g <  and < 
48.0483 g, > 48.0483 g), dietary fibre (<17.2846  g, 17.2846  g <  and < 22.4505 g, > 22.4505 g), cereals (<152.202 g, 152.202 g <  and 
< 218.014  g, > 218.014  g), fruit (<115.622 g, 115.622 g <  and < 224.174 g, > 224.174 g), vegetables (<113.755 g, 113.755 g <  and < 
197.250 g, > 197.250 g).  
 
Discussion 
In the present candidate gene study, we extended our previous study of HMOX1 A-413T polymorphism in 
relation to diet, lifestyle and colorectal carcinogenesis in a study group of 383 CRC cases and 763 members 
of the comparison group to a larger cohort encompassing 928 number of cases and 1726 members of the 
comparison group and included more dietary factors. We found no association between HMOX1 A-413T and 
CRC risk and no interactions between diet and lifestyle and HMOX1 A-413T. Although no statistically 
significant interactions were found, we found that meat intake was associated with increased risk of CRC 
among carriers of both genotypes. Also, fibre intake was associated with lowered risk of CRC among carriers 
of both genotypes. We thus reproduced the previous finding that the studied HMOX1 polymorphism was not 
associated with risk of CRC 3. Our analyses suggest that genetically determined variation in heme 
oxygenase activity does not modify risk of CRC. Furthermore, we observed no interaction with meat intake. 
Thus, the results do not support that intake of heme or heme iron from meat is linked to CRC. The 
investigated HMOX1 A-413T polymorphism was selected based on the role of the gene product in heme 
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metabolism and the functional effect of the polymorphism. Of the two strongly linked HMOX1 promoter 
polymorphisms, the (GT)n repeats and the A-413T, the A-413T genotype was most likely responsible for the 
effect on the promoter activity 1. Accordingly, this polymorphism has been found to be associated with 
various diseases 1,20,21. To the best of our knowledge, apart from our previous analysis, no other large 
studies of heme oxygenase in relation to CRC have been performed to date 3. 
Table 5: Interaction between NSAID use and HMOX1 A-413T (rs2071746) in relation to CRC risk. 
HMOX1 NSAID use 
ncases/nsub-cohort 
NSAID use 
IRR (95% CI)a 
NSAID use 
IRR (95% CI)b 
P-
valuec 
No Yes No Yes No Yes 
rs2071746  
AA+TA  
TT 
 
539/1004 
104/181 
 
217/447 
68/94 
 
1.00 (ref.) 
1.05 (0.85-1.30) 
 
0.95 (0.81-1.11) 
1.32 (1.03-1.70) 
 
1.00 (ref.) 
1.04 (0.84-1.29) 
 
0.94 (0.80-1.10) 
1.30 (1.01-1.66) 
 
0.11 
a Crude – adjusted for age and sex. 
b In addition, adjusted for smoking status, alcohol, HRT status (women only), BMI, intake of red and processed meat, and dietary fibre. 
c P-value for interaction for the adjusted estimates. 
 
The study design has several strengths. The study design used in this study is well suited for analysing 
interactions between genes and meat intake due to the collection of dietary and life style factors before 
diagnosis, the cases and controls being drawn from the same population, the large sample size and the 
relatively high meat intake 3,5-9,14 which may contribute to differential association pattern among populations 
with high and low meat intakes 22. Study limitation includes limited power for detecting interactions. This 
study has more than 92% to detect a dominant effect of 1.4 had it been there 18. The average meat intake 
among controls was 109 g/day in the present study group, which is associated with a 10% increased risk of 
CRC. The present study has approximately 80% chance of detecting a 3-fold difference in effect of meat 
intake with a primary effect of meat intake of 0.1 and an allele frequency of 0.41 19. Intake of meat may be 
associated with other CRC risk factors such as low fibre intake. However, we have adjusted for known risk 
factors in this cohort to minimize potential confounding.  
The results reproduced our previous findings and do not support a link between heme or heme iron and 
colorectal cancer.  The result should be evaluated in prospective cohorts with high meat intake. 
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Table 6: Interaction between smoking status and HMOX1/rs2071746 in relation to risk of colorectal cancer. 
HMOX1 Never 
smokers 
Past 
smokers 
Current 
smokers 
Never smokers Past smokers Current 
smokers 
Never smokers Past smokers Current 
smokers 
P-valuec 
ncases/nsub-
cohort 
ncases/nsub-
cohort 
ncases/nsub-
cohort 
IRR (95%CI)a IRR (95%CI)a IRR (95%CI)a IRR (95%CI)b IRR (95%CI)b IRR (95%CI)b 
rs2071746  
AA+TA  
TT 
 
228/484 
49/87 
 
232/416 
52/92 
 
296/551 
71/96 
 
1.00 (ref.) 
1.24 (0.90-1.69) 
 
1.07 (0.89-1.28) 
1.11 (0.83-1.50) 
 
1.12 (0.94-1.33) 
1.34 (1.02-1.75) 
 
1.00 (ref.) 
1.20 (0.88-1.64) 
 
1.06 (0.88-1.27) 
1.10 (0.82-1.48) 
 
1.08 (0.90-1.28) 
1.30 (0.98-1.71) 
 
0.75 
a Crude – adjusted for age and sex. 
b In addition, adjusted for alcohol, HRT status (women only), BMI, use of NSAID, intake of red and processed meat, and dietary fibre. 
c P-value for interaction for adjusted risk estimates. 
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Abstract 
Alcohol consumption is associated with increased risk of breast cancer (BC), and the underlying mechanism 
is thought to be sex-hormone driven. In vitro and observational studies have suggested that a mechanism 
involving peroxisome proliferator-activated receptor gamma (PPARγ) in a complex with peroxisome 
proliferator-activated receptor gamma coactivator (PGC) 1α and interaction with aromatase (encoded by 
CYP19A1) is involved in alcohol-related increase in circulating female sex-hormone levels eventually leading 
to BC. Additionally, use of non-steroidal anti-inflammatory drugs (NSAIDs) seems to be an effect modifier in 
alcohol-related BC due to their interaction with PPARγ. In the present study we assess whether genetic 
variation in CYP19A1 is associated with hormone levels and risk of BC in a case-control study group nested 
within the Danish “Diet, Cancer and Health” cohort and search for gene-gene interaction with PPARG and 
PPARGC1A and gene-alcohol and gene-NSAID interactions. Furthermore, we perform a pilot human 
intervention trial to determine the effect of the PPARG Pro12Ala polymorphism and the PPARγ stimulator, 
Ibuprofen, on sex-hormone levels following alcohol intake in postmenopausal women. Our results show that 
variations in CYP19A1 are associated with hormone levels and interact with alcohol intake in relation to 
hormone levels. These polymorphisms were not, however associated with BC risk. Acute intake of alcohol 
decreased blood estrone, estrone sulphate and SHBG levels, but Ibuprofen intake and PPARG Pro12Ala 
variant allele carrier status did not affect the found sex-hormone levels. These studies suggest that acute 
and chronic alcohol consumption have different effect on biosynthesis and metabolism of sex-hormones, and 
we were therefore not able to put PPARγ and the aromatase in the same pathway linking alcohol-related BC. 
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Introduction 
Alcohol is a well-known risk factor for breast cancer (BC) 1-3, and observational studies have shown that 
intake of alcohol is associated with 7-10% increased risk of BC for every 10 gram alcohol consumed per day 
4-9. It is believed that at least part of the underlying mechanism is sex-hormone driven 1,10,11. Several 
controlled experimental and observational human studies demonstrate associations between alcohol intake 
and increased female sex-hormone blood concentrations in pre- and postmenopausal women 12-25. 
Additionally, alcohol is more strongly associated to hormone-sensitive BCs than hormone-insensitive 
subtypes 26. Increased aromatization 27,28, impairment of the metabolism of estrogens in the liver 27 or 
stimulation of adrenal steroidogenesis 17 are possible mechanisms by which alcohol  increases sex-hormone 
concentrations in women.  
The use of genetic epidemiology in BC research may elucidate the involved molecular pathways and define 
subpopulations of women being more sensitive to alcohol consumption in relation to BC. Indeed, in the 
Danish prospective study “Diet, Cancer and Health” (DCH), variant carriers of the PPARG Pro12Ala 
(rs1801282) polymorphism had a 20% increased risk of BC per 10 gram of alcohol consumed per day, 
whereas carriage of the wild type was not associated with alcohol-related BC 29, thus implicating peroxisome 
proliferator-activated receptor gamma (PPARγ) in alcohol-related breast carcinogenesis. In an updated study 
including 798 BC cases, the risk estimate was increased by 13% per 10 gram alcohol per day 30. PPARγ is a 
transcription factor regulating adipocyte differentiation and expression of several adipocyte specific genes by 
binding to regulatory response elements in target genes as a heterodimer with retinoid X receptor (RXR) 31. 
The single nucleotide polymorphism (SNP), PPARG Pro12Ala, only exists in the PPARγ2 isoform, which is 
primarily expressed in adipose tissue 31. The PPARG Pro12Ala substitution causes a 30% reduction in target 
gene transcription 32. In postmenopausal women, estrogens are primarily synthesized in adipose tissue, 
where aromatase (encoded by CYP19A1) catalyses the biosynthesis of estrogens 33. Intake of alcohol 
increases the expression of aromatase in rat adipocytes 34, and aromatase is negatively regulated by PPARγ 
at the transcriptional level 35,36 by a mechanism involving binding of the PPARγ-RXR complex to peroxisome 
proliferator-activated receptor gamma coactivator (PGC) 1α 37. An in vitro study has shown that ethanol 
inhibits the PPARγ-PGC-1α complex at physiologically relevant concentrations 30. Moreover, Petersen et al. 
also illustrated that PGC-1α dependent co-activation of the PPARγ-complex is compromised for the rarer 
variant of PPARG Pro12Ala. Thus, it was proposed that alcohol inhibits PPARγ-mediated inhibition of 
aromatase transcription, thus resulting in increased aromatase transcription and increased levels of sex 
hormones. 
PPARγ interacts with commonly used non-steroidal anti-inflammatory drugs (NSAIDs) 38 which are 
suspected to function as endocrine disruptors 39,40. In the DCH cohort study, interaction between use of 
NSAIDs and the PPARG Pro12Ala polymorphism was observed 29. NSAID use did not modify the risk of 
alcohol-related BC among PPARG Pro12Ala wild type carriers, however, among variant carriers, only users of 
NSAIDs were at risk. This study indicates that NSAIDs activate the less active PPARγ 12Ala variant so that it 
has the same effect as the wild type PPARγ Pro12 transcription factor. In a meta-analysis, the use of NSAIDs 
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has been associated with decreased risk of BC 41. However, in the DCH cohort, female NSAID users, with an 
intake of more than 13 gram alcohol per day had a 1.60 fold increased risk of BC compared to non-users of 
NSAIDs who consumed less than 3 gram of alcohol per day 42, indicating that alcohol consumption modifies 
BC risk among users of NSAID. 
In the present study we further pursue the proposed mechanism of action of alcohol-related BC. We assess 
whether genetic variation in CYP19A1 is associated with hormone levels and risk of BC in a case-control 
study group nested within the DCH cohort and search for gene-gene interactions with PPARG and 
PPARGC1A and gene-alcohol and gene-NSAID interactions. Furthermore, we perform a pilot intervention 
study to determine the effect of PPARG Pro12Ala and the PPARγ stimulator, Ibuprofen 38, on sex-hormone 
levels following alcohol intake in postmenopausal women. 
Methods 
DHC cohort study 
Participants 
The subjects were selected from the ongoing Danish DCH cohort study. The present study group has been 
described previously 8,30. In short, 79,729 women aged 50–64 years, born in Denmark, living in the 
Copenhagen or Aarhus areas and having no previous cancers at the time of invitation were invited to 
participate in the study between December 1993 and May 1997. A total of 29,875 women accepted the 
invitation, corresponding to 37% of the invited women. 
Study participants were followed up for diagnosis of BC from date of entry until either the date of diagnosis of 
cancer using record linkage to the Danish Cancer Registry until 2003 and afterwards by linkage to the 
Danish Pathology Databank, date of death, date of emigration, or April 27th, 2006, whichever came first. A 
total of 975 women were diagnosed with BC during the follow-up period. For each case, one matched control 
was selected 8,30. The control was cancer-free at the exact age at diagnosis of the case and was further 
matched on age at inclusion into the cohort (half-year intervals), use of hormone replacement therapy (HRT) 
(current/former/never) and on certainty of postmenopausal status (known/probably postmenopausal) upon 
inclusion into the cohort 8,30. 72 individuals were excluded because of missing information about one or more 
of the potential confounding variables. Additionally 201 individuals were excluded because of failed 
genotyping or no buffy coat was available. 265 individuals were excluded because of a missing partner in the 
case-control pair, due to the above mentioned exclusions leaving 687 pairs for data analyses. 
Data on covariates 
From the baseline questionnaires we obtained information on duration of school education, smoking status, 
HRT use, birth pattern (number of births and age at first birth) and alcohol intake. BMI was computed based 
on measurements of height and weight at enrolment. Intake of alcohol was inferred from the food-frequency 
questionnaire and life-style questionnaire as described in details in 8,30. Abstainers were defined as those 
who reported no intake of alcohol on the food-frequency questionnaire and no drinking occasions on the 
 153 
 
lifestyle questionnaire. The lifestyle questionnaire included this question regarding use of NSAID: Have you 
taken more than one pain relieving pill per month during the last year? If the answer was yes, the participant 
was asked to record how frequent they took each of the following medications: ‘aspirin’, ‘paracetamol’, 
‘ibuprofen’, or ‘other pain relievers’. The latter category included NSAID preparations other than aspirin and 
ibuprofen. Based on all records, we classified study subjects according to use of ‘any NSAID’ (≥2 pills per 
month during one year) at baseline. Findings on all of these known risk factors have been reported 
previously for both the entire DCH cohort, for a subset of the present study, and for the present study group 
5,8,29,42-44. 
Human intervention study 
Participants 
The human intervention study was conducted at the Department of Nutrition, Exercise and Sports, University 
of Copenhagen, Denmark. The participants were recruited by advertisements in the Copenhagen area, in 
local newspapers and at the webpage www.forsogsperson.dk. To be eligible, women had to meet the 
following requirements: 1) aged 50-70 years and postmenopausal (last menses at least 1 year earlier); 2) 
having no history of hysterectomy before last menses with preservation of both ovaries (unless a medical 
confirmation for the postmenopausal status exists or the participant is 60 years or older); 3) having no major 
health problems, such as ulcers, heart diseases, diabetes or cancer; 4) having a weekly alcohol use of less 
than 14 drinks, but not being an abstainer and having no history of alcohol abuse; 5) not using HRT; 6) not 
taking prescription medications that could interfere with the study (i.e. daily use of NSAIDs and/or medication 
that interact with PPARγ e.g. cholesterol lowering medicine); 7) having a BMI of 18-35; 8) not being allergic 
to alcohol and/or Ibuprofen; 9) being a non-smoker. The research protocol was approved by The National 
Committee on Health Research Ethics for the Capital Region of Denmark, protocol number: H-3-2013-056. 
All participants received oral and written information concerning the study before they gave their written 
consent. 
Fourty-three postmenopausal women were enrolled in the initial screening procedure which included 
anthropometric measures, completing of questionnaires (regarding alcohol habits, medical history and 
medicine use) and donating a blood sample for genotyping. Power calculation showed that we had an 80% 
change of finding a 10% change in estradiol level if 11 participants were included in each group (α=5%). In 
order to take drop out into account, we decided to enrol 18 women in each group. However, only 7 (16%) 
women were PPARG 12Ala carriers, and they were all included in the study as well as 18 homozygous wild 
type carriers of the PPARG Pro12 allele. The 18 wild type carriers were chosen based on their questionnaires 
data; that is, those that did not take any form of medication, were preferred. All 25 participants, 7 PPARG 
12Ala carriers and 18 PPARG Pro12 carriers completed the study. 
Study design 
The study was performed as a randomised, double-blinded, placebo controlled 2x24 h crossover study. The 
volunteers were randomised to 1 of 2 groups and served an alcoholic drink and a placebo tablet (treatment 
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1) or an alcoholic drink and an Ibuprofen tablet (treatment 2). The two treatments were separated by a 5-7 
week washout period. Alcohol was supplied as 96% ethanol (Navimer, G.D.C., Jumet, Belgium) in an 8% 
solution with 1:8 Rose’s Lime Flavour Cordial Mixer® (Dr Pepper Snapple Group Inc., Plano, Texas), 1:8 
Rose’s Sugar Cane Flavour Cordial Mixer® (Dr Pepper Snapple Group Inc., Plano, Texas) and water. 
Placebo and Ibuprofen tablets looked identical, and were supplied by The Pharmacy of the Capital Region of 
Denmark (Herlev, Denmark), and Ibuprofen by Nycomed ApS (Roskilde, Denmark).  
Fourty-eight hours before each intervention, participants were asked to refrain from alcohol consumption and 
any form of painkillers. The participants showed up fasting and were served lunch at 
the University’s dining facility two hours before drinking (Figure 1). The lunch 
consisted of a sandwich, which was identical for each participant at each intervention, 
and was eaten within 30 minutes. All blood samples were collected following 10 
minutes supine resting. The first blood sample was drawn 40 minutes before serving 
the drink. Just after this blood collection and 30 minutes prior to drinking, participants 
had their Ibuprofen or placebo tablet administered. This time point was chosen in 
order to capture the plasma concentration peak of Ibuprofen which is 1-2 hours after 
administration 45,46. After another 30 minutes, the alcoholic beverage was 
administered and consumed within 30 minutes under the surveillance of a research 
assistant to ensure that the drink was ingested slowly over the entire period. The 
participants were offered ice cubes to put in the drink and water ad libitum during the 
whole day. After 30, 60 and 90 minutes, blood was collected. These time points were 
selected based on two other studies reporting peak in blood estradiol concentrations 
between 30 and 60 minutes after alcohol consumption 16,20. After the last blood 
collection and after checking blood alcohol level in an alcometer, the participants went 
home. The next morning, they showed up again for the last blood collection. This time 
point was chosen to enable the comparison of our results with those obtained in long 
term intervention or cohort studies where blood typically is collected the day after 
having consumed alcohol. Since estrone sulphate has a half-life of 5-7 hours 17, an 
alcohol induced change in estrone sulphate caused by disruption in estrogen 
biosynthesis would be measurable in this morning blood sample. 
Blood sampling and storage 
For the genotype screening, blood was collected in 6 ml EDTA BD Vacutainer® Blood 
Collection Tubes (Becton, Dickinson and Company) and buffy coat was separated by 
centrifugation (4000 rpm, 4°C) and frozen at -80°C. During the intervention, blood 
was collected in 10 ml silicone-coated serum BD Vacutainer® Blood Collection Tubes (Becton, Dickinson 
and Company) for ethanol and hormone measurements. The tubes were left at room temperature for >30 
minutes, centrifuged (4000 rpm, 4°C) and aliquots were frozen at -80°C. To avoid ethanol evaporation from 
the tubes during storage, serum for ethanol analysis was kept in tubes with airtight caps. 
-120 min: Meal    
(30 min)
-40 min: Blood 
collection
0 min: Alcohol 
intake (30 min)    
+30 min:
Blood collection
+60 min:
Blood collection
+90 min:
Blood collection
-30 min: Placebo/
Ibuprofen
+19-21 hours:
Blood collection
Figure 1. The study 
course for each 
participant at each 
intervention. 
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Laboratory methods 
DCH cohort study 
DNA from the DCH participants was extracted from frozen lymphocytes as described 47. PPARG Pro12Ala 
(rs1801282), PPARGC1A Gly482Ser (rs8192678) and PPARGC1A Thr612Met (rs3736265) were determined 
as previously described 30 and have been published previously 29,30. Ten tagging SNPs of the CYP19A1 
gene were selected using publicly available HapMap 48 genotyping data set from Utah residents with 
ancestry from Northern and Western Europe (CEU, version 3, release 2) in combination with Haploview 
(version 4.2, Broad Institute, Cambridge USA) 49 comprising the major variations in CYP19A1.  Criteria for 
SNP inclusions were a minor allele frequency (MAF) of minimum 5% and an r2 threshold of 0.1. Tagging of 
SNPs with an r2 higher than 0.1 resulted in several SNPs being in complete linkage disequilibrium. Moreover, 
our intention was to include only major variations of the gene. Four polymorphisms were force included in the 
aggressive SNP tagging (rs10046, rs749292, rs1062033 and rs10519297) due to their documented impact 
on aromatase RNA expression, blood hormone levels and/or BC risk 11,50-57. Moreover, one of the tag SNPs 
(rs4646) has been associated with BC 57 and blood estrogen levels 51,54,58; another tag SNP (rs2445762) was 
associated with low estradiol levels in GWAS 59; and rs3751591 is located in a recombination spot between 
two haplotype blocks (Figure S1).   
Four of the polymorphisms (rs10046, rs749292, rs1062033 and rs10519297) were determined using the ABI 
7900HT RT-PCR system (Applied Biosystems, Nærum, Denmark): rs10046 and rs1062033 were determined 
using the TaqMan® Pre-designed SNP genotyping; assay ID C_8234732_30 and C_8794680_30, 
respectively (Applied Biosystems, Nærum, Denmark). rs749292: Primers: F: 5’-GCT TCT GCC AGT CCT 
TCT TCA-3’, R: 5’-GCT TAG GGC CTG ATA GAA ATT GTG-3’ (TAGCopenhagen, Copenhagen, Denmark), 
G-allele: 5’-FAM-CTC GGA GTC GAG GAT-MGB-3’, A-allele: 5’-VIC-TCG GAG TCA AGG ATT-MGB-3’ 
(Applied Biosystems, Nærum, Denmark). rs10519297: Primers: F: 5’CCT TGC CTG AGC CAT CTC TT-3’, 
R: 5’- CTT GGC AGT CAA AAG CAG TAG TAG TC-3’ (TAGCopenhagen, Copenhagen, Denmark), G-allele: 
5’-FAM-CTC CGA CAT GGG TC-MGB-3’, A-allele: 5’-VIC-TCT CCG ACA TAG GTC-MGB-3’ (Applied 
Biosystems, Nærum, Denmark). 
The remaining six CYP19A1 polymorphisms (rs2008691, rs2445762, rs3751591, rs4646, rs6493487 and 
rs749292) were genotyped by KBioscience (KBioscience, Hoddesdon, United Kingdom) by PCR-based 
KASP™ genotyping assay (http://www.lgcgenomics.com/). To confirm reproducibility, genotyping was 
repeated for 10 % of the samples yielding 100% identical genotypes. 
Serum levels of estrone, estrone sulphate and sex-hormone binding globulin (SHBG) were previously 
determined for a subset of the DCH study (434 participants) in blood samples collected at entry into the DCH 
cohort 60. Estrone and estrone sulphate were measured by radioimmunoassay and SHBG by use of 
immunofluorometric analysis. 
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Human intervention study 
DNA was isolated from frozen lymphocytes as described by Miller et al. 47. Genotypes were determined 
using RT-PCR and allelic discrimination on ABI 7900HT instruments (Applied Biosystems, Nærum, 
Denmark). Generally, 40-200 ng/µl DNA was obtained and 10 ng of DNA was genotyped in six μl containing 
50% 2 × Mastermix (Applied Biosystems, Nærum, Denmark), 100 nM probes, and 900 nM primers. PPARG 
Pro12Ala (rs1801282) primers and probes were: primers: 5’-GTT ATG GGT GAA ACT CTG GGA GAT-3’ and 
5’-GTT ATG GGT GAA ACT CTG GGA GAT-3’: probes: C-allele: 5’'-FAM-CTC CTA TTG ACG CAG AAA 
GCG ATT C-BHQ-1-3’ and G-allele: 5’-Yakima Yellow-TCC TAT TGA CCC AGA AAG CGA TTC C-BHQ-1-
3’. Serum ethanol concentration was measured by the enzymatic rate assay (kat. no. 11776312190, Roche 
Diagnostics GmbH, Mannheim, Germany) using the ABX Pentra 400 (Horiba Medical, Brøndby, Denmark) 
instrument with inter- and intra assay variation of  <4%. All samples were measured in duplicates in random 
order and in the same batch to decrease analytical variation.  
Analyses of estrogens and SHBG levels were performed at the Department of Clinical Biochemistry and 
Immunology, Statens Serum Institute, Copenhagen, Denmark. Estrogens were extracted by Solid-Phase 
Extraction and the extracts were analyzed using Liquid-Chromatography (LC) coupled to Mass-Spectrometry 
(MS). All samples were analyzed in duplicate and the average of both measurements was used. Within the 
working range of the method (20 pmol/L to 50 nmol/L) the CV’s for all analytes are 10% for estrone, estrone 
sulphate and 17β-estradiol and the CV’s increase below the working range and reach 20% at the limit of 
detection. Due to the low recovery rate of estradiol (60%), these measurements were excluded from 
statistical analyses. SHBG was determined on an Abbott Architect using Abbotts SHBG kit (Abbott, Abbott 
Park, Illinois). The LOD and the intra- and inter-assay coefficients of variation were 0.1 nmol/l, 4% and 6%, 
respectively.  
Statistical methods 
DCH cohort study 
Deviation from Hardy-Weinberg equilibrium was assessed using a Chi square test.   
The analysis of the association between the exposure variables and the BC incidence rate ratios (IRR) was 
based on a conditional logistic regression analysis corresponding to a Cox Proportional Hazard model due to 
the used study design 61. Age was used as the time axis. Two-sided 95% confidence intervals (CI) for the 
IRR were calculated on the basis of Wald’s test of the regression parameter, that is, on the log rate ratio 
scale. All models were adjusted for baseline values of risk factors for BC such as parity (entered as two 
variables; parous/nulliparous and number of births), age at first birth, length of school education (low, 
medium and high), duration of HRT use, and BMI. Analyses not concerning interaction between alcohol 
intake and the polymorphisms were further adjusted for alcohol intake of 10 gram per day. For the different 
genetic variations, we investigated different interactions with alcohol intake and use of NSAID, using the 
likelihood ratio test. IRR was calculated separately for heterozygous and homozygous variant allele carriers. 
For all the SNPs except for rs3751591, variant allele carriers were subsequently grouped for interaction 
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analyses since no recessive effects were observed. For rs3751591, a recessive mode was used in the 
subsequent analyses. Haplotypes of CYP19A1 were inferred manually as done previously 62-64. 
For the analyses with sex-hormone levels as outcome, multiple log-linear regression analyses of the 
association between CYP19A1 genotypes and serum levels of estrone, estrone sulphate and SHBG were 
performed with adjustment for potential confounders i.e., age (linear), smoking (categorical: never, past and 
current) and BMI (linear). All values of hormone concentrations were log-transformed to correct for left-
skewed distribution. The statistical analyses were carried out using SAS (release 9.3, SAS Institute, Inc, 
Cary, North Carolina, USA). 
Human intervention study 
This study was divided up into two types of analyses using two different models. Model A only involved the 
time at the beginning of the study period and the end (time=0 and time=1200 minutes) whereas model B 
involved the time 0, 30, 60, and 90 minutes after start. Since the response was not linear with the time over 
the whole period (0 to 1200 minutes) it made more sense to divide the analysis up in this way. 
Model A used a mixed model with id as the random effect nested with genotype and order (geno*order). The 
explanatory categorical variables were treatment (treat), order in which they were given treatment A or B first 
(order), genotype (geno), and time (0 and1200). BMI was included as a covariate.  
Model B also used a mixed model with id as the random effect nested with genotype and order (geno*order). 
The explanatory categorical variables were treatment (treat), order in which they were given treatment A or B 
first (order), genotype (geno), and time (0, 30, 60, 90). BMI was included as a covariate. Time was also 
included as repeated measurement with id(geno*treat*order) as the subject.   
The response variables = estrone sulphate was log-transformed to correct for right-skewed distribution. The 
response variables = estrone and SHBG were not log-transformed, since the conditional residuals were not 
or only very little skewed.  
Results 
DCH cohort study 
We assessed 10 tag CYP19A1 SNPs including two functional polymorphisms in relation to BC risk in a 
nested, prospective case-control cohort of 687 BC cases with matched controls within the prospective DCH 
Study.  
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Table 1:  Baseline characteristics of the DCH study participants by selected demographic and 
established BC risk factors. 
Variable Cases Controls IRRa (95% CI) 
n (%) Median (5-95%) n (%) Median (5-95%)  
Women 687 (100)  687 (100)   
Age at inclusion, years  57 (51-64)  57 (51-64)  
School education 
Short 
Medium 
Long 
 
198 (29) 
344 (50) 
145 (21) 
  
257 (37) 
316 (46) 
114 (17) 
  
1.0 (ref.) 
1.39 (1.07-1.79) 
1.59 (1.13-2.24) 
Body mass index, kg/m2  25 (20-34)  25 (20-34) 1.01 (0.96-1.07)b 
Nulliparous 102 (15)  78 (11)  1.02 (0.64-1.60)c 
Number of births  2 (1-4)  2 (1-4) 0.92 (0.79-1.06) 
Age at first birth, years  23 (18-31)  23 (18-32) 1.07 (0.91-1.25)d 
Use of HRT, yearse  6 (0.5-19)  5 (0.5-20) 1.00 (0.87-1.15)f 
Abstainers 15 (2)  22 (3)  0.80 (0.40-1.61)g 
Alcohol intake, g/day  11 (1-43)  9 (1-40) 1.12 (1.04-1.21)h 
NSAID usei 286 (42)  239 (35)  1.33 (1.07-1.66) 
Values are expressed as medians (5th and 95th percentiles) or as fractions (%).  
a The risk estimates for breast cancer are mutually adjusted.  
b The risk is estimated per additional 2 kg/m2.  
c The risk is estimated for nulliparous versus one birth at age 35.  
d The risk is estimated per additional 5 years.  
e Among ever users of HRT.  
f The risk is estimated per additional 5-year of HRT use.  
g The risk for abstainers compared to the increment of 10 g alcohol per day.  
h Among current drinkers, risk estimate is estimated for the increment of 10 g alcohol per day.  
i NSAID use is defined as  ≥ 2 pills per month during one year. 
 
 
The aim was to assess the association of CYP19A1 SNPs with sex-hormone levels and BC risk and to 
assess a possible interaction with polymorphisms in PPARG and PPARGC1A, alcohol intake and use of 
NSAIDs in relation to risk of BC in order to evaluate the hypothesis that alcohol intake causes BC by 
increasing circulating levels of estrogens mediated by interaction between PPARγ/PGC-1α and CYP19A1. 
Baseline characteristics of the present study group including BC risk factors are presented in Table 1 as 
published previously 8,30.  Among the controls, the genotype distributions of the studied polymorphisms were 
in Hardy–Weinberg equilibrium (results not shown).  
Associations with hormone levels 
Serum estrone, estrone sulphate and SHBG have been measured for 434 women from the DCH cohort. The 
hormone levels differed significantly for five of the ten polymorphisms. Variant T-carriers of the 
CYP19A1/rs11070844 polymorphism had 17% higher estrone levels (P=0.009) and 14% higher estrone 
sulphate levels (P=0.01) than the wild type (Table 2). SHBG levels were 37% higher among CC-carriers of 
the CYP19A1/rs3751591 polymorphism compared to T-carriers (P=0.03). Carriers of the variant alleles of the 
two CYP19A1 polymorphisms rs749292 and rs1062033 had decreased levels of 12% of estrone sulphate 
compared to the wild type (P=0.004 and 0.007, respectively), whereas variant carriers of the 
CYP19A1/rs10519297 polymorphism had 12% increased levels of estrone sulphate compared to the wild 
type (P=0.03). Thus, several of the studied SNPs were associated with hormone levels. 
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Table 2: Plasma levels of estrone, estrone sulphate and SHBG among 339 never and past users of 
hormone replacement therapy as percentage change in hormonal measurements in relation to 
CYP19A1 polymorphisms. 
Genotype n (%) 
n=339 
Estrone  P-valueb Estrone sulphate P-valueb SHBG P-valueb 
∆ (95% CI)a ∆ (95% CI)a ∆ (95% CI)a 
rs10519297 
AA 
AG 
GG 
AG+GG 
 
81 (24) 
187 (55) 
71 (21) 
258 (56) 
 
0 (ref.) 
8 (-4;21) 
1 (-13;16) 
6 (-6;18) 
 
 
0.35 
 
0.34 
 
0 (ref.) 
10 (-1;21) 
16 (3;31) 
12 (1;23) 
 
 
0.05 
 
0.03 
 
0 (ref.) 
-5 (-14;6) 
-2 (-14;11) 
-4 (-13;6) 
 
 
0.66 
 
0.44 
rs749292 
GG 
AG 
AA 
AG+AA 
 
101 (30) 
169 (50)  
69 (20) 
238 (70) 
 
0 (ref.) 
-5 (-15;6) 
-5 (-17;9) 
-5 (-14;5) 
 
 
0.62 
 
0.33 
 
0 (ref.) 
-11 (-19;-2) 
-16 (-26;-6) 
-12 (-20;-4) 
 
 
0.007 
 
0.004 
 
0 (ref.) 
-3 (-12;7) 
11 (-2;26) 
1 (-8;11) 
 
 
0.07 
 
0.82 
rs1062033 
CC 
CG 
GG 
CG+GG 
 
88 (26) 
180 (53) 
71 (21) 
251 (74) 
 
0 (ref.) 
-2 (-13;10) 
-7 (-20;6) 
-4 (-14;7) 
 
 
0.53 
 
0.51 
 
0 (ref.) 
-10 (-19;-1) 
-16 (-26;-6) 
-12 (-20;-3) 
 
 
0.01 
 
0.007 
 
0 (ref.) 
-1 (-11;9) 
6 (-7;21) 
1 (-9;11) 
 
 
0.45 
 
0.88 
rs10046 
AA 
AG 
GG 
AG+GG 
 
93 (27) 
177 (52) 
69 (20) 
246 (73) 
 
0 (ref.) 
2 (-9;15) 
-4 (-17;10) 
0 (-10;12) 
 
 
0.58 
 
0.93 
 
0 (ref.) 
4 (-5;15) 
11 (-2;25) 
6 (-3;16) 
 
 
0.26 
 
0.21 
 
0 (ref.) 
-1 (-10;10) 
-2 (-14;11) 
-1 (-10;9) 
 
 
0.94 
 
0.82 
rs4646 
CC 
CA 
AA 
CA+AA 
 
186 (55) 
133 (39) 
20 (6) 
153 (45) 
 
0 (ref.) 
3 (-7;14) 
-6 (-23;16) 
2 (-8;12) 
 
 
0.68 
 
0.73 
 
0 (ref.) 
5 (-3;15) 
10 (-8;31) 
6 (-3;15) 
 
 
0.38 
 
0.18 
 
0 (ref.) 
-4 (-13;5) 
-5 (-21;15) 
-4 (-13;4) 
 
 
0.59 
 
0.30 
rs6493487 
AA 
GA 
GG 
GA+GG 
 
203 (60) 
127 (38) 
9 (3) 
136 (41) 
 
0 (ref.) 
-5 (-14;5) 
-19 (-40;9) 
-6 (-15;4) 
 
 
0.27 
 
0.23 
 
0 (ref.) 
4 (-4;14) 
0 (-23;29) 
4 (-4;13) 
 
 
0.63 
 
0.36 
 
0 (ref.) 
-5 (-13;4) 
-14 (-34;13) 
-5 (-13;3) 
 
 
0.37 
 
0.22 
rs2008691 
AA 
GA 
GG 
GA+GG 
 
220 (65) 
109 (32) 
10 (3) 
119 (35) 
 
0 (ref.) 
4 (-6;15) 
21 (-9;60) 
5 (-4;16) 
 
 
0.35 
 
0.29 
 
0 (ref.) 
3 (-6;12) 
0 (-21;28) 
2 (-6;12) 
 
 
0.83 
 
0.57 
 
0 (ref.) 
2 (-7;12) 
27 (-1;64) 
4 (-5;14) 
 
 
0.17 
 
0.37 
rs3751591 
TT 
TC 
CC 
CC vs. TT+TC 
 
241 (71) 
90 (27) 
8 (2) 
8 (2) 
 
0 (ref.) 
2 (-9;13) 
19 (-13;63) 
18 (-14;62) 
 
 
0.55 
 
0.29 
 
0 (ref.) 
1 (-8;10) 
18 (-10;54) 
17 (-10;53) 
 
 
0.50 
 
0.24 
 
0 (ref.) 
1 (-9;11) 
38 (4;83) 
37 (4;82) 
 
 
0.09 
 
0.03 
rs2445762 
TT 
TC 
CC 
TC+CC 
 
175 (52) 
142 (42) 
22 (6) 
164 (48) 
 
0 (ref.) 
-3 (-12;7) 
-7 (-24;13) 
-3 (-12;6) 
 
 
0.71 
 
0.47 
 
0 (ref.) 
-1 (-9;8) 
-7 (-21;10) 
-2 (-10;6) 
 
 
0.71 
 
0.63 
 
0 (ref.) 
-3 (-19;16) 
-5 (-13;4) 
-5 (-13;4) 
 
 
0.53 
 
0.27 
rs11070844 
CC 
TC 
TT 
TC+TT 
 
267 (79) 
68 (20) 
4 (1) 
72 (21) 
 
0 (ref.) 
17 (4;31) 
16 (-26;79) 
17 (4;31) 
 
 
0.03 
 
0.009 
 
0 (ref.) 
13 (2;25) 
23 (-16;79) 
14 (3;25) 
 
 
0.04 
 
0.01 
 
0 (ref.) 
6 (-5;18) 
36 (-9;103) 
7 (-3;19) 
 
 
0.20 
 
0.18 
Δ Percentage change in hormonal measurements compared to WT. 
a Adjusted for age, smoking (never, past, current), alcohol intake (increment of 10 g per day) and BMI (kg/m2) at baseline. 
b P-value for interaction. 
SHBG: Sex-hormone binding globulin. 
 
Three of the ten CYP19A1 polymorphisms had alcohol dependent changes in hormone levels according to 
genotype (Table 3). Carriers of the CYP19A1/rs2008691 and CYP19A1/rs1062033 polymorphism had 3% 
and 1% higher estrone sulphate levels, respectively, than the wild type (P=0.02 and 0.03, respectively) per 
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10 gram alcohol intake per day. Variant T-carriers of the CYP19A1/rs11070844 polymorphism had 3% 
decreased levels of SHBG compared to the wild type carriers (P=0.03) per 10 gram daily alcohol intake.  
Table 3: Plasma levels of estrone, estrone sulphate and SHBG among 325 never and past users of 
hormone replacement therapy as percentage change in hormonal measurements per 10 g/day in 
alcohol intake. 
Genotype n (%) 
n=325 
Estrone  P-valueb Estrone sulphate P-valueb SHBG P-valueb 
∆ (95% CI)a ∆ (95% CI)a ∆ (95% CI)a 
rs10519297 
AA 
AG 
GG 
AG+GG 
 
74 (23) 
182 (56) 
69 (21) 
251 (77) 
 
2 (-4;9) 
3 (-1;6) 
1 (-5;6) 
2 (-1;5) 
 
 
0.82 
 
0.54 
 
3 (-3;9) 
3 (0;7) 
4 (0;9) 
4 (1;6) 
 
 
0.17 
 
0.08 
 
-5 (-11;0) 
-6 (-9;-3) 
-3 (-7;2) 
-5 (-8;-2) 
 
 
0.23 
 
0.27 
rs749292 
GG 
AG 
AA 
AG+AA 
 
98 (30) 
165 (51) 
62 (19) 
227 (70) 
 
3 (-2;7) 
1 (-3;6) 
2 (-5;10) 
1 (-2;5) 
 
 
0.96 
 
0.85 
 
4 (1;8) 
3 (0;7) 
-1 (-7;6) 
3 (-1;6) 
 
 
0.38 
 
0.15 
 
-5 (-8;-1) 
-6 (-9;-2) 
0 (-7;6) 
-5 (-8;-1) 
 
 
0.94 
 
0.95 
rs1062033 
CC 
CG 
GG 
CG+GG 
 
86 (26) 
175 (54) 
64 (20) 
239 (74) 
 
1 (-3;6)  
3 (-1;7) 
1 (-6;8) 
2 (-1;6) 
 
 
0.76 
 
0.45 
 
4 (0;8) 
4 (0;7) 
1 (-4;7) 
3 (0;7) 
 
 
0.11 
 
0.03 
 
-5 (-9;-1) 
-5 (-8;-2) 
-4 (-9;2) 
-5 (-8;-2) 
 
 
0.67 
 
0.90 
rs10046 
AA 
AG 
GG 
AG+GG 
 
85 (26) 
173 (53) 
67 (21) 
240 (74) 
 
3 (-3;10) 
2 (-1;7) 
1 (-4;5) 
2 (-1;5) 
 
 
0.89 
 
0.64 
 
4 (-2;10) 
3 (0;7) 
3 (0;8) 
3 (1;6) 
 
 
0.29 
 
0.22 
 
-7 (-12;-1) 
-6 (-9;-3) 
-3 (-7;1) 
-5 (-7;-2) 
 
 
0.06 
 
0.24 
rs4646 
CC 
CA 
AA 
CA+AA 
 
177 (54) 
129 (40) 
19 (6) 
148 (46) 
 
3 (-2;7) 
2 (-2;6) 
-6 (-18;7) 
1 (-2;5) 
 
 
0.49 
 
0.41 
 
4 (0;7) 
3 (0;7) 
6 (-5;19) 
3 (0;7) 
 
 
0.30 
 
0.14 
 
-4 (-8;-1) 
-5 (-8;-2) 
-8 (-18;4) 
-5 (-8;-2) 
 
 
0.87 
 
0.59 
rs6493487 
AA 
GA 
GG 
GA+GG 
 
192 (59) 
125 (39) 
8 (2) 
133 (41) 
 
3 (-1;8)  
2 (-2;5) 
-1 (-11;11) 
1 (-2;5) 
 
 
0.79 
 
0.79 
 
3 (-1;7) 
4 (1;8) 
-1 (-10;9) 
4 (1;7) 
 
 
0.64 
 
0.97 
 
-5 (-9;-1)  
-5 (-8;-2) 
-5 (-14;5) 
-5 (-8;-2) 
 
 
0.60 
 
0.33 
rs2008691 
AA 
GA 
GG 
GA+GG 
 
210 (65) 
106 (32) 
9 (3) 
115 (35) 
 
2 (-2;6)  
2 (-2;6) 
12 (-4;31) 
2 (-2;7) 
 
 
0.67 
 
0.70 
 
5 (2;8) 
1 (-2;5) 
10 (-3;26) 
2 (-2;6) 
 
 
0.03 
 
0.02 
 
-6 (-9;-3) 
-4 (-8;0) 
6 (-7;22) 
-4 (-7;0) 
 
 
0.41 
 
0.31 
rs3751591 
TT 
TC 
CC 
CC vs. TT+TC 
 
232 (72) 
85 (26) 
8 (2) 
317 (98) 
 
2 (-1;6)  
1 (-3;6)  
11 (-7;31) 
2 (-1;5) 
 
 
0.78 
 
0.81 
 
4 (1;7) 
2 (-2;6) 
9 (-6;26) 
3 (1;6) 
 
 
0.70 
 
0.74 
 
-5 (-8;-2)  
-5 (-8;-1) 
10 (-6;28) 
-5 (-8;-2) 
 
 
0.90 
 
0.86 
rs2445762 
TT 
TC 
CC 
TC+CC 
 
166 (51) 
139 (43) 
20 (6) 
159 (49) 
 
2 (-1;6) 
1 (-3;6) 
3 (-9;16) 
1 (-3;6) 
 
 
0.94 
 
1.00 
 
3 (0;6) 
5 (1;9) 
-2 (-11;8) 
4 (0;8) 
 
 
0.19 
 
0.17 
 
-4 (-7;-1) 
-6 (-10;-2) 
-8 (-17;2) 
-6 (-10;-3) 
 
 
0.72 
 
0.61 
rs11070844 
CC 
TC 
TT 
TC+TT 
 
255 (78) 
66 (21) 
4 (1) 
70 (22) 
 
1 (-2;5) 
5 (-1;11) 
4 (-20;37) 
5 (-1;11) 
 
 
0.73 
 
0.42 
 
3 (0;6) 
7 (1;12) 
15 (-9;45) 
7 (2;12) 
 
 
0.92 
 
0.74 
 
-4 (-7;-1)  
-7 (-12;-3) 
11 (-13;42) 
-7 (-12;-2) 
 
 
0.06 
 
0.03 
ΔPercentage change in hormonal measurements per 10 g/day change in alcohol intake. 
aAdjusted for age, smoking (never, past, current) and BMI (kg/m2) at baseline. 
bP-value for interaction 
SHBG: Sex-hormone binding globulin. 
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In general, estrone and estrone sulphate levels increased whereas SHBG levels decreased for every 10 
gram alcohol consumed per day irrespectively of genotype (Table 3).  Estrone sulphate levels differed 
significantly according to CYP19A1/rs3751591 genotype for NSAID users and non-users, respectively 
(P=0.008) (Table S1). Carriers of the CC genotype had 48% higher levels of estrone sulphate when using 
NSAID compared to T-carriers who did not use NSAID (95% CI: 3;114), whereas T-carriers who were also 
NSAID users had 13% decreased levels of estrone sulphate (95% CI; -20;-5).  However, these estimates 
were based on very small numbers. There was also a borderline statistically significant interaction between 
NSAID usage and the CYP19A1/rs6493487 polymorphism in relation to SHBG levels (P=0.05).  Overall, 
NSAID users had higher levels of SHBG and lower levels of estrone and estrone sulphate (Table S1). Thus, 
some of the studied CYP19A1 SNPs were associated with hormone levels and a few other SNPs interacted 
with alcohol intake in relation to hormone levels. CYP19A1/rs1062033 was associated to both hormone 
levels and to alcohol-dependent differences in hormone levels. 
Associations with BC risk 
Homozygous variant carriers of the CYP19A1/rs3751591 polymorphism were at 2.12-fold increased risk of 
BC (95% CI:  1.02-4.43; P=0.04) compared to wild-type carriers (Table 4). Carriers of the haplotype 
combination GGG/GAG (CYP19A1/A-rs10046-G, A-rs6493487-G, A-rs10519297-G) were at 56% increased 
risk of BC (IRR=1.56; 95% CI: 1.02-2.40) (Table S2). Thus, CYP19A1/rs3751591 was both associated with 
SHBG levels and with risk of BC such that homozygous variant allele carriers had increased levels of serum 
SHBG and were at increased risk of BC. 
None of the CYP19A1 polymorphisms interacted with alcohol (Table S3) or NSAID usage (Table S4) in 
relation to BC risk. All risk estimates showed increased risk of BC of 10-66% per 10 gram alcohol per day 
regardless of genotype (Table S3). NSAID usage also increased BC risk compared to non-users 
irrespectively of genotype (Table S4). There was no interaction between any of the CYP19A1 
polymorphisms and being carrier of either of the PPARG Pro12Ala alleles (Table S5). However, we found 
interaction between CYP19A1/rs3751591 and PPARGC1A Gly482Ser (P=0.02) in relation to BC risk (Table 
S6); and interaction between CYP19A1/rs4646 and PPARGC1A Thr612Met (P=0.002) in relation to BC risk 
(Table S7). Wild type carriers of CYP19A1/rs4646, who were also variant Met-carriers of PPARGC1A 
Thr612Met were at 2.06-fold increased risk of BC (95% CI: 1.17-3.65). Conversely, variant CYP19A1/rs4646-
carriers, who also carry the variant PPARGC1A Thr612Met allele had a 38% decreased risk of BC (IRR=0.62; 
95% CI: 0.36-1.08) (Table S7). When including alcohol in the model as 10 gram alcohol per day, practically 
all CYP19A1 polymorphisms interacted with PPARG Pro12Ala (P-values between 0.03-0.10) (Table S8). Only 
PPARG Pro12Ala wild type carriers were at significantly increased risk of BC. Neither PPARGC1A Gly482Ser 
nor PPARGC1A Thr612Met interacted with any of the CYP19A1 polymorphisms when inferring the BC risk 
per 10 gram alcohol per day (Tables S9 and S10). There were no interactions with NSAID use for 
combinations of CYP19A1 genotypes for 10 gram alcohol per day (Table S11). 
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Table 4: IRR for BC in relation to the studied polymorphisms. 
 ncases (%) 
(n=687) 
ncontrol (%) 
(n=687) 
IRRa (95% CI) IRRb (95% CI) P-valuec 
rs10519297 
AA 
AG 
GG 
AG+GG 
 
170 (25) 
341 (50) 
176 (25) 
511 (75) 
 
174 (25) 
361 (53) 
152 (22) 
513 (54) 
 
1.00 (ref.) 
0.98 (0.76-1.27) 
1.23 (0.90-1.68) 
1.05 (0.82-1.34) 
 
1.00 (ref.) 
0.94 (0.72-1.23) 
1.25 (0.91-1.72) 
1.03 (0.80-1.32) 
 
 
0.15 
 
0.83 
rs749292 
GG 
AG 
AA 
AG+AA 
 
216 (31) 
332 (48) 
139 (20) 
471 (68) 
 
203 (30) 
352 (51) 
132 (19) 
484 (70) 
 
1.00 (ref.) 
0.89 (0.69-1.14) 
0.97 (0.71-1.33) 
0.91 (0.72-1.15) 
 
1.00 (ref.) 
0.89 (0.69-1.16) 
0.99 (0.72-1.37) 
0.92 (0.72-1.17) 
 
 
0.62 
 
0.50 
rs1062033 
CC 
CG 
GG 
CG+GG 
 
203 (30) 
333 (48) 
151 (22) 
484 (70) 
 
186 (27) 
354 (52) 
147 (21) 
501 (73) 
 
1.00 (ref.) 
0.85 (0.66-1.10) 
0.92 (0.67-1.25) 
0.87 (0.68-1.11) 
 
1.00 (ref.) 
0.85 (0.65-1.11) 
0.94 (0.68-1.28) 
0.88 (0.68-1.12) 
 
 
0.46 
 
0.30 
rs10046 
AA 
AG 
GG 
AG+GG 
 
182 (27) 
346 (50) 
159 (23) 
505 (73) 
 
188 (28) 
353 (51) 
146 (21) 
499 (72) 
 
1.00 (ref.) 
1.02 (0.79-1.31) 
1.16 (0.85-1.57) 
1.06 (0.84-1.34) 
 
1.00 (ref.) 
0.97 (0.75-1.26) 
1.15 (0.84-1.57) 
1.02 (0.80-1.31) 
 
 
0.52 
 
0.86 
rs4646 
CC 
CA 
AA 
CA+AA 
 
372 (54) 
265 (39) 
50 (7) 
315 (46) 
 
371 (54) 
262 (38) 
54 (8) 
316 (46) 
 
1.00 (ref.) 
1.00 (0.80-1.25) 
0.96 (0.63-1.45) 
0.99 (0.81-1.22) 
 
1.00 (ref.) 
0.97 (0.77-1.21) 
1.00 (0.65-1.53) 
0.97 (0.78-1.20) 
 
 
0.95 
 
0.78 
rs6493487 
AA 
GA 
GG 
GA+GG 
 
407 (59) 
245 (36) 
35 (5) 
280 (40) 
 
430 (62) 
218 (32) 
39 (6) 
257 (38) 
 
1.00 (ref.) 
1.23 (0.98-1.55) 
0.96 (0.60-1.54) 
1.19 (0.95-1.48) 
 
1.00 (ref.) 
1.24 (0.98-1.58) 
0.88 (0.54-1.44) 
1.18 (0.94-1.48) 
 
 
0.16 
 
0.16 
rs2008691 
AA 
GA 
GG 
GA+GG 
 
479 (70) 
179 (26) 
29 (4) 
208 (30) 
 
470 (68) 
198 (29) 
19 (3) 
217 (32) 
 
1.00 (ref.) 
0.88 (0.69-1.11) 
1.43 (0.80-2.57) 
0.93 (0.74-1.17) 
 
1.00 (ref.) 
0.88 (0.69-1.12) 
1.45 (0.80-2.64) 
0.93 (0.74-1.18) 
 
 
0.25 
 
0.57 
rs3751591 
TT 
TC 
CC 
TC+CC 
CC vs. TT+TCd 
 
479 (70) 
182 (26) 
26 (4) 
208 (30) 
26 (4) 
 
498 (72) 
176 (26) 
13 (2) 
189 (28) 
13 (2) 
 
1.00 (ref.) 
1.07 (0.84-1.36) 
2.13 (1.04-4.39) 
1.13 (0.89-1.42) 
2.09 (1.02-4.29) 
 
1.00 (ref.) 
1.07 (0.83-1.37) 
2.12 (1.02-4.43) 
1.13 (0.89-1.44) 
2.09 (1.00-4.34) 
 
 
0.60 
0.04 
0.31 
0.05 
rs2445762 
TT 
TC 
CC 
TC+CC 
 
359 (52) 
278 (40) 
50 (8) 
328 (48) 
 
365 (53) 
276 (40) 
46 (7) 
322 (47) 
 
1.00 (ref.) 
1.02 (0.81-1.27) 
1.10 (0.72-1.69) 
1.03 (0.83-1.27) 
 
1.00 (ref.) 
1.04 (0.83-1.31) 
1.19 (0.76-1.85) 
1.06 (0.85-1.32) 
 
 
0.74 
 
0.61 
rs11070844 
CC 
TC 
TT 
TC+TT 
 
552 (80) 
129 (19) 
6 (1) 
135 (20) 
 
556 (81) 
125 (18) 
6 (1) 
131 (19) 
 
1.00 (ref.) 
1.06 (0.801-1.39) 
1.01 (0.33-3.13) 
1.06 (0.81-1.38) 
 
1.00 (ref.) 
1.06 (0.80-1.40) 
0.86 (0.27-2.73) 
1.05 (0.80-1.38) 
 
 
0.88 
 
0.73 
a Crude. 
b Adjusted for parous/nulliparous, number of births, age at first birth, length of school education (low, medium, high), duration of HRT 
use (years), BMI (kg/m2) and alcohol intake (10 g/day). 
c P-value for trend. 
d CC versus TT and TC.  
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Human intervention study 
We assessed the impact of PPARG Pro12Ala on female sex-hormone concentrations after consumption of 
alcohol and the possible interaction with the NSAID Ibuprofen in postmenopausal women. Baseline 
characteristics of the study participants are presented in Table 5, and mean hormone, ethanol and SHBG 
concentrations in Table S12. Baseline measurements (time=0) did not differ between the two treatment 
groups (results not shown). Intake of Ibuprofen and inherent variation according to PPARG Pro12Ala 
genotype did not affect hormone or SHBG concentrations (treat was not significant - neither in model A nor 
in model B). However, there was a statistically significant effect of time on the hormone measurements 
(model B); that is, estrone, estrone sulphate and SHBG concentrations declined over the time period from 0 
to 90 minutes (Figure 2-4), whereas ethanol concentration increased as expected (Figure 5). Results from 
model A showed that time was not significant from the beginning of the study to the end except from estrone 
that ended at a higher level than at the beginning. BMI affected the analyses with SHBG and ethanol and 
were nearly significant in the analyses with estrone sulphat (P=0.07) and estrone (P=0.09) so that women 
with high BMI also had high blood concentrations of hormones, SHBG and ethanol. 
In the analyses of estrone sulphat an outlier was removed from the data set. Id=5650 was very dominating 
and had a high Cook’s D value and a relatively large residual value. 
Table 5. Characteristics of the study participants in the human intervention study. 
Characteristic PPARγ2 Pro12 (n=18) PPARγ2 12Ala (n=7) P-valuesd 
Mean±SD Mean±SD 
Agea, y 59.4±6.2 56.4±6.0 0.28 
Weight, kg 66.0±9.0 61.9±5.1 0.27 
BMI, kg/m2 23.5±2.4 21.9±2.0 0.14 
Years since last menses 8.6±6.9 6.4±4.6 0.46 
Alcohol intake/week 7.3±4.9 6.5±3.6 0.70 
Characteristic PPARγ2 Pro12 (n=18) PPARγ2 12Ala (n=7)  
No. % No. %  
Menopause type      
Naturalb 17 94.4 6 85.7  
Hysterectomyc 1 6.6 1 14.3  
Smoking status      
Never 10 55.6 5 71.4  
Former 8 44.4 2 28.6  
Characteristics of participants from the human intervention study divided by genotype. 
a One participant was only 48 years, but had not had her menses for 6 years. All other participants were older than 50 years.  
b One participant had had a unilateral oophorectomy.  
c One participant had a combined hysterectomy and oophorectomy; and one participant had a hysterectomy before last menses, but 
was older than 60 years. 
d P-values for comparison of baseline characteristics using Student’s t-test. 
 
Discussion 
In the present study, we find that polymorphisms in CYP19A1 are associated with circulating blood levels of 
female sex-hormones and interact with alcohol consumption. These same polymorphisms are not, however, 
associated with BC risk. In addition we find indications of interaction between use of NSAID, CYP19A1 
polymorphisms and levels of circulating female sex-hormones. We show that CYP19A1 polymorphisms 
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interact with polymorphisms in PPARGC1A in relation to risk of BC, but alcohol intake does not interact. 
Additionally, we show that acute alcohol consumption affects circulating blood hormone and SHBG levels, 
but Ibuprofen intake and being a carrier of either of the PPARG Pro12Ala alleles do not affect the found sex-
hormone concentrations. 
In the prospective study, we were able to show that inherent variations in CYP19A1 predict female sex-
hormone levels, but these genetically determined changes were not associated with BC risk. These results 
support several other studies showing association between CYP19A1 polymorphisms and estrogens 
51,53,54,65, but not BC 66-68. It is, however, evident that alcohol consumption, and to some extent also NSAID 
use, has major impact on the circulating sex-hormones. Nevertheless, CYP19A1/rs3751591 and the 
GGG/GAG (CYP19A1/A-rs10046-G, A-rs6493487-G, A-rs10519297-G) haplotype combination were 
associated with BC risk, but both results were based on very low number of cases and should therefore be 
interpreted with caution and must be replicated in other, larger studies along with the other findings on this 
specific polymorphism. CYP19A1/rs3751591 has no known function; it was chosen as a tag SNP and is 
located in a recombination spot.  
We found no evidence of interaction between aromatase and PPARγ. When alcohol was included in the 
model, we found that only the PPARG Pro12Ala wild type carriers were at significantly increased risk of BC 
irrespective of CYP19A1 polymorphisms. This indicates that the effect of the PPARG Pro12Ala polymorphism 
is very strong and that the CYP19A1 polymorphisms only have minor influence on the BC risk. We did 
observe a possible interaction between aromatase and PGC-1α, however, none of the PPARGC1A 
polymorphisms interacted with CYP19A1 polymorphisms in the presence of alcohol.  Almost all risk 
estimates were above unity indicating a strong effect of alcohol regardless of genotype combination. We 
have previously found evidence of PPARG and PPARGC1A being involved in alcohol-related BC 30; 
however, based on the present findings, we cannot extend this mechanism to involve aromatase. 
After acute ingestion of alcohol, estrone, estrone sulphate and SHBG levels declined significantly and 
correlated inversely with ethanol blood levels. Both controlled acute trials 16,20-23,69, controlled trials with fixed 
amounts of alcohol over longer periods 17,18 and observational studies 12-15,24,25 have found increased levels 
of estrogens after consumption of alcohol. Most acute studies have only measured estradiol levels, which 
have been consistently increased after consumption of alcohol 16,19-23, whereas estrone has only been 
measured in two acute studies in women using oral contraceptives 23 and HRT 20, respectively. In the study 
by Sarkola et al., estradiol increased after alcohol administration, but alcohol intake had no effect on estrone 
levels. However, the estradiol-to-estrone ratio was significantly increased. In the other study by Ginsburg et 
al., estrone declined after alcohol consumption, whereas estradiol increased. Long-term interventional and 
observational studies most consistently report either increased levels of estradiol 13,15,18,25,70-72 and/or estrone 
12,13,18,71,72 and/or estrone sulphate 14,17,71 and decreased SHBG levels 12,71-73 among alcohol drinkers in both 
pre- and postmenopausal women. However, estradiol and estrone have very short half-lives of 35 minutes, 
whereas estrone sulphate has a half-life of 5-7 hours 17. 
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Figure 2. Estrone concentrations as a function of time. Values represent pooled mean 
measurements ± SEM (n=50). Ptime (0-90minutes)=<0.001; Ptime (0-1200minutes)=0.02. 
 
 
 
Figure 3. Estrone sulphate concentrations as a function of time. Values represent 
pooled mean measurements ± SEM (n=50). Ptime (0-90minutes)=<0.001. 
 
 
Figure 4. SHBG concentrations as a function of time. Values represent pooled mean 
measurements ± SEM (n=50).  Ptime (0-90minutes)=0.009. 
 
 
 
Figure 5. Ethanol concentrations as a function of time. Values represent pooled mean 
measurements ± SEM (n=50). Ptime (0-90minutes)=<0.001. 
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Therefore, only acute studies, where blood is collected immediately after alcohol ingestion, are able to 
correctly measure the effect of alcohol on estradiol and estrone blood levels. On the other hand, acute 
ingestion of alcohol may have a different effect on sex-steroids than chronic alcohol consumption, as 
illustrated by studies on alcohol consumption and immune effects74. It has been suggested that acute 
ingestion of alcohol affects catabolism of the hormones in the liver rather than synthesis 22,23,75,76. In the liver, 
alcohol consumption increases the [NADH]:[NAD+] ratio which leads to a decreased catabolism of sex-
hormones mediated by 17b-hydroxysteroid dehydrogenase type 2 enzyme resulting in increased levels of 
testosterone and estradiol and decreased levels of androstendione and estrone. Furthermore, it has been 
shown that only long-term chronic ingestion of alcohol induces aromatase 22,34. We also detected a decline in 
estrone sulphate levels shortly after ingestion of alcohol, supporting that acute alcohol intake affects 
metabolism of female sex-hormone. Therefore, if acute intake of alcohol only affects hormone metabolism 
and not synthesis, which involves the interaction between aromatase and PPARγ, then we would not be able 
to detect neither the PPARG Pro12Ala genotype effect, nor the effect of Ibuprofen, which is a known PPARγ 
stimulator 38.  
We used a nested case-control design for the prospective study, which together with complete follow-up 
minimizes selection bias. In addition, information on life style factors was collected at enrolment, which 
minimizes the risk for differential misclassification between cases and controls. The study is fairly large to 
study main effects, it is homogenous and alcohol consumption is very high in the DCH cohort 77 making it 
suitable for studying gene-environment interactions. However, we are aware that there are several limitations 
in studying gene-environment interaction with NSAID use including the limited power. The information on 
NSAID use retrieved from the FFQ may not necessarily reflect a long-term chronic use which is considered 
necessary to confer an effect on carcinogenesis 78. Moreover, use of NSAID was defined as a combined 
group of different types of pain killers including paracetamol, aspirin and Ibuprofen, which have different 
pharmacological effects and also different effect in relation to BC risk 42. The genes were carefully selected 
based on their role in steroidogenesis and alcohol-related BC. The CYP19A1 polymorphisms were mainly 
tag SNPs, whereas the PPARG and PPARGC1A polymorphisms were functional. However, only the 
interaction between CYP19A1/rs4646 and PPARGC1A Thr612Met, and the effect of CYP19A1A/rs749292 on 
estrone sulphate levels withstood correction for multiple analyses.  Therefore, some of the results based on 
the prospective study may be due to chance. 
The human intervention trial also has several limitations. Our aim was to conduct a pilot study to examine 
whether the PPARG Pro12Ala polymorphisms had influence on the blood hormone level after consumption of 
alcohol with and without concurrent intake of Ibuprofen. Based on a controlled long-term feeding study 17, we 
should have an 80% chance of detecting a change in hormone levels of 10% on a 5% significance level 
(α=0.05) with 11 participants in each group. However, we were only able to recruit 7 PPARG 12Ala variant-
carriers. Nevertheless, we found statistically significant decreases in estrone, estrone sulphate and SHBG 
levels. We did not include an alcohol placebo group because our main aim was to examine the effect of 
concurrent use of Ibuprofen and alcohol consumption on circulating hormone levels. Therefore, the hormone 
effect could potentially be an effect of the ingredients in the alcoholic drink. However, other interventional 
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studies have used similar ingredients in the alcoholic test drink e.g. different types of fruit juices 
17,18,20,22,23,69,79 or pure glucose 16 without an effect on hormone levels. In order to verify the results from the 
present study, a new study should preferably include a placebo group, and if feasible for ethical reasons 
should also consider altered effects over a longer exposure period. Moreover, other steroid hormones should 
be included to examine other effects of alcohol consumption on steroidogenesis and metabolism. The 
method used to measure hormones differs from all the other studies mentioned in this paper. We determined 
the hormones by LC-MS because of its documented specificity 80 and to avoid overestimation due to lack of 
specificity of antibodies, which is a well-known challenge with conventional radioimmunoassays 80,81. 
However, MS methods suffer from lack of sensitivity and, consequently, we were not able to include results 
on estradiol measurements and 11% of the estrone measurements had levels below zero which further 
decreased the statistical power. 
In conclusion, our results show that alcohol consumption and inherent variations in CYP19A1 influence the 
level of circulating sex-hormones. In addition, our results indicate that acute and chronic alcohol 
consumption may affect metabolism and biosynthesis of estrogens differently. However, we were not able to 
confirm our primary hypothesis that PPARγ and the aromatase is part of the same pathway in alcohol-related 
BC or that NSAID (Ibuprofen) use has major impact on steroidogenesis. 
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Abstract 
Alcohol consumption and increased estrogen levels are major risk factors for breast cancer (BC); and 
peroxisome proliferator-activated receptor γ (PPARγ) plays an important role in alcohol-induced BC. PPARγ 
activity is inhibited by ethanol, leading to increased aromatase activity and estrogen biosynthesis ultimately 
leading to BC. If other organic solvents inhibit PPARγ activity, they should also lead to increased estrogen 
biosynthesis, and thus be potential breast carcinogens. 10 commonly used hydrophilic organic solvents were 
first tested in a cell-based screening assay for inhibitory effects on PPARγ transactivation. The chemicals 
shown to inhibit PPARγ were tested with vectors encoding PPARγ with deleted AB domains and only the 
LBD domain to rule out unspecific toxicity. Next, the effects on biosynthesis of estradiol, testosterone and 
estrone sulphate were measured in the H295R steroidogenesis assay after incubation with the chemicals. 
Ethylene glycol, ethyl acetate and DMSO inhibited PPARγ transactivation in a dose-dependent manner. The 
inhibitory effect on PPARγ was specific for PPARγ since the AB domain of PPARγ was required for the 
inhibitory effect. In the second step, ethylene glycol significantly increased production of estradiol by 19% 
(P<0.05) and ethyl acetate inhibited production of testosterone (P<0.05). We here show that screening of 10 
commonly used organic solvents for the ability to inhibit PPARγ transactivation followed by a well-
established steroidogenesis assay  for production of sex hormones in exposed H295R cells may provide a 
screening tool for potential breast carcinogens. This initial screening thus identified ethylene glycol and 
possibly ethyl acetate as potential breast carcinogens.   
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Introduction 
Breast cancer (BC) is the most common form of cancer among women worldwide, with the highest incidence 
in the industrialised countries 1. The incidence of BC has doubled over the last 30 years 1. Both 
environmental and genetic factors are known to contribute to the aetiology of BC 2. The majority of the well-
established risk factors are associated with prolonged exposure to increased levels of estrogens e.g. early 
menarche, late menopause, few or no full-term pregnancies, short or no post-partum lactation, and late 
childbirth 2,3. Alcohol consumption is a well-known risk factor for BC 4-6 and intake of one drink per day is 
associated with 7-10% increased risk of BC 2,7-11. Controlled human and observational studies have shown 
that alcohol consumption is associated with increased blood levels of several sex hormones in pre- and 
postmenopausal women 12-18.   
A single nucleotide polymorphism in the PPARG2 gene has been associated with alcohol-related BC in 
postmenopausal women 19. Wild type allele carriers of PPARG2 Pro12Ala had a 20% increased risk of BC 
per 10 g alcohol (corresponding to one drink) per day, whereas variant allele carriers had no risk of alcohol-
related BC 19. This indicates that the peroxisome proliferator-activated receptor γ (PPARγ), which is encoded 
by PPARG, is an important modulator in alcohol-related breast carcinogenesis.  PPARγ regulates the 
expression of many adipose-specific genes via binding of the heterodimer PPARγ/Retinoic X receptor (RXR) 
to specific DNA response elements (PPREs) in target gene promoters 20. PPARγ is a negative regulator of 
aromatase expression in a complex with the co-activator peroxisome proliferator-activated receptor γ co-
activator (PGC-1α) 21,22. Estrogen is synthesised from testosterone in the biosynthesis step catalysed by 
aromatase 23. We have shown that ethanol inhibits the PPARγ-PGC-1α complex and inhibits PPARγ activity 
24. Animal studies have demonstrated that ethanol intake leads to increased aromatase transcription 25 
which, in turn, leads to increased estrogen biosynthesis. In support of this notion, we have confirmed that 
ethanol increases estrogen excretion in the human H295R cell line 24. These experiments collectively 
suggest that alcohol increases BC risk by inhibition of PPARγ activity, resulting in obviation of a PPARγ-
mediated inhibition of aromatase expression, leading to an alcohol-dependent increase in female sex 
hormone synthesis and thus increased BC risk 24. Inhibitors of PPARγ activity should therefore be 
considered as potential breast carcinogens. 
We hypothesized that other chemicals which inhibit PPARγ activity may cause BC by a mechanism similar to 
alcohol. Consequently, screening chemicals for the ability to inhibit PPARγ activity may provide a tool for 
identifying breast carcinogens. Indeed, several occupational studies have linked exposure of different 
chemicals, including organic solvents, to BC 26-30. The largest study to date encompassing 15 million people 
aged 30-64 years with 373,361 cases of incident female BC, shows major occupational variation in BC risk 
27. Some of the variation may be explained by differences in birth pattern, education and physical activity, 
however, as Hansen and Meersohn discuss in their Danish study, the differences in risk of BC point to 
exposure in the working environment 26. Consistent with this, working with organic solvents for just one year 
was associated with a 20-70% increased risk of BC in another study by Hansen 30. The risk estimates tended 
to increase with increasing duration of employment. All analyses were adjusted for social class, age at first 
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child, and number of children emphasising the significance of work-related exposure to organic solvents as 
an isolated risk factor for BC 30. 
Most mammary carcinogens among organic solvents are lipophilic 31-33. They are hypothesized to cause 
cancer due to their ability to reside in the adipose tissue surrounding the breast parenchyma and lobules 
where the solvents and their bioactivated metabolites may exert harmful local effects 31. In the present study, 
we hypothesize that organic solvents may inhibit PPARγ in a manner similar to the organic solvent ethanol. 
Furthermore, we hypothesize that such solvents will also lead to increased estrogen biosynthesis in the 
H295R assay. To test this hypothesis, we screened 10 chemicals for their ability to inhibit PPARγ 
transactivation in a widely used HEK293 cell-based screening assay 34,35. The examined organic solvents 
were selected based on the following criteria: miscibility with water (>3% in water), widely used in Denmark 
with “very probable exposure”, according to the Danish SPIN2000 database 36 , suspected as being a 
mammary carcinogen 32,33 and/or found in human breast milk with a milk/plasma ratio above 1 31.  
Afterwards, the positive candidates from the initial screening were assessed for estrogen biosynthesis in an 
OECD validated method for testing of chemicals and their effect on androgen or estrogen steroid hormone 
production 37. We show that exposure to some widely used hydrophilic organic solvents increases female 
sex hormone levels possibly by a PPARγ-dependent mechanism and may thereby increase the risk of 
female BC. 
Methods 
Test compounds 
12 organic solvents were initially included in the study (CAS number in brackets): Methanol (67-56-1), 
Dimethyl sulfoxide (DMSO) (67-68-5), isopropanol (67-63-0), ethylene glycol (107-21-1), 1-Propanol (71-23-
8), acetone (67-64-1), 1,4-dioxane (123-91-1),  benzaldehyde (100-52-7)  (Sigma-Aldrich®, Copenhagen, 
Denmark),  acetonitrile (75-05-8) (Merck®, Darmstadt; Germany), N,N-dimethylformamide (68-12-2) 
(Fluka®, Copenhagen, Denmark ), ethyl acetate (141-78-6) and diethyl ether (60-29-7)  (Rathburn 
Chemicals Ltd., Højbjerg, Denmark).  Diethyl ether, however, cannot be pipetted in small amounts due to its 
high vapour pressure; and benzaldehyde was extremely cytotoxic, even in small doses. Consequently, these 
two chemicals were excluded, leaving 10 organic solvents in the study. 
Transient transfection 
Human Embryonic Kidney (HEK293) cells 38 were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and antibiotics (62.5 µg/ml penicillin and 100 µg/ml 
streptomycin). HEK293 cells were transfected using 0.11 µl Metafectene®Easy+ (Biontex) per well in a 96-
well plate. The plasmids used were the PPARγ-responsive luciferase reporter plasmid 39, pcDNA3.1 
(Invitrogen) based expression constructs containing the full-length human PPARγ2 cDNA (wild type) and 
pRL-CMV normalization vector (Promega). All organic solvents tested positive, by giving indication of an 
inhibitory or inducing effect, were tested with 1) The same assay as above except that the pcDNA3 
expression construct contains human PPARγ2 with deleted AB domains (N-terminal region) 
 179 
 
(pcDNA3hPPARγΔAB containing aa 110-475 (PPARγ1 coordinates)) 40; and 2) An assay with the following 
plasmids: A Gal4 responsive photinus luciferase expressing reporter plasmid (UAS-Gal), a pM1 based 
expression construct containing the ligand binding domain (LBD) (aa 174-475 (hPPARγ1 coordinates)) of 
human PPARγ1 (donated by Dr. Jan Fleckner, Novo Nordic, Denmark) and the pRL-CMV normalization 
vector. For each well in a 96-well dish, 30 ng reporter, 15 ng expression vector and 5.0 ng normalization 
vector were used. Six hours after transfection, the cells were supplemented with fresh media containing 
vehicle, rosiglitazone (1 µM) and test substance (0.1, 0.3, 1 or 3%). Some of the solvents showed severe 
sign of cytotoxicity at 3% and the top dose was consequently reduced to 1%. Cells were harvested after 18 h 
and Photinus and Renilla luciferase activities were measured directly in the plate using EnVision 2104 
Multilabel Reader (PerkinElmer). Photinus luciferase values were normalized to Renilla luciferase values to 
correct for differences in transfection efficiency and cytotoxicity or other cellular stress. All experiments were 
performed with four replicates and repeated twice. Each experiment represents one data point (mean value) 
leading to n=3 in the data analyses. 
Cell culture 
Human adrenocortical carcinoma NCI-H295R cells (ATCC CRL-2128) 37 were cultured in Dulbecco's 
modified Eagle's medium/Nutrient Mixture F-12 Ham without phenol red (Sigma) supplemented with 1% ITS 
Plus premix (BD Biosciences), 2.5% NuSerum (VWR), 1% L-glutamine (Gibco) and 1% antibiotic/antimycotic 
(Gibco). The cells were cultured as monolayers in a humidified environment at 37 °C with 5% CO2 
Analysis of hormone production 
NCI-H295R cells were cultured as described above and used to investigate if treatment with ethylene glycol, 
ethyl acetate, acetone or DMSO altered the production of estradiol, testosterone and/or estrone sulphate. 
The cytotoxic effect of each compound was assayed using the CellTiter 96 AQueous One kit (Promega). The 
hormone production assay was then performed with the highest concentration of each compound, which 
gave rise to a cell viability decrease of maximum 10% in four independent determinations leading to n=4. 
NCI-H295R cells were plated in 24 well plates and cultured for 48 hours. The cell culture medium was then 
renewed and the cells were treated with ethylene glycol, ethyl acetate, acetone or DMSO or left untreated 
(control) for 40 hours. The culture medium was then collected and the hormone levels analysed. Production 
of estradiol, testosterone and estrone sulphate was measured by enzyme-linked immunosorbent assay 
(ELISA). The ELISA kits (DE4399, DE1559, and DEV9933) were purchased from Demeditec Diagnostics 
GmbH, Germany. The analyses were performed in accordance with the manufacturer's recommendations. 
Statistical methods 
Transient transfection: One-way analysis of variance (ANOVA) was performed followed by a Dunnett's post-
test to examine differences between exposed groups and controls using GraphPad Prism 5. 
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Fig 1. Transient transcription activation of PPARγ in a luciferase reporter gene in the presence of 10 different organic 
solvents. The full-length PPARγ2 cDNA was transiently transfected into HEK293 cells in combination with a PPRE 
luciferase reporter construct and PPARγ mediated transcription activation was measured. Reporter activity was 
normalized to pRL-CMV values. Some of the experiments showed cytotoxicity at 3% and the top dose was 
consequently reduced to 1%. All transfections were performed independently three times in four replicates (i.e. n=3). 
Results are presented as mean±SD. * denotes significant difference between treated and non-treated samples (*: P<0.05; 
**: P<0.01; ***: P<0.001)  
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Hormone production: Kruskal-Wallis test was used to compare mean concentrations of the hormones. When 
results of the Kruskal-Wallis test were statistically significant, the groups were reanalysed using the Mann–
Whitney test. These tests were conducted in Minitab 16. 
Data were assessed for normal distribution and homogeneity of variances. The criteria for statistical 
significance were P=0.05, P=0.01, and P=0.001 leading to the marking *, **, and ***, respectively.  
Results 
A transient transfection screening assay using a PPARγ2 expression construct 24 was performed in order to 
measure a possible inhibitory effect on PPARγ transactivation of 10 frequently used hydrophilic organic 
solvents.  
Four of the tested solvents (ethyl acetate, ethylene glycol, DMSO and N,N-dimethylformamide) inhibited 
PPARγ- mediated transcriptional activation statistically significantly in a dose-dependent manner (Fig. 1). 
However, the apparent inhibitory effect of N,N-dimethylformamide was caused by an increased expression of 
the pRL-CMV normalization vector, rather than by inhibition of PPARγ induced transcription. Consequently, 
N,N-dimethylformamide was excluded from further analyses. Ethyl acetate, ethylene glycol, DMSO and 1,4-
dioxane were also able to inhibit rosiglitazone-induced PPARγ transactivation (Fig. 2). Rosiglitazone is a 
selective PPARγ ligand which was included in the assays to assess potential inhibition during ligand 
dependent activation of PPARγ. 
In order to clarify whether inhibition of PPARγ was related to the region encompassing the PPARγ Pro12Ala 
substitution (i.e. the N terminal part of the AB domain) and to ensure that the observed inhibitory effect was 
not caused by general toxicity; we performed additional transactivation assays with vectors encoding PPARγ 
with deleted AB domains and PPARγ encompassing only the LBD domain, respectively.  
Ethylene glycol and ethyl acetate did not inhibit transcriptional activation by hPPARγ(∆AB) nor 
hPPARγ(LBD) (Fig. 3 and 4). However, they did inhibit the rosiglitazone-induced transcription mediated by 
both constructs at 3% (Fig. 3 and 4) and ethyl acetate also inhibited the rosiglitazone-induced transcription 
by the hPPARγ(∆AB) at 1% (Fig. 4). DMSO inhibited hPPARγ(∆AB) mediated expression at 1%, but not 
hPPARγ(LBD) expression (Fig. 5). DMSO was able to inhibit the rosiglitazone-induced expression via both 
the hPPARγ(∆AB) and the hPPARγ(LBD) construct, but only at the highest dose (3%) (Fig. 5).  This 
indicates that the effect is PPARγ specific and that the AB domain was required for the inhibitory effects of 
ethylene glycol and ethyl acetate; and to some extent also of DMSO. Furthermore, in concordance with 
previous observations 40, the ligand rosiglitazone only enhanced transactivation by full-length hPPARγ or 
hPPARγ(ΔAB) by 4-6 and 6-8-fold, respectively, whereas ligand-dependent activation of the hPPARγ(LBD) 
construct was up to 30-fold . 
We hypothesized that inhibition of PPARγ transactivation would lead to increased aromatase activity and 
thus increased estrogen biosynthesis. 
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Fig 2. The same experiment as in figure 1, but with 1 µM Rosiglitazone added in combination with the test compound. 
Rosiglitazone contains 0.1 % DMSO; therefore, a negative DMSO containing control is added to each experiment in 
order to isolate the DMSO effect. All transfections were performed independently three times in four replicates (i.e. 
n=3). Results are presented as mean±SD. * denotes significant difference between non-treated samples (i.e. with 
Rosiglitazone, but no test compound) and treated samples (*: P<0.05; **: P<0.01; ***: P<0.001). 
In order to examine a direct effect on sex hormone levels, estradiol, testosterone and estrone sulphate 
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production were measured in H295R cells after incubation with ethylene glycol, DMSO and ethyl acetate for 
40 hours. Moreover, acetone was included as a “negative control” since acetone appeared to have no effect 
on PPARγ transcriptional activation. The highest concentration with maximum 10% effect on cell viability was 
considered as the no observed effect concentration for toxicity, and was used in the test. A concentration of 
0.3% ethylene glycol significantly increased production of estradiol with 19% (P<0.05) (Fig. 6); and 3% ethyl 
acetate significantly inhibited production of testosterone (P<0.05) (Fig. 7). None of the tested solvents had 
any effect on estrone sulphate production (result not shown). All results are provided in Table S1 as 
numerically values. 
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Fig. 3. Effect of Ethylene glycol on PPARγ constructs by transient transfections in HEK293 cells using either vectors 
encoding PPARγ with deleted AB domains (A and B) or pM1-PPARγ(LBD) (C and D) fusions with the appropriate 
luciferase reporter constructs. In B and D, Rosiglitazone is added to all wells except for DMSO controls. Reporter 
activity was normalized to pRL-CMV values. All transfections were performed independently three times in four 
replicates (i.e. n=3). Results are presented as mean±SD. * denotes significant difference between treated and non-
treated samples (*: P<0.05; **: P<0.01). 
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Discussion  
Alcohol inhibits PPARγ-mediated inhibition of aromatase activity, which leads to increasing levels of 
circulating female sex hormones potentially increasing the risk of BC. We hypothesized that exposure to 
other organic solvents may cause BC by a similar mechanism. To test this hypothesis, we designed a two-
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step screening. We used an in vitro transactivation assay to screen for inhibition of PPARγ transactivation, 
and as a second step, screened candidates for increased estrogen biosynthesis. Ten different hydrophilic 
organic solvents were selected for the screening based on their widespread use in Denmark and, hence, 
exposure potential. Moreover, 1,4 dioxane is a known mammary carcinogen 32 and methanol has been found 
in human breast milk 31 indicating exposure. 
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Fig. 4. Effect of Ethyl acetate on PPARγ constructs by transient transfections in HEK293 cells using either vectors 
encoding PPARγ with deleted AB domains (A and B) or pM1-PPARγ(LBD) (C and D) fusions with the appropriate 
luciferase reporter constructs. In B and D, Rosiglitazone is added to all wells except for DMSO controls. Reporter 
activity was normalized to pRL-CMV values. All transfections were performed independently three times in four 
replicates (i.e. n=3). Results are presented as mean±SD. * denotes significant difference between treated and non-
treated samples (*: P<0.05; **: P<0.01; ***: P<0.001). 
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We show that three out of 10 tested chemicals inhibit PPARγ transactivation in a dose-dependent manner 
using transient transfections with plasmids expressing three different PPARγ constructs – full length 
PPARγ2, PPARγ with deleted AB domains and a construct consisting of only the LBD of PPARγ. The AB 
domain which encompasses the PPARγ Pro12Ala polymorphism seems to be essential for the inhibitory 
effect, especially for ethylene glycol and ethyl acetate where inhibition was confined to full-length PPARγ2. 
This confirms that the observed inhibition of PPARγ is not caused by general toxic mechanisms such as 
denaturation of all enzymes. In the second screening step, ethylene glycol, ethyl acetate, DMSO and 
acetone were tested in the H295R steroidogenesis assay for production of estradiol, testosterone and 
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estrone sulphate production to determine whether inhibition of PPARγ results in increased female sex 
hormone levels. Acetone was included as a non PPARγ inhibitor. Ethylene glycol increased production of 
estradiol statistically significantly at a concentration of only 0.3% and ethyl acetate inhibited production of 
testosterone with statistical significance at a concentration of 3%. Increased estradiol levels could be a result 
of an increased synthesis from testosterone catalysed by aromatase or to inhibition of the subsequent 
metabolism of estradiol to sulphate conjugate, catalysed by SULT1E1. Inhibition of SULT1E1 would result in 
accumulation of both estradiol and estrone. None of the tested chemicals affected estrone sulphate 
production (results not shown). Thus, the results were consistent with the interpretation that ethylene glycol 
inhibited PPARγ transactivation and caused increased estradiol synthesis in H295R cells. 
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Fig. 5. Effect of DMSO on PPARγ constructs by transient transfections in HEK293 cells using either vectors encoding 
PPARγ with deleted AB domains (A and B) or pM1-PPARγ(LBD) (C and D) fusions with the appropriate luciferase 
reporter constructs. In B and D, Rosiglitazone is added to all wells except for DMSO controls. Reporter activity was 
normalized to pRL-CMV values. All transfections were performed independently three times in four replicates (i.e. 
n=3). Results are presented as mean±SD. * denotes significant difference between treated and non-treated samples (**: 
P<0.01; ***: P<0.001). 
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PPARγ is an important modulator of alcohol-induced BC 19,24 and the current study shows that PPARγ may 
be an important regulator of chemical-induced hormone changes. Thus, many chemicals have been shown 
to lower sex hormone production by stimulating PPARγ activity, leading to female infertility and male 
genitalia malformations 41-43. Interestingly, PPARγ agonists have been suggested to have therapeutic utility in 
the treatment of postmenopausal BC due to their anti-estrogenic properties 23. Here, we screen for chemicals 
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with the opposite, inhibitory effects on PPARγ transactivation activity, leading to increased estrogen levels 
and BC risk.  
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Fig. 6. NCI-H295R cells were cultured for 48 hours and treated with ethylene glycol, ethyl acetate, acetone or DMSO 
or left untreated (control) for 40 hours. The culture medium was then collected and the estradiol production was 
measured by enzyme-linked immunosorbent assay. The hormone production assay was performed with the highest 
concentration of each compound, which gave rise to a cell viability decrease of maximum 10%. Results are presented as 
mean±SD, n=4. * denotes significant difference between treated and non-treated samples (*: P<0.05). 
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The decreased testosterone production after exposure to ethyl acetate could be caused by interference with 
other targets located prior to testosterone synthesis in steroidogenesis. However, if the substrate for 
estradiol production (i.e. testosterone) is low, then the level of estradiol could also become low. That 
indicates that there is indeed an increase in estradiol production, but due to the low concentration of the 
substrate, the level of estradiol is comparable with that of the control. Therefore, ethyl acetate and ethylene 
glycol may act via a similar mechanism. Our results therefore indicate that ethyl acetate also interferes with 
other targets in steroidogenesis. Indeed, it is a well-known phenomenon that chemicals affect more than one 
target in steroidogenesis 44.  
It has previously been demonstrated that ethylene glycol is weakly estrogenic in rainbow trout due to 
induction of the estrogen receptor 45, however, to our knowledge, no other studies have investigated the 
effect of ethylene glycol or ethyl acetate on steroidogenesis. DMSO, conversely, has proven to induce a 
variety of effects including numerous effects on lipid metabolism (summarized in 46). Our results on DMSO 
are in agreement with these observations, since PPARγ is a major regulator of genes involved in lipid and 
lipoprotein metabolism 20.  
The present study was intended as an initial screening of commonly used hydrophilic organic solvents and 
their ability to 1) inhibit PPARγ in a well-established high-throughput cell-based screening assay; and 2) 
increase endogen estrogen levels in the H295R steroidogenesis assay. Since the H295R steroidogenesis 
assay is far more time-consuming and expensive, but has been proven to correlate with in vivo mechanisms, 
we use the initial screening comprising of the HEK293 cells which are easy to grow and transfect very readily 
to select appropriate candidates for this assay 47. However, since organic solvents possess different 
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properties, some of the negative findings in the transient transfection assay may simply be due to the 
chemicals not being able to enter the cells. Moreover, there may be discrepancies in the effect of absorption 
and metabolism of the test chemicals in different cell lines. The H295R steroidogenesis assay is designed to 
identify substances that affect targets in steroidogenesis from cholesterol to the production of the terminal 
steroid hormones, that is, not substances that affect steroidogenesis via a mechanism that involves the 
hypothalamic-pituitary-gonadal axis 37. Therefore, stimulation of the aromatase activity caused by inhibition 
of PPARγ is a plausible mechanism for the effects observed in the present study, but we did not assess 
PPARγ activity in the H295R assay; nor did we examine aromatase mRNA expression. However, H295R 
cells are of adrenal gland origin, which indicates that this specific mechanism is not limited to adipocytes. 
The genotype of the H295R cell line have previously been genotyped to carry the PPARG Pro12Ala wild-type 
24, proving that the H295R cell assay is capable of PPARγ-PGC-1α interaction as the PGC-1α-dependent co-
activation of the PPARγ-complex is compromised for the PPARγ Ala12 variant. 
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Fig. 7. NCI-H295R cells were cultured for 48 hours and treated with ethylene glycol, ethyl acetate, acetone or DMSO 
or left untreated (control) for 40 hours. The culture medium was then collected and the testosterone production was 
measured by enzyme-linked immunosorbent assay. The hormone production assay was performed with the highest 
concentration of each compound, which gave rise to a cell viability decrease of maximum 10%. Results are presented as 
mean±SD, n=4. * denotes significant difference between treated and non-treated samples (*: P<0.05). 
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It is highly important to identify human carcinogens as a mean to prevent future exposures. Mutagenic 
carcinogens are identified in a number of in vitro 48,49 and in vivo screening tests 50. However, non-mutagenic 
carcinogens are more difficult to identify. We have previously provided evidence that ethanol causes BC by a 
PPARγ-dependent increase in aromatase activity 24. Based on this proposed mechanism-of-action, we here 
propose a screening approach for identification of breast carcinogens. We demonstrate that an in vitro 
screening of inhibition of PPARγ transactivation can be used to identify chemicals which may be breast 
carcinogens. As the second screening step, we used the H295R steroidogenesis assay to confirm an 
activation of aromatase activity. We show that at least one of three chemicals, ethylene glycol, leads to 
increased estradiol synthesis in H295R cells. The next screening step would be to show a similar effect in 
vivo in rodent models or in epidemiological studies. It has previously been demonstrated that ethanol intake 
increased aromatase activity and transcription levels in adipose tissue in orally dosed rats 25. Conversely, 
human studies like register-based epidemiological studies are difficult to interpret since exposure often is a 
 188 
 
mixture of chemicals and they often lack information of important potential confounders such as cigarette 
smoking, alcohol intake and hormone replacement therapy 51. 
Furthermore, our results indicate that some of the widely used organic solvents may possess endocrine 
disrupting properties possibly via a PPARγ-dependent mechanism. 0.3% ethylene glycol caused a 19% 
increase in estradiol biosynthesis. It is not clear whether the observed inhibitory effect will cause increased 
hormone levels at occupationally relevant exposure levels. However, it is possible that mixed exposure to 
several organic solvents, including alcohol consumption, may contribute to BC risk by the proposed 
mechanism, and as such, explains the observed association between exposure to organic solvents and BC 
risk 30. 
Based on knowledge of the mechanism of action of ethanol-mediated breast carcinogenesis, we propose a 
screening method for breast carcinogens. We show that screening of chemicals for the ability to inhibit 
PPARγ transactivation followed by a screening for increased estradiol biosynthesis in exposed H295R cells 
may provide a screening for potential breast carcinogens. This initial screening identified ethylene glycol and 
possibly ethyl acetate as potential breast carcinogens. These candidates should be tested in rodent model 
systems for their effect on aromatase expression and activity in adipose tissues. 
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Summarizing and supplementary discussion 
In the present PhD thesis, several biological mechanisms have been investigated in relation to three major 
cancer types. For PC and CRC, the main mechanism investigated involved inflammation as a precursor to 
neoplastic progression, whereas the effect of alcohol consumption and exposure to other organic solvents on 
circulating female sex-hormone levels was the focus in relation to BC.  
Based on the results from Paper I, inflammation does not seem to be a major risk factor for aggressive PC, 
whereas the results on non-aggressive PC were equivocal. In contrast, Paper II and III indicated that the 
immune system is indeed involved in the carcinogenesis of CRC. Carriage of the pro-inflammatory del-allele 
of NFKB1 -94Ins/delATTG, was not associated with aggressive PC risk, but was associated to lowered risk 
of non-aggressive PC, and increased the risk of CRC. Even though none of the results were strong 
statistically, they demonstrate that cancer is a very heterogeneous disease; and indicated that inflammation 
may not be a risk factor for (aggressive) PC, whereas in relation to CRC, inflammation seems important. 
Indeed, inflammation is already an established risk factor for CRC 1-3, but the underlying mechanisms are not 
yet established. In addition, replication of results is important in genetic epidemiology in order to eliminate 
population-specific effects. In Paper III, a new possible mechanism involving ABC transporters, IL-10 and 
dietary fibre in relation to protection against inflammation-induced CRC was identified through gene-gene-
environment interaction. Furthermore, use of NSAIDs seemed to interact with the ABC transporters and IL-
10. 
A diet high in red meat has consistently been associated with risk of CRC 4 and several hypotheses have 
been proposed and were tested in this thesis. First, high meat intake may disrupt the balance between 
commensal bacteria and the mucosal immune system by interacting with TLR4 – the pattern-recognition 
receptor that regulates inflammation and barrier function in the gut – and  NF-κB, which is activated by TLR4.  
Second, intestinal exposure to the meat-related mutagens and animal carcinogens, HCAs and PAHs, may 
interact with enzymes involved in transport of these potentially harmful substances modifying the risk of 
CRC. Third, heme iron, which is abundant in red meat, is metabolized by HO-1. HO-1 activity reduces 
cellular oxidative stress by removing the pro-oxidant heme and at the same time produces pro-inflammatory 
iron. Thus inherent variations in the genes encoding TLR4, NF-κB, the ABC transporters and HO-1 may 
interact with different components in the meat modifying the risk of CRC.  
However, red and processed meat intake did not interact with any of the polymorphisms assessed in this 
thesis. In addition, studies of polymorphisms in the N-acetyltransferase genes, NAT1 and NAT2, which 
encode the enzymes that activates HCAs and PAHs, do not consistently support that high intake of 
processed meat is associated with CRC risk either 5-7. On the other hand, in Paper II, high intake of red meat 
combined with an inherently increased inflammatory response, was associated with increased risk of CRC. 
Moreover, in a recent study using the same CRC cohort study group 8, meat intake interacted with a 
polymorphism in COX-2 increasing the risk of CRC among variant carriers. This finding is consistent with a 
Chinese prospective, population-based cohort study showing a positive association between this specific 
COX-2 SNP and CRC among subjects with high n-6 PUFA intake (which is abundant in meat). Therefore, a 
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diet high in meat may induce inflammation in the gut by a mechanism involving COX-2, NF-κB and TLR4, 
which may contribute to meat-related colorectal carcinogenesis. 
There may also be another explanation for the association between red meat intake and CRC. Several 
studies have shown that a high intake of red and processed meat is associated with a generally unhealthy 
lifestyle both with respect to diet: high intake of refined sugar and alcohol, low intake of fruits, vegetables, 
fibre and whole grain; and behavioral factors: low physical activity, smoking and obesity 9-11. Consistent with 
this, adherence to five lifestyle recommendations i.e, no smoking, physically activity, low alcohol intake, low 
waist circumference and healthy dietary intake (≥600 g fruit and vegetables/day, ≤500 g of red and 
processed meat/week, ≥3 g dietary fibre per MJ of dietary energy and ≤30% of the total energy from fat) was 
considerably associated with reduced risk of CRC 12. Furthermore, calculations suggested that 23% of the 
CRC case could have been prevented had the participants followed the five recommendations 12. In order to 
study the independent effect of meat on CRC risk, all these factors should be adjusted for. In the present 
thesis, most of these factors were included in the models; however, that may not have been sufficient. In 
addition, it has also been shown that the effect meat has on colorectal carcinogenesis may differ by 
anatomic tumor site, by gender, the type of meat consumed 9,13 and the preparation method 14. All analyses 
in this thesis were adjusted for gender, but dividing the analyses by tumor site, the type of meat consumed 
and preparation method would have decreased the statistical power drastically.  
In the Danish study by Andersen et al., 2013 dietary fibre intake interacted with polymorphisms in the 
inflammatory genes COX-2 and IL10, indicating a protective effect of fibre that involves these proteins 8. In 
Paper III, intake of fibre also interacted with a functional polymorphism in ABCB1, suggesting that carriers of 
the low activity allele did not benefit from fibre intake. This result is in line with a study illustrating decreased 
transport of cytokines among carriers of the same allele 15. The fact that there was interaction between the 
polymorphisms in IL10 and ABCB1, suggests that fibre interferes with cytokine transport in the gut, which 
again have impact on the intestinal inflammatory state. Conversely, since intake of fibre, especially from 
whole grain, is associated with a healthy life style – opposite to red meat intake 10,11; these results needs to 
be further investigated in order to clarify whether the fibre has a functional effect or intake of fibre is just a 
marker of a healthy life style that reduces inflammation in the colon and rectum. 
Paper V illustrated that genetic variations in CYP19A1 predicts circulating hormone levels in post-
menopausal women, and that alcohol intake affects female sex-hormone concentrations. However, we were 
not able to put PPARγ and the aromatase in the same pathway in alcohol-related BC; and the possible effect 
modification of concurrent use of NSAIDs and alcohol consumption was not confirmed. Nevertheless, results 
from Paper VI, indicated that exposure to commonly used organic solvents may act via PPARγ modulating 
female sex-hormone levels. However, whether there is a common mechanism linking the aromatase and 
PPARγ, and also whether these differences in hormone levels increases risk of BC, still needs to be 
elucidated. Furthermore, these studies illustrated that acute and chronic alcohol consumption may have 
different effects on sex-hormone biosynthesis and metabolism, and that it is not straightforward to compare 
epidemiological studies with experimental studies. 
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It is worth mentioning that the PPARG Pro12Ala has opposite effects on BC and CRC, respectively, in 
relation to alcohol intake. Variant Ala-carriers are at increased risk of CRC when drinking alcohol, whereas 
wild type carriers are not at risk of developing CRC 16. The exact opposite is seen in relation to BC, where 
only wild type carriers have increased risk of BC for 10 gram consumed alcohol per day 17. Additionally, HRT 
use also seems to have opposite effects on BC and CRC; thus, whereas use of HRT is an established risk 
factor for BC, HRT use is associated with lowered risk of CRC 18. In line with this, men have higher incidence 
of CRC than women, which supports the evidence that estrogens protect against CRC 18,19. Consequently, 
these findings indicate that PPARγ is certainly involved in hormone-related BC, but the underlying 
mechanism is not yet clarified.  
External validity of the DCH cohort has been examined 20, where information regarding socioeconomic 
factors of all 160,725 invited participants was obtained from statistical registers in Statistics Denmark 21. 
Participants from the DCH study had higher educational levels, had a higher taxable income, had been 
employed for longer times and had bigger houses compared to non-participants. Moreover, participants were 
more often married compared to non-participants 20. However, even though there are clearly differences in 
several socioeconomic factors between participants and non-participants, which could also have impact on 
diet and life style factors, this should not have impact on the internal validity and, hence, the studies used in 
the present PhD thesis since nested case-control (Paper I and VI) or case-cohort designs (Paper II-IV) have 
been used. 
Prospective data has the advantage of minimizing the introduction of selection and information bias contrary 
to data from classical, retrospective case-control studies. Though, prospective cohort studies need to be very 
large to study rare diseases and gene-environment interactions. In this PhD thesis, the studied cancer types 
are amongst the most common in Denmark which increases the statistical power 20. Other important factors 
for the statistical power are the effect size and allele frequency 22,23. In the DCH cohort, both meat intake and 
alcohol consumption is high 24,25, and the effect of these factors on cancer risk has proven considerable. 
Most of the studied polymorphisms in the present PhD thesis have an allele frequency above 0.20 which 
should be sufficient to detect gene-environment interactions in the used study groups even when the main 
effect is modest 22,23,26. Thus, there may not have been enough power to detect gene-environment 
interactions among some of the low frequency polymorphisms and environmental factors with low exposure 
and low effect size. To overcome the problem with limited power, multicentre studies and GWAS have been 
used to study gene-environment interactions. However, these types of studies suffer from heterogeneity of 
both the environmental exposures, such as dietary and life style factors, and genetics. GWAS also lack 
information on the functionality of the identified loci. In the present PhD project, the study groups were very 
homogenous consisting of Danes aged 50-64 years eliminating population specific genetics and dietary 
patterns. Additionally, many of the polymorphisms were functional allowing interpretation of the biological 
mechanism.  
Overall, this PhD thesis has shown that genetic epidemiology can be used to study biological mechanisms in 
combination with other mechanistic studies. However, there are several limitations in conducting these types 
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of studies which include missing knowledge of confounders and limited power to study gene-environment 
interactions.  
Future research could establish whether and how dietary fibre, IL-10 and ABC transporters are connected in 
reducing the risk of CRC. Correspondingly, whether red meat per se, specific preparation methods or the life 
style associated with high red meat intake are carcinogenic should be clarified in future studies. The 
acquired knowledge would improve the current dietary recommendations regarding red meat and fibre 
intake. 
There also seem to be several yet unknown effects of NSAID usage that need to be clarified. Information of 
these potential (side) effects would lead to better medication regimens and, hence, improved public health. 
Also, further knowledge of the harmful health effects related to alcohol consumption, including the potential 
effect modification with concurrent use of NSAIDs, would lead to improved public preventive strategies. 
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Table S1. IRR for CRC in relation to combinations of NFKB1/rs2836249 and TLR4/rs5030728 genotypes. 
Genotype  NFKB1/rs2836249 NFKB1/rs2836249  NFKB1/rs2836249 P-valuec  
Ins/Ins 
ncases/nsub-cohort  
Ins/Del+Del/Del 
ncase/nsub-cohort 
Ins/Ins 
IRR (95% CI)a 
Ins/Del+Del/Del 
IRR (95% CI) a 
Ins/Ins 
IRR (95% CI)b  
Ins/Del+Del/Del 
IRR (95% CI)b 
TLR4/rs5030728  
GG 
GA 
AA 
 
GG+GA 
AA 
 
145/335 
131/281 
44/63 
 
276/616 
44/63 
 
260/491 
268/450 
67/99 
 
528/941 
67/99 
 
1.00 (ref.) 
1.11 (0.88-1.40) 
1.53 (1.10-2.14) 
 
1.00 (ref.) 
1.46 (1.07-2.00) 
 
1.22 (1.00-1.49) 
1.32 (1.08-1.61) 
1.43 (1.07-1.91) 
 
1.21 (1.05-1.40) 
1.37 (1.04-1.78) 
 
1.00 (ref.) 
1.12 (0.89-1.41) 
1.50 (1.08-2.10) 
 
1.00 (ref.) 
1.43 (1.04-1.96) 
 
1.22 (1.00-1.49) 
1.33 (1.09-1.62) 
1.44 (1.08-1.93) 
 
1.21 (1.05-1.40) 
1.37 (1.05-1.80) 
 
0.55 
 
 
 
0.27 
a Crude – adjusted for age and sex. 
b In addition, adjusted for smoking status, alcohol intake, HRT status (women only), BMI, use of NSAID, intake of red and processed meat, and dietary fibre. 
c P-value for interaction for the adjusted risk estimates. 
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Table S2. Interaction between dietary factors and the studied polymorphisms in relation to CRC risk. 
  IRRa (95% CI) P-valueb IRRa (95% CI) P-valueb IRRa (95% CI) P-valueb IRRa (95% CI) P-valueb 
  Red and processed meat per 25 g/day Fish per 25 g/day Dietary cereal per 50 g/day Dietary fibre per 10 g/day 
TLR4 
 
rs4986790  
AA 
GA+GG 
 
1.03 (1.00-1.06) 
0.99 (0.87-1.13) 
 
0.56 
 
0.96 (0.89-1.03) 
0.95 (0.75-1.20) 
 
0.96 
 
1.02 (0.95-1.10) 
1.06 (0.91-1.25) 
 
0.61 
 
0.88 (0.80-0.97) 
0.85 (0.60-1.21) 
 
0.86 
 rs5030728  
GG 
GA+AA 
 
1.01 (0.97-1.06) 
1.04 (1.01-1.08) 
 
0.29 
 
1.00 (0.90-1.10) 
0.92 (0.85-1.01) 
 
0.24 
 
1.05 (0.96-1.14) 
1.01 (0.93-1.10) 
 
0.44 
 
0.88 (0.77-1.00) 
0.88 (0.77-1.00) 
 
0.96 
NFKB1 rs28362491  
Ins/Ins 
Ins/Del+Del/Del 
 
1.01 (0.97-1.06) 
1.04 (1.00-1.07) 
 
0.46 
 
0.95 (0.86-1.05) 
0.96 (0.89-1.04) 
 
0.84 
 
1.02 (0.92-1.12) 
1.04 (0.96-1.12) 
 
0.63 
 
0.89 (0.76-1.04) 
0.87 (0.77-0.98) 
 
0.83 
  Fruit per 50 g/day Vegetables per 50 g/day Alcohol per 10 g/dayc  
TLR4 
 
rs4986790  
AA 
GA+GG 
 
0.98 (0.96-1.01) 
0.96 (0.90-1.03) 
 
0.58 
 
1.02 (0.98-1.07) 
0.96 (0.85-1.09) 
 
0.36 
 
1.04 (1.01-1.07) 
0.98 (0.88-1.09) 
 
0.29 
  
 rs5030728  
GG 
GA+AA 
 
0.97 (0.94-1.01) 
0.98 (0.95-1.02) 
 
0.63 
 
1.02 (0.96-1.07) 
1.02 (0.97-1.07) 
 
0.91 
 
1.05 (1.01-1.10) 
1.02 (0.98-1.06) 
 
0.31 
  
NFKB1 rs28362491  
Ins/Ins 
Ins/Del+Del/Del 
 
0.98 (0.94-1.02) 
0.98 (0.95-1.01) 
 
0.97 
 
1.03 (0.97-1.09) 
1.01 (0.96-1.06) 
 
0.58 
 
1.07 (1.02-1.12) 
1.02 (0.98-1.05) 
 
0.10 
  
a Adjusted for age, sex, smoking status, alcohol, HRT status (women only), BMI, use of NSAID, intake of red and processed meat, and dietary fibre. 
b P-value for interaction for adjusted risk estimates. 
c Among current drinkers only. 
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Table S3. Interaction between NSAID use and the studied polymorphisms in relation to CRC risk. 
  NSAID use 
ncases/nsub-cohort 
NSAID use 
IRR (95% CI)a 
NSAID use 
IRR (95% CI)b 
P-valuec 
No Yes No Yes No Yes 
TLR4 
 
rs4986790  
AA 
GA+GG 
 
604/1051 
51/100 
 
261/500 
25/42 
 
1.00 (ref.) 
0.95 (0.72-1.27) 
 
0.98 (0.85-1.13) 
0.98 (0.66-1.43) 
 
1.00 (ref.) 
0.96 (0.72-1.28) 
 
0.97 (0.84-1.12) 
0.95 (0.64-1.42) 
 
0.94 
 rs5030728  
GG 
GA 
AA 
 
GG+GA 
AA 
 
556/556 
291/489 
67/106 
 
847/1649 
67/106 
 
122/256 
117/233 
47/53 
 
239/489 
47/53 
 
1.00 (ref.) 
1.10 (0.94-1.29) 
1.15 (0.88-1.50) 
 
1.00 (ref.) 
1.10 (0.85-1.42) 
 
0.95 (0.77-1.17) 
1.01 (0.92-1.25) 
1.50 (1.11-2.03) 
 
0.94 (0.81-1.09) 
1.43 (1.07-1.92) 
 
1.00 (ref.) 
1.11 (0.94-1.30) 
1.14 (0.88-1.49) 
 
1.00 (ref.) 
1.09 (0.84-1.40) 
 
0.95 (0.77-1.17) 
1.00 (0.81-1.24) 
1.47 (1.08-2.00) 
 
0.93 (0.80-1.07) 
1.40 (1.04-1.88) 
 
 
0.26 
 
 
0.11 
NFKB1 rs28362491  
Ins/Ins 
Ins/Del+Del/Del 
 
236/455 
419/696 
 
93/215 
240/327 
 
1.00 (ref.) 
1.12 (0.96-1.32) 
 
0.90 (0.71-1.14) 
1.16 (0.96-1.40) 
 
1.00 (ref.) 
1.13 (0.96-1.32) 
 
0.89 (0.70-1.13) 
1.15 (0.95-1.38) 
 
0.37 
a Crude – adjusted for age and sex. 
b In addition, adjusted for smoking status, alcohol, HRT status (women only), BMI, intake of red and processed meat, and dietary fibre. 
c P-value for interaction for the adjusted estimates. 
 
Table S4. Interaction between smoking status and the studied polymorphisms in relation to risk of CRC. 
Gene Genotype Never 
smokers 
Past 
smokers 
Current 
smokers 
Never smokers Past smokers Current smokers Never smokers Past smokers Current smokers P-valuec 
ncases/nsub-
cohort 
ncases/nsub-
cohort 
ncases/nsub-
cohort 
IRR (95%CI)a IRR (95%CI)a IRR (95%CI)a IRR (95%CI)b IRR (95%CI)b IRR (95%CI)b 
TLR4 
 
rs4986790  
AA 
GA+GG 
 
249/524 
25/48 
 
258/470 
22/43 
 
332/583 
29/51 
 
1.00 (ref.) 
1.08 (0.72-1.62) 
 
1.05 (0.88-1.25) 
0.99 (0.64-1.52) 
 
1.15 (0.98-1.36) 
1.11 (0.76-1.61) 
 
1.00 (ref.) 
1.04 (0.69-1.58) 
 
1.05 (0.88-1.25) 
0.99 (0.63-1.53) 
 
1.11 (0.94-1.31) 
1.11 (0.76-1.62) 
 
 
0.94 
 rs5030728  
GG 
GA 
AA 
 
GG+GA  
AA 
 
113/279 
124/237 
37/56 
 
237/516 
37/56 
 
130/251 
114/216 
36/46 
 
244/467 
36/46 
 
162/296 
161/278 
38/60 
 
323/574 
38/60 
 
1.00 (ref.) 
1.29 (1.00-1.66) 
1.56 (1.07-2.29) 
 
1.00 (ref.) 
1.38 (0.97-1.98) 
 
1.17 (0.91-1.50) 
1.19 (0.92-1.54) 
1.53 (1.05-2.24) 
 
1.04 (0.87-1.25) 
1.36 (0.95-1.93) 
 
1.31 (1.03-1.67) 
1.35 (1.07-1.71) 
1.46 (1.02-2.09) 
 
1.18 (1.00-1.39) 
1.29 (0.92-1.80) 
 
1.00 (ref.) 
1.30 (1.01-1.68) 
1.59 (1.09-2.31) 
 
1.00 (ref.) 
1.39 (0.98-1.99) 
 
1.18 (0.92-1.51) 
1.22 (0.94-1.58) 
1.53 (1.05-2.25) 
 
1.05 (0.88-1.26) 
1.35 (0.94-1.93) 
 
1.28 (1.01-1.63) 
1.32 (1.04-1.67) 
1.40 (0.98-2.01) 
 
1.14 (0.96-1.36) 
1.23 (0.88-1.73) 
 
 
 
0.50 
 
 
0.57 
NFKB1 rs28362491  
Ins/Ins 
Ins/Del+Del/Del 
 
97/221 
177/351 
 
85/212 
195/301 
 
138/246 
223/388 
 
1.00 (ref.) 
1.17 (0.91-1.49) 
 
0.91 (0.68-1.21) 
1.29 (1.01-1.64) 
 
1.24 (0.96-1.60) 
1.27 (1.00-1.61) 
 
1.00 (ref.) 
1.17 (0.92-1.50) 
 
0.91 (0.68-1.22) 
1.30 (1.02-1.66) 
 
1.21 (0.94-1.57) 
1.24 (0.97-1.57) 
 
 
0.13 
a Crude – adjusted for age and sex. 
b In addition, adjusted for alcohol intake, HRT status (women only), BMI, use of NSAID, intake of red and processed meat, and dietary fibre. 
c P-value for interaction for adjusted risk estimates. 
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Table S5. Interaction between NSAID use and the studied polymorphisms per 25 g red and processed meat intake per day in relation to CRC 
risk. 
Gene Genotype NSAID use 
ncases/nsub-cohort 
NSAID use 
IRR (95% CI)a 
P-valueb 
No Yes No Yes 
TLR4 
 
rs4986790  
AA 
GA+GG 
 
604/1051 
51/100 
 
261/500 
25/42 
 
1.03 (1.00-1.07) 
1.03 (0.89-1.18) 
 
1.03 (0.98-1.08) 
0.89 (0.65-1.22) 
 
0.84 
 rs5030728  
GG 
GA 
AA 
 
GG+GA 
AA 
 
556/556 
291/489 
67/106 
 
847/1649 
67/106 
 
122/256 
117/233 
47/53 
 
239/489 
47/53 
 
1.00 (0.95-1.05) 
1.04 (1.00-1.09) 
1.11 (1.02-1.22) 
 
1.02 (0.99-1.06) 
1.11 (1.02-1.22) 
 
1.04 (0.98-1.10) 
1.02 (0.95-1.10) 
0.98 (0.85-1.12) 
 
1.03 (0.98-1.08) 
0.98 (0.85-1.12) 
 
 
0.39 
 
 
0.30 
NFKB1 rs28362491  
Ins/Ins 
Ins/Del+Del/Del 
 
236/455 
419/696 
 
93/215 
240/327 
 
1.00 (0.94-1.05) 
1.05 (1.01-1.09) 
 
1.06 (0.98-1.16) 
1.00 (0.95-1.06) 
 
0.27 
a Adjusted for age, sex, smoking status, alcohol intake, HRT status (women only), BMI, and dietary fibre. 
b P-value for interaction for the adjusted estimates. 
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Table S1: Risk estimates for different combinations of ABCB1 haplotypes in relation to risk of CRC. 
Haplotypea TTC CCT TCT CCC TCC CTC TTT 
TTC 1.00 (ref.) 
(132/273) 
1.03 (0.85-1.25) 
(234/432) 
1.13 (0.89-1.45) 
(97/159) 
0.99 (0.73-1.34) 
(53/113) 
0.90 (0.56-1.45) 
(18/35) 
1.11 (0.67-1.83) 
(15/24) 
1.04 (0.63-1.73) 
(15/26) 
CCT  0.99 (0.77-1.28) 
(88/172) 
0.93 (0.71-1.22) 
(75/168) 
1.18 (0.88-1.60) 
(54/93) 
* 1.30 (0.75-2.26) 
(14/20) 
1.15 (0.68-1.93) 
(16/27) 
TCT   0.84 (0.49-1.42) 
(12/30) 
1.41 (1.01-1.95) 
(41/58) 
1.06 (0.48-2.34) 
(6/10) 
* 1.14 (0.43-2.98) 
(5/10) 
CCC    1.77 (1.00-3.13) (10/8) 1.06 (0.46-2.45) (5/7) 0.24 (0.04-1.58) (1/7) * 
TCC     - (0/2) Som nr. 9 * 
CTC      - (1/0) 1.29 (0.64-2.60) (5/8) 
TTT       - (0/1) 
IRR (95% CI) for BC for different combinations of haplotypes. The number of cases and controls in each cell is listed. Variant alleles are bold. Adjusted for smoking status, alcohol, HRT 
status (women only), BMI, use of NSAID, intake of red and processed meat, and dietary fibre. *Dublicate. 
aHaplotype sequence: rs1045642, rs1128503, rs3789243 
 
 
Table S2: Risk estimates for different combinations of BCRP/ABCG2 haplotypes in relation to risk of CRC. 
Haplotypea GGC GGT GTC AGC 
GGC 1.00 (ref.) (327/583) 1.02 (0.87-1.18) (295/534) 0.94 (0.76-1.15) (117/231) 0.94 (0.64-1.38) (29/56) 
GGT  0.79 (0.58-1.08) (48/113) 0.61 (0.44-0.86) (37/118) 0.89 (0.52-1.50) (16/37) 
GTC   1.19 (0.72-1.98) (14/23) 1.10 (0.59-2.06) (9/13) 
AGC    1.40 (0.18-10.73) (1/1) 
IRR (95% CI) for CRC for different combinations of haplotypes. The number of cases and controls in each cell is listed. Variant alleles are bold. Adjusted for smoking status, alcohol intake, 
HRT status (women only), BMI, use of NSAID, intake of red and processed meat, and dietary fibre. 
aHaplotype sequence: rs2231137, rs2231142, rs2622604. 
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Table S3: IRR for CRC for tertiles of intake of dietary factors for the studied polymorphisms. 
 1.tertile 2.tertile 3.tertile 1.tertile 2.tertile 3.tertile P-
valueb 
1.tertile 2.tertile 3.tertile 1.tertile 2.tertile 3.tertile P-
value
b  Nc Ns Nc Ns Nc Ns IRR (95%CI)
a IRR (95%CI)a IRR (95%CI)a Nc Ns Nc Ns Nc Ns IRR (95%CI)a IRR (95%CI)a IRR (95%CI)a 
ABCB1/rs1045642 (TT as wild type) Red and processed meat        Fish  
TT 93 206 99 147 108 210 1.00 (ref.) 1.33 (1.01-1.77) 1.12 (0.85-1.49)  101 173 97 181 102 209 1.00 (ref.) 0.91 (0.69-1.20) 0.80 (0.60-1.07)  
TC+CC 216 451 208 360 211 364 1.00 (0.78-1.28) 1.27 (0.99-1.63) 1.27 (0.99-1.62) 0.53 210 410 215 374 210 391 0.92 (0.72-1.17) 0.96 (0.75-1.22) 0.89 (0.69-1.15) 0.55 
       Dietary cereal        Dietary fibre  
TT 79 164 106 183 115 216 1.00 (ref.) 1.17 (0.87-1.58) 1.29 (0.93-1.79)  84 179 104 166 112 218 1.00 (ref.) 1.24 (0.93-1.65) 1.11 (0.83-1.48)  
TC+CC 234 335 206 399 195 441 1.37 (1.06-1.79) 1.11 (0.84-1.46) 1.10 (0.81-1.50) 0.01 228 350 209 345 198 480 1.33 (1.03-1.71) 1.26 (0.97-1.63) 0.91 (0.71-1.18) 0.006 
       Fruit        Vegetables  
TT 91 190 105 186 104 187 1.00 (ref.) 1.12 (0.84-1.49) 1.13 (0.83-1.54)  101 165 111 202 88 196 1.00 (ref.) 1.05 (0.80-1.38) 0.93 (0.69-1.27)  
TC+CC 219 335 209 414 207 426 1.26 (0.98-1.61) 1.06 (0.82-1.37) 1.04 (0.79-1.38) 0.10 211 335 196 422 228 418 1.03 (0.81-1.31) 0.93 (0.73-1.20) 1.12 (0.86-1.45) 0.19 
       Alcohol            
TT 171 96 114 210 90 182 1.00 (ref.) 0.96 (0.73-1.25) 0.92 (0.69-1.22)            
TC+CC 232 398 188 423 215 354 1.00 (0.79-1.26) 0.85 (0.66-1.08) 1.12 (0.88-1.43) 0.16           
ABCB1/rs1045642 (gene-dose model) Red and processed meat        Fish  
TT 93 206 99 147 108 210 1.00 (ref.) 1.34 (1.01-1.79) 1.12 (0.85-1.49)  101 173 97 181 102 209 1.00 (ref.) 0.91 (0.69-1.20) 0.80 (0.60-1.07)  
TC 149 327 150 265 158 263 0.96 (0.74-1.25) 1.26 (0.98-1.64) 1.29 (0.99-1.66) 0.75 147 288 158 276 152 291 0.91 (0.70-1.18) 0.96 (0.74-1.24) 0.87 (0.67-1.14) 0.83 
CC 67 124 58 95 53 101 1.09 (0.80-1.49) 1.29 (0.92-1.81) 1.22 (0.87-1.71)  63 122 57 98 58 100 0.93 (0.67-1.29) 0.95 (0.68-1.32) 0.96 (0.68-1.33)  
       Dietary cereal        Dietary fibre  
TT 79 164 106 183 115 216 1.00 (ref.) 1.17 (0.87-1.58) 1.29 (0.93-1.78)  84 179 104 166 112 218 1.00 (ref.) 1.24 (0.94-1.65) 1.11 (0.83-1.48)  
TC 162 239 144 286 151 330 1.32 (1.00-1.74) 1.10 (0.82-1.47) 1.12 (0.82-1.54) 0.05 163 237 150 257 144 361 1.37 (1.05-1.79) 1.23 (0.94-1.62) 0.89 (0.67-1.16) 0.02 
CC 72 96 62 113 44 111 1.51 (1.08-2.09) 1.12 (0.80-1.58) 1.03 (0.69-1.53)  65 113 59 88 54 119 1.24 (0.89-1.72) 1.33 (0.95-1.86) 1.01 (0.72-1.41)  
       Fruit        Vegetables  
TT 91 190 105 186 104 187 1.00 (ref.) 1.12 (0.85-1.49) 1.14 (0.84-1.55)  101 165 111 202 88 196 1.00 (ref.) 1.05 (0.81-1.38) 0.93 (0.69-1.27)  
TC 161 234 152 298 144 323 1.31 (1.01-1.70) 1.08 (0.82-1.41) 0.96 (0.72-1.29) 0.05 155 546 137 305 165 304 1.02 (0.80-1.32) 0.91 (0.69-1.19) 1.11 (0.85-1.47) 0.47 
CC 58 101 57 116 63 103 1.13 (0.81-1.56) 1.02 (0.73-1.43) 1.31 (0.92-1.85)  56 89 59 117 63 114 1.04 (0.75-1.45) 0.99 (0.71-1.38) 1.11 (0.80-1.54)  
       Alcohol            
TT 171 96 114 210 90 182 1.00 (ref.) 0.96 (0.73-1.25) 0.92 (0.69-1.22)            
TC 168 292 132 317 157 246 1.00 (0.77-1.28) 0.80 (0.62-1.04) 1.16 (0.90-1.49) 0.23           
CC 64 106 56 106 58 108 1.00 (0.73-1.37) 0.98 (0.70-1.37) 1.04 (0.75-1.44)            
ABCB1/rs1045642 (CC as wild type) Red and processed meat        Fish  
CC 67 124 58 95 53 101 1.00 (ref.) 1.19 (0.83-1.69) 1.12 (0.78-1.60)  63 122 57 98 58 100 1.00 (ref.) 1.02 (0.71-1.46) 1.03 (0.72-1.48)  
 211 
 
TC+TT 242 533 249 412 266 473 0.90 (0.68-1.17) 1.18 (0.90-1.55) 1.11 (0.85-1.46) 0.75 248 461 255 457 254 500 1.01 (0.77-1.34) 1.01 (0.77-1.33) 0.91 (0.68-1.20) 0.82 
       Dietary cereal        Dietary fibre  
CC 72 96 62 113 44 111 1.00 (ref.) 0.75 (0.53-1.06) 0.68 (0.46-1.02)  65 113 59 88 54 119 1.00 (ref.) 1.07 (0.75-1.54) 0.81 (0.57-1.17)  
TC+TT 241 403 250 469 266 546 0.79 (0.61-1.04) 0.75 (0.57-0.99) 0.79 (0.58-1.07) 0.13 247 416 254 423 256 579 0.98 (0.74-1.30) 1.00 (0.76-1.32) 0.78 (0.59-1.04) 0.23 
       Fruit        Vegetables  
CC 58 101 57 116 63 103 1.00 (ref.) 0.91 (0.63-1.31) 1.16 (0.80-1.69)  56 89 59 117 63 114 1.00 (ref.) 0.95 (0.65-1.38) 1.07 (0.74-1.55)  
TC+TT 252 424 257 484 248 510 1.05 (0.79-1.39) 0.97 (0.73-1.29) 0.91 (0.67-1.24) 0.18 256 411 248 507 253 500 0.97 (0.73-1.30) 0.93 (0.69-1.25) 1.00 (0.73-1.37) 0.85 
       Alcohol            
CC 64 106 56 106 58 108 1.00 (ref.) 0.98 (0.68-1.40) 1.04 (0.73-1.49)            
TC+TT 264 463 246 527 247 428 1.00 (0.76-1.31) 0.86 (0.66-1.14) 1.06 (0.80-1.40) 0.75           
ABCB1/rs1128503 Red and processed meat        Fish  
CC 110 212 101 187 89 174 1.00 (ref.) 1.13 (0.86-1.48) 1.16 (0.88-1.54)  97 209 106 179 97 185 1.00 (ref.) 1.15 (0.87-1.52) 1.04 (0.78-1.38)  
CT+TT 199 449 211 327 226 407 0.91 (0.72-1.15) 1.27 (1.01-1.60) 1.11 (0.88-1.40) 0.35 216 378 208 383 212 422 1.14 (0.89-1.45) 1.07 (0.84-1.36) 0.96 (0.75-1.24) 0.31 
       Dietary cereal        Dietary fibre  
CC 109 167 100 204 91 202 1.00 (ref.) 0.75 (0.57-0.99) 0.87 (0.64-1.19)  108 184 97 166 95 223 1.00 (ref.) 0.94 (0.71-1.24) 0.77 (0.58-1.01)  
CT+TT 201 343 214 389 221 451 0.84 (0.66-1.06) 0.86 (0.68-1.09) 0.88 (0.67-1.15) 0.15 201 355 220 354 215 474 0.91 (0.71-1.15) 1.00 (0.80-1.26) 0.77 (0.61-0.98) 0.25 
       Fruit        Vegetables  
CC 100 177 109 194 91 202 1.00 (ref.) 1.02 (0.78-1.35) 0.91 (0.67-1.23)  98 164 96 204 106 205 1.00 (ref.) 0.94 (0.70-1.25) 1.13 (0.84-1.51)  
CT+TT 209 356 207 410 220 417 1.03 (0.81-1.30) 0.92 (0.73-1.17) 0.96 (0.74-1.25) 0.52 213 346 215 424 208 413 1.00 (0.79-1.27) 1.01 (0.79-1.28) 1.02 (0.78-1.33) 0.65 
       Alcohol            
CC 109 198 91 195 100 180 1.00 (ref.) 0.94 (0.71-1.25) 1.15 (0.88-1.52)            
CT+TT 225 379 212 445 199 359 1.09 (0.87-1.38) 0.93 (0.73-1.17) 1.06 (0.83-1.34) 0.78           
ABCB1/rs3789243 Red and processed meat        Fish  
CC 81 186 83 121 75 175 1.00 (ref.) 1.42 (1.04-1.92) 1.04 (0.76-1.43)  77 163 90 145 72 174 1.00 (ref.) 1.19 (0.87-1.61) 0.88 (0.63-1.23)  
CT+TT 228 475 224 386 239 409 1.07 (0.83-1.39) 1.34 (1.03-1.73) 1.33 (1.03-1.73) 0.26 237 424 220 412 234 434 1.19 (0.91-1.56) 1.10 (0.84-1.44) 1.06 (0.81-1.40) 0.19 
       Dietary cereal        Dietary fibre  
CC 71 139 83 158 85 185 1.00 (ref.) 1.02 (0.74-1.41) 1.02 (0.72-1.45)  68 151 86 146 85 185 1.00 (ref.) 1.22 (0.89-1.67) 0.99 (0.71-1.37)  
CT+TT 235 363 232 434 224 473 1.17 (0.89-1.54) 1.06 (0.80-1.40) 1.12 (0.82-1.52) 0.81 239 383 226 372 226 515 1.29 (0.98-1.69) 1.27 (0.96-1.67) 0.99 (0.75-1.31) 0.16 
       Fruit        Vegetables  
CC 76 160 74 153 89 169 1.00 (ref.) 1.04 (0.75-1.43) 1.10 (0.80-1.53)  75 163 82 148 82 171 1.00 (ref.) 1.32 (0.97-1.81) 1.15 (0.82-1.60)  
CT+TT 229 370 241 451 221 449 1.24 (0.95-1.61) 1.13 (0.86-1.47) 1.09 (0.82-1.46) 0.41 236 349 225 471 230 450 1.31 (1.01-1.70) 1.15 (0.88-1.51) 1.32 (0.99-1.76) 0.09 
       Alcohol            
CC 80 151 87 187 72 144 1.00 (ref.) 0.87 (0.64-1.18) 0.97 (0.71-1.33)            
 212 
 
CT+TT 249 422 211 455 231 393 1.04 (0.81-1.34) 0.92 (0.71-1.18) 1.14 (0.88-1.47) 0.51           
ABCG2/rs2231142 Red and processed meat        Fish  
GG 240 524 252 401 255 443 1.00 (ref.) 1.29 (1.07-1.54) 1.21 (1.01-1.45)  244 465 256 419 247 484 1.00 (ref.) 1.09 (0.91-1.31) 0.90 (0.74-1.09)  
TG+TT 71 139 55 111 61 147 0.97 (0.75-1.26) 1.18 (0.88-1.57) 1.03 (0.78-1.36) 0.99 67 130 58 144 62 123 0.99 (0.75-1.29) 0.75 (0.57-1.00) 0.99 (0.74-1.31) 0.05 
       Dietary cereal        Dietary fibre  
GG 251 400 253 457 243 511 1.00 (ref.) 0.93 (0.77-1.12) 0.94 (0.75-1.18)  241 416 259 410 247 542 1.00 (ref.) 1.06 (0.89-1.26) 0.82 (0.68-0.98)  
TG+TT 59 107 58 138 70 152 0.89 (0.67-1.18) 0.74 (0.55-0.99) 0.98 (0.73-1.32) 0.26 67 122 56 114 64 161 0.93 (0.71-1.23) 0.87 (0.66-1.16) 0.78 (0.59-1.02) 0.40 
       Fruit        Vegetables  
GG 247 404 251 477 249 487 1.00 (ref.) 0.93 (0.78-1.12) 0.91 (0.74-1.13)  240 406 255 488 252 474 1.00 (ref.) 1.01 (0.84-1.21) 1.09 (0.88-1.34)  
TG+TT 64 132 63 127 60 138 0.89 (0.68-1.18) 0.85 (0.65-1.11) 0.83 (0.61-1.13) 0.80 71 104 47 146 59 147 1.05 (0.81-1.35) 0.86 (0.64-1.16) 0.89 (0.66-1.20) 0.44 
       Alcohol            
GG 265 443 242 506 240 419 1.00 (ref.) 0.87 (0.73-1.04) 1.01 (0.85-1.21)            
TG+TT 65 135 58 138 64 124 0.85 (0.65-1.12) 0.75 (0.57-0.99) 1.01 (0.77-1.33) 0.52           
ABCG2/rs2231137 Red and processed meat        Fish  
GG 289 622 290 477 293 542 1.00 (ref.) 1.30 (1.10-1.53) 1.20 (1.02-1.42)  294 553 289 521 289 567 1.00 (ref.) 0.99 (0.84-1.16) 0.90 (0.76-1.07)  
GA+AA 20 43 20 39 23 41 1.05 (0.64-1.72) 1.22 (0.77-1.96) 1.23 (0.82-1.84) 0.88 18 40 26 44 19 39 0.82 (0.59-1.38) 1.12 (0.77-1.63) 0.95 (0.58-1.55) 0.56 
       Dietary cereal        Dietary fibre  
GG 289 473 287 552 296 616 1.00 (ref.) 0.91 (0.76-1.08) 1.01 (0.81-1.25)  285 504 286 485 301 652 1.00 (ref.) 1.05 (0.89-1.24) 0.88 (0.74-1.04)  
GA+AA 19 36 27 41 17 46 1.02 (0.61-1.70) 1.21 (0.81-1.82) 0.72 (0.44-1.19) 0.14 22 33 29 40 12 50 1.40 (0.88-2.22) 1.23 (0.83-1.82) 0.47 (0.27-0.82) 0.01 
       Fruit        Vegetables  
GG 285 501 298 560 289 580 1.00 (ref.) 0.97 (0.82-1.15) 0.94 (0.77-1.15)  288 479 291 593 293 569 1.00 (ref.) 0.98 (0.83-1.17) 1.08 (0.89-1.31)  
GA+AA 23 34 17 45 23 44 1.16 (0.76-1.79) 0.77 (0.47-1.27) 1.01 (0.64-1.61) 0.44 22 32 20 39 21 52 1.14 (0.74-1.76) 1.05 (0.66-1.72) 0.91 (0.57-1.45) 0.60 
       Alcohol            
GG 313 540 275 601 284 500 1.00 (ref.) 0.84 (0.72-1.00) 1.04 (0.88-1.23)            
GA+AA 17 41 24 42 22 40 0.74 (0.45-1.21) 1.09 (0.71-1.68) 1.07 (0.68-1.66) 0.16           
ABCG2/rs2622604 Red and processed meat        Fish  
CC+TC 290 618 293 475 295 535 1.00 (ref.) 1.30 (1.10-1.53) 1.21 (1.03-1.43)  298 548 293 518 287 562 1.00 (ref.) 1.00 (0.85-1.18) 0.91 (0.77-1.08)  
TT 18 41 17 39 18 45 1.00 (0.61-1.64) 0.97 (0.58-1.64) 0.88 (0.55-1.42) 0.97 16 40 17 45 20 40 0.90 (0.52-1.57) 0.77 (0.48-1.25) 0.73 (0.46-1.17) 0.83 
       Dietary cereal        Dietary fibre  
CC+TC 293 479 293 548 292 601 1.00 (ref.) 0.93 (0.78-1.11) 0.99 (0.80-1.22)  293 499 298 488 287 641 1.00 (ref.) 1.04 (0.88-1.22) 0.82 (0.70-0.97)  
TT 16 28 21 45 16 52 1.01 (0.61-1.67) 0.77 (0.48-1.24) 0.68 (0.40-1.15) 0.50 16 34 14 33 23 58 0.95 (0.56-1.62) 0.72 (0.43-1.22) 0.69 (0.44-1.07) 0.45 
       Fruit        Vegetables  
CC+TC 293 487 296 569 289 572 1.00 (ref.) 0.91 (0.77-1.08) 0.90 (0.74-1.10)  296 478 288 578 294 572 1.00 (ref.) 0.96 (0.81-1.14) 1.05 (0.87-1.28)  
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TT 15 42 18 33 20 50 0.69 (0.40-1.20) 0.91 (0.56-1.46) 0.72 (0.44-1.16) 0.43 15 31 18 46 20 48 0.86 (0.50-1.48) 0.86 (0.53-1.40) 0.77 (0.48-1.24) 0.80 
       Alcohol            
CC+TC 307 529 281 592 290 507 1.00 (ref.) 0.88 (0.74-1.03) 1.06 (0.90-1.25)            
TT 21 46 19 47 13 32 0.82 (0.52-1.30) 0.76 (0.48-1.22) 0.79 (0.44-1.42) 0.30           
ABCC2/rs2273697 Red and processed meat        Fish  
GG+AG 292 636 298 495 299 556 1.00 (ref.) 1.30 (1.10-1.53) 1.21 (1.03-1.43)  298 571 303 538 288 578 1.00 (ref.) 1.02 (0.86-1.20) 0.89 (0.75-1.06)  
AA 17 25 10 18 19 18 1.38 (0.87-2.19) 1.24 (0.71-2.17) 1.60 (1.01-2.53) 0.70 16 21 11 18 19 22 1.25 (0.76-2.07) 0.92 (0.54-1.54) 1.39 (0.85-2.17) 0.27 
       Dietary cereal        Dietary fibre  
GG+AG 295 486 297 564 297 637 1.00 (ref.) 0.91 (0.77-1.09) 0.94 (0.76-1.17)  294 507 293 502 302 678 1.00 (ref.) 1.01 (0.86-1.19) 0.82 (0.69-0.96)  
AA 17 19 15 23 14 19 1.31 (0.82-2.09) 0.99 (0.61-1.60) 1.27 (0.76-2.14) 0.63 19 27 18 19 9 15 1.16 (0.74-1.83) 1.23 (0.79-1.91) 1.10 (0.61-1.97) 0.67 
       Fruit        Vegetables  
GG+AG 293 506 298 584 298 597 1.00 (ref.) 0.92 (0.77-1.09) 0.92 (0.76-1.13)  290 488 293 604 306 595 1.00 (ref.) 0.98 (0.83-1.17) 1.07 (0.88-1.30)  
AA 16 26 18 19 12 16 0.89 (0.55-1.44) 1.45 (0.94-2.24) 1.35 (0.79-2.30) 0.21 22 21 15 22 9 18 1.38 (0.91-2.09) 1.21 (0.75-1.95) 1.08 (0.56-2.06) 0.69 
       Alcohol            
GG+AG 315 551 286 621 288 515 1.00 (ref.) 0.87 (0.74-1.03) 1.06 (0.89-1.25)            
AA 14 22 15 19 17 20 1.03 (0.62-1.70) 1.23 (0.77-1.97) 1.36 (0.84-2.20) 0.21           
ABCC2/rs717620 Red and processed meat        Fish  
GG 202 450 213 333 211 354 1.00 (ref.) 1.38 (1.13-1.67) 1.30 (1.07-1.59)  216 387 201 371 209 379 1.00 (ref.) 0.97 (0.80-1.17) 0.94 (0.77-1.15)  
AG+AA 108 211 94 176 105 222 1.08 (0.85-1.37) 1.21 (0.94-1.55) 1.14 (0.89-1.44) 0.36 99 200 110 184 98 225 0.96 (0.75-1.23) 1.00 (0.80-1.26) 0.78 (0.61-1.01) 0.34 
       Dietary cereal        Dietary fibre  
GG 201 327 218 371 207 439 1.00 (ref.) 1.01 (0.83-1.24) 0.94 (0.74-1.19)  209 349 212 331 205 457 1.00 (ref.) 1.01 (0.83-1.23) 0.79 (0.65-0.97)  
AG+AA 111 173 94 217 102 219 1.06 (0.84-1.34) 0.75 (0.58-0.97) 0.99 (0.74-1.31) 0.04 101 183 100 186 106 240 0.91 (0.71-1.16) 0.93 (0.73-1.19) 0.78 (0.62-0.99) 0.50 
       Fruit        Vegetables  
GG 218 355 210 400 198 382 1.00 (ref.) 0.91 (0.75-1.11) 0.93 (0.74-1.16)  220 324 210 422 196 391 1.00 (ref.) 0.88 (0.73-1.07) 0.95 (0.76-1.18)  
AG+AA 91 171 102 202 114 236 0.92 (0.72-1.19) 0.88 (0.69-1.12) 0.87 (0.67-1.12) 0.72 91 180 99 204 117 225 0.77 (0.60-0.99) 0.91 (0.71-1.16) 0.98 (0.76-1.25) 0.15 
       Alcohol            
GG 218 389 207 407 201 341 1.00 (ref.) 0.93 (0.77-1.13) 1.09 (0.90-1.33)            
AG+AA 113 192 92 227 102 190 1.00 (0.80-1.26) 0.80 (0.63-1.03) 1.03 (0.81-1.31) 0.48           
a Analysis adjusted for smoking status, alcohol intake, abstainers, HRT status (women only), BMI, use of NSAID, intake of red and processed meat, and dietary fibre. 
b P-value for interaction between polymorphisms and dietary factors  
Women: Tertiles of red and processed meat (<75.0270 g, 75.0270 g <  and < 101.420 g, >101.420 g), fish (<26.9891 g, 26.9891 g <  and < 42.7091 g, > 42.7091 g), dietary fibre (<16.9912 
g, 16.9912 g <  and < 22.0971 g, > 22.0971 g), cereals (<136.126 g, 136.126 g <  and < 191.124 g, > 191.124 g), fruit (<141.858 g, 141.858 g <  and < 263.602 g, > 263.602 g), vegetables 
(<122.013 g, 122.013 g <  and < 213.125 g, > 213.125 g), alcohol (<4.48446 g, 4.48446 g < and < 13.0941 g, > 13.0941 g). 
Men: Tertiles of red and processed meat (<116.935 g, 116.935 g <  and < 159.387 g, >159.387 g), fish (<32.2760 g, 32.2760 g <  and < 48.0483 g, > 48.0483 g), dietary fibre (<17.5329  g, 
17.5329  g <  and < 22.5676 g, > 22.5676 g), cereals (<166.378 g, 166.378 g <  and < 233.488 g, > 233.488 g), fruit (<90.4576 g, 90.4576 g <  and < 196.277 g, > 196.277 g), vegetables 
(<106.053 g, 106.053 g <  and < 187.468 g, > 187.468 g), alcohol (<14.4960 g, 14.4960 g < and < 37.1134 g, > 37.1134 g). 
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Table S4: IRR for CRC in relation to combinations of ABCB1/rs1045642 and IL10/rs3024505 genotypes and use of NSAID. 
Genotype combinations NSAID use 
ncases/nsub-cohort 
NSAID use 
IRR (95% CI)a 
NSAID use 
IRR (95% CI)b 
P-valuec 
No Yes No Yes No Yes 
 
rs1045642-CC/rs3024505-CC 
rs1045642-CC/rs3024505-CT+TT 
rs1045642-CT+TT/rs3024505-CC 
rs1045642-CT+TT/rs3024505-CT+TT 
 
68/154 
36/57 
360/659 
174/321 
 
55/67 
17/41 
149/291 
64/142 
 
1.00 (ref.) 
1.22 (0.84-1.78) 
1.17 (0.93-1.48) 
1.13 (0.88-1.46) 
 
1.78 (1.27-2.50) 
1.00 (0.61-1.64) 
1.12 (0.86-1.47) 
1.00 (0.73-1.38) 
 
1.00 (ref.) 
1.22 (0.83-1.77) 
1.20 (0.95-1.52) 
1.17 (0.90-1.51) 
 
1.77 (1.27-1.48) 
1.02 (0.62-1.67) 
1.13 (0.87-1.48) 
1.03 (0.75-1.41) 
 
0.007 
 
 
 
a Crude – adjusted for age and sex. 
b In addition, adjusted for smoking status, alcohol intake, HRT status (women only), BMI, intake of red and processed meat, and dietary fibre. 
c P-value for interaction for the adjusted risk estimates. 
 
 
 
 
Table S5: IRR for CRC in relation to combinations of ABCG2/rs2231137 and IL10/rs3024505 genotypes and use of NSAID. 
Genotype combination NSAID use 
ncases/nsub-cohort 
NSAID use 
IRR (95% CI)a 
NSAID use 
IRR (95% CI)b 
P-valuec 
No Yes No Yes No Yes 
 
rs2231137-GG/rs3024505-CC 
rs2231137-GG/rs3024505-CT+TT 
rs2231137-GA+AA/rs3024505-CC 
rs2231137-GA+AA/rs3024505-CT+TT 
 
388/768 
198/354 
35/57 
11/27 
 
199/340 
71/174 
7/25 
10/13 
 
1.00 (ref.) 
1.00 (0.85-1.18) 
1.13 (0.79-1.62) 
0.92 (0.50-1.71) 
 
1.12 (0.95-1.33) 
0.81 (0.64-1.04) 
0.53 (0.24-1.14) 
1.44 (0.79-2.61) 
 
1.00 (ref.) 
1.01 (0.86-1.19) 
1.19 (0.84-1.70) 
0.90 (0.48-1.67) 
 
1.11 (0.94-1.32) 
0.82 (0.64-1.05) 
0.52 (0.24-1.13) 
1.40 (0.78-2.51) 
 
0.02 
 
 
 
a Crude – adjusted for age and sex. 
b In addition, adjusted for smoking status, alcohol intake, HRT status (women only), BMI, intake of red and processed meat, and dietary fibre. 
c P-value for interaction for the adjusted risk estimates. 
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Table S6: Interaction between smoking status and the studied polymorphisms in relation to risk of CRC. 
Gene Genotype Never 
smokers 
Past 
smokers 
Current 
smokers 
Never smokers Past smokers Current smokers Never smokers Past smokers Current smokers P-valuec 
ncases/nsub-
cohort 
ncases/nsub-
cohort 
ncases/nsub-
cohort 
IRR (95%CI)a IRR (95%CI)a IRR (95%CI)a IRR (95%CI)b IRR (95%CI)b IRR (95%CI)b 
ABCB1 
 
rs1045642 
TT 
TC+CC 
 
TT 
TC 
CC 
 
CC 
TC+TT 
 
102/190 
180/385 
 
102/190 
127/287 
53/98 
 
53/98 
229/477 
 
93/161 
188/353 
 
93/161 
134/246 
54/107 
 
54/107 
227/407 
 
105/212 
267/437 
 
105/212 
196/322 
71/115 
 
71/115 
301/534 
 
1.00 (ref.) 
0.91 (0.71-1.15) 
 
1.00 (ref.) 
0.86 (0.66-1.11) 
1.05 (0.75-1.46) 
 
1.00 (ref.) 
0.88 (0.65-1.18) 
 
1.00 (0.76-1.31) 
0.93 (0.73-1.18) 
 
1.00 (0.76-1.31) 
0.93 (0.72-1.20) 
0.93 (0.67-1.29) 
 
0.89 (0.61-1.29) 
0.91 (0.68-1.23) 
 
0.91 (0.70-1.19) 
1.11 (0.89-1.39) 
 
0.91 (0.70-1.19) 
1.10 (0.87-1.40) 
1.12 (0.83-1.50) 
 
1.07 (0.75-1.52) 
0.98 (0.73-1.31) 
 
1.00 (ref.) 
0.89 (0.70-1.13) 
 
1.00 (ref.) 
0.85 (0.65-1.10) 
1.00 (0.72-1.39) 
 
1.00 (ref.) 
0.91 (0.67-1.22) 
 
0.97 (0.73-1.28) 
0.92 (0.72-1.17) 
 
0.96 (0.73-1.28) 
0.93 (0.72-1.20) 
0.90 (0.65-1.25) 
 
0.90 (0.62-1.32) 
0.94 (0.70-1.27) 
 
0.86 (0.65-1.13) 
1.06 (0.85-1.33) 
 
0.86 (0.65-1.13) 
1.06 (0.84-1.35) 
1.05 (0.78-1.42) 
 
1.05 (0.74-1.49) 
0.98 (0.73-1.31) 
 
0.12 
 
 
 
0.27 
 
 
0.84 
 rs1128503 
CC 
CT+TT 
 
89/178 
193/407 
 
97/181 
188/338 
 
114/214 
255/438 
 
1.00 (ref.) 
0.93 (0.72-1.20) 
 
0.98 (0.74-1.30) 
0.98 (0.76-1.26) 
 
1.03 (0.80-1.34) 
1.08 (0.85-1.37) 
 
1.00 (ref.) 
0.95 (0.74-1.23) 
 
1.00 (0.75-1.33) 
0.99 (0.77-1.29) 
 
1.05 (0.79-1.38) 
1.06 (0.83-1.36) 
 
0.93 
 rs3789243 
CC 
CT+TT 
 
75/165 
204/417 
 
77/132 
203/382 
 
87/185 
284/471 
 
1.00 (ref.) 
1.06 (0.82-1.38) 
 
1.14 (0.83-1.56) 
1.05 (0.80-1.36) 
 
0.98 (0.72-1.33) 
1.25 (0.98-1.61) 
 
1.00 (ref.) 
1.06 (0.81-1.38) 
 
1.14 (0.83-1.56) 
1.04 (0.80-1.36) 
 
0.94 (0.69-1.28) 
1.22 (0.94-1.57) 
 
0.16 
ABCG2 
 
rs2231142 
GG 
TG+TT 
 
236/460 
42/126 
 
228/407 
55/114 
 
283/501 
90/157 
 
1.00 (ref.) 
0.73 (0.52-1.01) 
 
0.99 (0.83-1.19) 
0.90 (0.67-1.21) 
 
1.08 (0.91-1.29) 
1.07 (0.84-1.36) 
 
1.00 (ref.) 
0.73 (0.53-1.02) 
 
0.99 (0.82-1.19) 
0.92 (0.69-1.24) 
 
1.05 (0.88-1.25) 
1.05 (0.83-1.33) 
 
0.25 
 rs2231137 
GG 
GA+AA 
 
262/546 
19/43 
 
266/479 
17/41 
 
344/616 
27/39 
 
1.00 (ref.) 
1.01 (0.62-1.64) 
 
1.04 (0.88-1.24) 
0.86 (0.52-1.42) 
 
1.12 (0.95-1.32) 
1.27 (0.85-1.89) 
 
1.00 (ref.) 
1.08 (0.67-1.74) 
 
1.05 (0.88-1.25) 
0.84 (0.50-1.39) 
 
1.09 (0.92-1.29) 
1.25 (0.84-1.86) 
 
0.47 
 rs2622604 
CC+TC  
TT 
 
257/530 
20/54 
 
270/487 
14/30 
 
351/611 
19/41 
 
1.00 (ref.) 
0.75 (0.47-1.20) 
 
1.03 (0.86-1.22) 
0.83 (0.48-1.44) 
 
1.12 (0.95-1.31) 
0.99 (0.61-1.59) 
 
1.00 (ref.) 
0.75 (0.47-1.21) 
 
1.03 (0.86-1.22) 
0.83 (0.48-1.44) 
 
1.09 (0.92-1.28) 
0.98 (0.61-1.58) 
 
0.77 
ABCC2 
 
rs2273697 
GG+AG  
AA 
 
267/564 
13/18 
 
268/498 
14/20 
 
354/625 
19/23 
 
1.00 (ref.) 
1.53 (0.88-2.65) 
 
1.05 (0.88-1.24) 
1.05 (0.65-1.72) 
 
1.14 (0.97-1.34) 
1.53 (1.00-2.32) 
 
1.00 (ref.) 
1.48 (0.86-2.56) 
 
1.05 (0.88-1.24) 
1.02 (0.62-1.69) 
 
1.11 (0.94-1.31) 
1.49 (0.98-2.26) 
 
0.43 
 rs717620 
GG 
AG+AA 
 
182/378 
96/201 
 
201/338 
83/180 
 
243/421 
128/228 
 
1.00 (ref.) 
0.99 (0.77-1.27) 
 
1.09 (0.89-1.33) 
0.90 (0.69-1.17) 
 
1.12 (0.93-1.36) 
1.14 (0.91-1.42) 
 
1.00 (ref.) 
0.99 (0.77-1.27) 
 
1.10 (0.90-1.35) 
0.89 (0.68-1.16) 
 
1.09 (0.90-1.33) 
1.09 (0.87-1.38) 
 
0.38 
a Crude – adjusted for age and sex. 
b In addition, adjusted for alcohol intake, HRT status (women only), BMI, use of NSAID, intake of red and processed meat, and dietary fibre. 
c P-value for interaction for the adjusted estimates. 
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Figure S1. LD plot for CYP19A1 illustrating two large haplotype blocks with the recombination spot where rs3751591 is located 
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Table S1: Plasma levels of estrone, estrone sulphate and SHBG among 335 never and past users of hormone replacement therapy as 
percentage change in hormonal measurements in relation to CYP19A1 polymorphisms divided by usage of NSAID. 
Genotype No 
n (%) 
n=217 
Yes 
n (%) 
n=118 
Estrone P-value Estrone sulphate P-value SHBG P-value 
No Yes No Yes No Yes 
∆ (95% CI)a ∆ (95% CI)a ∆ (95% CI)a ∆ (95% CI)a ∆ (95% CI)a ∆ (95% CI)a 
rs10519297 
AA 
AG+GG 
 
51 (24) 
166 (76) 
 
28 (24) 
90 (76) 
 
0 (ref.) 
3 (-10;19) 
 
-14 (-30;6) 
-8 (-21;7) 
 
 
0.84 
 
0 (ref.) 
11 (-1;25) 
 
-11 (-25;6) 
-1 (-13;12) 
 
 
0.94 
 
0 (ref.) 
-8 (-19;5) 
 
-3 (-20;17) 
2 (-12;17) 
 
 
0.23 
rs749292 
GG 
AG+AA 
 
68 (31) 
149 (69) 
 
33 (28) 
85 (72) 
 
0 (ref.) 
-5 (-16;8) 
 
-14 (-28;4) 
-16 (-27;-3) 
 
 
0.79 
 
0 (ref.) 
-15 (-24;-6) 
 
-18 (-30;-5) 
-22 (-30;-12) 
 
 
0.18 
 
0 (ref.) 
0 (-11;12) 
 
6 (-11;25) 
8 (-5;22) 
 
 
0.87 
rs1062033 
CC 
CG+GG 
 
58 (27) 
159 (73) 
 
30 (25) 
88 (75) 
 
0 (ref.) 
-3 (-15;10) 
 
-13 (-28;6) 
-15 (-26;-1) 
 
 
0.92 
 
0 (ref.) 
-14 (-23;-4) 
 
-16 (-29;-1) 
-22 (-31;-11) 
 
 
0.43 
 
0 (ref.) 
3 (-9;17) 
 
13 (-5;35) 
8 (-5;24) 
 
 
0.47 
rs10046 
AA 
AG+GG 
 
54 (25) 
163 (75) 
 
37 (31) 
81 (69) 
 
0 (ref.) 
-1 (-14;14) 
 
-11 (-26;7) 
-13 (-25;1) 
 
 
0.89 
 
0 (ref.) 
7 (-5;21) 
 
-7 (-21;10) 
-6 (-18;7) 
 
 
0.50 
 
0 (ref.) 
-3 (-15;10) 
 
1 (-15;20) 
6 (-8;22) 
 
 
0.45 
rs4646 
CC 
CA+AA 
 
119 (55) 
98 (45) 
 
64 (54) 
54 (46) 
 
0 (ref.) 
1 (-10;14) 
 
-11 (-22;2) 
-12 (-24;1) 
 
 
0.83 
 
0 (ref.) 
7 (-3;19) 
 
-9 (-19;2) 
-7 (-18;5) 
 
 
0.57 
 
0 (ref.) 
-6 (-15;5) 
 
4 (-8;18) 
4 (-9;18) 
 
 
0.57 
rs6493487 
AA 
GA+GG 
 
121 (56) 
96 (44) 
 
80 (68) 
38 (32) 
 
0 (ref.) 
-9 (-19;2) 
 
-14 (-24;-3) 
-19 (-31;-5) 
 
 
0.74 
 
0 (ref.) 
4 (-6;16) 
 
-9 (-18;1) 
-10 (-22;3) 
 
 
0.55 
 
0 (ref.) 
-10 (-19;0) 
 
-1 (-11;11) 
8 (-7;25) 
 
 
0.05 
rs2008691 
AA 
GA+GG 
 
148 (68) 
69 (32) 
 
68 (58) 
50 (42) 
 
0 (ref.) 
11 (-2;26) 
 
-9 (-20;3) 
-9 (-21;5) 
 
 
0.31 
 
0 (ref.) 
2 (-8;14) 
 
-13 (-22;2) 
-8 (-18;4) 
 
 
0.73 
 
0 (ref.) 
1 (-10;14) 
 
4 (-8;17) 
12 (-1;28) 
 
 
0.49 
rs3751591 
TT+TC 
CC  
 
213 (98) 
4 (2) 
 
114 (97) 
4 (3) 
 
0 (ref.) 
10 (-29;71) 
 
-13 (-21;-3) 
15 (-26;77) 
 
 
0.59 
 
0 (ref.) 
-16 (-42;21) 
 
-13 (-20;-5) 
48 (3;114) 
 
 
0.008 
 
0 (ref.) 
71 (15;154) 
 
8 (-2;18) 
17 (-21;74) 
 
 
0.12 
rs2445762 
TT 
TC+CC 
 
118 (54) 
99 (46) 
 
54 (46) 
64 (54) 
 
0 (ref.) 
-3 (-14;9) 
 
-12 (-23;2) 
-14 (-25;-2) 
 
 
0.98 
 
0 (ref.) 
-1 (-10;10) 
 
-10 (-20;2) 
-13 (-22;-2) 
 
 
0.75 
 
0 (ref.) 
-4 (-14;7) 
 
10 (-4;25) 
2 (-10;15) 
 
 
0.69 
rs11070844 
CC 
TC+TT 
 
173 (80) 
44 (20) 
 
92 (78) 
26 (22) 
 
0 (ref.) 
14 (-1;31) 
 
-15 (-24;-5) 
13 (-5;35) 
 
 
0.20 
 
0 (ref.) 
16 (3;32) 
 
-11 (-19;-2) 
2 (-12;19) 
 
 
0.93 
 
0 (ref.) 
8 (-6;23) 
 
8 (-3;19) 
11 (-6;31) 
 
 
0.69 
Δ Percentage change in hormonal measurements compared to WT divided by usage of NSAID. 
a Adjusted for age, smoking (never, past, current), abstainers, alcohol intake (increment of 10 g per day) and BMI (kg/m2) at baseline. 
b P-value for interaction. 
SHBG: Sex-hormone binding globulin. 
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Table S2: Risk estimates for different combinations of CYP19A1 haplotypes in relation to risk of BC. 
Haplotypea AAA GAG GGG 
AAA 1.00 (ref.) (164/162) 0.91 (0.68-1.22) (164/182) 1.17 (0.86-1.59) (156/143) 
GAG  1.25 (0.79-1.97) (48/43) 1.56 (1.02-2.40) (74/56) 
GGG   0.99 (0.59-1.68) (34/35) 
IRR (95% CI) for BC for different combinations of haplotypes. The number of cases and controls in each cell is listed. Variant alleles are bold. Adjusted for parous/nulliparous, number of 
births, age at first birth, length of school education (low, medium, high), duration of HRT use (years), BMI (kg/m2) and alcohol intake (10 g/day). 
aHaplotype sequence: rs10046, rs6493487, rs10519297 
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Table S3: IRR for BC in relation to CYP19A1 polymorphisms per increment of 10 g alcohol per day. 
Genotype ncases (%) 
(n=651) 
ncontrols (%) 
(n=651) 
IRRa (95% CI) IRRb (95% CI) P-valuec 
rs10519297 
AA 
AG+GG 
 
159 (24) 
492 (76) 
 
162 (25) 
489 (75) 
 
1.13 (0.96-1.33) 
1.16 (1.06-1.27) 
 
1.12 (0.94-1.32) 
1.14 (1.05-1.25) 
 
 
0.79 
rs749292 
GG 
AG+AA 
 
208 (32) 
443 (68) 
 
193 (30) 
458 (70) 
 
1.23 (1.07-1.42) 
1.12 (1.02-1.23) 
 
1.23 (1.07-1.43) 
1.10 (1.00-1.21) 
 
 
0.18 
rs1062033 
CC 
CG+GG 
 
196 (30) 
455 (70) 
 
177 (27) 
474 (73) 
 
1.24 (1.07-1.43) 
1.13 (1.03-1.23) 
 
1.23 (1.06-1.43) 
1.10 (1.01-1.21) 
 
 
0.22 
rs10046 
AA 
AG+GG 
 
171 (26) 
480 (74) 
 
176 (27) 
475 (73) 
 
1.16 (0.73-1.48) 
1.15 (1.06-1.26) 
 
1.14 (0.96-1.34) 
1.14 (1.04-1.24) 
 
 
0.98 
rs4646 
CC 
CA+AA 
 
355 (55) 
296 (45) 
 
349 (54) 
302 (46) 
 
1.14 (1.03-1.27) 
1.17 (1.04-1.31) 
 
1.18 (1.00-1.24) 
1.16 (1.04-1.30) 
 
 
0.62 
rs6493487 
AA 
GA+GG 
 
384 (59) 
267 (41) 
 
405 (62) 
246 (38) 
 
1.13 (1.02-1.25) 
1.18 (1.04-1.33) 
 
1.12 (1.01-1.24) 
1.16 (1.03-1.31) 
 
 
0.64 
rs2008691 
AA 
GA+GG 
 
453 (70) 
198 (30) 
 
443 (68) 
208 (32) 
 
1.13 (1.03-1.23) 
1.22 (1.05-1.41) 
 
1.11 (1.01-1.22) 
1.20 (1.04-1.38) 
 
 
0.37 
rs3751591 
TT+TC 
CC 
 
626 (96) 
25 (4) 
 
638 (98) 
13 (2) 
 
1.15 (1.06-1.24) 
1.66 (0.86-3.18) 
 
1.13 (1.04-1.22) 
1.66 (0.88-3.14) 
 
 
0.24 
rs2445762 
TT 
TC+CC 
 
339 (52) 
312 (48) 
 
347 (53) 
304 (47) 
 
1.13 (1.02-1.25) 
1.18 (1.06-1.32) 
 
1.11 (1.00-1.23) 
1.18 (1.05-1.32) 
 
 
0.43 
rs11070844 
CC 
TC+TT 
 
520 (80) 
131 (20) 
 
526 (81) 
125 (19) 
 
1.17 (1.07-1.27) 
1.11 (0.95-1.30) 
 
1.18 (1.05-1.25) 
1.11 (0.95-1.29) 
 
 
0.69 
aCrude. 
bAdjusted for parity (parous/nulliparous, number of births, age at first birth), length of school education (low, medium, high), duration of HRT use (years) and body mass index (kg/m2) at 
baseline. 
cP-value for interaction for adjusted risk estimates. 
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Table S4. IRR for BC in relation to use of NSAID and CYP19A1 polymorphisms. 
Genotype  No  
ncases/  
ncontrols  
(n=675)  
Yes  
ncases/  
ncontrols  
(n=675)  
No  
IRR (95% CI)a  
Yes  
IRR (95% CI)a  
No  
IRR (95% CI)b  
Yes  
IRR (95% CI)b  
P-valuec  
rs10519297 
AA 
AG+GG 
 
87/111 
305/358 
 
81/59 
202/177 
 
1.00 (ref.) 
1.21 (0.87-1.68) 
 
1.69 (1.08-2.63) 
1.45 (1.03-2.05) 
 
1.00 (ref.) 
1.16 (0.82-1.63) 
 
1.65 (1.05-2.59) 
1.44 (1.00-2.05) 
 
 
0.30 
rs749292 
GG 
AG+AA 
 
122/134 
270/305 
 
91/67 
192/169 
 
1.00 (ref.) 
0.96 (0.71-1.31) 
 
1.44 (0.98-2.12) 
1.21 (0.88-1.67) 
 
1.00 (ref.) 
1.00 (0.73-1.36) 
 
1.53 (1.03-2.28) 
1.26 (0.90-1.75) 
 
 
0.42 
rs1062033 
CC 
CG+GG 
 
114/120 
278/319 
 
86/62 
197/174 
 
1.00 (ref.) 
0.89 (0.65-1.22) 
 
1.40 (0.94-2.10) 
1.14 (0.82-1.59) 
 
1.0 (ref.) 
0.92 (0.67-1.26) 
 
1.48 (0.98-2.23) 
1.18 (0.84-1.65) 
 
 
0.58 
rs10046 
AA 
AG+GG 
 
93/120 
299/319 
 
86/63 
197/173 
 
1.00 (ref.) 
1.22 (0.89-1.68) 
 
1.69 (1.11-2.58) 
1.46 (1.04-2.04) 
 
1.00 (ref.) 
1.17 (0.84-1.61) 
 
1.68 (1.09-2.59) 
1.43 (1.01-2.02) 
 
 
0.24 
rs4646 
CC 
CA+AA 
 
204/230 
188/209 
 
163/132 
120/104 
 
1.00 (ref.) 
1.01 (0.76-1.32) 
 
1.32 (0.99-1.76) 
1.30 (0.94-1.80) 
 
1.00 (ref.) 
0.97 (0.73-1.28) 
 
1.33 (0.99-1.78) 
1.30 (0.94-1.82) 
 
 
0.95 
rs6493487 
AA 
GA+GG 
 
223/277 
169/162 
 
177/146 
106/90 
 
1.00 (ref.) 
1.31 (1.00-1.73) 
 
1.46 (1.11-1.92) 
1.46 (1.05-2.03) 
 
1.00 (ref.) 
1.30 (0.98-1.73) 
 
1.49 (1.12-1.97) 
1.47 (1.05-2.08) 
 
 
0.26 
rs2008691 
AA 
GA+GG 
 
273/297 
119/142 
 
197/164 
86/72 
 
1.00 (ref.) 
0.89 (0.66-1.19) 
 
1.26 (0.96-1.64) 
1.27 (0.90-1.79) 
 
1.00 (ref.) 
0.88 (0.65-1.19) 
 
1.27 (0.96-1.67) 
1.31 (0.92-1.87) 
 
 
0.51 
rs3751591 
TT+TC 
CC 
 
374/429 
18/10 
 
275/233 
8/3 
 
1.00 (ref.) 
2.14 (0.93-4.91) 
 
1.32 (1.06-1.65) 
3.04 (0.80-11.60) 
 
1.00 (ref.) 
2.09 (0.90-4.88) 
 
1.35 (1.08-1.69) 
3.37 (0.85-13.36) 
 
 
0.83 
rs2445762 
TT 
TC+CC 
 
207/228 
185/211 
 
147/128 
136/108 
 
1.00 (ref.) 
0.96 (0.73-1.27) 
 
1.24 (0.92-1.67) 
1.35 (0.98-1.84) 
 
1.0 (ref.) 
0.97 (0.73-1.29) 
 
1.24 (0.91-1.68) 
1.43 (1.03-1.97) 
 
 
0.48 
rs11070844 
CC 
TC+TT 
 
325/357 
67/82 
 
216/192 
67/44 
 
1.0 (ref.) 
0.91 (0.64-1.31) 
 
1.21 (0.95-1.54) 
1.62 (1.09-2.41) 
 
1.00 (ref.) 
0.94 (0.65-1.36) 
 
1.26 (0.98-1.61) 
1.59 (1.05-2.39) 
 
 
0.30 
aCrude.  
bAdjusted for parity (parous/nulliparous, number of births, age at first birth), length of school education (low, medium, high), duration of HRT use (years), body mass index (kg/m2), and 
alcohol intake (increment of 10 g per day) at baseline.  
cP-value for interaction for adjusted risk estimates. 
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Table S5: IRR for BC in relation to combinations of PPARG Pro12Ala and CYP19A1 genotypes 
Genotype  PPARG Pro12Ala PPARG Pro12Ala  PPARG Pro12Ala P-valuec  
Pro/Pro  
ncases/ 
ncontrols  
(n=685)  
 
Ala-
carriers  
ncase/ 
ncontrols 
(n=685) 
Pro/Pro  
IRR (95% CI)a 
Ala-carriers  
IRR (95% CI) a 
Pro/Pro  
IRR (95% CI)b  
 
Ala-carriers  
IRR (95% CI)b 
rs10519297 
AA 
AG+GG 
 
132/121 
396/367 
 
37/51 
120/146 
 
1.0 (ref.) 
0.99 (0.75-1.31) 
 
0.65 (0.39-1.08) 
0.75 (0.52-1.08) 
 
1.0 (ref.) 
0.95 (0.71-1.27) 
 
0.61 (0.36-1.03) 
0.75 (0.52-1.09) 
 
0.38 
rs749292 
GG 
AG+AA 
 
165/143 
363/345 
 
51/60 
106/137 
 
1.0 (ref.) 
0.91 (0.68-1.21) 
 
0.73 (0.46-1.14) 
0.67 (0.47-0.94) 
 
1.00 (ref.) 
0.92 (0.68-1.23) 
 
0.75 (0.47-1.18) 
0.68 (0.48-0.98) 
 
1.00 
rs1062033 
CC 
CG+GG 
 
152/132 
376/356 
 
51/54 
106/143 
 
1.00 (ref.) 
0.90 (0.67-1.21) 
 
0.81 (0.51-1.27) 
0.63 (0.45-0.91) 
 
1.00 (ref.) 
0.91 (0.68-1.23) 
 
0.84 (0.52-1.34) 
0.65 (0.45-0.93) 
 
0.57 
rs10046 
AA 
AG+GG 
 
137/131 
391/357 
 
44/55 
113/142 
 
1.00 (ref.) 
1.04 (0.79-1.36) 
 
0.76 (0.47-1.21) 
0.75 (0.53-1.08) 
 
1.00 (ref.) 
1.00 (0.76-1.32) 
 
0.75 (0.47-1.22) 
0.75 (0.51-1.08) 
 
0.97 
rs4646 
CC 
CA+AA 
 
286/252 
242/236 
 
84/117 
73/80 
 
1.00 (ref.) 
0.90 (0.71-1.14) 
 
0.62 (0.44-0.87) 
0.80 (0.56-1.16) 
 
1.00 (ref.) 
0.88 (0.69-1.13) 
 
0.63 (0.44-0.90) 
0.80 (0.55-1.15) 
 
0.17 
 
rs6493487 
AA 
GA+GG 
 
306/302 
222/186 
 
99/126 
58/71 
 
1.00 (ref.) 
1.20 (0.93-1.54) 
 
0.78 (0.57-1.06) 
0.82 (0.54-1.24) 
 
1.00 (ref.) 
1.18 (0.91-1.53) 
 
0.78 (0.57-1.08) 
0.84 (0.55-1.29) 
 
0.74 
rs2008691 
AA 
GA+GG 
 
372/334 
156/154 
 
106/134 
51/63 
 
1.00 (ref.) 
0.89 (0.69-1.17) 
 
0.70 (0.52-0.96) 
0.71 (0.47-1.07) 
 
1.00 (ref.) 
0.89 (0.67-1.17) 
 
0.71 (0.52-0.97) 
0.74 (0.49-1.13) 
 
0.53 
rs3751591 
TT+TC 
CC 
 
508/478 
20/10 
 
151/194 
6/3 
 
1.00 (ref.) 
1.83 (0.82-4.10) 
 
0.74 (0.57-0.95) 
2.11 (0.41-10.97) 
 
1.00 (ref.) 
1.68 (0.74-3.81) 
 
0.75 (0.57-0.97) 
2.88 (0.54-15.33) 
 
0.37 
rs2445762 
TT 
TC+CC 
 
271/260 
257/228 
 
87/104 
70/93 
 
1.00 (ref.) 
1.07 (0.84-1.36) 
 
0.79 (0.56-1.12) 
0.71 (0.50-1.03) 
 
1.00 (ref.) 
1.11 (0.87-1.43) 
 
0.83 (0.59-1.18) 
0.74 (0.51-1.07) 
 
0.37 
rs11070844 
CC 
TC+TT 
 
435/396 
93/92 
 
116/159 
41/38 
 
1.00 (ref.) 
0.94 (0.69-1.29) 
 
0.66 (0.50-0.88) 
0.99 (0.62-1.58) 
 
1.00 (ref.) 
0.96 (0.70-1.33) 
 
0.68 (0.52-0.92) 
0.96 (0.59-1.55) 
 
0.24 
 
aCrude. 
bAdjusted for parity (parous/nulliparous, number of births, age at first birth), length of school education (low, medium, high), duration of HRT use (years), body mass index (kg/m2) and alcohol 
intake (increment of 10 g per day) at baseline. 
cP-value for interaction for the adjusted risk estimates. 
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Table S6: IRR for BC in relation to combinations of PPARGC1A Gly482Ser and CYP19A1 genotypes 
Genotype  PPARGC1A Gly482Ser PPARGC1A Gly482Ser  PPARGC1A Gly482Ser P-valuec  
Gly-carriers 
ncases/ ncontrols  
(n=686)  
Ser/Ser 
ncase/ ncontrols 
(n=686) 
Gly-carriers 
IRR (95% CI)a 
Ser/Ser  
IRR (95% CI) a 
Gly-carriers 
IRR (95% CI)b  
 
Ser/Ser 
IRR (95% CI)b 
rs10519297 
AA 
AG+GG 
 
147/148 
461/449 
 
21/26 
55/63 
 
1.00 (ref.) 
1.04 (0.80-1.36) 
 
0.83 (0.45-1.52) 
0.89 (0.57-1.37) 
 
1.00 (ref.) 
1.02 (0.77-1.34) 
 
0.78 (0.42-1.46) 
0.83 (0.53-1.29) 
 
0.92 
rs749292 
GG 
AG+AA 
 
192/181 
418/416 
 
24/22 
52/67 
 
1.00 (ref.) 
0.94 (0.73-1.21) 
 
1.10 (0.57-2.12) 
0.72 (0.47-1.11) 
 
1.00 (ref.) 
0.95 (0.73-1.23) 
 
1.02 (0.52-2.00) 
0.69 (0.44-1.08) 
 
0.41 
rs1062033 
CC 
CG+GG 
 
179/166 
431/431 
 
24/20 
52/69 
 
1.00 (ref.) 
0.91 (0.71-1.17) 
 
1.22 (0.62-2.39) 
0.67 (0.43-1.04) 
 
1.00 (ref.) 
0.91 (0.70-1.18) 
 
1.14 (0.57-2.26) 
0.64 (0.41-1.01) 
 
0.24 
rs10046 
AA 
AG+GG 
 
162/164 
448/433 
 
20/24 
56/65 
 
1.00 (ref.) 
1.07 (0.83-1.37) 
 
0.86 (0.46-1.62) 
0.89 (0.58-1.36) 
 
1.00 (ref.) 
1.03 (0.80-1.34) 
 
0.84 (0.44-1.60) 
0.81 (0.52-1.26) 
 
0.88 
rs4646 
CC 
CA+AA 
 
326/326 
284/271 
 
45/45 
31/44 
 
1.00 (ref.) 
1.06 (0.84-1.32) 
 
1.00 (0.64-1.55) 
0.72 (0.44-1.16) 
 
1.00 (ref.) 
1.04 (0.82-1.31) 
 
0.98 (0.62-1.54) 
0.65 (0.40-1.07) 
 
0.21 
rs6493487 
AA 
GA+GG 
 
364/369 
246/228 
 
43/60 
33/29 
 
1.00 (ref.) 
1.12 (0.89-1.42) 
 
0.74 (0.49-1.13) 
1.24 (0.71-2.18) 
 
1.00 (ref.) 
1.10 (0.86-1.40) 
 
0.68 (0.44-1.05) 
1.23 (0.69-2.19) 
 
0.19 
rs2008691 
AA 
GA+GG 
 
427/406 
183/191 
 
51/63 
25/26 
 
1.00 (ref.) 
0.91 (0.71-1.15) 
 
0.78 (0.52-1.16) 
0.92 (0.52-1.62) 
 
1.00 (ref.) 
0.91 (0.71-1.17) 
 
0.73 (0.48-1.11) 
0.89 (0.50-1.60) 
 
0.43 
rs3751591 
TT+TC 
CC 
 
584/586 
25/9 
 
76/87 
-/2 
 
1.00 (ref.) 
2.50 (1.15-5.42) 
 
0.91 (0.65-1.27) 
- 
 
1.00 (ref.) 
2.52 (1.15-5.56) 
 
0.87 (0.61-1.23) 
- 
 
0.02 
rs2445762 
TT 
TC+CC 
 
322/319 
288/278 
 
36/46 
40/43 
 
1.00 (ref.) 
1.02 (0.81-1.29) 
 
0.79 (0.49-1.27) 
0.91 (0.58-1.44) 
 
1.00 (ref.) 
1.05 (0.83-1.34) 
 
0.76 (0.47-1.23) 
0.89 (0.56-1.41) 
 
0.76 
rs11070844 
CC 
TC+TT 
 
493/480 
117/117 
 
59/75 
17/14 
 
1.00 (ref.) 
0.99 (0.75-1.31) 
 
0.77 (0.53-1.11) 
1.26 (0.61-2.61) 
 
1.00 (ref.) 
0.99 (0.74-1.32) 
 
0.74 (0.50-1.07) 
1.16 (0.55-2.44) 
 
0.29 
aCrude. 
bAdjusted for parity (parous/nulliparous, number of births, age at first birth), length of school education (low, medium, high), duration of HRT use (years), body mass index (kg/m2) and alcohol 
intake (increment of 10 g per day) at baseline. 
cP-value for interaction for the adjusted risk estimates. 
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Table S7: IRR for BC in relation to combinations of PPARGC1A Thr612Met and CYP19A1 genotypes 
Genotype  PPARGC1A Thr612Met PPARGC1A Thr612Met  PPARGC1A Thr612Met P-valuec  
Thr/Thr 
ncases/ 
ncontrols  
(n=686)  
Met-
carriers 
ncase/ 
ncontrols 
(n=686) 
Thr/Thr 
IRR (95% CI)a 
Met-carriers 
IRR (95% CI) a 
Thr/Thr 
IRR (95% CI)b  
 
Met-carriers 
IRR (95% CI)b 
rs10519297 
AA 
AG+GG 
 
152/164 
465/460 
 
18/10 
51/52 
 
1.00 (ref.) 
1.10 (0.85-1.42) 
 
2.12 (0.89-5.05) 
1.08 (0.69-1.68) 
 
1.00 (ref.) 
1.07 (0.82-1.39) 
 
1.87 (0.77-4.55) 
1.02 (0.65-1.62) 
 
0.16 
rs749292 
GG 
AG+AA 
 
195/178 
422/446 
 
21/24 
48/38 
 
1.00 (ref.) 
0.85 (0.66-1.09) 
 
0.77 (0.41-1.42) 
1.20 (0.73-1.97) 
 
1.00 (ref.) 
0.86 (0.67-1.12) 
 
0.77 (0.41-1.45) 
1.13 (0.68-1.89) 
 
0.18 
rs1062033 
CC 
CG+GG 
 
186/163 
431/461 
 
17/22 
52/40 
 
1.00 (ref.) 
0.81 (0.63-1.05) 
 
0.70 (0.36-1.34) 
1.16 (0.71-1.91) 
 
1.00 (ref.) 
0.82 (0.63-1.07) 
 
0.71 (0.36-1.38) 
1.09 (0.65-1.81) 
 
0.13 
rs10046 
AA 
AG+GG 
 
163/177 
454/447 
 
19/11 
50/51 
 
1.00 (ref.) 
1.12 (0.87-1.43) 
 
2.04 (0.89-4.67) 
1.09 (0.70-1.70) 
 
1.00 (ref.) 
1.07 (0.83-1.38) 
 
1.82 (0.78-4.26) 
1.02 (0.65-1.61) 
 
0.63 
rs4646 
CC 
CA+AA 
 
326/347 
291/277 
 
45/24 
24/38 
 
1.00 (ref.) 
1.11 (0.89-1.39) 
 
2.17 (1.25-3.76) 
0.66 (0.38-1.12) 
 
1.00 (ref.) 
1.09 (0.87-1.36) 
 
2.06 (1.17-3.65) 
0.62 (0.36-1.08) 
 
0.002 
 
rs6493487 
AA 
GA+GG 
 
366/396 
241/228 
 
41/34 
28/28 
 
1.00 (ref.) 
1.22 (0.97-1.54) 
 
1.29 (0.79-2.11) 
1.16 (0.67-2.00) 
 
1.00 (ref.) 
1.21 (0.95-1.53) 
 
1.20 (0.73-1.99) 
1.12 (0.63-1.97) 
 
0.49 
rs2008691 
AA 
GA+GG 
 
427/428 
190/196 
 
51/41 
18/21 
 
1.00 (ref.) 
0.96 (0.76-1.22) 
 
1.30 (0.83-2.04) 
0.82 (0.43-1.57) 
 
1.00 (ref.) 
0.97 (0.76-1.23) 
 
1.23 (0.77-1.95) 
0.80 (0.41-1.57) 
 
0.35 
rs3751591 
TT+TC 
CC 
 
592/614 
25/10 
 
68/59 
1/3 
 
1.00 (ref.) 
2.59 (1.20-5.59) 
 
1.20 (0.82-1.76) 
- 
 
1.00 (ref.) 
2.49 (1.14-5.45) 
 
1.14 (0.77-1.69) 
- 
 
0.06 
rs2445762 
TT 
TC+CC 
 
320/331 
297/293 
 
38/33 
31/29 
 
1.00 (ref.) 
1.05 (0.84-1.31) 
 
1.22 (0.75-1.99) 
1.09 (0.63-1.89) 
 
1.00 (ref.) 
1.08 (0.86-1.36) 
 
1.17 (0.70-1.94) 
1.06 (0.60-1.87) 
 
0.64 
rs11070844 
CC 
TC+TT 
 
498/504 
119/120 
 
53/51 
16/11 
 
1.00 (ref.) 
1.02 (0.77-1.35) 
 
1.06 (0.70-1.62) 
1.47 (0.68-3.17) 
 
1.00 (ref.) 
1.02 (0.76-1.36) 
 
1.02 (0.66-1.58) 
1.36 (0.61-3.02) 
 
0.58 
aCrude. 
bAdjusted for parity (parous/nulliparous, number of births, age at first birth), length of school education (low, medium, high), duration of HRT use (years), body mass index (kg/m2) and alcohol 
intake (increment of 10 g per day) at baseline. 
cP-value for interaction for the adjusted risk estimates. 
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Table S8: IRR for BC per 10 g alcohol/day for combinations of PPARG Pro12Ala and CYP19A1 genotypes 
Genotype  PPARG Pro12Ala PPARG Pro12Ala  PPARG Pro12Ala P-valuec  
Pro/Pro  
ncases/ 
ncontrols  
(n=650)  
 
Ala-
carriers  
ncase/ 
ncontrols 
(n=650) 
Pro/Pro  
IRR (95% CI)a 
Ala-carriers  
IRR (95% CI) a 
Pro/Pro  
IRR (95% CI)b  
 
Ala-carriers  
IRR (95% CI)b 
rs10519297 
AA 
AG+GG 
 
128/115 
375/350 
 
31/46 
116/139 
 
1.17 (0.96-1.42) 
1.24 (1.11-1.38) 
 
1.06 (0.77-1.46) 
0.97 (0.82-1.14) 
 
1.15 (0.94-1.41) 
1.23 (1.10-1.36) 
 
1.06 (0.77-1.47) 
0.95 (0.81-1.12) 
 
0.08 
rs749292 
GG 
AG+AA 
 
158/136 
345/329 
 
50/57 
97/128 
 
1.39 (1.15-1.67) 
1.16 (1.04-1.29) 
 
0.98 (0.77-1.23) 
0.99 (0.83-1.19) 
 
1.39 (1.15-1.68) 
1.14 (1.02-1.27) 
 
0.98 (0.77-1.24) 
0.97 (0.80-1.17) 
 
0.03 
rs1062033 
CC 
CG+GG 
 
146/126 
357/339 
 
50/51 
97/134 
 
1.37 (1.13-1.66) 
1.17 (1.05-1.30) 
 
1.01 (0.80-1.29) 
0.96 (0.80-1.16) 
 
1.37 (1.13-1.66) 
1.15 (1.03-1.29) 
 
1.01 (0.79-1.28) 
0.95 (0.78-1.14) 
 
0.04 
rs10046 
AA 
AG+GG 
 
133/125 
370/340 
 
38/50 
109/135 
 
1.18 (0.98-1.41) 
1.24 (1.11-1.37) 
 
1.12 (0.79-1.58) 
0.96 (0.81-1.12) 
 
1.15 (0.95-1.39) 
1.22 (1.10-1.36) 
 
1.12 (0.79-1.58) 
0.94 (0.80-1.11) 
 
0.07 
rs4646 
CC 
CA+AA 
 
276/240 
227/225 
 
78/108 
69/77 
 
1.20 (1.06-1.35) 
1.25 (1.09-1.43) 
 
0.95 (0.77-1.18) 
1.00 (0.82-1.22) 
 
1.18 (1.04-1.33) 
1.24 (1.08-1.43) 
 
0.93 (0.74-1.16) 
1.00 (0.82-1.22) 
 
0.08 
rs6493487 
AA 
GA+GG 
 
293/287 
210/178 
 
90/117 
57/68 
 
1.18 (1.04-1.34) 
1.27 (1.10-1.48) 
 
1.02 (0.84-1.23) 
0.94 (0.76-1.18) 
 
1.16 (1.03-1.32) 
1.26 (1.08-1.46) 
 
1.01 (0.83-1.22) 
0.93 (0.74-1.16) 
 
0.07 
rs2008691 
AA 
GA+GG 
 
355/318 
148/147 
 
98/124 
49/61 
 
1.21 (1.08-1.34) 
1.25 (1.05-1.50) 
 
0.90 (0.75-1.09) 
1.12 (0.88-1.43) 
 
1.19 (1.07-1.33) 
1.23 (1.03-1.47) 
 
0.89 (0.73-1.07) 
1.11 (0.87-1.41) 
 
0.04 
rs3751591 
TT+TC 
CC 
 
483/455 
20/10 
 
142/182 
5/3 
 
1.21 (1.11-1.33) 
1.66 (0.84-3.29) 
 
0.99 (0.85-1.14) 
2.24 (0.27-18.71) 
 
1.20 (1.09-1.32) 
1.71 (0.88-3.34) 
 
0.98 (0.84-1.13) 
2.18 (0.25-19.35) 
 
0.07 
rs2445762 
TT 
TC+CC 
 
256/246 
247/219 
 
82/100 
65/85 
 
1.20 (1.06-1.36) 
1.25 (1.09-1.43) 
 
0.97 (0.80-1.18) 
1.01 (0.81-1.26) 
 
1.17 (1.03-1.33) 
1.25 (1.09-1.43) 
 
0.96 (0.79-1.17) 
0.99 (0.79-1.24) 
 
0.09 
rs11070844 
CC 
TC+TT 
 
411/378 
92/87 
 
109/148 
38/37 
 
1.23 (1.11-1.36) 
1.17 (0.96-1.42) 
 
0.99 (0.84-1.16) 
0.96 (0.71-1.30) 
 
1.22 (1.09-1.35) 
1.16 (0.95-1.41) 
 
0.97 (0.82-1.15) 
0.97 (0.71-1.31) 
 
0.10 
aCrude. 
bAdjusted for parity (parous/nulliparous, number of births, age at first birth), length of school education (low, medium, high), duration of HRT use (years) and body mass index (kg/m2). 
cP-value for comparison of the adjusted risk estimates. 
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Table S9: IRR for BC per 10 g alcohol/day for combinations PPARGC1A Gly482Ser and CYP19A1 genotypes 
Genotype  PPARGC1A Gly482Ser PPARGC1A Gly482Ser  PPARGC1A Gly482Ser P-valuec  
Gly-
carriers 
ncases/ 
ncontrols  
(n=650)  
Ser/Ser 
ncase/ 
ncontrols 
(n=650) 
Gly-carriers 
IRR (95% CI)a 
Ser/Ser  
IRR (95% CI) a 
Gly-carriers 
IRR (95% CI)b  
 
Ser/Ser 
IRR (95% CI)b 
rs10519297 
AA 
AG+GG 
 
139/136 
437/427 
 
20/26 
54/61 
 
1.16 (0.97-1.38) 
1.17 (1.07-1.29) 
 
0.97 (0.59-1.59) 
1.12 (0.89-1.42) 
 
1.13 (0.94-1.36) 
1.16 (1.05-1.27) 
 
0.99 (0.59-1.63) 
1.10 (0.87-1.40) 
 
0.92 
rs749292 
GG 
AG+AA 
 
185/172 
391/391 
 
23/21 
41/66 
 
1.27 (1.09-1.49) 
1.13 (1.03-1.25) 
 
1.05 (0.77-1.44) 
1.11 (0.83-1.47) 
 
1.27 (1.08-1.49) 
1.11 (1.00-1.22) 
 
1.08 (0.79-1.49) 
1.06 (0.79-1.42) 
 
0.50 
rs1062033 
CC 
CG+GG 
 
173/157 
403/406 
 
23/20 
41/67 
 
1.25 (1.06-1.47) 
1.14 (1.04-1.26) 
 
1.16 (0.81-1.64) 
1.04 (0.79-1.38) 
 
1.24 (1.05-1.46) 
1.13 (1.02-1.24) 
 
1.19 (0.84-1.69) 
1.00 (0.75-1.33) 
 
0.59 
rs10046 
AA 
AG+GG 
 
152/152 
424/411 
 
19/24 
55/63 
 
1.18 (0.99-1.40) 
1.17 (1.06-1.28) 
 
0.99 (0.60-1.64) 
1.12 (0.88-1.41) 
 
1.15 (0.97-1.38) 
1.15 (1.05-1.27) 
 
1.00 (0.60-1.67) 
1.10 (0.87-1.39) 
 
0.94 
rs4646 
CC 
CA+AA 
 
311/305 
265/258 
 
43/44 
31/43 
 
1.15 (1.03-1.28) 
1.20 (1.05-1.35) 
 
1.06 (0.76-1.47) 
1.12 (0.85-1.47) 
 
1.13 (1.01-1.26) 
1.18 (1.04-1.34) 
 
1.01 (0.72-1.42) 
1.14 (0.86-1.50) 
 
0.84 
rs6493487 
AA 
GA+GG 
 
342/345 
234/218 
 
42/59 
32/28 
 
1.14 (1.02-1.28) 
1.19 (1.05-1.36) 
 
1.11 (0.86-1.44) 
1.08 (0.74-1.57) 
 
1.12 (1.00-1.26) 
1.18 (1.04-1.34) 
 
1.12 (0.87-1.45) 
1.03 (0.70-1.52) 
 
0.89 
rs2008691 
AA 
GA+GG 
 
403/381 
173/182 
 
49/61 
25/26 
 
1.16 (1.05-1.28) 
1.19 (1.02-1.40) 
 
0.97 (0.73-1.28) 
1.42 (0.91-2.21) 
 
1.14 (1.04-1.26) 
1.17 (1.01-1.37) 
 
0.94 (0.71-1.25) 
1.40 (0.91-2.13) 
 
0.43 
rs3751591 
TT+TC 
CC 
 
551/552 
25/11 
 
74/85 
-/2 
 
1.16 (1.07-1.26) 
3.85 (1.02-14.58) 
 
1.12 (0.90-1.39) 
- 
 
1.14 (1.05-1.24) 
3.70 (0.99-13.85) 
 
1.11 (0.89-1.38) 
- 
 
0.37 
rs2445762 
TT 
TC+CC 
 
303/301 
273/262 
 
39/46 
35/41 
 
1.13 (1.01-1.26) 
1.22 (1.08-1.38) 
 
1.21 (0.91-1.60) 
0.95 (0.68-1.33) 
 
1.10 (0.98-1.23) 
1.21 (1.07-1.37) 
 
1.19 (0.90-1.58) 
0.94 (0.67-1.32) 
 
0.42 
rs11070844 
CC 
TC+TT 
 
463/451 
113/113 
 
57/74 
17/13 
 
1.17 (1.07-1.29) 
1.15 (0.96-1.38) 
 
1.13 (0.86-1.49) 
0.97 (0.69-1.36) 
 
1.16 (1.05-1.27) 
1.14 (0.95-1.37) 
 
1.10 (0.83-1.46) 
0.98 (0.70-1.38) 
 
0.83 
aCrude. 
bAdjusted for parity (parous/nulliparous, number of births, age at first birth), length of school education (low, medium, high), duration of HRT use (years) and  body mass index (kg/m2). 
cP-value for comparison of the adjusted risk estimates. 
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Table S10: IRR for BC per 10 g alcohol/day for combinations of PPARGC1A Thr612Met and CYP19A1 genotypes 
Genotype  PPARGC1A Thr612Met PPARGC1A Thr612Met  PPARGC1A Thr612Met P-valuec  
Thr/Thr 
ncases/ 
ncontrols  
(n=650)  
Met-
carriers 
ncase/ 
ncontrols 
(n=650) 
Thr/Thr 
IRR (95% CI)a 
Met-carriers 
IRR (95% CI) a 
Thr/Thr 
IRR (95% CI)b  
 
Met-carriers 
IRR (95% CI)b 
rs10519297 
AA 
AG+GG 
 
144/154 
445/440 
 
15/8 
56/48 
 
1.11 (0.92-1.33) 
1.16 (1.06-1.28) 
 
1.24 (0.75-2.06) 
1.15 (0.88-1.52) 
 
1.10 (0.91-1.32) 
1.15 (1.05-1.26) 
 
1.22 (0.72-2.06) 
1.11 (0.85-1.47) 
 
0.96 
rs749292 
GG 
AG+AA 
 
190/174 
399/424 
 
18/22 
43/34 
 
1.23 (1.06-1.43) 
1.12 (1.01-1.24) 
 
1.24 (0.73-2.11) 
1.13 (0.86-1.48) 
 
1.23 (1.06-1.44) 
1.10 (0.99-1.22) 
 
1.21 (0.71-2.06) 
1.09 (0.83-1.43) 
 
0.63 
rs1062033 
CC 
CG+GG 
 
182/156 
407/438 
 
14/20 
47/36 
 
1.22 (1.05-1.43) 
1.13 (1.02-1.24) 
 
1.40 (0.79-2.47) 
1.10 (0.85-1.43) 
 
1.22 (1.04-1.43) 
1.11 (1.01-1.23) 
 
1.36 (0.77-2.40) 
1.06 (0.81-1.38) 
 
0.64 
rs10046 
AA 
AG+GG 
 
155/167 
434/427 
 
16/9 
45/47 
 
1.13 (0.95-1.35) 
1.16 (1.05-1.27) 
 
1.31 (0.78-2.21) 
1.14 (0.87-1.49) 
 
1.12 (0.93-1.33) 
1.14 (1.04-1.26) 
 
1.28 (0.74-2.20) 
1.10 (0.84-1.44) 
 
0.96 
rs4646 
CC 
CA+AA 
 
315/328 
274/266 
 
39/21 
22/35 
 
1.11 (0.99-1.25) 
1.19 (1.06-1.34) 
 
1.25 (0.87-1.79) 
0.91 (0.58-1.42) 
 
1.09 (0.97-1.23) 
1.19 (1.05-1.34) 
 
1.21 (0.84-1.73) 
0.86 (0.55-1.36) 
 
0.49 
rs6493487 
AA 
GA+GG 
 
348/375 
241/219 
 
36/30 
25/26 
 
1.13 (1.02-1.26) 
1.18 (1.03-1.34) 
 
1.16 (0.85-1.58) 
1.24 (0.87-1.77) 
 
1.12 (1.00-1.25) 
1.16 (1.02-1.33) 
 
1.11 (0.80-1.52) 
1.22 (0.85-1.73) 
 
0.95 
rs2008691 
AA 
GA+GG 
 
406/405 
183/189 
 
46/37 
15/19 
 
1.11 (1.01-1.23) 
1.24 (1.07-1.45) 
 
1.24 (0.94-1.64) 
0.86 (0.45-1.64) 
 
1.10 (1.00-1.21) 
1.22 (1.05-1.42) 
 
1.20 (0.91-1.59) 
0.80 (0.41-1.58) 
 
0.46 
rs3751591 
TT+TC 
CC 
 
565/584 
24/10 
 
60/53 
1/3 
 
1.15 (1.06-1.24) 
1.46 (0.76-2.79) 
 
1.17 (0.92-1.48) 
- 
 
1.13 (1.04-1.23) 
1.50 (0.79-2.85) 
 
1.13 (0.90-1.44) 
- 
 
0.86 
rs2445762 
TT 
TC+CC 
 
305/317 
284/277 
 
33/29 
28/27 
 
1.13 (1.01-1.26) 
1.18 (1.05-1.32) 
 
1.15 (0.87-1.53) 
1.24 (0.81-1.91) 
 
1.11 (0.99-1.24) 
1.17 (1.04-1.32) 
 
1.10 (0.83-1.47) 
1.21 (0.78-1.86) 
 
0.90 
rs11070844 
CC 
TC+TT 
 
473/478 
116/116 
 
46/47 
15/9 
 
1.18 (1.08-1.29) 
1.07 (0.90-1.26) 
 
1.07 (0.82-1.41) 
1.62 (0.84-3.10) 
 
1.16 (1.06-1.28) 
1.07 (0.90-1.26) 
 
1.03 (0.78-1.36) 
1.51 (0.80-2.84) 
 
0.55 
aCrude. 
bAdjusted for parity (parous/nulliparous, number of births, age at first birth), length of school education (low, medium, high), duration of HRT use (years) and body mass index (kg/m2) at 
baseline. 
cP-value for comparison of the adjusted risk estimates. 
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Table S11. IRR for BC per 10 g alcohol/day in relation to combinations of NSAID use and CYP19A1 polymorphisms 
Genotype  No  
ncases/  
ncontrols  
(n=640)  
Yes  
ncases/  
ncontrols  
(n=640)  
No  
IRR (95% CI)a  
Yes  
IRR (95% CI)a  
No  
IRR (95% CI)b  
Yes  
IRR (95% CI)b  
P-valuec  
rs10519297 
AA 
AG+GG 
 
81/104 
286/315 
 
76/55 
197/166 
 
1.16 (0.92-1.45) 
1.12 (1.00-1.26) 
 
1.14 (0.89-1.46)  
1.18 (1.04-1.35) 
 
1.13 (0.89-1.43) 
1.10 (0.98-1.24) 
 
1.14 (0.88-1.47) 
1.17 (1.02-1.33) 
 
0.94 
rs749292 
GG 
AG+AA 
 
119/128 
248/291 
 
86/63 
187/158 
 
1.14 (0.95-1.37) 
1.13 (0.99-1.28) 
 
1.35 (1.06-1.69) 
1.11 (0.97-1.28) 
 
1.14 (0.95-1.38) 
1.10 (0.96-1.25) 
 
1.33 (1.06-1.68) 
1.09 (0.95-1.26) 
 
0.49 
rs1062033 
CC 
CG+GG 
 
111/115 
256/304 
 
82/58 
191/163 
 
1.16 (0.95-1.41) 
1.12 (0.99-1.27) 
 
1.30 (1.03-1.64) 
1.13 (0.99-1.29) 
 
1.17 (0.96-1.43) 
1.09 (0.96-1.24) 
 
1.28 (1.02-1.61) 
1.12 (0.97-1.28) 
 
0.67 
rs10046 
AA 
AG+GG 
 
87/113 
280/306 
 
81/59 
192/162 
 
1.17 (0.94-1.47) 
1.12 (0.99-1.25) 
 
1.18 (0.93-1.50) 
1.17 (1.03-1.34) 
 
1.14 (0.90-1.44) 
1.10 (0.97-1.24) 
 
1.17 (0.91-1.50) 
1.16 (1.01-1.32) 
 
0.93 
rs4646 
CC 
CA+AA 
 
193/219 
174/200 
 
157/122 
116/99 
 
1.12 (0.97-1.29) 
1.14 (0.98-1.33) 
 
1.16 (0.99-1.36) 
1.19 (1.00-1.43) 
 
1.09 (0.94-1.26) 
1.13 (0.97-1.32) 
 
1.14 (0.98-1.34) 
1.18 (0.99-1.41) 
 
0.91 
rs6493487 
AA 
GA+GG 
 
209/263 
158/156 
 
169/136 
104/87 
 
1.14 (0.99-1.31) 
1.11 (0.94-1.30) 
 
1.14 (0.97-1.33) 
1.23 (1.02-1.48) 
 
1.12 (0.98-1.29) 
1.08 (0.91-1.28) 
 
1.12 (0.96-1.31) 
1.21 (1.01-1.46) 
 
0.83 
rs2008691 
AA 
GA+GG 
 
253/282 
114/137 
 
192/153 
81/68 
 
1.11 (0.99-1.26) 
1.18 (0.97-1.43) 
 
1.15 (1.00-1.31) 
1.25 (1.00-1.56) 
 
1.08 (0.96-1.23) 
1.17 (0.96-1.43) 
 
1.14 (0.99-1.31) 
1.21 (0.97-1.50) 
 
0.81 
rs3751591 
TT+TC 
CC 
 
350/409 
17/10 
 
265/218 
8/3 
 
1.12 (1.00-1.24) 
1.47 (0.76-2.82) 
 
1.17 (1.04-1.32) 
32 (0.42-2483) 
 
1.09 (0.97-1.21) 
1.60 (0.83-3.08) 
 
1.16 (1.03-1.31) 
26.0 (0.32-2191) 
 
0.29 
rs2445762 
TT 
TC+CC 
 
192/217 
175/192 
 
142/122 
131/99 
 
1.16 (1.00-1.35) 
1.10 (0.96-1.27) 
 
1.09 (0.95-1.26) 
1.32 (1.09-1.61) 
 
1.13 (0.97-1.32) 
1.09 (0.94-1.26) 
 
1.07 (0.93-1.23) 
1.33 (1.09-1.62) 
 
0.35 
rs11070844 
CC 
TC+TT 
 
303/340 
64/79 
 
207/180 
66/41 
 
1.18 (1.06-1.33) 
0.91 (0.71-1.16) 
 
1.14 (0.99-1.30) 
1.32 (1.00-1.75) 
 
1.16 (1.03-1.31) 
0.89 (0.69-1.16) 
 
1.12 (0.98-1.28) 
1.31 (1.00-1.72) 
 
0.20 
aCrude.  
bAdjusted for parity (parous/nulliparous, number of births, age at first birth), length of school education (low, medium, high), duration of HRT use (years) and body mass index (kg/m2) at 
baseline.  
cP-value for comparison of the adjusted risk estimates. 
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Table S12. Hormones, SHBG and ethanol measurements after acute ingestion of alcohol. 
 
PPARG wild types (n=18) PPARG 12Ala carriers (n=7) 
Alcohol+ 
placebo 
Alcohol+ 
Ibuprofen 
Alcohol+ 
placebo 
Alcohol+ 
Ibuprofen 
Estrone pmol/l     
0 min 26.25±12.94 27.50±16.53 14.60±7.31 31.50±2.50 
30 min 16.50±13.10 15.23±10.17 10.00±10.00 19.00±15.58 
60 min 15.36±10.41 11.60±9.19 9.83±8.90 8.00±8.04 
90 min 13.20±12.69 9.00±9.18 13.67±9.88 13.50±9.54 
1200 min 24.56±17.71 30.45±19.61 18.40±11.81 32.00±32.47 
Estrone sulphate pmol/l     
0 min 797.45±493.44 731.39±473.95 492.29±162.22 714.79±422.03 
30 min 575.78±285.18 714.56±519.96 426.64±105.34 699.14±415.42 
60 min 578.29±473.07 627.67±452.80 413.36±110.07 640.21±395.21 
90 min 750.38±527.00 659.56±496.70 428.07±124.82 652.29±389.76 
1200 min 626.89±375.54 698.11±505.23 468.29±149.23 871.14±764.29 
SHBG nmol/l     
0 min 64.96±26.99 65.01±22.27 69.23±16.00 66.58±13.90 
30 min 61.62±21.74  67.75±25.31 71.18±17.00 68.26±13.80 
60 min 62.41±23.93 61.38±18.45 65.18±12.54 66.32±12.08 
90 min 59.90±23.59 62.82±21.64 69.51±16.20 59.67±13.12 
1200 min 65.39±30.15 64.58±22.25 70.58±15.71 65.51±22.00 
Ethanol g/l     
0 min <0.00 <0.00 <0.00 <0.00 
30 min 0.19±0.12 0.20±0.11 0.11±0.076 0.19±0.086 
60 min 0.32±0.094 0.34±0.088 0.29±0.036 0.33±0.048 
90 min 0.30±0.070 0.31±0.062 0.28±0.028 0.32±0.047 
1200 min <0.00 <0.00 <0.00 <0.00 
Blood concentrations of estrone, estrone sulphate, SHBG and ethanol before and after 30, 60, 90 and 1200 minutes of drinking, respectively. Values are presented as means ± SD. 
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Table S1. Result from Fig. 1-7 presented as values ±SD and %CV. 
Transient transfection assays 
 Full-length PPARγ2 Full-length PPARγ2 with 1 µM Rosiglitazone 
Conc. (%) 0.1 0.3 1.0 3.0** 0.0*** 0.1 0.3 1.0 3.0** 
 DMSO DMSO 
Mean* (±SD) 0.90 (±0.12) 0.73 (±0.09) 0.47 (±0.16) 0.14 (±0.13) 5.83 (±2.11) 5.87 (±1.88) 4.92 (±0.82) 2.93 (±1.14) 0.56 (±0.45) 
%CV 12.96 12.07 33.46 90.02 36.16 32.03 16.64 39.01 80.47 
 Isopropanol Isopropanol 
Mean* (±SD) 0.99 (±0.07) 0.92 (±0.05) 0.89 (±0.24) 0.88 (±0.29) 4.57 (±0.27) 4.36 (±0.68) 4.70 (±0.31) 4.34 (±0.73) 3.53 (±1.18) 
%CV 6.60 5.24 26.66 33.43 5.82 15.61 6.70 16.82 33.35 
 Methanol Methanol 
Mean* (±SD) 0.94 (±0.15) 0.86 (±0.20) 0.78 (±0.17) 0.57 (±0.41) 5.26 (±0.89) 5.31 (±0.86) 4.74 (±0.30) 4.32 (±0.41) 3.07 (±2.26) 
%CV 16.31 23.53 21.80 71.93 16.90 16.22 6.36 9.59 73.48 
 Ethylene glycol Ethylene glycol 
Mean* (±SD) 0.94 (±0.08) 0.90 (±0.08) 0.71 (±0.12) 0.58 (±0.10) 5.39 (±0.93) 5.37 (±0.67) 5.36 (±0.90) 4.77 (±0.34) 3.18 (±0.27) 
%CV 8.85 8.90 16.24 18.22 17.23 12.46 16.74 7.23 8.42 
 1-Propanol 1-Propanol 
Mean* (±SD) 0.75 (±0.12) 0.74 (±0.10) 0.93 (±0.22)  4.66 (±0.85) 4.20 (±0.35) 4.13 (±0.71) 4.02 (±0.24)  
%CV 16.02 14.18 23.96  18.18 8.26 17.12 5.85  
 Acetone Acetone 
Mean* (±SD) 1.04 (±0.43) 1.12 (±0.58) 1.17 (±0.59)  5.53 (±0.75) 4.80 (±0.41) 4.46 (±0.58) 4.92 (±1.16)  
%CV 41.40 52.23 50.09  13.62 8.51 12.94 23.56  
 Acetonitril Acetonitril 
Mean* (±SD) 0.92 (±0.03) 0.82 (±0.07) 0.90 (±0.06)  5.06 (±0.22) 5.20 (±0.63) 4.75 (±0.24) 5.09 (±0.88)  
%CV 3.50 8.27 6.26  4.37 12.18 5.12 17.30  
 N,N-Dimethylformamide N,N-Dimethylformamide 
Mean* (±SD) 0.73 (±0.06) 0.61 (±0.06) 0.27 (±0.03)  5.05 (±1.09) 4.17 (±0.48) 3.10 (±0.55) 1.23 (±0.19)  
%CV 7.86 9.43 11.17  21.66 11.39 17.78 15.78  
 Ethyl acetate Ethyl acetate 
Mean* (±SD) 0.89 (±0.03) 0.79 (±0.10) 0.74 (±0.05) 0.61 (±0.14) 5.75 (±1.00) 5.27 (±0.75) 5.01 (±0.75) 4.44 (±0.20) 3.89 (±0.54) 
%CV 3.39 12.53 6.49 23.43 17.42 14.25 15.03 4.47 13.82 
 1,4-Dioxane 1,4-Dioxane 
Mean* (±SD) 0.92 (±0.17) 0.72 (±0.18) 0.59 (±0.29)  6.49 (±0.78) 6.46 (±1.32) 5.11 (±0.81) 3.25 (±1.32)  
%CV 17.97 25.02 49.63  12.01 20.37 15.79 40.54  
 pcDNA3hPPARγ∆AB pcDNA3hPPARγ∆AB with 1 µM Rosiglitazone 
Conc. (%) 0.1 0.3 1.0 3.0** 0.0*** 0.1 0.3 1.0 3.0** 
 DMSO DMSO 
Mean* (±SD) 0.89 (±0.14) 0.76 (±0.17) 0.56 (±0.16) 0.23 (±0.07) 5.89 (±1.02) 5.25 (±0.25) 5.62 (±1.08) 4.70 (±0.82) 1.12 (±0.29) 
%CV 15.73 21.90 29.59 29.02 17.30 4.86 19.26 17.52 25.87 
 Ethylene glycol Ethylene glycol 
Mean* (±SD) 0.95 (±0.14) 0.90 (±0.16) 0.92 (±0.28) 0.58 (±0.19) 8.79 (±0.53) 8.96 (±0.65) 9.26 (±0.78) 8.09 (±1.64) 5.39 (±1.41) 
 230 
 
%CV 14.50 17.36 30.32 32.63 6.05 7.28 8.39 20.27 26.22 
 Ethyl acetate Ethyl acetate 
Mean* (±SD) 1.29 (±0.54) 1.14 (±0.25) 1.02 (±0.27) 0.86 (±0.20) 7.50 (±1.05) 7.73 (±0.65) 7.84 (±0.23) 5.52 (±1.13) 2.41 (±0.38) 
%CV 41.70 22.11 26.58 23.53 14.03 8.46 2.98 20.50 15.71 
 pM1-hPPARγLBD pM1-hPPARγLBD 
Conc. (%) 0.1 0.3 1.0 3.0** 0.0*** 0.1 0.3 1.0 3.0** 
 DMSO DMSO 
Mean* (±SD) 1.09 (±0.11) 0.92 (±0.07) 0.78 (±0.08) 0.82 (±0.15) 16.86 (±4.16) 17.15 (±3.61) 16.59 (±3.32) 11.94 (±1.70) 2.78 (±0.60) 
%CV 9.74 7.60 10.84 18.09 24.69 21.08 20.04 14.26 21.58 
 Ethylene glycol Ethylene glycol 
Mean* (±SD) 1.20 (±0.09) 1.07 (±0.17) 1.08 (±0.29) 0.98 (±0.29) 23.71 (±7.00) 20.15 (±6.30) 19.80 (±7.83) 16.11 (±5.91) 9.51 (±4.99) 
%CV 7.88 15.53 26.47 30.17 29.53 31.26 39.51 36.69 52.48 
 Ethyl acetate Ethyl acetate 
Mean* (±SD) 1.16 (±0.07) 1.34 (±0.23) 1.37 (±0.16) 1.60 (±0.96) 14.10 (±0.24) 14.29 (±2.70) 13.36 (±0.67) 8.13 (±4.67) 5.25 (±3.08) 
%CV 5.99 16.88 11.35 60.07 1.74 18.88 5.01 57.47 58.66 
Hormone measurements 
Estradiol (pg/ml) Testosterone (ng/ml) 
Control 0.3% Etylene  
glycol 
0.3% DMSO 3% Acetone 3% Etyl 
 acetate 
Control 0.3% Etylene  
glycol 
0.3% DMSO 3% Acetone 3% Etyl  
acetate 
Mean (±SD) 
242.90 (±20.28) 288.83 (±7.01) 248.68 (±13.06) 260.13 (±5.97) 230.25 (±28.75) 1.21 (±0.07) 1.12 (±0.07) 1.29 (±0.08) 1.07 (±0.02) 1.04 (±0.04) 
%CV 
8.35 2.43 5.25 2.30 12.49 5.79 6.25 6.20 1.87 3.85 
* Normalized activity values (PPARγ/pRL-CMV). 
** Some of the solvents showed severe sign of cytotoxicity at 3% and the top dose was consequently reduced to 1%. 
*** DMSO control 
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